"Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.",anterior chamber flare is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('2-5', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('included', 'O'), ('anterior', 'B-ADR'), ('chamber', 'I-ADR'), ('flare', 'I-ADR'), (',', 'O'), ('corneal', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('dry', 'B-ADR'), ('eye', 'I-ADR'), (',', 'O'), ('iridocyclitis', 'B-ADR'), (',', 'O'), ('photophobia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('reduced', 'B-ADR'), ('visual', 'I-ADR'), ('acuity', 'I-ADR'), ('.', 'O')]"
"Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.",corneal edema is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('2-5', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('included', 'O'), ('anterior', 'B-ADR'), ('chamber', 'I-ADR'), ('flare', 'I-ADR'), (',', 'O'), ('corneal', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('dry', 'B-ADR'), ('eye', 'I-ADR'), (',', 'O'), ('iridocyclitis', 'B-ADR'), (',', 'O'), ('photophobia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('reduced', 'B-ADR'), ('visual', 'I-ADR'), ('acuity', 'I-ADR'), ('.', 'O')]"
"Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.",dry eye is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('2-5', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('included', 'O'), ('anterior', 'B-ADR'), ('chamber', 'I-ADR'), ('flare', 'I-ADR'), (',', 'O'), ('corneal', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('dry', 'B-ADR'), ('eye', 'I-ADR'), (',', 'O'), ('iridocyclitis', 'B-ADR'), (',', 'O'), ('photophobia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('reduced', 'B-ADR'), ('visual', 'I-ADR'), ('acuity', 'I-ADR'), ('.', 'O')]"
"Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.",iridocyclitis is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('2-5', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('included', 'O'), ('anterior', 'B-ADR'), ('chamber', 'I-ADR'), ('flare', 'I-ADR'), (',', 'O'), ('corneal', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('dry', 'B-ADR'), ('eye', 'I-ADR'), (',', 'O'), ('iridocyclitis', 'B-ADR'), (',', 'O'), ('photophobia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('reduced', 'B-ADR'), ('visual', 'I-ADR'), ('acuity', 'I-ADR'), ('.', 'O')]"
"Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.",photophobia is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('2-5', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('included', 'O'), ('anterior', 'B-ADR'), ('chamber', 'I-ADR'), ('flare', 'I-ADR'), (',', 'O'), ('corneal', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('dry', 'B-ADR'), ('eye', 'I-ADR'), (',', 'O'), ('iridocyclitis', 'B-ADR'), (',', 'O'), ('photophobia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('reduced', 'B-ADR'), ('visual', 'I-ADR'), ('acuity', 'I-ADR'), ('.', 'O')]"
"Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.",reduced visual acuity is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('2-5', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('included', 'O'), ('anterior', 'B-ADR'), ('chamber', 'I-ADR'), ('flare', 'I-ADR'), (',', 'O'), ('corneal', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('dry', 'B-ADR'), ('eye', 'I-ADR'), (',', 'O'), ('iridocyclitis', 'B-ADR'), (',', 'O'), ('photophobia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('reduced', 'B-ADR'), ('visual', 'I-ADR'), ('acuity', 'I-ADR'), ('.', 'O')]"
5.3 Delayed Healing      The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.,delay healing is an adverse reaction entity,"[('5.3', 'O'), ('Delayed', 'O'), ('Healing', 'O'), ('The', 'O'), ('use', 'O'), ('of', 'O'), ('steroids', 'O'), ('after', 'O'), ('cataract', 'O'), ('surgery', 'O'), ('may', 'O'), ('delay', 'B-ADR'), ('healing', 'I-ADR'), ('and', 'O'), ('increase', 'B-ADR'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('bleb', 'I-ADR'), ('formation', 'I-ADR'), ('.', 'O')]"
5.3 Delayed Healing      The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.,increase bleb formation is an adverse reaction entity,"[('5.3', 'O'), ('Delayed', 'O'), ('Healing', 'O'), ('The', 'O'), ('use', 'O'), ('of', 'O'), ('steroids', 'O'), ('after', 'O'), ('cataract', 'O'), ('surgery', 'O'), ('may', 'O'), ('delay', 'B-ADR'), ('healing', 'I-ADR'), ('and', 'O'), ('increase', 'B-ADR'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('bleb', 'I-ADR'), ('formation', 'I-ADR'), ('.', 'O')]"
"Severe hypoglycemia occurred in 0% and 0.7% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, was co-administered with a sulfonylurea.",hypoglycemia is an adverse reaction entity,"[('Severe', 'O'), ('hypoglycemia', 'B-ADR'), ('occurred', 'O'), ('in', 'O'), ('0', 'O'), ('%', 'O'), ('and', 'O'), ('0.7', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('when', 'O'), ('TRULICITY', 'O'), ('0.75', 'O'), ('mg', 'O'), ('and', 'O'), ('1.5', 'O'), ('mg', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('was', 'O'), ('co-administered', 'O'), ('with', 'O'), ('a', 'O'), ('sulfonylurea', 'O'), ('.', 'O')]"
PR Interval Prolongation and Adverse Reactions of First Degree Atrioventricular (AV) Block       A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated patients in contrast to a mean decrease of 0.9 millisecond in placebo-treated patients.,increase PR interval is an adverse reaction entity,"[('PR', 'O'), ('Interval', 'O'), ('Prolongation', 'O'), ('and', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('of', 'O'), ('First', 'O'), ('Degree', 'O'), ('Atrioventricular', 'O'), ('(', 'O'), ('AV', 'O'), (')', 'O'), ('Block', 'O'), ('A', 'O'), ('mean', 'O'), ('increase', 'B-ADR'), ('from', 'O'), ('baseline', 'O'), ('in', 'O'), ('PR', 'I-ADR'), ('interval', 'I-ADR'), ('of', 'O'), ('2-3', 'O'), ('milliseconds', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('TRULICITY-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('contrast', 'O'), ('to', 'O'), ('a', 'O'), ('mean', 'O'), ('decrease', 'O'), ('of', 'O'), ('0.9', 'O'), ('millisecond', 'O'), ('in', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"On electrocardiograms, a PR interval increase to at least 220 milliseconds was observed in 0.7%, 2.5% and 3.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",PR interval increase is an adverse reaction entity,"[('On', 'O'), ('electrocardiograms', 'O'), (',', 'O'), ('a', 'O'), ('PR', 'B-ADR'), ('interval', 'I-ADR'), ('increase', 'I-ADR'), ('to', 'O'), ('at', 'O'), ('least', 'O'), ('220', 'O'), ('milliseconds', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('0.7', 'O'), ('%', 'O'), (',', 'O'), ('2.5', 'O'), ('%', 'O'), ('and', 'O'), ('3.2', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), (',', 'O'), ('TRULICITY', 'O'), ('0.75', 'O'), ('mg', 'O'), ('and', 'O'), ('TRULICITY', 'O'), ('1.5', 'O'), ('mg', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
An analyses of adjudicated events revealed 5 cases of confirmed pancreatitis in patients exposed to TRULICITY (1.4 cases per 1000 patient years) versus 1 case in non-incretin comparators (0.88 cases per 1000 patient years).,pancreatitis is an adverse reaction entity,"[('An', 'O'), ('analyses', 'O'), ('of', 'O'), ('adjudicated', 'O'), ('events', 'O'), ('revealed', 'O'), ('5', 'O'), ('cases', 'O'), ('of', 'O'), ('confirmed', 'O'), ('pancreatitis', 'B-ADR'), ('in', 'O'), ('patients', 'O'), ('exposed', 'O'), ('to', 'O'), ('TRULICITY', 'O'), ('(', 'O'), ('1.4', 'O'), ('cases', 'O'), ('per', 'O'), ('1000', 'O'), ('patient', 'O'), ('years', 'O'), (')', 'O'), ('versus', 'O'), ('1', 'O'), ('case', 'O'), ('in', 'O'), ('non-incretin', 'O'), ('comparators', 'O'), ('(', 'O'), ('0.88', 'O'), ('cases', 'O'), ('per', 'O'), ('1000', 'O'), ('patient', 'O'), ('years', 'O'), (')', 'O'), ('.', 'O')]"
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",NSF is an adverse reaction entity,"[('NSF', 'B-ADR'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('fatal', 'B-ADR'), ('or', 'O'), ('debilitating', 'O'), ('fibrosis', 'B-ADR'), ('affecting', 'O'), ('the', 'O'), ('skin', 'O'), (',', 'O'), ('muscle', 'O'), ('and', 'O'), ('internal', 'O'), ('organs', 'O'), ('.', 'O')]"
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fatal is an adverse reaction entity,"[('NSF', 'B-ADR'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('fatal', 'B-ADR'), ('or', 'O'), ('debilitating', 'O'), ('fibrosis', 'B-ADR'), ('affecting', 'O'), ('the', 'O'), ('skin', 'O'), (',', 'O'), ('muscle', 'O'), ('and', 'O'), ('internal', 'O'), ('organs', 'O'), ('.', 'O')]"
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fibrosis is an adverse reaction entity,"[('NSF', 'B-ADR'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('fatal', 'B-ADR'), ('or', 'O'), ('debilitating', 'O'), ('fibrosis', 'B-ADR'), ('affecting', 'O'), ('the', 'O'), ('skin', 'O'), (',', 'O'), ('muscle', 'O'), ('and', 'O'), ('internal', 'O'), ('organs', 'O'), ('.', 'O')]"
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",NSF is an adverse reaction entity,"[('NSF', 'B-ADR'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('fatal', 'B-ADR'), ('or', 'O'), ('debilitating', 'O'), ('fibrosis', 'B-ADR'), ('affecting', 'O'), ('the', 'O'), ('skin', 'O'), (',', 'O'), ('muscle', 'O'), ('and', 'O'), ('internal', 'O'), ('organs', 'O'), ('.', 'O')]"
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fatal is an adverse reaction entity,"[('NSF', 'B-ADR'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('fatal', 'B-ADR'), ('or', 'O'), ('debilitating', 'O'), ('fibrosis', 'B-ADR'), ('affecting', 'O'), ('the', 'O'), ('skin', 'O'), (',', 'O'), ('muscle', 'O'), ('and', 'O'), ('internal', 'O'), ('organs', 'O'), ('.', 'O')]"
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fibrosis is an adverse reaction entity,"[('NSF', 'B-ADR'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('fatal', 'B-ADR'), ('or', 'O'), ('debilitating', 'O'), ('fibrosis', 'B-ADR'), ('affecting', 'O'), ('the', 'O'), ('skin', 'O'), (',', 'O'), ('muscle', 'O'), ('and', 'O'), ('internal', 'O'), ('organs', 'O'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",Angina pectoris is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",arrhythmias is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",atrial fibrillation is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",cardiac failure is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",hypertensive heart disease is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",myocardial infarction is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",myocardial ischemia is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",pericardial effusion is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",pericarditis is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",stroke is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Cardiac disorders:  Angina pectoris, arrhythmias, atrial fibrillation, cardiac failure, hypertensive heart disease, myocardial infarction, myocardial ischemia, pericardial effusion, pericarditis, stroke and transient ischemic attack.",transient ischemic attack is an adverse reaction entity,"[('Cardiac', 'O'), ('disorders', 'O'), (':', 'O'), ('Angina', 'B-ADR'), ('pectoris', 'I-ADR'), (',', 'O'), ('arrhythmias', 'B-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('hypertensive', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('myocardial', 'B-ADR'), ('ischemia', 'I-ADR'), (',', 'O'), ('pericardial', 'B-ADR'), ('effusion', 'I-ADR'), (',', 'O'), ('pericarditis', 'B-ADR'), (',', 'O'), ('stroke', 'B-ADR'), ('and', 'O'), ('transient', 'B-ADR'), ('ischemic', 'I-ADR'), ('attack', 'I-ADR'), ('.', 'O')]"
"Autoantibodies         In clinical studies in Crohn's disease, 4% of patients treated with CIMZIA and 2% of patients treated with placebo that had negative baseline ANA titers developed positive titers during the studies.",ANA titers positive is an adverse reaction entity,"[('Autoantibodies', 'O'), ('In', 'O'), ('clinical', 'O'), ('studies', 'O'), ('in', 'O'), ('Crohn', 'O'), (""'s"", 'O'), ('disease', 'O'), (',', 'O'), ('4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('CIMZIA', 'O'), ('and', 'O'), ('2', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('that', 'O'), ('had', 'O'), ('negative', 'O'), ('baseline', 'O'), ('ANA', 'B-ADR'), ('titers', 'I-ADR'), ('developed', 'O'), ('positive', 'I-ADR'), ('titers', 'O'), ('during', 'O'), ('the', 'O'), ('studies', 'O'), ('.', 'O')]"
"In clinical trials of TNF blockers, including CIMZIA, in patients with RA, some patients have developed ANA.",ANA is an adverse reaction entity,"[('In', 'O'), ('clinical', 'O'), ('trials', 'O'), ('of', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('including', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('RA', 'O'), (',', 'O'), ('some', 'O'), ('patients', 'O'), ('have', 'O'), ('developed', 'O'), ('ANA', 'B-ADR'), ('.', 'O')]"
Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.,infections is an adverse reaction entity,"[('Most', 'O'), ('patients', 'O'), ('who', 'O'), ('developed', 'O'), ('these', 'O'), ('infections', 'B-ADR'), ('were', 'O'), ('taking', 'O'), ('concomitant', 'O'), ('immunosuppressants', 'O'), ('such', 'O'), ('as', 'O'), ('methotrexate', 'O'), ('or', 'O'), ('corticosteroids', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.",Invasive fungal infections is an adverse reaction entity,"[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.",lymphoma is an adverse reaction entity,"[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.",malignancies is an adverse reaction entity,"[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.","Heart failure, worsening is an adverse reaction entity","[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.",Heart failure new onset is an adverse reaction entity,"[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.",Anaphylaxis is an adverse reaction entity,"[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.",allergic reactions is an adverse reaction entity,"[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"If an infection develops, monitor carefully, and stop CIMZIA if infection becomes serious (  5.1  )   *  Invasive fungal infections - for patients who develop a systemic illness on CIMZIA, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  )   *  Cases of lymphoma and other malignancies have been observed among patients receiving TNF blockers (  5.2  )   *  Heart failure, worsening or new onset may occur (  5.3  )   *  Anaphylaxis or serious allergic reactions may occur (  5.4  )   *  Hepatitis B virus reactivation - test for HBV infection before starting CIMZIA.",Hepatitis B virus reactivation is an adverse reaction entity,"[('If', 'O'), ('an', 'O'), ('infection', 'O'), ('develops', 'O'), (',', 'O'), ('monitor', 'O'), ('carefully', 'O'), (',', 'O'), ('and', 'O'), ('stop', 'O'), ('CIMZIA', 'O'), ('if', 'O'), ('infection', 'O'), ('becomes', 'O'), ('serious', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), ('-', 'O'), ('for', 'O'), ('patients', 'O'), ('who', 'O'), ('develop', 'O'), ('a', 'O'), ('systemic', 'O'), ('illness', 'O'), ('on', 'O'), ('CIMZIA', 'O'), (',', 'O'), ('consider', 'O'), ('empiric', 'O'), ('antifungal', 'O'), ('therapy', 'O'), ('for', 'O'), ('those', 'O'), ('who', 'O'), ('reside', 'O'), ('or', 'O'), ('travel', 'O'), ('to', 'O'), ('regions', 'O'), ('where', 'O'), ('mycoses', 'O'), ('are', 'O'), ('endemic', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Heart', 'B-ADR'), ('failure', 'I-ADR'), (',', 'I-ADR'), ('worsening', 'I-ADR'), ('or', 'O'), ('new', 'I-ADR'), ('onset', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Anaphylaxis', 'B-ADR'), ('or', 'O'), ('serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('reactivation', 'I-ADR'), ('-', 'O'), ('test', 'O'), ('for', 'O'), ('HBV', 'O'), ('infection', 'O'), ('before', 'O'), ('starting', 'O'), ('CIMZIA', 'O'), ('.', 'O')]"
"In the controlled portions of clinical trials of all the TNF blockers, more cases of lymphoma have been observed among patients receiving TNF blockers compared to control patients.",lymphoma is an adverse reaction entity,"[('In', 'O'), ('the', 'O'), ('controlled', 'O'), ('portions', 'O'), ('of', 'O'), ('clinical', 'O'), ('trials', 'O'), ('of', 'O'), ('all', 'O'), ('the', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('more', 'O'), ('cases', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('among', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TNF', 'O'), ('blockers', 'O'), ('compared', 'O'), ('to', 'O'), ('control', 'O'), ('patients', 'O'), ('.', 'O')]"
"In controlled studies of CIMZIA for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia-treated patients and one case of Hodgkin's lymphoma among 1,319 placebo-treated patients.",lymphoma is an adverse reaction entity,"[('In', 'O'), ('controlled', 'O'), ('studies', 'O'), ('of', 'O'), ('CIMZIA', 'O'), ('for', 'O'), ('Crohn', 'O'), (""'s"", 'O'), ('disease', 'O'), ('and', 'O'), ('other', 'O'), ('investigational', 'O'), ('uses', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('among', 'O'), ('2,657', 'O'), ('Cimzia-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('Hodgkin', 'B-ADR'), (""'s"", 'I-ADR'), ('lymphoma', 'I-ADR'), ('among', 'O'), ('1,319', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"In controlled studies of CIMZIA for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 Cimzia-treated patients and one case of Hodgkin's lymphoma among 1,319 placebo-treated patients.",Hodgkin's lymphoma is an adverse reaction entity,"[('In', 'O'), ('controlled', 'O'), ('studies', 'O'), ('of', 'O'), ('CIMZIA', 'O'), ('for', 'O'), ('Crohn', 'O'), (""'s"", 'O'), ('disease', 'O'), ('and', 'O'), ('other', 'O'), ('investigational', 'O'), ('uses', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('lymphoma', 'B-ADR'), ('among', 'O'), ('2,657', 'O'), ('Cimzia-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('Hodgkin', 'B-ADR'), (""'s"", 'I-ADR'), ('lymphoma', 'I-ADR'), ('among', 'O'), ('1,319', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"CIMZIA has not been formally studied in patients with CHF; however, in clinical studies in patients with CHF with another TNF blocker, worsening congestive heart failure (CHF) and increased mortality due to CHF were observed.",worsening congestive heart failure is an adverse reaction entity,"[('CIMZIA', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('formally', 'O'), ('studied', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('in', 'O'), ('clinical', 'O'), ('studies', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), ('with', 'O'), ('another', 'O'), ('TNF', 'O'), ('blocker', 'O'), (',', 'O'), ('worsening', 'B-ADR'), ('congestive', 'I-ADR'), ('heart', 'I-ADR'), ('failure', 'I-ADR'), ('(', 'O'), ('CHF', 'I-ADR'), (')', 'O'), ('and', 'O'), ('increased', 'B-ADR'), ('mortality', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('CHF', 'B-ADR'), ('were', 'O'), ('observed', 'O'), ('.', 'O')]"
"CIMZIA has not been formally studied in patients with CHF; however, in clinical studies in patients with CHF with another TNF blocker, worsening congestive heart failure (CHF) and increased mortality due to CHF were observed.",worsening CHF is an adverse reaction entity,"[('CIMZIA', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('formally', 'O'), ('studied', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('in', 'O'), ('clinical', 'O'), ('studies', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), ('with', 'O'), ('another', 'O'), ('TNF', 'O'), ('blocker', 'O'), (',', 'O'), ('worsening', 'B-ADR'), ('congestive', 'I-ADR'), ('heart', 'I-ADR'), ('failure', 'I-ADR'), ('(', 'O'), ('CHF', 'I-ADR'), (')', 'O'), ('and', 'O'), ('increased', 'B-ADR'), ('mortality', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('CHF', 'B-ADR'), ('were', 'O'), ('observed', 'O'), ('.', 'O')]"
"CIMZIA has not been formally studied in patients with CHF; however, in clinical studies in patients with CHF with another TNF blocker, worsening congestive heart failure (CHF) and increased mortality due to CHF were observed.",increased mortality is an adverse reaction entity,"[('CIMZIA', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('formally', 'O'), ('studied', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('in', 'O'), ('clinical', 'O'), ('studies', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), ('with', 'O'), ('another', 'O'), ('TNF', 'O'), ('blocker', 'O'), (',', 'O'), ('worsening', 'B-ADR'), ('congestive', 'I-ADR'), ('heart', 'I-ADR'), ('failure', 'I-ADR'), ('(', 'O'), ('CHF', 'I-ADR'), (')', 'O'), ('and', 'O'), ('increased', 'B-ADR'), ('mortality', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('CHF', 'B-ADR'), ('were', 'O'), ('observed', 'O'), ('.', 'O')]"
"CIMZIA has not been formally studied in patients with CHF; however, in clinical studies in patients with CHF with another TNF blocker, worsening congestive heart failure (CHF) and increased mortality due to CHF were observed.",CHF is an adverse reaction entity,"[('CIMZIA', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('formally', 'O'), ('studied', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('in', 'O'), ('clinical', 'O'), ('studies', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'O'), ('with', 'O'), ('another', 'O'), ('TNF', 'O'), ('blocker', 'O'), (',', 'O'), ('worsening', 'B-ADR'), ('congestive', 'I-ADR'), ('heart', 'I-ADR'), ('failure', 'I-ADR'), ('(', 'O'), ('CHF', 'I-ADR'), (')', 'O'), ('and', 'O'), ('increased', 'B-ADR'), ('mortality', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('CHF', 'B-ADR'), ('were', 'O'), ('observed', 'O'), ('.', 'O')]"
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Mortality: There were more deaths reported with BENLYSTA than with placebo during the controlled period of clinical trials.,Mortality is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Mortality', 'B-ADR'), (':', 'O'), ('There', 'O'), ('were', 'O'), ('more', 'O'), ('deaths', 'B-ADR'), ('reported', 'O'), ('with', 'O'), ('BENLYSTA', 'O'), ('than', 'O'), ('with', 'O'), ('placebo', 'O'), ('during', 'O'), ('the', 'O'), ('controlled', 'O'), ('period', 'O'), ('of', 'O'), ('clinical', 'O'), ('trials', 'O'), ('.', 'O')]"
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Mortality: There were more deaths reported with BENLYSTA than with placebo during the controlled period of clinical trials.,deaths is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Mortality', 'B-ADR'), (':', 'O'), ('There', 'O'), ('were', 'O'), ('more', 'O'), ('deaths', 'B-ADR'), ('reported', 'O'), ('with', 'O'), ('BENLYSTA', 'O'), ('than', 'O'), ('with', 'O'), ('placebo', 'O'), ('during', 'O'), ('the', 'O'), ('controlled', 'O'), ('period', 'O'), ('of', 'O'), ('clinical', 'O'), ('trials', 'O'), ('.', 'O')]"
"(  2.2  ,  5.4  )   *    Depression: Depression and suicidality have been reported in trials with BENLYSTA.",Depression is an adverse reaction entity,"[('(', 'O'), ('2.2', 'O'), (',', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Depression', 'B-ADR'), (':', 'O'), ('Depression', 'B-ADR'), ('and', 'O'), ('suicidality', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('trials', 'O'), ('with', 'O'), ('BENLYSTA', 'O'), ('.', 'O')]"
"(  2.2  ,  5.4  )   *    Depression: Depression and suicidality have been reported in trials with BENLYSTA.",Depression is an adverse reaction entity,"[('(', 'O'), ('2.2', 'O'), (',', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Depression', 'B-ADR'), (':', 'O'), ('Depression', 'B-ADR'), ('and', 'O'), ('suicidality', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('trials', 'O'), ('with', 'O'), ('BENLYSTA', 'O'), ('.', 'O')]"
"(  2.2  ,  5.4  )   *    Depression: Depression and suicidality have been reported in trials with BENLYSTA.",suicidality is an adverse reaction entity,"[('(', 'O'), ('2.2', 'O'), (',', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Depression', 'B-ADR'), (':', 'O'), ('Depression', 'B-ADR'), ('and', 'O'), ('suicidality', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('trials', 'O'), ('with', 'O'), ('BENLYSTA', 'O'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",infusion reactions is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",hypersensitivity reactions is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",bradycardia is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",myalgia is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",headache is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",rash is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",urticaria is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension.",hypotension is an adverse reaction entity,"[('Serious', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('excluding', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0.5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.4', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('and', 'O'), ('included', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypotension', 'B-ADR'), ('.', 'O')]"
"Serious depression was reported in 0.4% (6/1,458) of patients receiving BENLYSTA and 0.1% (1/675) of patients receiving placebo.",depression is an adverse reaction entity,"[('Serious', 'O'), ('depression', 'B-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('0.4', 'O'), ('%', 'O'), ('(', 'O'), ('6/1,458', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BENLYSTA', 'O'), ('and', 'O'), ('0.1', 'O'), ('%', 'O'), ('(', 'O'), ('1/675', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('.', 'O')]"
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",Somnolence is an adverse reaction entity,"[('Somnolence', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('events', 'O'), (':', 'O'), ('somnolence', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypersomnia', 'B-ADR'), ('.', 'O')]"
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",somnolence is an adverse reaction entity,"[('Somnolence', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('events', 'O'), (':', 'O'), ('somnolence', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypersomnia', 'B-ADR'), ('.', 'O')]"
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",sedation is an adverse reaction entity,"[('Somnolence', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('events', 'O'), (':', 'O'), ('somnolence', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypersomnia', 'B-ADR'), ('.', 'O')]"
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",hypersomnia is an adverse reaction entity,"[('Somnolence', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('events', 'O'), (':', 'O'), ('somnolence', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hypersomnia', 'B-ADR'), ('.', 'O')]"
"Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.",Dystonic symptoms is an adverse reaction entity,"[('Dystonic', 'B-ADR'), ('symptoms', 'I-ADR'), ('include', 'O'), (':', 'O'), ('spasm', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('neck', 'I-ADR'), ('muscles', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('progressing', 'O'), ('to', 'O'), ('tightness', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('throat', 'I-ADR'), (',', 'O'), ('swallowing', 'B-ADR'), ('difficulty', 'I-ADR'), (',', 'O'), ('difficulty', 'B-ADR'), ('breathing', 'I-ADR'), (',', 'O'), ('and/or', 'O'), ('protrusion', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('tongue', 'I-ADR'), ('.', 'O')]"
"Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.",spasm of the neck muscles is an adverse reaction entity,"[('Dystonic', 'B-ADR'), ('symptoms', 'I-ADR'), ('include', 'O'), (':', 'O'), ('spasm', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('neck', 'I-ADR'), ('muscles', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('progressing', 'O'), ('to', 'O'), ('tightness', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('throat', 'I-ADR'), (',', 'O'), ('swallowing', 'B-ADR'), ('difficulty', 'I-ADR'), (',', 'O'), ('difficulty', 'B-ADR'), ('breathing', 'I-ADR'), (',', 'O'), ('and/or', 'O'), ('protrusion', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('tongue', 'I-ADR'), ('.', 'O')]"
"Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.",tightness of the throat is an adverse reaction entity,"[('Dystonic', 'B-ADR'), ('symptoms', 'I-ADR'), ('include', 'O'), (':', 'O'), ('spasm', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('neck', 'I-ADR'), ('muscles', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('progressing', 'O'), ('to', 'O'), ('tightness', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('throat', 'I-ADR'), (',', 'O'), ('swallowing', 'B-ADR'), ('difficulty', 'I-ADR'), (',', 'O'), ('difficulty', 'B-ADR'), ('breathing', 'I-ADR'), (',', 'O'), ('and/or', 'O'), ('protrusion', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('tongue', 'I-ADR'), ('.', 'O')]"
"Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.",swallowing difficulty is an adverse reaction entity,"[('Dystonic', 'B-ADR'), ('symptoms', 'I-ADR'), ('include', 'O'), (':', 'O'), ('spasm', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('neck', 'I-ADR'), ('muscles', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('progressing', 'O'), ('to', 'O'), ('tightness', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('throat', 'I-ADR'), (',', 'O'), ('swallowing', 'B-ADR'), ('difficulty', 'I-ADR'), (',', 'O'), ('difficulty', 'B-ADR'), ('breathing', 'I-ADR'), (',', 'O'), ('and/or', 'O'), ('protrusion', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('tongue', 'I-ADR'), ('.', 'O')]"
"Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.",difficulty breathing is an adverse reaction entity,"[('Dystonic', 'B-ADR'), ('symptoms', 'I-ADR'), ('include', 'O'), (':', 'O'), ('spasm', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('neck', 'I-ADR'), ('muscles', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('progressing', 'O'), ('to', 'O'), ('tightness', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('throat', 'I-ADR'), (',', 'O'), ('swallowing', 'B-ADR'), ('difficulty', 'I-ADR'), (',', 'O'), ('difficulty', 'B-ADR'), ('breathing', 'I-ADR'), (',', 'O'), ('and/or', 'O'), ('protrusion', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('tongue', 'I-ADR'), ('.', 'O')]"
"Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue.",protrusion of the tongue is an adverse reaction entity,"[('Dystonic', 'B-ADR'), ('symptoms', 'I-ADR'), ('include', 'O'), (':', 'O'), ('spasm', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('neck', 'I-ADR'), ('muscles', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('progressing', 'O'), ('to', 'O'), ('tightness', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('throat', 'I-ADR'), (',', 'O'), ('swallowing', 'B-ADR'), ('difficulty', 'I-ADR'), (',', 'O'), ('difficulty', 'B-ADR'), ('breathing', 'I-ADR'), (',', 'O'), ('and/or', 'O'), ('protrusion', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('tongue', 'I-ADR'), ('.', 'O')]"
"In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, the incidences of EPS-related events, excluding events related to akathisia, were 4%, 3%, and 5% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 3% for placebo-treated patients.",EPS-related events is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('3-week', 'O'), (',', 'O'), ('placebo-controlled', 'O'), ('pediatric', 'O'), ('trial', 'O'), ('with', 'O'), ('bipolar', 'O'), ('I', 'O'), ('disorder', 'O'), (',', 'O'), ('the', 'O'), ('incidences', 'O'), ('of', 'O'), ('EPS-related', 'B-ADR'), ('events', 'I-ADR'), (',', 'O'), ('excluding', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('akathisia', 'B-ADR'), (',', 'O'), ('were', 'O'), ('4', 'O'), ('%', 'O'), (',', 'O'), ('3', 'O'), ('%', 'O'), (',', 'O'), ('and', 'O'), ('5', 'O'), ('%', 'O'), ('for', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('SAPHRIS', 'O'), ('2.5', 'O'), ('mg', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('10', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('3', 'O'), ('%', 'O'), ('for', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, the incidences of EPS-related events, excluding events related to akathisia, were 4%, 3%, and 5% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 3% for placebo-treated patients.",akathisia is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('3-week', 'O'), (',', 'O'), ('placebo-controlled', 'O'), ('pediatric', 'O'), ('trial', 'O'), ('with', 'O'), ('bipolar', 'O'), ('I', 'O'), ('disorder', 'O'), (',', 'O'), ('the', 'O'), ('incidences', 'O'), ('of', 'O'), ('EPS-related', 'B-ADR'), ('events', 'I-ADR'), (',', 'O'), ('excluding', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('akathisia', 'B-ADR'), (',', 'O'), ('were', 'O'), ('4', 'O'), ('%', 'O'), (',', 'O'), ('3', 'O'), ('%', 'O'), (',', 'O'), ('and', 'O'), ('5', 'O'), ('%', 'O'), ('for', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('SAPHRIS', 'O'), ('2.5', 'O'), ('mg', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('10', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('3', 'O'), ('%', 'O'), ('for', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Prolactin:  In short-term, placebo-controlled adult schizophrenia trials, the mean decreases in prolactin levels were 6.5 ng/mL for SAPHRIS-treated patients compared to 10.7 ng/mL for placebo-treated patients.",decreases in prolactin levels is an adverse reaction entity,"[('Prolactin', 'O'), (':', 'O'), ('In', 'O'), ('short-term', 'O'), (',', 'O'), ('placebo-controlled', 'O'), ('adult', 'O'), ('schizophrenia', 'O'), ('trials', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('decreases', 'B-ADR'), ('in', 'I-ADR'), ('prolactin', 'I-ADR'), ('levels', 'I-ADR'), ('were', 'O'), ('6.5', 'O'), ('ng/mL', 'O'), ('for', 'O'), ('SAPHRIS-treated', 'O'), ('patients', 'O'), ('compared', 'O'), ('to', 'O'), ('10.7', 'O'), ('ng/mL', 'O'), ('for', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"In a long-term (52-week), double-blind, comparator-controlled adult trial that included primarily patients with schizophrenia, the mean decrease in prolactin from baseline for SAPHRIS-treated patients was 26.9 ng/mL.",decrease in prolactin is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('long-term', 'O'), ('(', 'O'), ('52-week', 'O'), (')', 'O'), (',', 'O'), ('double-blind', 'O'), (',', 'O'), ('comparator-controlled', 'O'), ('adult', 'O'), ('trial', 'O'), ('that', 'O'), ('included', 'O'), ('primarily', 'O'), ('patients', 'O'), ('with', 'O'), ('schizophrenia', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('decrease', 'B-ADR'), ('in', 'I-ADR'), ('prolactin', 'I-ADR'), ('from', 'O'), ('baseline', 'O'), ('for', 'O'), ('SAPHRIS-treated', 'O'), ('patients', 'O'), ('was', 'O'), ('26.9', 'O'), ('ng/mL', 'O'), ('.', 'O')]"
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,death is an adverse reaction entity,"[('Elderly', 'O'), ('patients', 'O'), ('with', 'O'), ('dementia-related', 'O'), ('psychosis', 'O'), ('treated', 'O'), ('with', 'O'), ('antipsychotic', 'O'), ('drugs', 'O'), ('are', 'O'), ('at', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('death', 'B-ADR'), ('.', 'O')]"
(5.2)   *   Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring.,Neuroleptic Malignant Syndrome is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Neuroleptic', 'B-ADR'), ('Malignant', 'I-ADR'), ('Syndrome', 'I-ADR'), (':', 'O'), ('Manage', 'O'), ('with', 'O'), ('immediate', 'O'), ('discontinuation', 'O'), ('and', 'O'), ('close', 'O'), ('monitoring', 'O'), ('.', 'O')]"
"(5.6)   *   Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",Orthostatic Hypotension is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Orthostatic', 'B-ADR'), ('Hypotension', 'I-ADR'), (',', 'O'), ('Syncope', 'B-ADR'), (',', 'O'), ('and', 'O'), ('Other', 'O'), ('Hemodynamic', 'B-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Dizziness', 'B-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), ('or', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('syncope', 'B-ADR'), ('may', 'O'), ('occur', 'O'), (',', 'O'), ('especially', 'O'), ('early', 'O'), ('in', 'O'), ('treatment', 'O'), ('.', 'O')]"
"(5.6)   *   Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",Syncope is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Orthostatic', 'B-ADR'), ('Hypotension', 'I-ADR'), (',', 'O'), ('Syncope', 'B-ADR'), (',', 'O'), ('and', 'O'), ('Other', 'O'), ('Hemodynamic', 'B-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Dizziness', 'B-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), ('or', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('syncope', 'B-ADR'), ('may', 'O'), ('occur', 'O'), (',', 'O'), ('especially', 'O'), ('early', 'O'), ('in', 'O'), ('treatment', 'O'), ('.', 'O')]"
"(5.6)   *   Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",Hemodynamic Effects is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Orthostatic', 'B-ADR'), ('Hypotension', 'I-ADR'), (',', 'O'), ('Syncope', 'B-ADR'), (',', 'O'), ('and', 'O'), ('Other', 'O'), ('Hemodynamic', 'B-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Dizziness', 'B-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), ('or', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('syncope', 'B-ADR'), ('may', 'O'), ('occur', 'O'), (',', 'O'), ('especially', 'O'), ('early', 'O'), ('in', 'O'), ('treatment', 'O'), ('.', 'O')]"
"(5.6)   *   Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",Dizziness is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Orthostatic', 'B-ADR'), ('Hypotension', 'I-ADR'), (',', 'O'), ('Syncope', 'B-ADR'), (',', 'O'), ('and', 'O'), ('Other', 'O'), ('Hemodynamic', 'B-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Dizziness', 'B-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), ('or', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('syncope', 'B-ADR'), ('may', 'O'), ('occur', 'O'), (',', 'O'), ('especially', 'O'), ('early', 'O'), ('in', 'O'), ('treatment', 'O'), ('.', 'O')]"
"(5.6)   *   Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",tachycardia is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Orthostatic', 'B-ADR'), ('Hypotension', 'I-ADR'), (',', 'O'), ('Syncope', 'B-ADR'), (',', 'O'), ('and', 'O'), ('Other', 'O'), ('Hemodynamic', 'B-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Dizziness', 'B-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), ('or', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('syncope', 'B-ADR'), ('may', 'O'), ('occur', 'O'), (',', 'O'), ('especially', 'O'), ('early', 'O'), ('in', 'O'), ('treatment', 'O'), ('.', 'O')]"
"(5.6)   *   Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",bradycardia is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Orthostatic', 'B-ADR'), ('Hypotension', 'I-ADR'), (',', 'O'), ('Syncope', 'B-ADR'), (',', 'O'), ('and', 'O'), ('Other', 'O'), ('Hemodynamic', 'B-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Dizziness', 'B-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), ('or', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('syncope', 'B-ADR'), ('may', 'O'), ('occur', 'O'), (',', 'O'), ('especially', 'O'), ('early', 'O'), ('in', 'O'), ('treatment', 'O'), ('.', 'O')]"
"(5.6)   *   Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",syncope is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Orthostatic', 'B-ADR'), ('Hypotension', 'I-ADR'), (',', 'O'), ('Syncope', 'B-ADR'), (',', 'O'), ('and', 'O'), ('Other', 'O'), ('Hemodynamic', 'B-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Dizziness', 'B-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), ('or', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('syncope', 'B-ADR'), ('may', 'O'), ('occur', 'O'), (',', 'O'), ('especially', 'O'), ('early', 'O'), ('in', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.",Galactorrhea is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.",amenorrhea is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.",gynecomastia is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.",impotence is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"In a 3-week, bipolar mania pediatric trial, the incidence of adverse events related to abnormal prolactin levels were 0% in the SAPHRIS 2.5 mg twice daily treatment group, 2% in the SAPHRIS 5 mg twice daily treatment group, and 1% in the SAPHRIS 10 mg twice daily treatment group versus to 1% for patients treated with placebo  [see Adverse Reactions (6.1)]  .",abnormal prolactin levels is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('3-week', 'O'), (',', 'O'), ('bipolar', 'O'), ('mania', 'O'), ('pediatric', 'O'), ('trial', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('adverse', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('abnormal', 'B-ADR'), ('prolactin', 'I-ADR'), ('levels', 'I-ADR'), ('were', 'O'), ('0', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('SAPHRIS', 'O'), ('2.5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), ('treatment', 'O'), ('group', 'O'), (',', 'O'), ('2', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('SAPHRIS', 'O'), ('5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), ('treatment', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('1', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('SAPHRIS', 'O'), ('10', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), ('treatment', 'O'), ('group', 'O'), ('versus', 'O'), ('to', 'O'), ('1', 'O'), ('%', 'O'), ('for', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"5.11 Seizures        Seizures were reported in 0% and 0.3% (0/572, 1/379) of adult patients treated with doses of 5 mg and 10 mg twice daily of SAPHRIS, respectively, compared to 0% (0/503, 0/203) of patients treated with placebo in short-term schizophrenia and bipolar mania trials, respectively.",Seizures is an adverse reaction entity,"[('5.11', 'O'), ('Seizures', 'O'), ('Seizures', 'B-ADR'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('0', 'O'), ('%', 'O'), ('and', 'O'), ('0.3', 'O'), ('%', 'O'), ('(', 'O'), ('0/572', 'O'), (',', 'O'), ('1/379', 'O'), (')', 'O'), ('of', 'O'), ('adult', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('doses', 'O'), ('of', 'O'), ('5', 'O'), ('mg', 'O'), ('and', 'O'), ('10', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), ('of', 'O'), ('SAPHRIS', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('0', 'O'), ('%', 'O'), ('(', 'O'), ('0/503', 'O'), (',', 'O'), ('0/203', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('in', 'O'), ('short-term', 'O'), ('schizophrenia', 'O'), ('and', 'O'), ('bipolar', 'O'), ('mania', 'O'), ('trials', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"Somnolence (including sedation) led to discontinuation in 0.6% (12/1953) of patients in short-term, placebo-controlled trials.",Somnolence is an adverse reaction entity,"[('Somnolence', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('sedation', 'B-ADR'), (')', 'O'), ('led', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('in', 'O'), ('0.6', 'O'), ('%', 'O'), ('(', 'O'), ('12/1953', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('short-term', 'O'), (',', 'O'), ('placebo-controlled', 'O'), ('trials', 'O'), ('.', 'O')]"
"Somnolence (including sedation) led to discontinuation in 0.6% (12/1953) of patients in short-term, placebo-controlled trials.",sedation is an adverse reaction entity,"[('Somnolence', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('sedation', 'B-ADR'), (')', 'O'), ('led', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('in', 'O'), ('0.6', 'O'), ('%', 'O'), ('(', 'O'), ('12/1953', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('short-term', 'O'), (',', 'O'), ('placebo-controlled', 'O'), ('trials', 'O'), ('.', 'O')]"
"In a 3-week, placebo-controlled, bipolar I pediatric trial, the incidence of somnolence (including sedation and hypersomnia) for placebo, SAPHRIS 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, was 12% (12/101), 46% (48/104), 53% (52/99), and 49% (49/99), respectively.",somnolence is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('3-week', 'O'), (',', 'O'), ('placebo-controlled', 'O'), (',', 'O'), ('bipolar', 'O'), ('I', 'O'), ('pediatric', 'O'), ('trial', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('somnolence', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('sedation', 'B-ADR'), ('and', 'O'), ('hypersomnia', 'B-ADR'), (')', 'O'), ('for', 'O'), ('placebo', 'O'), (',', 'O'), ('SAPHRIS', 'O'), ('2.5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('and', 'O'), ('10', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('was', 'O'), ('12', 'O'), ('%', 'O'), ('(', 'O'), ('12/101', 'O'), (')', 'O'), (',', 'O'), ('46', 'O'), ('%', 'O'), ('(', 'O'), ('48/104', 'O'), (')', 'O'), (',', 'O'), ('53', 'O'), ('%', 'O'), ('(', 'O'), ('52/99', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('49', 'O'), ('%', 'O'), ('(', 'O'), ('49/99', 'O'), (')', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"In a 3-week, placebo-controlled, bipolar I pediatric trial, the incidence of somnolence (including sedation and hypersomnia) for placebo, SAPHRIS 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, was 12% (12/101), 46% (48/104), 53% (52/99), and 49% (49/99), respectively.",sedation is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('3-week', 'O'), (',', 'O'), ('placebo-controlled', 'O'), (',', 'O'), ('bipolar', 'O'), ('I', 'O'), ('pediatric', 'O'), ('trial', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('somnolence', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('sedation', 'B-ADR'), ('and', 'O'), ('hypersomnia', 'B-ADR'), (')', 'O'), ('for', 'O'), ('placebo', 'O'), (',', 'O'), ('SAPHRIS', 'O'), ('2.5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('and', 'O'), ('10', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('was', 'O'), ('12', 'O'), ('%', 'O'), ('(', 'O'), ('12/101', 'O'), (')', 'O'), (',', 'O'), ('46', 'O'), ('%', 'O'), ('(', 'O'), ('48/104', 'O'), (')', 'O'), (',', 'O'), ('53', 'O'), ('%', 'O'), ('(', 'O'), ('52/99', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('49', 'O'), ('%', 'O'), ('(', 'O'), ('49/99', 'O'), (')', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"In a 3-week, placebo-controlled, bipolar I pediatric trial, the incidence of somnolence (including sedation and hypersomnia) for placebo, SAPHRIS 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, was 12% (12/101), 46% (48/104), 53% (52/99), and 49% (49/99), respectively.",hypersomnia is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('3-week', 'O'), (',', 'O'), ('placebo-controlled', 'O'), (',', 'O'), ('bipolar', 'O'), ('I', 'O'), ('pediatric', 'O'), ('trial', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('somnolence', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('sedation', 'B-ADR'), ('and', 'O'), ('hypersomnia', 'B-ADR'), (')', 'O'), ('for', 'O'), ('placebo', 'O'), (',', 'O'), ('SAPHRIS', 'O'), ('2.5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('and', 'O'), ('10', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), (',', 'O'), ('was', 'O'), ('12', 'O'), ('%', 'O'), ('(', 'O'), ('12/101', 'O'), (')', 'O'), (',', 'O'), ('46', 'O'), ('%', 'O'), ('(', 'O'), ('48/104', 'O'), (')', 'O'), (',', 'O'), ('53', 'O'), ('%', 'O'), ('(', 'O'), ('52/99', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('49', 'O'), ('%', 'O'), ('(', 'O'), ('49/99', 'O'), (')', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
5.2 Hyperpyrexia and Confusion      Post-marketing cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported with NORTHERA use during post-marketing surveillance in Japan.,neuroleptic malignant syndrome is an adverse reaction entity,"[('5.2', 'O'), ('Hyperpyrexia', 'O'), ('and', 'O'), ('Confusion', 'O'), ('Post-marketing', 'O'), ('cases', 'O'), ('of', 'O'), ('a', 'O'), ('symptom', 'O'), ('complex', 'O'), ('resembling', 'O'), ('neuroleptic', 'B-ADR'), ('malignant', 'I-ADR'), ('syndrome', 'I-ADR'), ('(', 'O'), ('NMS', 'B-ADR'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('NORTHERA', 'O'), ('use', 'O'), ('during', 'O'), ('post-marketing', 'O'), ('surveillance', 'O'), ('in', 'O'), ('Japan', 'O'), ('.', 'O')]"
5.2 Hyperpyrexia and Confusion      Post-marketing cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported with NORTHERA use during post-marketing surveillance in Japan.,NMS is an adverse reaction entity,"[('5.2', 'O'), ('Hyperpyrexia', 'O'), ('and', 'O'), ('Confusion', 'O'), ('Post-marketing', 'O'), ('cases', 'O'), ('of', 'O'), ('a', 'O'), ('symptom', 'O'), ('complex', 'O'), ('resembling', 'O'), ('neuroleptic', 'B-ADR'), ('malignant', 'I-ADR'), ('syndrome', 'I-ADR'), ('(', 'O'), ('NMS', 'B-ADR'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('NORTHERA', 'O'), ('use', 'O'), ('during', 'O'), ('post-marketing', 'O'), ('surveillance', 'O'), ('in', 'O'), ('Japan', 'O'), ('.', 'O')]"
"None of these 4 patients had neutralizing antibodies.The presence of ADA to ERWINAZE is associated with a higher risk of hypersensitivity reactions in patients who received ERWINAZE through intravenous infusion compared to intramuscular administration of ERWINAZE.Immunogenicity assay are highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",hypersensitivity reactions is an adverse reaction entity,"[('None', 'O'), ('of', 'O'), ('these', 'O'), ('4', 'O'), ('patients', 'O'), ('had', 'O'), ('neutralizing', 'O'), ('antibodies.The', 'O'), ('presence', 'O'), ('of', 'O'), ('ADA', 'O'), ('to', 'O'), ('ERWINAZE', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('higher', 'O'), ('risk', 'O'), ('of', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('received', 'O'), ('ERWINAZE', 'O'), ('through', 'O'), ('intravenous', 'O'), ('infusion', 'O'), ('compared', 'O'), ('to', 'O'), ('intramuscular', 'O'), ('administration', 'O'), ('of', 'O'), ('ERWINAZE.Immunogenicity', 'O'), ('assay', 'O'), ('are', 'O'), ('highly', 'O'), ('dependent', 'O'), ('on', 'O'), ('the', 'O'), ('sensitivity', 'O'), ('and', 'O'), ('specificity', 'O'), ('of', 'O'), ('the', 'O'), ('assay', 'O'), ('and', 'O'), ('may', 'O'), ('be', 'O'), ('influenced', 'O'), ('by', 'O'), ('several', 'O'), ('factors', 'O'), ('such', 'O'), ('as', 'O'), (':', 'O'), ('assay', 'O'), ('methodology', 'O'), (',', 'O'), ('sample', 'O'), ('handling', 'O'), (',', 'O'), ('timing', 'O'), ('of', 'O'), ('sample', 'O'), ('collection', 'O'), (',', 'O'), ('concomitant', 'O'), ('medications', 'O'), (',', 'O'), ('and', 'O'), ('underlying', 'O'), ('disease', 'O'), ('.', 'O')]"
"6 ADVERSE REACTIONS    EXCERPT:   Most commonly reported adverse reactions were flushing (2%), headache (1%), increased blood pressure (2%), nausea (1%), and dizziness (1%).",flushing is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('flushing', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('dizziness', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"6 ADVERSE REACTIONS    EXCERPT:   Most commonly reported adverse reactions were flushing (2%), headache (1%), increased blood pressure (2%), nausea (1%), and dizziness (1%).",headache is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('flushing', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('dizziness', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"6 ADVERSE REACTIONS    EXCERPT:   Most commonly reported adverse reactions were flushing (2%), headache (1%), increased blood pressure (2%), nausea (1%), and dizziness (1%).",increased blood pressure is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('flushing', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('dizziness', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"6 ADVERSE REACTIONS    EXCERPT:   Most commonly reported adverse reactions were flushing (2%), headache (1%), increased blood pressure (2%), nausea (1%), and dizziness (1%).",nausea is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('flushing', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('dizziness', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"6 ADVERSE REACTIONS    EXCERPT:   Most commonly reported adverse reactions were flushing (2%), headache (1%), increased blood pressure (2%), nausea (1%), and dizziness (1%).",dizziness is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('flushing', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('dizziness', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  ECG Changes and Potential for Cardiac Arrhythmias: Not recommended in patients with pre-existing cardiac disease, long QT syndrome, and concomitant use of Class IA and Class III antiarrhythmics (  5.2  )             5.1 Drug-Drug Interactions      Eliglustat is a CYP2D6 and CYP3A substrate.",ECG Changes is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('ECG', 'B-ADR'), ('Changes', 'I-ADR'), ('and', 'O'), ('Potential', 'O'), ('for', 'O'), ('Cardiac', 'B-ADR'), ('Arrhythmias', 'I-ADR'), (':', 'O'), ('Not', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('pre-existing', 'O'), ('cardiac', 'O'), ('disease', 'O'), (',', 'O'), ('long', 'O'), ('QT', 'O'), ('syndrome', 'O'), (',', 'O'), ('and', 'O'), ('concomitant', 'O'), ('use', 'O'), ('of', 'O'), ('Class', 'O'), ('IA', 'O'), ('and', 'O'), ('Class', 'O'), ('III', 'O'), ('antiarrhythmics', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('5.1', 'O'), ('Drug-Drug', 'O'), ('Interactions', 'O'), ('Eliglustat', 'O'), ('is', 'O'), ('a', 'O'), ('CYP2D6', 'O'), ('and', 'O'), ('CYP3A', 'O'), ('substrate', 'O'), ('.', 'O')]"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  ECG Changes and Potential for Cardiac Arrhythmias: Not recommended in patients with pre-existing cardiac disease, long QT syndrome, and concomitant use of Class IA and Class III antiarrhythmics (  5.2  )             5.1 Drug-Drug Interactions      Eliglustat is a CYP2D6 and CYP3A substrate.",Cardiac Arrhythmias is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('ECG', 'B-ADR'), ('Changes', 'I-ADR'), ('and', 'O'), ('Potential', 'O'), ('for', 'O'), ('Cardiac', 'B-ADR'), ('Arrhythmias', 'I-ADR'), (':', 'O'), ('Not', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('pre-existing', 'O'), ('cardiac', 'O'), ('disease', 'O'), (',', 'O'), ('long', 'O'), ('QT', 'O'), ('syndrome', 'O'), (',', 'O'), ('and', 'O'), ('concomitant', 'O'), ('use', 'O'), ('of', 'O'), ('Class', 'O'), ('IA', 'O'), ('and', 'O'), ('Class', 'O'), ('III', 'O'), ('antiarrhythmics', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('5.1', 'O'), ('Drug-Drug', 'O'), ('Interactions', 'O'), ('Eliglustat', 'O'), ('is', 'O'), ('a', 'O'), ('CYP2D6', 'O'), ('and', 'O'), ('CYP3A', 'O'), ('substrate', 'O'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",anemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",leukopenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",neutropenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",thrombocytopenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",diarrhea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",fatigue is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",nausea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",vomiting is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",constipation is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",asthenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",abdominal pain is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",hematuria is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",back pain is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",anorexia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",peripheral neuropathy is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",pyrexia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",dyspnea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",dysguesia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",cough is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",arthralgia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
"The most common (>= 10%) grade 1-4 adverse reactions were anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysguesia, cough, arthralgia, and alopecia.",alopecia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('grade', 'O'), ('1-4', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('constipation', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('anorexia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dysguesia', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('alopecia', 'B-ADR'), ('.', 'O')]"
The most common adverse reaction leading to treatment discontinuation in the JEVTANA group was neutropenia (2%).,neutropenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reaction', 'O'), ('leading', 'O'), ('to', 'O'), ('treatment', 'O'), ('discontinuation', 'O'), ('in', 'O'), ('the', 'O'), ('JEVTANA', 'O'), ('group', 'O'), ('was', 'O'), ('neutropenia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"(  4  )(  5.2  )   *  Gastrointestinal disorders: Nausea, vomiting, and diarrhea may occur.",Gastrointestinal disorders is an adverse reaction entity,"[('(', 'O'), ('4', 'O'), (')', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('disorders', 'I-ADR'), (':', 'O'), ('Nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"(  4  )(  5.2  )   *  Gastrointestinal disorders: Nausea, vomiting, and diarrhea may occur.",Nausea is an adverse reaction entity,"[('(', 'O'), ('4', 'O'), (')', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('disorders', 'I-ADR'), (':', 'O'), ('Nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"(  4  )(  5.2  )   *  Gastrointestinal disorders: Nausea, vomiting, and diarrhea may occur.",vomiting is an adverse reaction entity,"[('(', 'O'), ('4', 'O'), (')', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('disorders', 'I-ADR'), (':', 'O'), ('Nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"(  4  )(  5.2  )   *  Gastrointestinal disorders: Nausea, vomiting, and diarrhea may occur.",diarrhea is an adverse reaction entity,"[('(', 'O'), ('4', 'O'), (')', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('disorders', 'I-ADR'), (':', 'O'), ('Nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"5.3 Gastrointestinal Adverse Reactions      Nausea, vomiting and severe diarrhea, at times, may occur.",Nausea is an adverse reaction entity,"[('5.3', 'O'), ('Gastrointestinal', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('Nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), ('and', 'O'), ('severe', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('at', 'O'), ('times', 'O'), (',', 'O'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"5.3 Gastrointestinal Adverse Reactions      Nausea, vomiting and severe diarrhea, at times, may occur.",vomiting is an adverse reaction entity,"[('5.3', 'O'), ('Gastrointestinal', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('Nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), ('and', 'O'), ('severe', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('at', 'O'), ('times', 'O'), (',', 'O'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"5.3 Gastrointestinal Adverse Reactions      Nausea, vomiting and severe diarrhea, at times, may occur.",diarrhea is an adverse reaction entity,"[('5.3', 'O'), ('Gastrointestinal', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('Nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), ('and', 'O'), ('severe', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('at', 'O'), ('times', 'O'), (',', 'O'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"5.5 Use in Elderly Patients      In the randomized clinical trial, 3 of 131 (2%) patients < 65 years of age and 15 of 240 (6%) >= 65 years of age died of causes other than disease progression within 30 days of the last cabazitaxel dose.",died is an adverse reaction entity,"[('5.5', 'O'), ('Use', 'O'), ('in', 'O'), ('Elderly', 'O'), ('Patients', 'O'), ('In', 'O'), ('the', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trial', 'O'), (',', 'O'), ('3', 'O'), ('of', 'O'), ('131', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('<', 'O'), ('65', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('and', 'O'), ('15', 'O'), ('of', 'O'), ('240', 'O'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('>', 'O'), ('=', 'O'), ('65', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('died', 'B-ADR'), ('of', 'O'), ('causes', 'O'), ('other', 'O'), ('than', 'O'), ('disease', 'O'), ('progression', 'O'), ('within', 'O'), ('30', 'O'), ('days', 'O'), ('of', 'O'), ('the', 'O'), ('last', 'O'), ('cabazitaxel', 'O'), ('dose', 'O'), ('.', 'O')]"
(  5.2  )   *  Direct Coombs' test seroconversion has been reported with Teflaro.,Direct Coombs' test seroconversion is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Direct', 'B-ADR'), ('Coombs', 'I-ADR'), (""'"", 'I-ADR'), ('test', 'I-ADR'), ('seroconversion', 'I-ADR'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('Teflaro', 'O'), ('.', 'O')]"
Long-term cumulative radiation exposure is associated with an increased risk for cancer.,cancer is an adverse reaction entity,"[('Long-term', 'O'), ('cumulative', 'O'), ('radiation', 'O'), ('exposure', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('for', 'O'), ('cancer', 'B-ADR'), ('.', 'O')]"
Bleeding events were counted during treatment or within 2 days of stopping study treatment (on-treatment period).,Bleeding is an adverse reaction entity,"[('Bleeding', 'B-ADR'), ('events', 'O'), ('were', 'O'), ('counted', 'O'), ('during', 'O'), ('treatment', 'O'), ('or', 'O'), ('within', 'O'), ('2', 'O'), ('days', 'O'), ('of', 'O'), ('stopping', 'O'), ('study', 'O'), ('treatment', 'O'), ('(', 'O'), ('on-treatment', 'O'), ('period', 'O'), (')', 'O'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",gingival bleeding is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",epistaxis is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",contusion is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",hematuria is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",rectal hemorrhage is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",hematoma is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",menorrhagia is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
"Common adverse reactions (>=1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.",hemoptysis is an adverse reaction entity,"[('Common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('gingival', 'B-ADR'), ('bleeding', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('contusion', 'B-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('rectal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), (',', 'O'), ('menorrhagia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('hemoptysis', 'B-ADR'), ('.', 'O')]"
Adverse reactions related to bleeding occurred in 417 (15.6%) ELIQUIS-treated patients compared to 661 (24.6%) enoxaparin/warfarin-treated patients.,bleeding is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('related', 'O'), ('to', 'O'), ('bleeding', 'B-ADR'), ('occurred', 'O'), ('in', 'O'), ('417', 'O'), ('(', 'O'), ('15.6', 'O'), ('%', 'O'), (')', 'O'), ('ELIQUIS-treated', 'O'), ('patients', 'O'), ('compared', 'O'), ('to', 'O'), ('661', 'O'), ('(', 'O'), ('24.6', 'O'), ('%', 'O'), (')', 'O'), ('enoxaparin/warfarin-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"(2.4    , 5.1,     14.1)         (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture.",Epidural hematomas is an adverse reaction entity,"[('(', 'O'), ('2.4', 'O'), (',', 'O'), ('5.1', 'O'), (',', 'O'), ('14.1', 'O'), (')', 'O'), ('(', 'O'), ('B', 'O'), (')', 'O'), ('SPINAL/EPIDURAL', 'O'), ('HEMATOMA', 'O'), (':', 'O'), ('Epidural', 'B-ADR'), ('or', 'O'), ('spinal', 'B-ADR'), ('hematomas', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('ELIQUIS', 'O'), ('who', 'O'), ('are', 'O'), ('receiving', 'O'), ('neuraxial', 'O'), ('anesthesia', 'O'), ('or', 'O'), ('undergoing', 'O'), ('spinal', 'O'), ('puncture', 'O'), ('.', 'O')]"
"(2.4    , 5.1,     14.1)         (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture.",spinal hematomas is an adverse reaction entity,"[('(', 'O'), ('2.4', 'O'), (',', 'O'), ('5.1', 'O'), (',', 'O'), ('14.1', 'O'), (')', 'O'), ('(', 'O'), ('B', 'O'), (')', 'O'), ('SPINAL/EPIDURAL', 'O'), ('HEMATOMA', 'O'), (':', 'O'), ('Epidural', 'B-ADR'), ('or', 'O'), ('spinal', 'B-ADR'), ('hematomas', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('ELIQUIS', 'O'), ('who', 'O'), ('are', 'O'), ('receiving', 'O'), ('neuraxial', 'O'), ('anesthesia', 'O'), ('or', 'O'), ('undergoing', 'O'), ('spinal', 'O'), ('puncture', 'O'), ('.', 'O')]"
"Immune System Disorders       Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria.",Hypersensitivity reactions is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('including', 'O'), ('anaphylaxis', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('urticaria', 'B-ADR'), ('.', 'O')]"
"Immune System Disorders       Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria.",anaphylaxis is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('including', 'O'), ('anaphylaxis', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('urticaria', 'B-ADR'), ('.', 'O')]"
"Immune System Disorders       Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria.",angioedema is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('including', 'O'), ('anaphylaxis', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('urticaria', 'B-ADR'), ('.', 'O')]"
"Immune System Disorders       Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria.",rash is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('including', 'O'), ('anaphylaxis', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('urticaria', 'B-ADR'), ('.', 'O')]"
"Immune System Disorders       Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria.",urticaria is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('including', 'O'), ('anaphylaxis', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('urticaria', 'B-ADR'), ('.', 'O')]"
(  5.3  )   *     Candida albicans infection of the mouth and pharynx may occur.,Candida albicans infection of the mouth is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Candida', 'B-ADR'), ('albicans', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('mouth', 'I-ADR'), ('and', 'O'), ('pharynx', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
(  5.3  )   *     Candida albicans infection of the mouth and pharynx may occur.,Candida albicans infection of the pharynx is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Candida', 'B-ADR'), ('albicans', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('mouth', 'I-ADR'), ('and', 'O'), ('pharynx', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.,death is an adverse reaction entity,"[('Currently', 'O'), ('available', 'O'), ('data', 'O'), ('are', 'O'), ('inadequate', 'O'), ('to', 'O'), ('determine', 'O'), ('whether', 'O'), ('concurrent', 'O'), ('use', 'O'), ('of', 'O'), ('inhaled', 'O'), ('corticosteroids', 'O'), ('or', 'O'), ('other', 'O'), ('long-term', 'O'), ('asthma', 'O'), ('control', 'O'), ('drugs', 'O'), ('mitigates', 'O'), ('the', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('asthma-related', 'O'), ('death', 'B-ADR'), ('from', 'O'), ('LABA', 'O'), ('.', 'O')]"
5.5 Pneumonia      An increase in the incidence of pneumonia has been observed in subjects with COPD receiving BREO ELLIPTA 100/25 in clinical trials.,pneumonia is an adverse reaction entity,"[('5.5', 'O'), ('Pneumonia', 'O'), ('An', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('pneumonia', 'B-ADR'), ('has', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('subjects', 'O'), ('with', 'O'), ('COPD', 'O'), ('receiving', 'O'), ('BREO', 'O'), ('ELLIPTA', 'O'), ('100/25', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('.', 'O')]"
There was fatal pneumonia in 1 subject receiving BREO ELLIPTA 100/25 and in 7 subjects receiving BREO ELLIPTA 200/25 (less than 1% for each treatment group).,fatal is an adverse reaction entity,"[('There', 'O'), ('was', 'O'), ('fatal', 'B-ADR'), ('pneumonia', 'B-ADR'), ('in', 'O'), ('1', 'O'), ('subject', 'O'), ('receiving', 'O'), ('BREO', 'O'), ('ELLIPTA', 'O'), ('100/25', 'O'), ('and', 'O'), ('in', 'O'), ('7', 'O'), ('subjects', 'O'), ('receiving', 'O'), ('BREO', 'O'), ('ELLIPTA', 'O'), ('200/25', 'O'), ('(', 'O'), ('less', 'O'), ('than', 'O'), ('1', 'O'), ('%', 'O'), ('for', 'O'), ('each', 'O'), ('treatment', 'O'), ('group', 'O'), (')', 'O'), ('.', 'O')]"
There was fatal pneumonia in 1 subject receiving BREO ELLIPTA 100/25 and in 7 subjects receiving BREO ELLIPTA 200/25 (less than 1% for each treatment group).,pneumonia is an adverse reaction entity,"[('There', 'O'), ('was', 'O'), ('fatal', 'B-ADR'), ('pneumonia', 'B-ADR'), ('in', 'O'), ('1', 'O'), ('subject', 'O'), ('receiving', 'O'), ('BREO', 'O'), ('ELLIPTA', 'O'), ('100/25', 'O'), ('and', 'O'), ('in', 'O'), ('7', 'O'), ('subjects', 'O'), ('receiving', 'O'), ('BREO', 'O'), ('ELLIPTA', 'O'), ('200/25', 'O'), ('(', 'O'), ('less', 'O'), ('than', 'O'), ('1', 'O'), ('%', 'O'), ('for', 'O'), ('each', 'O'), ('treatment', 'O'), ('group', 'O'), (')', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",Hematologic Toxicity is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",Infection is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",Hepatotoxicity is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",Tumor Lysis Syndrome is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",Gastrointestinal Toxicity is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",nausea is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",fatigue is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",pyrexia is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",anemia is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"*    Hematologic Toxicity  [see Warnings and Precautions (   5.1  )]    *    Infection [see Warnings and Precautions (  5.2  )]    *    Hepatotoxicity [see Warnings and Precautions (  5.3  )]    *    Tumor Lysis Syndrome [see Warnings and Precautions (  5.4  )]    *    Gastrointestinal Toxicity [see Warnings and Precautions (  5.5  )]       The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting  [see Clinical Studies  (    14    )  ]  .",vomiting is an adverse reaction entity,"[('*', 'O'), ('Hematologic', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Infection', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hepatotoxicity', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Tumor', 'B-ADR'), ('Lysis', 'I-ADR'), ('Syndrome', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('Toxicity', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.5', 'O'), (')', 'O'), (']', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('relapsed', 'O'), ('or', 'O'), ('refractory', 'O'), ('PTCL', 'O'), ('treated', 'O'), ('with', 'O'), ('Beleodaq', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.",pneumonia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('multi-organ', 'B-ADR'), ('failure', 'I-ADR'), ('.', 'O')]"
"The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.",pyrexia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('multi-organ', 'B-ADR'), ('failure', 'I-ADR'), ('.', 'O')]"
"The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.",infection is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('multi-organ', 'B-ADR'), ('failure', 'I-ADR'), ('.', 'O')]"
"The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.",anemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('multi-organ', 'B-ADR'), ('failure', 'I-ADR'), ('.', 'O')]"
"The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.",increased creatinine is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('multi-organ', 'B-ADR'), ('failure', 'I-ADR'), ('.', 'O')]"
"The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.",thrombocytopenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('multi-organ', 'B-ADR'), ('failure', 'I-ADR'), ('.', 'O')]"
"The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.",multi-organ failure is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('multi-organ', 'B-ADR'), ('failure', 'I-ADR'), ('.', 'O')]"
5.6 Pulmonary Toxicity      Cases of interstitial lung disease including pneumonitis and pulmonary fibrosis have been reported in patients treated with MULTAQ in the post-marketing setting [see  Adverse Reactions (6.2)  ]  .,interstitial lung disease is an adverse reaction entity,"[('5.6', 'O'), ('Pulmonary', 'O'), ('Toxicity', 'O'), ('Cases', 'O'), ('of', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), ('and', 'O'), ('pulmonary', 'B-ADR'), ('fibrosis', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('MULTAQ', 'O'), ('in', 'O'), ('the', 'O'), ('post-marketing', 'O'), ('setting', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
5.6 Pulmonary Toxicity      Cases of interstitial lung disease including pneumonitis and pulmonary fibrosis have been reported in patients treated with MULTAQ in the post-marketing setting [see  Adverse Reactions (6.2)  ]  .,pneumonitis is an adverse reaction entity,"[('5.6', 'O'), ('Pulmonary', 'O'), ('Toxicity', 'O'), ('Cases', 'O'), ('of', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), ('and', 'O'), ('pulmonary', 'B-ADR'), ('fibrosis', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('MULTAQ', 'O'), ('in', 'O'), ('the', 'O'), ('post-marketing', 'O'), ('setting', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
5.6 Pulmonary Toxicity      Cases of interstitial lung disease including pneumonitis and pulmonary fibrosis have been reported in patients treated with MULTAQ in the post-marketing setting [see  Adverse Reactions (6.2)  ]  .,pulmonary fibrosis is an adverse reaction entity,"[('5.6', 'O'), ('Pulmonary', 'O'), ('Toxicity', 'O'), ('Cases', 'O'), ('of', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), ('and', 'O'), ('pulmonary', 'B-ADR'), ('fibrosis', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('MULTAQ', 'O'), ('in', 'O'), ('the', 'O'), ('post-marketing', 'O'), ('setting', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
Small increases in creatinine levels (about 0.1 mg/dL) following dronedarone treatment initiation have been shown to be a result of inhibition of creatinine's tubular secretion.,increases in creatinine levels is an adverse reaction entity,"[('Small', 'O'), ('increases', 'B-ADR'), ('in', 'I-ADR'), ('creatinine', 'I-ADR'), ('levels', 'I-ADR'), ('(', 'O'), ('about', 'O'), ('0.1', 'O'), ('mg/dL', 'O'), (')', 'O'), ('following', 'O'), ('dronedarone', 'O'), ('treatment', 'O'), ('initiation', 'O'), ('have', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('inhibition', 'O'), ('of', 'O'), ('creatinine', 'O'), (""'s"", 'O'), ('tubular', 'O'), ('secretion', 'O'), ('.', 'O')]"
"EXCERPT:   The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",nausea is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('DALVANCE', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('5.5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('4.7', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('(', 'O'), ('4.4', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"EXCERPT:   The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",headache is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('DALVANCE', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('5.5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('4.7', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('(', 'O'), ('4.4', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"EXCERPT:   The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",diarrhea is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('DALVANCE', 'O'), ('were', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('5.5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('headache', 'B-ADR'), ('(', 'O'), ('4.7', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('(', 'O'), ('4.4', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"However, the incidence of nonfatal serious infections was 3.3% in the placebo and 4.0% in the Prolia groups.",infections is an adverse reaction entity,"[('However', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('nonfatal', 'O'), ('serious', 'O'), ('infections', 'B-ADR'), ('was', 'O'), ('3.3', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('and', 'O'), ('4.0', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('Prolia', 'O'), ('groups', 'O'), ('.', 'O')]"
"Atypical Subtrochanteric and Diaphyseal Fractures  In the osteoporosis clinical trial program, atypical femoral fractures were reported in patients treated with Prolia.",atypical femoral fractures is an adverse reaction entity,"[('Atypical', 'O'), ('Subtrochanteric', 'O'), ('and', 'O'), ('Diaphyseal', 'O'), ('Fractures', 'O'), ('In', 'O'), ('the', 'O'), ('osteoporosis', 'O'), ('clinical', 'O'), ('trial', 'O'), ('program', 'O'), (',', 'O'), ('atypical', 'B-ADR'), ('femoral', 'I-ADR'), ('fractures', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('Prolia', 'O'), ('.', 'O')]"
Pancreatitis  Pancreatitis was reported in 1 patient (0.8%) in the placebo group and 1 patient (0.8%) in the Prolia group.,Pancreatitis is an adverse reaction entity,"[('Pancreatitis', 'O'), ('Pancreatitis', 'B-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('1', 'O'), ('patient', 'O'), ('(', 'O'), ('0.8', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('and', 'O'), ('1', 'O'), ('patient', 'O'), ('(', 'O'), ('0.8', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('Prolia', 'O'), ('group', 'O'), ('.', 'O')]"
"Adverse reactions reported in >= 10% of Prolia-treated patients receiving ADT for prostate cancer or adjuvant AI therapy for breast cancer, and more frequently than in the placebo-treated patients were: arthralgia (13.0% placebo vs. 14.3% Prolia) and back pain (10.5% placebo vs. 11.5% Prolia).",arthralgia is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('reported', 'O'), ('in', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('Prolia-treated', 'O'), ('patients', 'O'), ('receiving', 'O'), ('ADT', 'O'), ('for', 'O'), ('prostate', 'O'), ('cancer', 'O'), ('or', 'O'), ('adjuvant', 'O'), ('AI', 'O'), ('therapy', 'O'), ('for', 'O'), ('breast', 'O'), ('cancer', 'O'), (',', 'O'), ('and', 'O'), ('more', 'O'), ('frequently', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('were', 'O'), (':', 'O'), ('arthralgia', 'B-ADR'), ('(', 'O'), ('13.0', 'O'), ('%', 'O'), ('placebo', 'O'), ('vs.', 'O'), ('14.3', 'O'), ('%', 'O'), ('Prolia', 'O'), (')', 'O'), ('and', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), ('(', 'O'), ('10.5', 'O'), ('%', 'O'), ('placebo', 'O'), ('vs.', 'O'), ('11.5', 'O'), ('%', 'O'), ('Prolia', 'O'), (')', 'O'), ('.', 'O')]"
"Adverse reactions reported in >= 10% of Prolia-treated patients receiving ADT for prostate cancer or adjuvant AI therapy for breast cancer, and more frequently than in the placebo-treated patients were: arthralgia (13.0% placebo vs. 14.3% Prolia) and back pain (10.5% placebo vs. 11.5% Prolia).",back pain is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('reported', 'O'), ('in', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('Prolia-treated', 'O'), ('patients', 'O'), ('receiving', 'O'), ('ADT', 'O'), ('for', 'O'), ('prostate', 'O'), ('cancer', 'O'), ('or', 'O'), ('adjuvant', 'O'), ('AI', 'O'), ('therapy', 'O'), ('for', 'O'), ('breast', 'O'), ('cancer', 'O'), (',', 'O'), ('and', 'O'), ('more', 'O'), ('frequently', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('were', 'O'), (':', 'O'), ('arthralgia', 'B-ADR'), ('(', 'O'), ('13.0', 'O'), ('%', 'O'), ('placebo', 'O'), ('vs.', 'O'), ('14.3', 'O'), ('%', 'O'), ('Prolia', 'O'), (')', 'O'), ('and', 'O'), ('back', 'B-ADR'), ('pain', 'I-ADR'), ('(', 'O'), ('10.5', 'O'), ('%', 'O'), ('placebo', 'O'), ('vs.', 'O'), ('11.5', 'O'), ('%', 'O'), ('Prolia', 'O'), (')', 'O'), ('.', 'O')]"
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Same Active Ingredient: Patients receiving Prolia should not receive XGEVA  (r)  (  5.1  )   *  Hypersensitivity including anaphylactic reactions may occur.,Hypersensitivity is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Same', 'O'), ('Active', 'O'), ('Ingredient', 'O'), (':', 'O'), ('Patients', 'O'), ('receiving', 'O'), ('Prolia', 'O'), ('should', 'O'), ('not', 'O'), ('receive', 'O'), ('XGEVA', 'O'), ('(', 'O'), ('r', 'O'), (')', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('including', 'O'), ('anaphylactic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Same Active Ingredient: Patients receiving Prolia should not receive XGEVA  (r)  (  5.1  )   *  Hypersensitivity including anaphylactic reactions may occur.,anaphylactic reactions is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Same', 'O'), ('Active', 'O'), ('Ingredient', 'O'), (':', 'O'), ('Patients', 'O'), ('receiving', 'O'), ('Prolia', 'O'), ('should', 'O'), ('not', 'O'), ('receive', 'O'), ('XGEVA', 'O'), ('(', 'O'), ('r', 'O'), (')', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('including', 'O'), ('anaphylactic', 'B-ADR'), ('reactions', 'I-ADR'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution.,fractures in the femoral shaft is an adverse reaction entity,"[('These', 'O'), ('fractures', 'B-ADR'), ('can', 'O'), ('occur', 'O'), ('anywhere', 'O'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('femoral', 'I-ADR'), ('shaft', 'I-ADR'), ('from', 'O'), ('just', 'O'), ('below', 'O'), ('the', 'O'), ('lesser', 'O'), ('trochanter', 'O'), ('to', 'O'), ('above', 'O'), ('the', 'O'), ('supracondylar', 'O'), ('flare', 'O'), ('and', 'O'), ('are', 'O'), ('transverse', 'O'), ('or', 'O'), ('short', 'O'), ('oblique', 'O'), ('in', 'O'), ('orientation', 'O'), ('without', 'O'), ('evidence', 'O'), ('of', 'O'), ('comminution', 'O'), ('.', 'O')]"
"Non-hematologic adverse reactions (any grade) in the TREANDA group that occurred with a frequency greater than 15% were pyrexia (24%), nausea (20%), and vomiting (16%).",pyrexia is an adverse reaction entity,"[('Non-hematologic', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('any', 'O'), ('grade', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('TREANDA', 'O'), ('group', 'O'), ('that', 'O'), ('occurred', 'O'), ('with', 'O'), ('a', 'O'), ('frequency', 'O'), ('greater', 'O'), ('than', 'O'), ('15', 'O'), ('%', 'O'), ('were', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('24', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('(', 'O'), ('16', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Non-hematologic adverse reactions (any grade) in the TREANDA group that occurred with a frequency greater than 15% were pyrexia (24%), nausea (20%), and vomiting (16%).",nausea is an adverse reaction entity,"[('Non-hematologic', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('any', 'O'), ('grade', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('TREANDA', 'O'), ('group', 'O'), ('that', 'O'), ('occurred', 'O'), ('with', 'O'), ('a', 'O'), ('frequency', 'O'), ('greater', 'O'), ('than', 'O'), ('15', 'O'), ('%', 'O'), ('were', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('24', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('(', 'O'), ('16', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Non-hematologic adverse reactions (any grade) in the TREANDA group that occurred with a frequency greater than 15% were pyrexia (24%), nausea (20%), and vomiting (16%).",vomiting is an adverse reaction entity,"[('Non-hematologic', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('any', 'O'), ('grade', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('TREANDA', 'O'), ('group', 'O'), ('that', 'O'), ('occurred', 'O'), ('with', 'O'), ('a', 'O'), ('frequency', 'O'), ('greater', 'O'), ('than', 'O'), ('15', 'O'), ('%', 'O'), ('were', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('24', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), ('(', 'O'), ('16', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Clinically important chemistry laboratory values that were new or worsened from baseline and occurred in >1% of patients at Grade 3 or 4,  in NHL patients treated in both single arm studies combined were hyperglycemia (3%), elevated creatinine (2%), hyponatremia (2%), and hypocalcemia (2%).",hyperglycemia is an adverse reaction entity,"[('Clinically', 'O'), ('important', 'O'), ('chemistry', 'O'), ('laboratory', 'O'), ('values', 'O'), ('that', 'O'), ('were', 'O'), ('new', 'O'), ('or', 'O'), ('worsened', 'O'), ('from', 'O'), ('baseline', 'O'), ('and', 'O'), ('occurred', 'O'), ('in', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('at', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), (',', 'O'), ('in', 'O'), ('NHL', 'O'), ('patients', 'O'), ('treated', 'O'), ('in', 'O'), ('both', 'O'), ('single', 'O'), ('arm', 'O'), ('studies', 'O'), ('combined', 'O'), ('were', 'O'), ('hyperglycemia', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('elevated', 'B-ADR'), ('creatinine', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hyponatremia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('hypocalcemia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Clinically important chemistry laboratory values that were new or worsened from baseline and occurred in >1% of patients at Grade 3 or 4,  in NHL patients treated in both single arm studies combined were hyperglycemia (3%), elevated creatinine (2%), hyponatremia (2%), and hypocalcemia (2%).",elevated creatinine is an adverse reaction entity,"[('Clinically', 'O'), ('important', 'O'), ('chemistry', 'O'), ('laboratory', 'O'), ('values', 'O'), ('that', 'O'), ('were', 'O'), ('new', 'O'), ('or', 'O'), ('worsened', 'O'), ('from', 'O'), ('baseline', 'O'), ('and', 'O'), ('occurred', 'O'), ('in', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('at', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), (',', 'O'), ('in', 'O'), ('NHL', 'O'), ('patients', 'O'), ('treated', 'O'), ('in', 'O'), ('both', 'O'), ('single', 'O'), ('arm', 'O'), ('studies', 'O'), ('combined', 'O'), ('were', 'O'), ('hyperglycemia', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('elevated', 'B-ADR'), ('creatinine', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hyponatremia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('hypocalcemia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Clinically important chemistry laboratory values that were new or worsened from baseline and occurred in >1% of patients at Grade 3 or 4,  in NHL patients treated in both single arm studies combined were hyperglycemia (3%), elevated creatinine (2%), hyponatremia (2%), and hypocalcemia (2%).",hyponatremia is an adverse reaction entity,"[('Clinically', 'O'), ('important', 'O'), ('chemistry', 'O'), ('laboratory', 'O'), ('values', 'O'), ('that', 'O'), ('were', 'O'), ('new', 'O'), ('or', 'O'), ('worsened', 'O'), ('from', 'O'), ('baseline', 'O'), ('and', 'O'), ('occurred', 'O'), ('in', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('at', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), (',', 'O'), ('in', 'O'), ('NHL', 'O'), ('patients', 'O'), ('treated', 'O'), ('in', 'O'), ('both', 'O'), ('single', 'O'), ('arm', 'O'), ('studies', 'O'), ('combined', 'O'), ('were', 'O'), ('hyperglycemia', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('elevated', 'B-ADR'), ('creatinine', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hyponatremia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('hypocalcemia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Clinically important chemistry laboratory values that were new or worsened from baseline and occurred in >1% of patients at Grade 3 or 4,  in NHL patients treated in both single arm studies combined were hyperglycemia (3%), elevated creatinine (2%), hyponatremia (2%), and hypocalcemia (2%).",hypocalcemia is an adverse reaction entity,"[('Clinically', 'O'), ('important', 'O'), ('chemistry', 'O'), ('laboratory', 'O'), ('values', 'O'), ('that', 'O'), ('were', 'O'), ('new', 'O'), ('or', 'O'), ('worsened', 'O'), ('from', 'O'), ('baseline', 'O'), ('and', 'O'), ('occurred', 'O'), ('in', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('at', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), (',', 'O'), ('in', 'O'), ('NHL', 'O'), ('patients', 'O'), ('treated', 'O'), ('in', 'O'), ('both', 'O'), ('single', 'O'), ('arm', 'O'), ('studies', 'O'), ('combined', 'O'), ('were', 'O'), ('hyperglycemia', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('elevated', 'B-ADR'), ('creatinine', 'I-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hyponatremia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('hypocalcemia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Serious drug-related adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion reactions  [see  Warnings and Precautions  (  5  )]  .",myelosuppression is an adverse reaction entity,"[('Serious', 'O'), ('drug-related', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('reported', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('included', 'O'), ('myelosuppression', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('tumor', 'B-ADR'), ('lysis', 'I-ADR'), ('syndrome', 'I-ADR'), ('and', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Serious drug-related adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion reactions  [see  Warnings and Precautions  (  5  )]  .",infection is an adverse reaction entity,"[('Serious', 'O'), ('drug-related', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('reported', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('included', 'O'), ('myelosuppression', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('tumor', 'B-ADR'), ('lysis', 'I-ADR'), ('syndrome', 'I-ADR'), ('and', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Serious drug-related adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion reactions  [see  Warnings and Precautions  (  5  )]  .",pneumonia is an adverse reaction entity,"[('Serious', 'O'), ('drug-related', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('reported', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('included', 'O'), ('myelosuppression', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('tumor', 'B-ADR'), ('lysis', 'I-ADR'), ('syndrome', 'I-ADR'), ('and', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Serious drug-related adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion reactions  [see  Warnings and Precautions  (  5  )]  .",tumor lysis syndrome is an adverse reaction entity,"[('Serious', 'O'), ('drug-related', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('reported', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('included', 'O'), ('myelosuppression', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('tumor', 'B-ADR'), ('lysis', 'I-ADR'), ('syndrome', 'I-ADR'), ('and', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Serious drug-related adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion reactions  [see  Warnings and Precautions  (  5  )]  .",infusion reactions is an adverse reaction entity,"[('Serious', 'O'), ('drug-related', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('reported', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('included', 'O'), ('myelosuppression', 'B-ADR'), (',', 'O'), ('infection', 'B-ADR'), (',', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('tumor', 'B-ADR'), ('lysis', 'I-ADR'), ('syndrome', 'I-ADR'), ('and', 'O'), ('infusion', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"5.5  Skin Reactions      Skin reactions have been reported with TREANDA treatment in clinical trials and postmarketing safety reports, including rash, toxic skin reactions and bullous exanthema.",Skin reactions is an adverse reaction entity,"[('5.5', 'O'), ('Skin', 'O'), ('Reactions', 'O'), ('Skin', 'B-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('TREANDA', 'O'), ('treatment', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('and', 'O'), ('postmarketing', 'O'), ('safety', 'O'), ('reports', 'O'), (',', 'O'), ('including', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), ('and', 'O'), ('bullous', 'B-ADR'), ('exanthema', 'I-ADR'), ('.', 'O')]"
"5.5  Skin Reactions      Skin reactions have been reported with TREANDA treatment in clinical trials and postmarketing safety reports, including rash, toxic skin reactions and bullous exanthema.",rash is an adverse reaction entity,"[('5.5', 'O'), ('Skin', 'O'), ('Reactions', 'O'), ('Skin', 'B-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('TREANDA', 'O'), ('treatment', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('and', 'O'), ('postmarketing', 'O'), ('safety', 'O'), ('reports', 'O'), (',', 'O'), ('including', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), ('and', 'O'), ('bullous', 'B-ADR'), ('exanthema', 'I-ADR'), ('.', 'O')]"
"5.5  Skin Reactions      Skin reactions have been reported with TREANDA treatment in clinical trials and postmarketing safety reports, including rash, toxic skin reactions and bullous exanthema.",toxic skin reactions is an adverse reaction entity,"[('5.5', 'O'), ('Skin', 'O'), ('Reactions', 'O'), ('Skin', 'B-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('TREANDA', 'O'), ('treatment', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('and', 'O'), ('postmarketing', 'O'), ('safety', 'O'), ('reports', 'O'), (',', 'O'), ('including', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), ('and', 'O'), ('bullous', 'B-ADR'), ('exanthema', 'I-ADR'), ('.', 'O')]"
"5.5  Skin Reactions      Skin reactions have been reported with TREANDA treatment in clinical trials and postmarketing safety reports, including rash, toxic skin reactions and bullous exanthema.",bullous exanthema is an adverse reaction entity,"[('5.5', 'O'), ('Skin', 'O'), ('Reactions', 'O'), ('Skin', 'B-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('TREANDA', 'O'), ('treatment', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('and', 'O'), ('postmarketing', 'O'), ('safety', 'O'), ('reports', 'O'), (',', 'O'), ('including', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), ('and', 'O'), ('bullous', 'B-ADR'), ('exanthema', 'I-ADR'), ('.', 'O')]"
"5.6  Other Malignancies      There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with TREANDA, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma.",pre-malignant diseases is an adverse reaction entity,"[('5.6', 'O'), ('Other', 'O'), ('Malignancies', 'O'), ('There', 'O'), ('are', 'O'), ('reports', 'O'), ('of', 'O'), ('pre-malignant', 'B-ADR'), ('and', 'O'), ('malignant', 'B-ADR'), ('diseases', 'I-ADR'), ('that', 'O'), ('have', 'O'), ('developed', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('TREANDA', 'O'), (',', 'O'), ('including', 'O'), ('myelodysplastic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('myeloproliferative', 'B-ADR'), ('disorders', 'I-ADR'), (',', 'O'), ('acute', 'B-ADR'), ('myeloid', 'I-ADR'), ('leukemia', 'I-ADR'), ('and', 'O'), ('bronchial', 'B-ADR'), ('carcinoma', 'I-ADR'), ('.', 'O')]"
"5.6  Other Malignancies      There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with TREANDA, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma.",malignant diseases is an adverse reaction entity,"[('5.6', 'O'), ('Other', 'O'), ('Malignancies', 'O'), ('There', 'O'), ('are', 'O'), ('reports', 'O'), ('of', 'O'), ('pre-malignant', 'B-ADR'), ('and', 'O'), ('malignant', 'B-ADR'), ('diseases', 'I-ADR'), ('that', 'O'), ('have', 'O'), ('developed', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('TREANDA', 'O'), (',', 'O'), ('including', 'O'), ('myelodysplastic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('myeloproliferative', 'B-ADR'), ('disorders', 'I-ADR'), (',', 'O'), ('acute', 'B-ADR'), ('myeloid', 'I-ADR'), ('leukemia', 'I-ADR'), ('and', 'O'), ('bronchial', 'B-ADR'), ('carcinoma', 'I-ADR'), ('.', 'O')]"
"5.6  Other Malignancies      There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with TREANDA, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma.",myelodysplastic syndrome is an adverse reaction entity,"[('5.6', 'O'), ('Other', 'O'), ('Malignancies', 'O'), ('There', 'O'), ('are', 'O'), ('reports', 'O'), ('of', 'O'), ('pre-malignant', 'B-ADR'), ('and', 'O'), ('malignant', 'B-ADR'), ('diseases', 'I-ADR'), ('that', 'O'), ('have', 'O'), ('developed', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('TREANDA', 'O'), (',', 'O'), ('including', 'O'), ('myelodysplastic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('myeloproliferative', 'B-ADR'), ('disorders', 'I-ADR'), (',', 'O'), ('acute', 'B-ADR'), ('myeloid', 'I-ADR'), ('leukemia', 'I-ADR'), ('and', 'O'), ('bronchial', 'B-ADR'), ('carcinoma', 'I-ADR'), ('.', 'O')]"
"5.6  Other Malignancies      There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with TREANDA, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma.",myeloproliferative disorders is an adverse reaction entity,"[('5.6', 'O'), ('Other', 'O'), ('Malignancies', 'O'), ('There', 'O'), ('are', 'O'), ('reports', 'O'), ('of', 'O'), ('pre-malignant', 'B-ADR'), ('and', 'O'), ('malignant', 'B-ADR'), ('diseases', 'I-ADR'), ('that', 'O'), ('have', 'O'), ('developed', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('TREANDA', 'O'), (',', 'O'), ('including', 'O'), ('myelodysplastic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('myeloproliferative', 'B-ADR'), ('disorders', 'I-ADR'), (',', 'O'), ('acute', 'B-ADR'), ('myeloid', 'I-ADR'), ('leukemia', 'I-ADR'), ('and', 'O'), ('bronchial', 'B-ADR'), ('carcinoma', 'I-ADR'), ('.', 'O')]"
"5.6  Other Malignancies      There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with TREANDA, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma.",acute myeloid leukemia is an adverse reaction entity,"[('5.6', 'O'), ('Other', 'O'), ('Malignancies', 'O'), ('There', 'O'), ('are', 'O'), ('reports', 'O'), ('of', 'O'), ('pre-malignant', 'B-ADR'), ('and', 'O'), ('malignant', 'B-ADR'), ('diseases', 'I-ADR'), ('that', 'O'), ('have', 'O'), ('developed', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('TREANDA', 'O'), (',', 'O'), ('including', 'O'), ('myelodysplastic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('myeloproliferative', 'B-ADR'), ('disorders', 'I-ADR'), (',', 'O'), ('acute', 'B-ADR'), ('myeloid', 'I-ADR'), ('leukemia', 'I-ADR'), ('and', 'O'), ('bronchial', 'B-ADR'), ('carcinoma', 'I-ADR'), ('.', 'O')]"
"5.6  Other Malignancies      There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with TREANDA, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia and bronchial carcinoma.",bronchial carcinoma is an adverse reaction entity,"[('5.6', 'O'), ('Other', 'O'), ('Malignancies', 'O'), ('There', 'O'), ('are', 'O'), ('reports', 'O'), ('of', 'O'), ('pre-malignant', 'B-ADR'), ('and', 'O'), ('malignant', 'B-ADR'), ('diseases', 'I-ADR'), ('that', 'O'), ('have', 'O'), ('developed', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('TREANDA', 'O'), (',', 'O'), ('including', 'O'), ('myelodysplastic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('myeloproliferative', 'B-ADR'), ('disorders', 'I-ADR'), (',', 'O'), ('acute', 'B-ADR'), ('myeloid', 'I-ADR'), ('leukemia', 'I-ADR'), ('and', 'O'), ('bronchial', 'B-ADR'), ('carcinoma', 'I-ADR'), ('.', 'O')]"
Table 2 Adverse Reactions with a Frequency >=0.5% Reported in Clinical Trials (n = 978 Administrations in 872 Subjects)     Adverse drug reaction      n (%)                       Injection / application site erythema  17 (1.7)                      Injection site irritation  12 (1.2)                      Injection site pain        38 (3.9),Injection site erythema is an adverse reaction entity,"[('Table', 'O'), ('2', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('with', 'O'), ('a', 'O'), ('Frequency', 'O'), ('>', 'O'), ('=0.5', 'O'), ('%', 'O'), ('Reported', 'O'), ('in', 'O'), ('Clinical', 'O'), ('Trials', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('978', 'O'), ('Administrations', 'O'), ('in', 'O'), ('872', 'O'), ('Subjects', 'O'), (')', 'O'), ('Adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('n', 'O'), ('(', 'O'), ('%', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('/', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('17', 'O'), ('(', 'O'), ('1.7', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), ('12', 'O'), ('(', 'O'), ('1.2', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), ('38', 'O'), ('(', 'O'), ('3.9', 'O'), (')', 'O')]"
Table 2 Adverse Reactions with a Frequency >=0.5% Reported in Clinical Trials (n = 978 Administrations in 872 Subjects)     Adverse drug reaction      n (%)                       Injection / application site erythema  17 (1.7)                      Injection site irritation  12 (1.2)                      Injection site pain        38 (3.9),application site erythema is an adverse reaction entity,"[('Table', 'O'), ('2', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('with', 'O'), ('a', 'O'), ('Frequency', 'O'), ('>', 'O'), ('=0.5', 'O'), ('%', 'O'), ('Reported', 'O'), ('in', 'O'), ('Clinical', 'O'), ('Trials', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('978', 'O'), ('Administrations', 'O'), ('in', 'O'), ('872', 'O'), ('Subjects', 'O'), (')', 'O'), ('Adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('n', 'O'), ('(', 'O'), ('%', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('/', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('17', 'O'), ('(', 'O'), ('1.7', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), ('12', 'O'), ('(', 'O'), ('1.2', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), ('38', 'O'), ('(', 'O'), ('3.9', 'O'), (')', 'O')]"
Table 2 Adverse Reactions with a Frequency >=0.5% Reported in Clinical Trials (n = 978 Administrations in 872 Subjects)     Adverse drug reaction      n (%)                       Injection / application site erythema  17 (1.7)                      Injection site irritation  12 (1.2)                      Injection site pain        38 (3.9),Injection site irritation is an adverse reaction entity,"[('Table', 'O'), ('2', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('with', 'O'), ('a', 'O'), ('Frequency', 'O'), ('>', 'O'), ('=0.5', 'O'), ('%', 'O'), ('Reported', 'O'), ('in', 'O'), ('Clinical', 'O'), ('Trials', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('978', 'O'), ('Administrations', 'O'), ('in', 'O'), ('872', 'O'), ('Subjects', 'O'), (')', 'O'), ('Adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('n', 'O'), ('(', 'O'), ('%', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('/', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('17', 'O'), ('(', 'O'), ('1.7', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), ('12', 'O'), ('(', 'O'), ('1.2', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), ('38', 'O'), ('(', 'O'), ('3.9', 'O'), (')', 'O')]"
Table 2 Adverse Reactions with a Frequency >=0.5% Reported in Clinical Trials (n = 978 Administrations in 872 Subjects)     Adverse drug reaction      n (%)                       Injection / application site erythema  17 (1.7)                      Injection site irritation  12 (1.2)                      Injection site pain        38 (3.9),Injection site pain is an adverse reaction entity,"[('Table', 'O'), ('2', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('with', 'O'), ('a', 'O'), ('Frequency', 'O'), ('>', 'O'), ('=0.5', 'O'), ('%', 'O'), ('Reported', 'O'), ('in', 'O'), ('Clinical', 'O'), ('Trials', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('978', 'O'), ('Administrations', 'O'), ('in', 'O'), ('872', 'O'), ('Subjects', 'O'), (')', 'O'), ('Adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('n', 'O'), ('(', 'O'), ('%', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('/', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('17', 'O'), ('(', 'O'), ('1.7', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), ('12', 'O'), ('(', 'O'), ('1.2', 'O'), (')', 'O'), ('Injection', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), ('38', 'O'), ('(', 'O'), ('3.9', 'O'), (')', 'O')]"
"(5.1)   *  Patients recently exposed to opioids are expected to be more sensitive to the effects of ENTEREG and therefore may experience abdominal pain, nausea and vomiting, and diarrhea.",abdominal pain is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Patients', 'O'), ('recently', 'O'), ('exposed', 'O'), ('to', 'O'), ('opioids', 'O'), ('are', 'O'), ('expected', 'O'), ('to', 'O'), ('be', 'O'), ('more', 'O'), ('sensitive', 'O'), ('to', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('ENTEREG', 'O'), ('and', 'O'), ('therefore', 'O'), ('may', 'O'), ('experience', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), ('and', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('.', 'O')]"
"(5.1)   *  Patients recently exposed to opioids are expected to be more sensitive to the effects of ENTEREG and therefore may experience abdominal pain, nausea and vomiting, and diarrhea.",nausea is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Patients', 'O'), ('recently', 'O'), ('exposed', 'O'), ('to', 'O'), ('opioids', 'O'), ('are', 'O'), ('expected', 'O'), ('to', 'O'), ('be', 'O'), ('more', 'O'), ('sensitive', 'O'), ('to', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('ENTEREG', 'O'), ('and', 'O'), ('therefore', 'O'), ('may', 'O'), ('experience', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), ('and', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('.', 'O')]"
"(5.1)   *  Patients recently exposed to opioids are expected to be more sensitive to the effects of ENTEREG and therefore may experience abdominal pain, nausea and vomiting, and diarrhea.",vomiting is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Patients', 'O'), ('recently', 'O'), ('exposed', 'O'), ('to', 'O'), ('opioids', 'O'), ('are', 'O'), ('expected', 'O'), ('to', 'O'), ('be', 'O'), ('more', 'O'), ('sensitive', 'O'), ('to', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('ENTEREG', 'O'), ('and', 'O'), ('therefore', 'O'), ('may', 'O'), ('experience', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), ('and', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('.', 'O')]"
"(5.1)   *  Patients recently exposed to opioids are expected to be more sensitive to the effects of ENTEREG and therefore may experience abdominal pain, nausea and vomiting, and diarrhea.",diarrhea is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Patients', 'O'), ('recently', 'O'), ('exposed', 'O'), ('to', 'O'), ('opioids', 'O'), ('are', 'O'), ('expected', 'O'), ('to', 'O'), ('be', 'O'), ('more', 'O'), ('sensitive', 'O'), ('to', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('ENTEREG', 'O'), ('and', 'O'), ('therefore', 'O'), ('may', 'O'), ('experience', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), ('and', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), ('.', 'O')]"
5.4 Anaphylaxis      AMPYRA can cause anaphylaxis and severe allergic reactions.,anaphylaxis is an adverse reaction entity,"[('5.4', 'O'), ('Anaphylaxis', 'O'), ('AMPYRA', 'O'), ('can', 'O'), ('cause', 'O'), ('anaphylaxis', 'B-ADR'), ('and', 'O'), ('severe', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('.', 'O')]"
5.4 Anaphylaxis      AMPYRA can cause anaphylaxis and severe allergic reactions.,allergic reactions is an adverse reaction entity,"[('5.4', 'O'), ('Anaphylaxis', 'O'), ('AMPYRA', 'O'), ('can', 'O'), ('cause', 'O'), ('anaphylaxis', 'B-ADR'), ('and', 'O'), ('severe', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), ('.', 'O')]"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity,"[('In', 'O'), ('these', 'O'), ('trials', 'O'), (',', 'O'), ('which', 'O'), ('had', 'O'), ('a', 'O'), ('median', 'O'), ('treatment', 'O'), ('duration', 'O'), ('of', 'O'), ('12', 'O'), ('weeks', 'O'), (',', 'O'), ('the', 'O'), ('estimated', 'O'), ('incidence', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('behavior', 'I-ADR'), ('or', 'O'), ('ideation', 'I-ADR'), ('among', 'O'), ('27,863', 'O'), ('AED-treated', 'O'), ('patients', 'O'), ('was', 'O'), ('0.43', 'O'), ('%', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('0.24', 'O'), ('%', 'O'), ('among', 'O'), ('16,029', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('representing', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('approximately', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thinking', 'I-ADR'), ('or', 'O'), ('behavior', 'I-ADR'), ('for', 'O'), ('every', 'O'), ('530', 'O'), ('patients', 'O'), ('treated', 'O'), ('.', 'O')]"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal ideation is an adverse reaction entity,"[('In', 'O'), ('these', 'O'), ('trials', 'O'), (',', 'O'), ('which', 'O'), ('had', 'O'), ('a', 'O'), ('median', 'O'), ('treatment', 'O'), ('duration', 'O'), ('of', 'O'), ('12', 'O'), ('weeks', 'O'), (',', 'O'), ('the', 'O'), ('estimated', 'O'), ('incidence', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('behavior', 'I-ADR'), ('or', 'O'), ('ideation', 'I-ADR'), ('among', 'O'), ('27,863', 'O'), ('AED-treated', 'O'), ('patients', 'O'), ('was', 'O'), ('0.43', 'O'), ('%', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('0.24', 'O'), ('%', 'O'), ('among', 'O'), ('16,029', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('representing', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('approximately', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thinking', 'I-ADR'), ('or', 'O'), ('behavior', 'I-ADR'), ('for', 'O'), ('every', 'O'), ('530', 'O'), ('patients', 'O'), ('treated', 'O'), ('.', 'O')]"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal thinking is an adverse reaction entity,"[('In', 'O'), ('these', 'O'), ('trials', 'O'), (',', 'O'), ('which', 'O'), ('had', 'O'), ('a', 'O'), ('median', 'O'), ('treatment', 'O'), ('duration', 'O'), ('of', 'O'), ('12', 'O'), ('weeks', 'O'), (',', 'O'), ('the', 'O'), ('estimated', 'O'), ('incidence', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('behavior', 'I-ADR'), ('or', 'O'), ('ideation', 'I-ADR'), ('among', 'O'), ('27,863', 'O'), ('AED-treated', 'O'), ('patients', 'O'), ('was', 'O'), ('0.43', 'O'), ('%', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('0.24', 'O'), ('%', 'O'), ('among', 'O'), ('16,029', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('representing', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('approximately', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thinking', 'I-ADR'), ('or', 'O'), ('behavior', 'I-ADR'), ('for', 'O'), ('every', 'O'), ('530', 'O'), ('patients', 'O'), ('treated', 'O'), ('.', 'O')]"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity,"[('In', 'O'), ('these', 'O'), ('trials', 'O'), (',', 'O'), ('which', 'O'), ('had', 'O'), ('a', 'O'), ('median', 'O'), ('treatment', 'O'), ('duration', 'O'), ('of', 'O'), ('12', 'O'), ('weeks', 'O'), (',', 'O'), ('the', 'O'), ('estimated', 'O'), ('incidence', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('behavior', 'I-ADR'), ('or', 'O'), ('ideation', 'I-ADR'), ('among', 'O'), ('27,863', 'O'), ('AED-treated', 'O'), ('patients', 'O'), ('was', 'O'), ('0.43', 'O'), ('%', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('0.24', 'O'), ('%', 'O'), ('among', 'O'), ('16,029', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('representing', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('approximately', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thinking', 'I-ADR'), ('or', 'O'), ('behavior', 'I-ADR'), ('for', 'O'), ('every', 'O'), ('530', 'O'), ('patients', 'O'), ('treated', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",DRESS is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",fever is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",rash is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",lymphadenopathy is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",hepatitis is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",nephritis is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",hematological abnormalities is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",myocarditis is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",myositis is an adverse reaction entity,"[('DRESS', 'B-ADR'), ('typically', 'O'), (',', 'O'), ('although', 'O'), ('not', 'O'), ('exclusively', 'O'), (',', 'O'), ('presents', 'O'), ('with', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and/or', 'O'), ('lymphadenopathy', 'B-ADR'), (',', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('organ', 'O'), ('system', 'O'), ('involvement', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('nephritis', 'B-ADR'), (',', 'O'), ('hematological', 'B-ADR'), ('abnormalities', 'I-ADR'), (',', 'O'), ('myocarditis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('myositis', 'B-ADR'), ('sometimes', 'O'), ('resembling', 'O'), ('an', 'O'), ('acute', 'O'), ('viral', 'O'), ('infection', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",somnolence is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",fatigue is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",fatigue is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",asthenia is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",malaise is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",hypersomnia is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",sedation is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Somnolence and Fatigue       APTIOM causes dose-dependent increases in somnolence and fatigue-related adverse reactions (fatigue, asthenia, malaise, hypersomnia, sedation, and lethargy).",lethargy is an adverse reaction entity,"[('Somnolence', 'O'), ('and', 'O'), ('Fatigue', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('somnolence', 'B-ADR'), ('and', 'O'), ('fatigue-related', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('malaise', 'B-ADR'), (',', 'O'), ('hypersomnia', 'B-ADR'), (',', 'O'), ('sedation', 'B-ADR'), (',', 'O'), ('and', 'O'), ('lethargy', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"Visual Changes       APTIOM causes dose-dependent increases in events related to visual changes including diplopia, blurred vision, and impaired vision.",visual changes is an adverse reaction entity,"[('Visual', 'O'), ('Changes', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('visual', 'B-ADR'), ('changes', 'I-ADR'), ('including', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('and', 'O'), ('impaired', 'B-ADR'), ('vision', 'I-ADR'), ('.', 'O')]"
"Visual Changes       APTIOM causes dose-dependent increases in events related to visual changes including diplopia, blurred vision, and impaired vision.",diplopia is an adverse reaction entity,"[('Visual', 'O'), ('Changes', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('visual', 'B-ADR'), ('changes', 'I-ADR'), ('including', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('and', 'O'), ('impaired', 'B-ADR'), ('vision', 'I-ADR'), ('.', 'O')]"
"Visual Changes       APTIOM causes dose-dependent increases in events related to visual changes including diplopia, blurred vision, and impaired vision.",blurred vision is an adverse reaction entity,"[('Visual', 'O'), ('Changes', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('visual', 'B-ADR'), ('changes', 'I-ADR'), ('including', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('and', 'O'), ('impaired', 'B-ADR'), ('vision', 'I-ADR'), ('.', 'O')]"
"Visual Changes       APTIOM causes dose-dependent increases in events related to visual changes including diplopia, blurred vision, and impaired vision.",impaired vision is an adverse reaction entity,"[('Visual', 'O'), ('Changes', 'O'), ('APTIOM', 'O'), ('causes', 'O'), ('dose-dependent', 'O'), ('increases', 'O'), ('in', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('visual', 'B-ADR'), ('changes', 'I-ADR'), ('including', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('and', 'O'), ('impaired', 'B-ADR'), ('vision', 'I-ADR'), ('.', 'O')]"
(5.1)   *    Paradoxical bronchospasm: Discontinue TUDORZA PRESSAIR and consider other treatments if paradoxical bronchospasm occurs.,Paradoxical bronchospasm is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Paradoxical', 'B-ADR'), ('bronchospasm', 'I-ADR'), (':', 'O'), ('Discontinue', 'O'), ('TUDORZA', 'O'), ('PRESSAIR', 'O'), ('and', 'O'), ('consider', 'O'), ('other', 'O'), ('treatments', 'O'), ('if', 'O'), ('paradoxical', 'O'), ('bronchospasm', 'O'), ('occurs', 'O'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",neutropenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",anemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",asthenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",fatigue is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",alopecia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",peripheral neuropathy is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",nausea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions (>=25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.",constipation is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=25', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('HALAVEN', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('asthenia/fatigue', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('neuropathy', 'I-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('constipation', 'B-ADR'), ('.', 'O')]"
Four percent (20/503) of patients experienced peripheral motor neuropathy of any grade and 2% (8/503) of patients developed Grade 3 peripheral motor neuropathy.,peripheral motor neuropathy is an adverse reaction entity,"[('Four', 'O'), ('percent', 'O'), ('(', 'O'), ('20/503', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('experienced', 'O'), ('peripheral', 'B-ADR'), ('motor', 'I-ADR'), ('neuropathy', 'I-ADR'), ('of', 'O'), ('any', 'O'), ('grade', 'O'), ('and', 'O'), ('2', 'O'), ('%', 'O'), ('(', 'O'), ('8/503', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('developed', 'O'), ('Grade', 'O'), ('3', 'O'), ('peripheral', 'B-ADR'), ('motor', 'I-ADR'), ('neuropathy', 'I-ADR'), ('.', 'O')]"
Four percent (20/503) of patients experienced peripheral motor neuropathy of any grade and 2% (8/503) of patients developed Grade 3 peripheral motor neuropathy.,peripheral motor neuropathy is an adverse reaction entity,"[('Four', 'O'), ('percent', 'O'), ('(', 'O'), ('20/503', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('experienced', 'O'), ('peripheral', 'B-ADR'), ('motor', 'I-ADR'), ('neuropathy', 'I-ADR'), ('of', 'O'), ('any', 'O'), ('grade', 'O'), ('and', 'O'), ('2', 'O'), ('%', 'O'), ('(', 'O'), ('8/503', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('developed', 'O'), ('Grade', 'O'), ('3', 'O'), ('peripheral', 'B-ADR'), ('motor', 'I-ADR'), ('neuropathy', 'I-ADR'), ('.', 'O')]"
One HALAVEN-treated patient without documented liver metastases had concomitant Grade 2 elevations in bilirubin and ALT; these abnormalities resolved and did not recur with re-exposure to HALAVEN.,elevations in bilirubin is an adverse reaction entity,"[('One', 'O'), ('HALAVEN-treated', 'O'), ('patient', 'O'), ('without', 'O'), ('documented', 'O'), ('liver', 'O'), ('metastases', 'O'), ('had', 'O'), ('concomitant', 'O'), ('Grade', 'O'), ('2', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('bilirubin', 'I-ADR'), ('and', 'O'), ('ALT', 'I-ADR'), (';', 'O'), ('these', 'O'), ('abnormalities', 'O'), ('resolved', 'O'), ('and', 'O'), ('did', 'O'), ('not', 'O'), ('recur', 'O'), ('with', 'O'), ('re-exposure', 'O'), ('to', 'O'), ('HALAVEN', 'O'), ('.', 'O')]"
One HALAVEN-treated patient without documented liver metastases had concomitant Grade 2 elevations in bilirubin and ALT; these abnormalities resolved and did not recur with re-exposure to HALAVEN.,elevations in ALT is an adverse reaction entity,"[('One', 'O'), ('HALAVEN-treated', 'O'), ('patient', 'O'), ('without', 'O'), ('documented', 'O'), ('liver', 'O'), ('metastases', 'O'), ('had', 'O'), ('concomitant', 'O'), ('Grade', 'O'), ('2', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('bilirubin', 'I-ADR'), ('and', 'O'), ('ALT', 'I-ADR'), (';', 'O'), ('these', 'O'), ('abnormalities', 'O'), ('resolved', 'O'), ('and', 'O'), ('did', 'O'), ('not', 'O'), ('recur', 'O'), ('with', 'O'), ('re-exposure', 'O'), ('to', 'O'), ('HALAVEN', 'O'), ('.', 'O')]"
The majority of the events were mild to moderate although serious infections were observed.,infections is an adverse reaction entity,"[('The', 'O'), ('majority', 'O'), ('of', 'O'), ('the', 'O'), ('events', 'O'), ('were', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('although', 'O'), ('serious', 'O'), ('infections', 'B-ADR'), ('were', 'O'), ('observed', 'O'), ('.', 'O')]"
The majority of the events were mild to moderate although serious infections were observed.,infections is an adverse reaction entity,"[('The', 'O'), ('majority', 'O'), ('of', 'O'), ('the', 'O'), ('events', 'O'), ('were', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('although', 'O'), ('serious', 'O'), ('infections', 'B-ADR'), ('were', 'O'), ('observed', 'O'), ('.', 'O')]"
Transient decreases in absolute neutrophil count (ANC) to less than 1x10  9  /L were reported in 3 patients (6.0%) in the ILARIS group compared to1 patient (2.0%) in the placebo group.,decreases in absolute neutrophil count is an adverse reaction entity,"[('Transient', 'O'), ('decreases', 'B-ADR'), ('in', 'I-ADR'), ('absolute', 'I-ADR'), ('neutrophil', 'I-ADR'), ('count', 'I-ADR'), ('(', 'O'), ('ANC', 'I-ADR'), (')', 'O'), ('to', 'O'), ('less', 'O'), ('than', 'O'), ('1x10', 'O'), ('9', 'O'), ('/L', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('3', 'O'), ('patients', 'O'), ('(', 'O'), ('6.0', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('ILARIS', 'O'), ('group', 'O'), ('compared', 'O'), ('to1', 'O'), ('patient', 'O'), ('(', 'O'), ('2.0', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O')]"
Transient decreases in absolute neutrophil count (ANC) to less than 1x10  9  /L were reported in 3 patients (6.0%) in the ILARIS group compared to1 patient (2.0%) in the placebo group.,decreases in ANC is an adverse reaction entity,"[('Transient', 'O'), ('decreases', 'B-ADR'), ('in', 'I-ADR'), ('absolute', 'I-ADR'), ('neutrophil', 'I-ADR'), ('count', 'I-ADR'), ('(', 'O'), ('ANC', 'I-ADR'), (')', 'O'), ('to', 'O'), ('less', 'O'), ('than', 'O'), ('1x10', 'O'), ('9', 'O'), ('/L', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('3', 'O'), ('patients', 'O'), ('(', 'O'), ('6.0', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('ILARIS', 'O'), ('group', 'O'), ('compared', 'O'), ('to1', 'O'), ('patient', 'O'), ('(', 'O'), ('2.0', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O')]"
"Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) were reported during ILARIS treatment.",unusual infections is an adverse reaction entity,"[('Isolated', 'O'), ('cases', 'O'), ('of', 'O'), ('unusual', 'B-ADR'), ('or', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('atypical', 'B-ADR'), ('mycobacterial', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('cytomegalovirus', 'I-ADR'), (',', 'O'), ('herpes', 'B-ADR'), ('zoster', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('during', 'O'), ('ILARIS', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) were reported during ILARIS treatment.",opportunistic infections is an adverse reaction entity,"[('Isolated', 'O'), ('cases', 'O'), ('of', 'O'), ('unusual', 'B-ADR'), ('or', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('atypical', 'B-ADR'), ('mycobacterial', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('cytomegalovirus', 'I-ADR'), (',', 'O'), ('herpes', 'B-ADR'), ('zoster', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('during', 'O'), ('ILARIS', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) were reported during ILARIS treatment.",infections cytomegalovirus is an adverse reaction entity,"[('Isolated', 'O'), ('cases', 'O'), ('of', 'O'), ('unusual', 'B-ADR'), ('or', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('atypical', 'B-ADR'), ('mycobacterial', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('cytomegalovirus', 'I-ADR'), (',', 'O'), ('herpes', 'B-ADR'), ('zoster', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('during', 'O'), ('ILARIS', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) were reported during ILARIS treatment.",aspergillosis is an adverse reaction entity,"[('Isolated', 'O'), ('cases', 'O'), ('of', 'O'), ('unusual', 'B-ADR'), ('or', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('atypical', 'B-ADR'), ('mycobacterial', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('cytomegalovirus', 'I-ADR'), (',', 'O'), ('herpes', 'B-ADR'), ('zoster', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('during', 'O'), ('ILARIS', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) were reported during ILARIS treatment.",atypical mycobacterial infections is an adverse reaction entity,"[('Isolated', 'O'), ('cases', 'O'), ('of', 'O'), ('unusual', 'B-ADR'), ('or', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('atypical', 'B-ADR'), ('mycobacterial', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('cytomegalovirus', 'I-ADR'), (',', 'O'), ('herpes', 'B-ADR'), ('zoster', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('during', 'O'), ('ILARIS', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Isolated cases of unusual or opportunistic infections (e.g., aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster) were reported during ILARIS treatment.",herpes zoster is an adverse reaction entity,"[('Isolated', 'O'), ('cases', 'O'), ('of', 'O'), ('unusual', 'B-ADR'), ('or', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('atypical', 'B-ADR'), ('mycobacterial', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('cytomegalovirus', 'I-ADR'), (',', 'O'), ('herpes', 'B-ADR'), ('zoster', 'I-ADR'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('during', 'O'), ('ILARIS', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Infections  In Study 1, 1% of patients treated with XTANDI compared to 0.3% of patients treated with placebo died from infections or sepsis.",died is an adverse reaction entity,"[('Infections', 'O'), ('In', 'O'), ('Study', 'O'), ('1', 'O'), (',', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('XTANDI', 'O'), ('compared', 'O'), ('to', 'O'), ('0.3', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('died', 'B-ADR'), ('from', 'O'), ('infections', 'B-ADR'), ('or', 'O'), ('sepsis', 'B-ADR'), ('.', 'O')]"
"Infections  In Study 1, 1% of patients treated with XTANDI compared to 0.3% of patients treated with placebo died from infections or sepsis.",infections is an adverse reaction entity,"[('Infections', 'O'), ('In', 'O'), ('Study', 'O'), ('1', 'O'), (',', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('XTANDI', 'O'), ('compared', 'O'), ('to', 'O'), ('0.3', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('died', 'B-ADR'), ('from', 'O'), ('infections', 'B-ADR'), ('or', 'O'), ('sepsis', 'B-ADR'), ('.', 'O')]"
"Infections  In Study 1, 1% of patients treated with XTANDI compared to 0.3% of patients treated with placebo died from infections or sepsis.",sepsis is an adverse reaction entity,"[('Infections', 'O'), ('In', 'O'), ('Study', 'O'), ('1', 'O'), (',', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('XTANDI', 'O'), ('compared', 'O'), ('to', 'O'), ('0.3', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('died', 'B-ADR'), ('from', 'O'), ('infections', 'B-ADR'), ('or', 'O'), ('sepsis', 'B-ADR'), ('.', 'O')]"
"In Study 2, 1 of 871 (0.1%) chemotherapy-naive patients treated with XTANDI and 1 of 844 (0.1%) patients treated with placebo experienced a seizure.",seizure is an adverse reaction entity,"[('In', 'O'), ('Study', 'O'), ('2', 'O'), (',', 'O'), ('1', 'O'), ('of', 'O'), ('871', 'O'), ('(', 'O'), ('0.1', 'O'), ('%', 'O'), (')', 'O'), ('chemotherapy-naive', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('XTANDI', 'O'), ('and', 'O'), ('1', 'O'), ('of', 'O'), ('844', 'O'), ('(', 'O'), ('0.1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('placebo', 'O'), ('experienced', 'O'), ('a', 'O'), ('seizure', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",Dizziness is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",Insomnia is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",Cough is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",Dyspnea is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",Dyspnea is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",acute respiratory failure is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",bronchial hyperactivity is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",bronchospasm is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",dyspnea is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",dyspnea exertional is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",respiratory distress is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",respiratory failure is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
"Dizziness            362014       31< 1       Psychiatric disorders       Insomnia            15        0       Respiratory, thoracic, and mediastinal disorders       Cough     DyspneaDyspnea includes the following terms: acute respiratory failure, bronchial hyperactivity, bronchospasm, dyspnea, dyspnea exertional, respiratory distress, respiratory failure, and wheezing.",wheezing is an adverse reaction entity,"[('Dizziness', 'B-ADR'), ('362014', 'O'), ('31', 'O'), ('<', 'O'), ('1', 'O'), ('Psychiatric', 'O'), ('disorders', 'O'), ('Insomnia', 'B-ADR'), ('15', 'O'), ('0', 'O'), ('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), (',', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), ('Cough', 'B-ADR'), ('DyspneaDyspnea', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('bronchial', 'B-ADR'), ('hyperactivity', 'I-ADR'), (',', 'O'), ('bronchospasm', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), ('exertional', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('distress', 'I-ADR'), (',', 'O'), ('respiratory', 'B-ADR'), ('failure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('wheezing', 'B-ADR'), ('.', 'O')]"
(  5.3  )   *  Effects on Ability to Drive and Use Machines: Advise patients to refrain from driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO is being administered.,Effects on Ability to Drive is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Effects', 'B-ADR'), ('on', 'I-ADR'), ('Ability', 'I-ADR'), ('to', 'I-ADR'), ('Drive', 'I-ADR'), ('and', 'O'), ('Use', 'I-ADR'), ('Machines', 'I-ADR'), (':', 'O'), ('Advise', 'O'), ('patients', 'O'), ('to', 'O'), ('refrain', 'O'), ('from', 'O'), ('driving', 'O'), ('and', 'O'), ('engaging', 'O'), ('in', 'O'), ('hazardous', 'O'), ('occupations', 'O'), ('or', 'O'), ('activities', 'O'), ('such', 'O'), ('as', 'O'), ('operating', 'O'), ('heavy', 'O'), ('or', 'O'), ('potentially', 'O'), ('dangerous', 'O'), ('machinery', 'O'), ('while', 'O'), ('BLINCYTO', 'O'), ('is', 'O'), ('being', 'O'), ('administered', 'O'), ('.', 'O')]"
(  5.3  )   *  Effects on Ability to Drive and Use Machines: Advise patients to refrain from driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO is being administered.,Effects on Ability to Use Machines is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Effects', 'B-ADR'), ('on', 'I-ADR'), ('Ability', 'I-ADR'), ('to', 'I-ADR'), ('Drive', 'I-ADR'), ('and', 'O'), ('Use', 'I-ADR'), ('Machines', 'I-ADR'), (':', 'O'), ('Advise', 'O'), ('patients', 'O'), ('to', 'O'), ('refrain', 'O'), ('from', 'O'), ('driving', 'O'), ('and', 'O'), ('engaging', 'O'), ('in', 'O'), ('hazardous', 'O'), ('occupations', 'O'), ('or', 'O'), ('activities', 'O'), ('such', 'O'), ('as', 'O'), ('operating', 'O'), ('heavy', 'O'), ('or', 'O'), ('potentially', 'O'), ('dangerous', 'O'), ('machinery', 'O'), ('while', 'O'), ('BLINCYTO', 'O'), ('is', 'O'), ('being', 'O'), ('administered', 'O'), ('.', 'O')]"
"5.8     Leukoencephalopathy      Cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO, especially in patients with prior treatment with cranial irradiation and antileukemic chemotherapy (including systemic high-dose methotrexate or intrathecal cytarabine).",leukoencephalopathy is an adverse reaction entity,"[('5.8', 'O'), ('Leukoencephalopathy', 'O'), ('Cranial', 'O'), ('magnetic', 'O'), ('resonance', 'O'), ('imaging', 'O'), ('(', 'O'), ('MRI', 'O'), (')', 'O'), ('changes', 'O'), ('showing', 'O'), ('leukoencephalopathy', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('BLINCYTO', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('prior', 'O'), ('treatment', 'O'), ('with', 'O'), ('cranial', 'O'), ('irradiation', 'O'), ('and', 'O'), ('antileukemic', 'O'), ('chemotherapy', 'O'), ('(', 'O'), ('including', 'O'), ('systemic', 'O'), ('high-dose', 'O'), ('methotrexate', 'O'), ('or', 'O'), ('intrathecal', 'O'), ('cytarabine', 'O'), (')', 'O'), ('.', 'O')]"
"Diarrhea, headache, and nausea were the most commonly reported adverse reactions.",Diarrhea is an adverse reaction entity,"[('Diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('and', 'O'), ('nausea', 'B-ADR'), ('were', 'O'), ('the', 'O'), ('most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('.', 'O')]"
"Diarrhea, headache, and nausea were the most commonly reported adverse reactions.",headache is an adverse reaction entity,"[('Diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('and', 'O'), ('nausea', 'B-ADR'), ('were', 'O'), ('the', 'O'), ('most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('.', 'O')]"
"Diarrhea, headache, and nausea were the most commonly reported adverse reactions.",nausea is an adverse reaction entity,"[('Diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('and', 'O'), ('nausea', 'B-ADR'), ('were', 'O'), ('the', 'O'), ('most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('.', 'O')]"
"Instances of suicidal ideation and behavior have been observed in 0.2% (3/1441) of subjects while receiving OTEZLA, compared to none in placebo treated subjects (0/495).",suicidal ideation is an adverse reaction entity,"[('Instances', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('ideation', 'I-ADR'), ('and', 'O'), ('behavior', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('0.2', 'O'), ('%', 'O'), ('(', 'O'), ('3/1441', 'O'), (')', 'O'), ('of', 'O'), ('subjects', 'O'), ('while', 'O'), ('receiving', 'O'), ('OTEZLA', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('none', 'O'), ('in', 'O'), ('placebo', 'O'), ('treated', 'O'), ('subjects', 'O'), ('(', 'O'), ('0/495', 'O'), (')', 'O'), ('.', 'O')]"
"Instances of suicidal ideation and behavior have been observed in 0.2% (3/1441) of subjects while receiving OTEZLA, compared to none in placebo treated subjects (0/495).",suicidal behavior is an adverse reaction entity,"[('Instances', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('ideation', 'I-ADR'), ('and', 'O'), ('behavior', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('0.2', 'O'), ('%', 'O'), ('(', 'O'), ('3/1441', 'O'), (')', 'O'), ('of', 'O'), ('subjects', 'O'), ('while', 'O'), ('receiving', 'O'), ('OTEZLA', 'O'), (',', 'O'), ('compared', 'O'), ('to', 'O'), ('none', 'O'), ('in', 'O'), ('placebo', 'O'), ('treated', 'O'), ('subjects', 'O'), ('(', 'O'), ('0/495', 'O'), (')', 'O'), ('.', 'O')]"
"In addition to the term injection site reaction (see Table 1), the following other types of injection site reactions also occurred more frequently on TANZEUM: injection site hematoma (1.9% versus 2.1% for placebo versus TANZEUM ), injection site erythema (0.4% versus 1.7% for placebo versus TANZEUM), injection site rash (0% versus 1.4% for placebo versus TANZEUM), injection site hypersensitivity (0% versus 0.8% for placebo versus TANZEUM), and injection site hemorrhage (0.6% versus 0.7% for placebo versus TANZEUM).",injection site reaction is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('term', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reaction', 'I-ADR'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('on', 'O'), ('TANZEUM', 'O'), (':', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hematoma', 'I-ADR'), ('(', 'O'), ('1.9', 'O'), ('%', 'O'), ('versus', 'O'), ('2.1', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('(', 'O'), ('0.4', 'O'), ('%', 'O'), ('versus', 'O'), ('1.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('rash', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('1.4', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hypersensitivity', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('(', 'O'), ('0.6', 'O'), ('%', 'O'), ('versus', 'O'), ('0.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), ('.', 'O')]"
"In addition to the term injection site reaction (see Table 1), the following other types of injection site reactions also occurred more frequently on TANZEUM: injection site hematoma (1.9% versus 2.1% for placebo versus TANZEUM ), injection site erythema (0.4% versus 1.7% for placebo versus TANZEUM), injection site rash (0% versus 1.4% for placebo versus TANZEUM), injection site hypersensitivity (0% versus 0.8% for placebo versus TANZEUM), and injection site hemorrhage (0.6% versus 0.7% for placebo versus TANZEUM).",injection site reactions is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('term', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reaction', 'I-ADR'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('on', 'O'), ('TANZEUM', 'O'), (':', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hematoma', 'I-ADR'), ('(', 'O'), ('1.9', 'O'), ('%', 'O'), ('versus', 'O'), ('2.1', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('(', 'O'), ('0.4', 'O'), ('%', 'O'), ('versus', 'O'), ('1.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('rash', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('1.4', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hypersensitivity', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('(', 'O'), ('0.6', 'O'), ('%', 'O'), ('versus', 'O'), ('0.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), ('.', 'O')]"
"In addition to the term injection site reaction (see Table 1), the following other types of injection site reactions also occurred more frequently on TANZEUM: injection site hematoma (1.9% versus 2.1% for placebo versus TANZEUM ), injection site erythema (0.4% versus 1.7% for placebo versus TANZEUM), injection site rash (0% versus 1.4% for placebo versus TANZEUM), injection site hypersensitivity (0% versus 0.8% for placebo versus TANZEUM), and injection site hemorrhage (0.6% versus 0.7% for placebo versus TANZEUM).",injection site hematoma is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('term', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reaction', 'I-ADR'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('on', 'O'), ('TANZEUM', 'O'), (':', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hematoma', 'I-ADR'), ('(', 'O'), ('1.9', 'O'), ('%', 'O'), ('versus', 'O'), ('2.1', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('(', 'O'), ('0.4', 'O'), ('%', 'O'), ('versus', 'O'), ('1.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('rash', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('1.4', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hypersensitivity', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('(', 'O'), ('0.6', 'O'), ('%', 'O'), ('versus', 'O'), ('0.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), ('.', 'O')]"
"In addition to the term injection site reaction (see Table 1), the following other types of injection site reactions also occurred more frequently on TANZEUM: injection site hematoma (1.9% versus 2.1% for placebo versus TANZEUM ), injection site erythema (0.4% versus 1.7% for placebo versus TANZEUM), injection site rash (0% versus 1.4% for placebo versus TANZEUM), injection site hypersensitivity (0% versus 0.8% for placebo versus TANZEUM), and injection site hemorrhage (0.6% versus 0.7% for placebo versus TANZEUM).",injection site erythema is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('term', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reaction', 'I-ADR'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('on', 'O'), ('TANZEUM', 'O'), (':', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hematoma', 'I-ADR'), ('(', 'O'), ('1.9', 'O'), ('%', 'O'), ('versus', 'O'), ('2.1', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('(', 'O'), ('0.4', 'O'), ('%', 'O'), ('versus', 'O'), ('1.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('rash', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('1.4', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hypersensitivity', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('(', 'O'), ('0.6', 'O'), ('%', 'O'), ('versus', 'O'), ('0.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), ('.', 'O')]"
"In addition to the term injection site reaction (see Table 1), the following other types of injection site reactions also occurred more frequently on TANZEUM: injection site hematoma (1.9% versus 2.1% for placebo versus TANZEUM ), injection site erythema (0.4% versus 1.7% for placebo versus TANZEUM), injection site rash (0% versus 1.4% for placebo versus TANZEUM), injection site hypersensitivity (0% versus 0.8% for placebo versus TANZEUM), and injection site hemorrhage (0.6% versus 0.7% for placebo versus TANZEUM).",injection site rash is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('term', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reaction', 'I-ADR'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('on', 'O'), ('TANZEUM', 'O'), (':', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hematoma', 'I-ADR'), ('(', 'O'), ('1.9', 'O'), ('%', 'O'), ('versus', 'O'), ('2.1', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('(', 'O'), ('0.4', 'O'), ('%', 'O'), ('versus', 'O'), ('1.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('rash', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('1.4', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hypersensitivity', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('(', 'O'), ('0.6', 'O'), ('%', 'O'), ('versus', 'O'), ('0.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), ('.', 'O')]"
"In addition to the term injection site reaction (see Table 1), the following other types of injection site reactions also occurred more frequently on TANZEUM: injection site hematoma (1.9% versus 2.1% for placebo versus TANZEUM ), injection site erythema (0.4% versus 1.7% for placebo versus TANZEUM), injection site rash (0% versus 1.4% for placebo versus TANZEUM), injection site hypersensitivity (0% versus 0.8% for placebo versus TANZEUM), and injection site hemorrhage (0.6% versus 0.7% for placebo versus TANZEUM).",injection site hypersensitivity is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('term', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reaction', 'I-ADR'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('on', 'O'), ('TANZEUM', 'O'), (':', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hematoma', 'I-ADR'), ('(', 'O'), ('1.9', 'O'), ('%', 'O'), ('versus', 'O'), ('2.1', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('(', 'O'), ('0.4', 'O'), ('%', 'O'), ('versus', 'O'), ('1.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('rash', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('1.4', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hypersensitivity', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('(', 'O'), ('0.6', 'O'), ('%', 'O'), ('versus', 'O'), ('0.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), ('.', 'O')]"
"In addition to the term injection site reaction (see Table 1), the following other types of injection site reactions also occurred more frequently on TANZEUM: injection site hematoma (1.9% versus 2.1% for placebo versus TANZEUM ), injection site erythema (0.4% versus 1.7% for placebo versus TANZEUM), injection site rash (0% versus 1.4% for placebo versus TANZEUM), injection site hypersensitivity (0% versus 0.8% for placebo versus TANZEUM), and injection site hemorrhage (0.6% versus 0.7% for placebo versus TANZEUM).",injection site hemorrhage is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('term', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reaction', 'I-ADR'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('following', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('on', 'O'), ('TANZEUM', 'O'), (':', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hematoma', 'I-ADR'), ('(', 'O'), ('1.9', 'O'), ('%', 'O'), ('versus', 'O'), ('2.1', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('erythema', 'I-ADR'), ('(', 'O'), ('0.4', 'O'), ('%', 'O'), ('versus', 'O'), ('1.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('rash', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('1.4', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hypersensitivity', 'I-ADR'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('(', 'O'), ('0.6', 'O'), ('%', 'O'), ('versus', 'O'), ('0.7', 'O'), ('%', 'O'), ('for', 'O'), ('placebo', 'O'), ('versus', 'O'), ('TANZEUM', 'O'), (')', 'O'), ('.', 'O')]"
"*       b  In this trial, no documented symptomatic or severe hypoglycemia were reported for TANZEUM 50 mg and these data are omitted from the table.",hypoglycemia is an adverse reaction entity,"[('*', 'O'), ('b', 'O'), ('In', 'O'), ('this', 'O'), ('trial', 'O'), (',', 'O'), ('no', 'O'), ('documented', 'O'), ('symptomatic', 'O'), ('or', 'O'), ('severe', 'O'), ('hypoglycemia', 'B-ADR'), ('were', 'O'), ('reported', 'O'), ('for', 'O'), ('TANZEUM', 'O'), ('50', 'O'), ('mg', 'O'), ('and', 'O'), ('these', 'O'), ('data', 'O'), ('are', 'O'), ('omitted', 'O'), ('from', 'O'), ('the', 'O'), ('table', 'O'), ('.', 'O')]"
"Atrial Fibrillation/Flutte  r     In the pool of 7 placebo- and active-controlled trials, adverse reactions of atrial fibrillation (1.0%) and atrial flutter (0.2%) were reported more frequently for TANZEUM than for all comparators (0.5% and 0%, respectively).",atrial fibrillation is an adverse reaction entity,"[('Atrial', 'O'), ('Fibrillation/Flutte', 'O'), ('r', 'O'), ('In', 'O'), ('the', 'O'), ('pool', 'O'), ('of', 'O'), ('7', 'O'), ('placebo-', 'O'), ('and', 'O'), ('active-controlled', 'O'), ('trials', 'O'), (',', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('of', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), ('(', 'O'), ('1.0', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('atrial', 'B-ADR'), ('flutter', 'I-ADR'), ('(', 'O'), ('0.2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('more', 'O'), ('frequently', 'O'), ('for', 'O'), ('TANZEUM', 'O'), ('than', 'O'), ('for', 'O'), ('all', 'O'), ('comparators', 'O'), ('(', 'O'), ('0.5', 'O'), ('%', 'O'), ('and', 'O'), ('0', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O')]"
"Atrial Fibrillation/Flutte  r     In the pool of 7 placebo- and active-controlled trials, adverse reactions of atrial fibrillation (1.0%) and atrial flutter (0.2%) were reported more frequently for TANZEUM than for all comparators (0.5% and 0%, respectively).",atrial flutter is an adverse reaction entity,"[('Atrial', 'O'), ('Fibrillation/Flutte', 'O'), ('r', 'O'), ('In', 'O'), ('the', 'O'), ('pool', 'O'), ('of', 'O'), ('7', 'O'), ('placebo-', 'O'), ('and', 'O'), ('active-controlled', 'O'), ('trials', 'O'), (',', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('of', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), ('(', 'O'), ('1.0', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('atrial', 'B-ADR'), ('flutter', 'I-ADR'), ('(', 'O'), ('0.2', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('reported', 'O'), ('more', 'O'), ('frequently', 'O'), ('for', 'O'), ('TANZEUM', 'O'), ('than', 'O'), ('for', 'O'), ('all', 'O'), ('comparators', 'O'), ('(', 'O'), ('0.5', 'O'), ('%', 'O'), ('and', 'O'), ('0', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O')]"
WARNING: RISK OF THYROID C-CELL TUMORS       See full prescribing information for complete boxed warning.,THYROID C-CELL TUMORS is an adverse reaction entity,"[('WARNING', 'O'), (':', 'O'), ('RISK', 'O'), ('OF', 'O'), ('THYROID', 'B-ADR'), ('C-CELL', 'I-ADR'), ('TUMORS', 'I-ADR'), ('See', 'O'), ('full', 'O'), ('prescribing', 'O'), ('information', 'O'), ('for', 'O'), ('complete', 'O'), ('boxed', 'O'), ('warning', 'O'), ('.', 'O')]"
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *     Thyroid C-cell Tumors: See Boxed Warning.,Thyroid C-cell Tumors is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Thyroid', 'B-ADR'), ('C-cell', 'I-ADR'), ('Tumors', 'I-ADR'), (':', 'O'), ('See', 'O'), ('Boxed', 'O'), ('Warning', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",Anaphylaxis is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",cough is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",erythema is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",throat tightness is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",urticaria is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",flushing is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",cyanosis is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",hypotension is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",rash is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",dyspnea is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",chest discomfort is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",gastrointestinal symptoms is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",nausea is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",abdominal pain is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",retching is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",vomiting is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during Vimizim infusions, regardless of duration of the course of treatment.",urticaria is an adverse reaction entity,"[('Anaphylaxis', 'B-ADR'), (',', 'O'), ('presenting', 'O'), ('as', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('erythema', 'B-ADR'), (',', 'O'), ('throat', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), (',', 'O'), ('cyanosis', 'B-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('discomfort', 'I-ADR'), (',', 'O'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('symptoms', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('retching', 'B-ADR'), (',', 'O'), ('and', 'O'), ('vomiting', 'B-ADR'), (')', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('urticaria', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('occur', 'O'), ('during', 'O'), ('Vimizim', 'O'), ('infusions', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O')]"
These cases of anaphylaxis occurred as early as 30 minutes from the start of infusion and up to three hours after infusion.,anaphylaxis is an adverse reaction entity,"[('These', 'O'), ('cases', 'O'), ('of', 'O'), ('anaphylaxis', 'B-ADR'), ('occurred', 'O'), ('as', 'O'), ('early', 'O'), ('as', 'O'), ('30', 'O'), ('minutes', 'O'), ('from', 'O'), ('the', 'O'), ('start', 'O'), ('of', 'O'), ('infusion', 'O'), ('and', 'O'), ('up', 'O'), ('to', 'O'), ('three', 'O'), ('hours', 'O'), ('after', 'O'), ('infusion', 'O'), ('.', 'O')]"
"When Coartem Tablets are coadministered with an inhibitor of CYP3A4, including grapefruit juice it may result in increased concentrations of artemether and/or lumefantrine and potentiate QT prolongation.",QT prolongation is an adverse reaction entity,"[('When', 'O'), ('Coartem', 'O'), ('Tablets', 'O'), ('are', 'O'), ('coadministered', 'O'), ('with', 'O'), ('an', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('CYP3A4', 'O'), (',', 'O'), ('including', 'O'), ('grapefruit', 'O'), ('juice', 'O'), ('it', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('increased', 'O'), ('concentrations', 'O'), ('of', 'O'), ('artemether', 'O'), ('and/or', 'O'), ('lumefantrine', 'O'), ('and', 'O'), ('potentiate', 'O'), ('QT', 'B-ADR'), ('prolongation', 'I-ADR'), ('.', 'O')]"
"In Studies 102 and 103, bone fractures occurred in 27 subjects (3.9%) in the STRIBILD group, 8 subjects (2.3%) in the ATRIPLA group, and 19 subjects (5.4%) in the ATV + RTV + TRUVADA group.",bone fractures is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('102', 'O'), ('and', 'O'), ('103', 'O'), (',', 'O'), ('bone', 'B-ADR'), ('fractures', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('27', 'O'), ('subjects', 'O'), ('(', 'O'), ('3.9', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('STRIBILD', 'O'), ('group', 'O'), (',', 'O'), ('8', 'O'), ('subjects', 'O'), ('(', 'O'), ('2.3', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('ATRIPLA', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('19', 'O'), ('subjects', 'O'), ('(', 'O'), ('5.4', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('ATV', 'O'), ('+', 'O'), ('RTV', 'O'), ('+', 'O'), ('TRUVADA', 'O'), ('group', 'O'), ('.', 'O')]"
"Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and HBV who have discontinued EMTRIVA or VIREAD, two of the components of STRIBILD.",acute exacerbations of hepatitis B is an adverse reaction entity,"[('Severe', 'O'), ('acute', 'B-ADR'), ('exacerbations', 'I-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('coinfected', 'O'), ('with', 'O'), ('HIV-1', 'O'), ('and', 'O'), ('HBV', 'O'), ('who', 'O'), ('have', 'O'), ('discontinued', 'O'), ('EMTRIVA', 'O'), ('or', 'O'), ('VIREAD', 'O'), (',', 'O'), ('two', 'O'), ('of', 'O'), ('the', 'O'), ('components', 'O'), ('of', 'O'), ('STRIBILD', 'O'), ('.', 'O')]"
"Although cobicistat (a component of STRIBILD) may cause modest increases in serum creatinine and modest declines in estimated creatinine clearance without affecting renal glomerular function [see  Adverse Reactions (6.1)  ]  , patients who experience a confirmed increase in serum creatinine of greater than 0.4 mg per dL from baseline should be closely monitored for renal safety.",increases in serum creatinine is an adverse reaction entity,"[('Although', 'O'), ('cobicistat', 'O'), ('(', 'O'), ('a', 'O'), ('component', 'O'), ('of', 'O'), ('STRIBILD', 'O'), (')', 'O'), ('may', 'O'), ('cause', 'O'), ('modest', 'O'), ('increases', 'B-ADR'), ('in', 'I-ADR'), ('serum', 'I-ADR'), ('creatinine', 'I-ADR'), ('and', 'O'), ('modest', 'O'), ('declines', 'B-ADR'), ('in', 'I-ADR'), ('estimated', 'I-ADR'), ('creatinine', 'I-ADR'), ('clearance', 'I-ADR'), ('without', 'O'), ('affecting', 'O'), ('renal', 'O'), ('glomerular', 'O'), ('function', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('patients', 'O'), ('who', 'O'), ('experience', 'O'), ('a', 'O'), ('confirmed', 'O'), ('increase', 'O'), ('in', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('of', 'O'), ('greater', 'O'), ('than', 'O'), ('0.4', 'O'), ('mg', 'O'), ('per', 'O'), ('dL', 'O'), ('from', 'O'), ('baseline', 'O'), ('should', 'O'), ('be', 'O'), ('closely', 'O'), ('monitored', 'O'), ('for', 'O'), ('renal', 'O'), ('safety', 'O'), ('.', 'O')]"
"Although cobicistat (a component of STRIBILD) may cause modest increases in serum creatinine and modest declines in estimated creatinine clearance without affecting renal glomerular function [see  Adverse Reactions (6.1)  ]  , patients who experience a confirmed increase in serum creatinine of greater than 0.4 mg per dL from baseline should be closely monitored for renal safety.",declines in estimated creatinine clearance is an adverse reaction entity,"[('Although', 'O'), ('cobicistat', 'O'), ('(', 'O'), ('a', 'O'), ('component', 'O'), ('of', 'O'), ('STRIBILD', 'O'), (')', 'O'), ('may', 'O'), ('cause', 'O'), ('modest', 'O'), ('increases', 'B-ADR'), ('in', 'I-ADR'), ('serum', 'I-ADR'), ('creatinine', 'I-ADR'), ('and', 'O'), ('modest', 'O'), ('declines', 'B-ADR'), ('in', 'I-ADR'), ('estimated', 'I-ADR'), ('creatinine', 'I-ADR'), ('clearance', 'I-ADR'), ('without', 'O'), ('affecting', 'O'), ('renal', 'O'), ('glomerular', 'O'), ('function', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('patients', 'O'), ('who', 'O'), ('experience', 'O'), ('a', 'O'), ('confirmed', 'O'), ('increase', 'O'), ('in', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('of', 'O'), ('greater', 'O'), ('than', 'O'), ('0.4', 'O'), ('mg', 'O'), ('per', 'O'), ('dL', 'O'), ('from', 'O'), ('baseline', 'O'), ('should', 'O'), ('be', 'O'), ('closely', 'O'), ('monitored', 'O'), ('for', 'O'), ('renal', 'O'), ('safety', 'O'), ('.', 'O')]"
"5.8 Immune Reconstitution Syndrome      Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including STRIBILD.",Immune reconstitution syndrome is an adverse reaction entity,"[('5.8', 'O'), ('Immune', 'O'), ('Reconstitution', 'O'), ('Syndrome', 'O'), ('Immune', 'B-ADR'), ('reconstitution', 'I-ADR'), ('syndrome', 'I-ADR'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('combination', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), (',', 'O'), ('including', 'O'), ('STRIBILD', 'O'), ('.', 'O')]"
"No deaths, intubations, or serious adverse reactions related to asthma exacerbation were reported in this trial.",deaths is an adverse reaction entity,"[('No', 'O'), ('deaths', 'B-ADR'), (',', 'O'), ('intubations', 'O'), (',', 'O'), ('or', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('related', 'O'), ('to', 'O'), ('asthma', 'B-ADR'), ('exacerbation', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('this', 'O'), ('trial', 'O'), ('.', 'O')]"
"No deaths, intubations, or serious adverse reactions related to asthma exacerbation were reported in this trial.",asthma exacerbation is an adverse reaction entity,"[('No', 'O'), ('deaths', 'B-ADR'), (',', 'O'), ('intubations', 'O'), (',', 'O'), ('or', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('related', 'O'), ('to', 'O'), ('asthma', 'B-ADR'), ('exacerbation', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('this', 'O'), ('trial', 'O'), ('.', 'O')]"
"*   Serious asthma-related events, including death, were reported in clinical studies with ARCAPTA NEOHALER.",death is an adverse reaction entity,"[('*', 'O'), ('Serious', 'O'), ('asthma-related', 'O'), ('events', 'O'), (',', 'O'), ('including', 'O'), ('death', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('clinical', 'O'), ('studies', 'O'), ('with', 'O'), ('ARCAPTA', 'O'), ('NEOHALER', 'O'), ('.', 'O')]"
"In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",ECG changes is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), (',', 'O'), ('beta-agonists', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('produce', 'O'), ('ECG', 'B-ADR'), ('changes', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('flattening', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('T', 'I-ADR'), ('wave', 'I-ADR'), (',', 'O'), ('prolongation', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('QTc', 'I-ADR'), ('interval', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ST', 'B-ADR'), ('segment', 'I-ADR'), ('depression', 'I-ADR'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('clinical', 'O'), ('significance', 'O'), ('of', 'O'), ('these', 'O'), ('findings', 'O'), ('is', 'O'), ('unknown', 'O'), ('.', 'O')]"
"In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",flattening of the T wave is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), (',', 'O'), ('beta-agonists', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('produce', 'O'), ('ECG', 'B-ADR'), ('changes', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('flattening', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('T', 'I-ADR'), ('wave', 'I-ADR'), (',', 'O'), ('prolongation', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('QTc', 'I-ADR'), ('interval', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ST', 'B-ADR'), ('segment', 'I-ADR'), ('depression', 'I-ADR'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('clinical', 'O'), ('significance', 'O'), ('of', 'O'), ('these', 'O'), ('findings', 'O'), ('is', 'O'), ('unknown', 'O'), ('.', 'O')]"
"In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",prolongation of the QTc interval is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), (',', 'O'), ('beta-agonists', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('produce', 'O'), ('ECG', 'B-ADR'), ('changes', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('flattening', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('T', 'I-ADR'), ('wave', 'I-ADR'), (',', 'O'), ('prolongation', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('QTc', 'I-ADR'), ('interval', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ST', 'B-ADR'), ('segment', 'I-ADR'), ('depression', 'I-ADR'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('clinical', 'O'), ('significance', 'O'), ('of', 'O'), ('these', 'O'), ('findings', 'O'), ('is', 'O'), ('unknown', 'O'), ('.', 'O')]"
"In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",ST segment depression is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), (',', 'O'), ('beta-agonists', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('produce', 'O'), ('ECG', 'B-ADR'), ('changes', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('flattening', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('T', 'I-ADR'), ('wave', 'I-ADR'), (',', 'O'), ('prolongation', 'B-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('QTc', 'I-ADR'), ('interval', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ST', 'B-ADR'), ('segment', 'I-ADR'), ('depression', 'I-ADR'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('clinical', 'O'), ('significance', 'O'), ('of', 'O'), ('these', 'O'), ('findings', 'O'), ('is', 'O'), ('unknown', 'O'), ('.', 'O')]"
(5.1)     *  Hypotension and reflex tachycardia are potential consequences of rapid upward titration of Cleviprex.,Hypotension is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Hypotension', 'B-ADR'), ('and', 'O'), ('reflex', 'B-ADR'), ('tachycardia', 'I-ADR'), ('are', 'O'), ('potential', 'O'), ('consequences', 'O'), ('of', 'O'), ('rapid', 'O'), ('upward', 'O'), ('titration', 'O'), ('of', 'O'), ('Cleviprex', 'O'), ('.', 'O')]"
(5.1)     *  Hypotension and reflex tachycardia are potential consequences of rapid upward titration of Cleviprex.,reflex tachycardia is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Hypotension', 'B-ADR'), ('and', 'O'), ('reflex', 'B-ADR'), ('tachycardia', 'I-ADR'), ('are', 'O'), ('potential', 'O'), ('consequences', 'O'), ('of', 'O'), ('rapid', 'O'), ('upward', 'O'), ('titration', 'O'), ('of', 'O'), ('Cleviprex', 'O'), ('.', 'O')]"
"(  2.3  ,  5.3  )   *  Fluid Retention: Monitor patients and manage using standard of care treatment.",Fluid Retention is an adverse reaction entity,"[('(', 'O'), ('2.3', 'O'), (',', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Fluid', 'B-ADR'), ('Retention', 'I-ADR'), (':', 'O'), ('Monitor', 'O'), ('patients', 'O'), ('and', 'O'), ('manage', 'O'), ('using', 'O'), ('standard', 'O'), ('of', 'O'), ('care', 'O'), ('treatment', 'O'), ('.', 'O')]"
5.3 Hepatic Toxicity      One case consistent with drug induced liver injury (defined as concurrent elevations in ALT or AST greater than or equal to 3*ULN with total bilirubin greater than 2*ULN and alkaline phosphatase less than 2*ULN) occurred in a trial of BOSULIF in combination with letrozole.,drug induced liver injury is an adverse reaction entity,"[('5.3', 'O'), ('Hepatic', 'O'), ('Toxicity', 'O'), ('One', 'O'), ('case', 'O'), ('consistent', 'O'), ('with', 'O'), ('drug', 'B-ADR'), ('induced', 'I-ADR'), ('liver', 'I-ADR'), ('injury', 'I-ADR'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('concurrent', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('ALT', 'I-ADR'), ('or', 'O'), ('AST', 'I-ADR'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('3', 'O'), ('*', 'O'), ('ULN', 'O'), ('with', 'O'), ('total', 'B-ADR'), ('bilirubin', 'I-ADR'), ('greater', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), ('and', 'O'), ('alkaline', 'B-ADR'), ('phosphatase', 'I-ADR'), ('less', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('trial', 'O'), ('of', 'O'), ('BOSULIF', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('letrozole', 'O'), ('.', 'O')]"
5.3 Hepatic Toxicity      One case consistent with drug induced liver injury (defined as concurrent elevations in ALT or AST greater than or equal to 3*ULN with total bilirubin greater than 2*ULN and alkaline phosphatase less than 2*ULN) occurred in a trial of BOSULIF in combination with letrozole.,elevations in ALT is an adverse reaction entity,"[('5.3', 'O'), ('Hepatic', 'O'), ('Toxicity', 'O'), ('One', 'O'), ('case', 'O'), ('consistent', 'O'), ('with', 'O'), ('drug', 'B-ADR'), ('induced', 'I-ADR'), ('liver', 'I-ADR'), ('injury', 'I-ADR'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('concurrent', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('ALT', 'I-ADR'), ('or', 'O'), ('AST', 'I-ADR'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('3', 'O'), ('*', 'O'), ('ULN', 'O'), ('with', 'O'), ('total', 'B-ADR'), ('bilirubin', 'I-ADR'), ('greater', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), ('and', 'O'), ('alkaline', 'B-ADR'), ('phosphatase', 'I-ADR'), ('less', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('trial', 'O'), ('of', 'O'), ('BOSULIF', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('letrozole', 'O'), ('.', 'O')]"
5.3 Hepatic Toxicity      One case consistent with drug induced liver injury (defined as concurrent elevations in ALT or AST greater than or equal to 3*ULN with total bilirubin greater than 2*ULN and alkaline phosphatase less than 2*ULN) occurred in a trial of BOSULIF in combination with letrozole.,elevations in AST is an adverse reaction entity,"[('5.3', 'O'), ('Hepatic', 'O'), ('Toxicity', 'O'), ('One', 'O'), ('case', 'O'), ('consistent', 'O'), ('with', 'O'), ('drug', 'B-ADR'), ('induced', 'I-ADR'), ('liver', 'I-ADR'), ('injury', 'I-ADR'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('concurrent', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('ALT', 'I-ADR'), ('or', 'O'), ('AST', 'I-ADR'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('3', 'O'), ('*', 'O'), ('ULN', 'O'), ('with', 'O'), ('total', 'B-ADR'), ('bilirubin', 'I-ADR'), ('greater', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), ('and', 'O'), ('alkaline', 'B-ADR'), ('phosphatase', 'I-ADR'), ('less', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('trial', 'O'), ('of', 'O'), ('BOSULIF', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('letrozole', 'O'), ('.', 'O')]"
5.3 Hepatic Toxicity      One case consistent with drug induced liver injury (defined as concurrent elevations in ALT or AST greater than or equal to 3*ULN with total bilirubin greater than 2*ULN and alkaline phosphatase less than 2*ULN) occurred in a trial of BOSULIF in combination with letrozole.,total bilirubin greater than 2*ULN is an adverse reaction entity,"[('5.3', 'O'), ('Hepatic', 'O'), ('Toxicity', 'O'), ('One', 'O'), ('case', 'O'), ('consistent', 'O'), ('with', 'O'), ('drug', 'B-ADR'), ('induced', 'I-ADR'), ('liver', 'I-ADR'), ('injury', 'I-ADR'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('concurrent', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('ALT', 'I-ADR'), ('or', 'O'), ('AST', 'I-ADR'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('3', 'O'), ('*', 'O'), ('ULN', 'O'), ('with', 'O'), ('total', 'B-ADR'), ('bilirubin', 'I-ADR'), ('greater', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), ('and', 'O'), ('alkaline', 'B-ADR'), ('phosphatase', 'I-ADR'), ('less', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('trial', 'O'), ('of', 'O'), ('BOSULIF', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('letrozole', 'O'), ('.', 'O')]"
5.3 Hepatic Toxicity      One case consistent with drug induced liver injury (defined as concurrent elevations in ALT or AST greater than or equal to 3*ULN with total bilirubin greater than 2*ULN and alkaline phosphatase less than 2*ULN) occurred in a trial of BOSULIF in combination with letrozole.,alkaline phosphatase less than 2*ULN is an adverse reaction entity,"[('5.3', 'O'), ('Hepatic', 'O'), ('Toxicity', 'O'), ('One', 'O'), ('case', 'O'), ('consistent', 'O'), ('with', 'O'), ('drug', 'B-ADR'), ('induced', 'I-ADR'), ('liver', 'I-ADR'), ('injury', 'I-ADR'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('concurrent', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('ALT', 'I-ADR'), ('or', 'O'), ('AST', 'I-ADR'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('3', 'O'), ('*', 'O'), ('ULN', 'O'), ('with', 'O'), ('total', 'B-ADR'), ('bilirubin', 'I-ADR'), ('greater', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), ('and', 'O'), ('alkaline', 'B-ADR'), ('phosphatase', 'I-ADR'), ('less', 'I-ADR'), ('than', 'I-ADR'), ('2', 'I-ADR'), ('*', 'I-ADR'), ('ULN', 'I-ADR'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('trial', 'O'), ('of', 'O'), ('BOSULIF', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('letrozole', 'O'), ('.', 'O')]"
"Hypersensitivity reactions (dyspnea, angioedema, rash, and pruritus) have been reported.",Hypersensitivity reactions is an adverse reaction entity,"[('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pruritus', 'B-ADR'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O')]"
"Hypersensitivity reactions (dyspnea, angioedema, rash, and pruritus) have been reported.",dyspnea is an adverse reaction entity,"[('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pruritus', 'B-ADR'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O')]"
"Hypersensitivity reactions (dyspnea, angioedema, rash, and pruritus) have been reported.",angioedema is an adverse reaction entity,"[('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pruritus', 'B-ADR'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O')]"
"Hypersensitivity reactions (dyspnea, angioedema, rash, and pruritus) have been reported.",rash is an adverse reaction entity,"[('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pruritus', 'B-ADR'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O')]"
"Hypersensitivity reactions (dyspnea, angioedema, rash, and pruritus) have been reported.",pruritus is an adverse reaction entity,"[('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('dyspnea', 'B-ADR'), (',', 'O'), ('angioedema', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pruritus', 'B-ADR'), (')', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O')]"
"6             ADVERSE REACTIONS      EXCERPT:   Most common adverse reactions (> 1% and more common than with placebo): ocular irritation, application site irritation, and application site anesthesia and hypoesthesia.",ocular irritation is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('and', 'O'), ('more', 'O'), ('common', 'O'), ('than', 'O'), ('with', 'O'), ('placebo', 'O'), (')', 'O'), (':', 'O'), ('ocular', 'B-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('and', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('anesthesia', 'I-ADR'), ('and', 'O'), ('hypoesthesia', 'I-ADR'), ('.', 'O')]"
"6             ADVERSE REACTIONS      EXCERPT:   Most common adverse reactions (> 1% and more common than with placebo): ocular irritation, application site irritation, and application site anesthesia and hypoesthesia.",application site irritation is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('and', 'O'), ('more', 'O'), ('common', 'O'), ('than', 'O'), ('with', 'O'), ('placebo', 'O'), (')', 'O'), (':', 'O'), ('ocular', 'B-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('and', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('anesthesia', 'I-ADR'), ('and', 'O'), ('hypoesthesia', 'I-ADR'), ('.', 'O')]"
"6             ADVERSE REACTIONS      EXCERPT:   Most common adverse reactions (> 1% and more common than with placebo): ocular irritation, application site irritation, and application site anesthesia and hypoesthesia.",application site anesthesia is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('and', 'O'), ('more', 'O'), ('common', 'O'), ('than', 'O'), ('with', 'O'), ('placebo', 'O'), (')', 'O'), (':', 'O'), ('ocular', 'B-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('and', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('anesthesia', 'I-ADR'), ('and', 'O'), ('hypoesthesia', 'I-ADR'), ('.', 'O')]"
"6             ADVERSE REACTIONS      EXCERPT:   Most common adverse reactions (> 1% and more common than with placebo): ocular irritation, application site irritation, and application site anesthesia and hypoesthesia.",application site hypoesthesia is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('1', 'O'), ('%', 'O'), ('and', 'O'), ('more', 'O'), ('common', 'O'), ('than', 'O'), ('with', 'O'), ('placebo', 'O'), (')', 'O'), (':', 'O'), ('ocular', 'B-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('and', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('anesthesia', 'I-ADR'), ('and', 'O'), ('hypoesthesia', 'I-ADR'), ('.', 'O')]"
"In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy.",rash is an adverse reaction entity,"[('In', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('cases', 'O'), (',', 'O'), ('rash', 'B-ADR'), ('was', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), (',', 'O'), ('of', 'O'), ('macular/papular', 'I-ADR'), ('type', 'O'), (',', 'O'), ('and', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('second', 'O'), ('week', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O')]"
"In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy.",rash macular is an adverse reaction entity,"[('In', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('cases', 'O'), (',', 'O'), ('rash', 'B-ADR'), ('was', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), (',', 'O'), ('of', 'O'), ('macular/papular', 'I-ADR'), ('type', 'O'), (',', 'O'), ('and', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('second', 'O'), ('week', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O')]"
"In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy.",rash papular is an adverse reaction entity,"[('In', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('cases', 'O'), (',', 'O'), ('rash', 'B-ADR'), ('was', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), (',', 'O'), ('of', 'O'), ('macular/papular', 'I-ADR'), ('type', 'O'), (',', 'O'), ('and', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('second', 'O'), ('week', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O')]"
Immune System Disorders  : Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported [  see  Warnings and Precautions (5.1)    ].,hypersensitivity is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), (':', 'O'), ('Severe', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'O'), ('including', 'O'), ('DRESS', 'B-ADR'), ('and', 'O'), ('cases', 'O'), ('of', 'O'), ('hepatic', 'B-ADR'), ('failure', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
Immune System Disorders  : Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported [  see  Warnings and Precautions (5.1)    ].,DRESS is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), (':', 'O'), ('Severe', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'O'), ('including', 'O'), ('DRESS', 'B-ADR'), ('and', 'O'), ('cases', 'O'), ('of', 'O'), ('hepatic', 'B-ADR'), ('failure', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
Immune System Disorders  : Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported [  see  Warnings and Precautions (5.1)    ].,hepatic failure is an adverse reaction entity,"[('Immune', 'O'), ('System', 'O'), ('Disorders', 'O'), (':', 'O'), ('Severe', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'O'), ('including', 'O'), ('DRESS', 'B-ADR'), ('and', 'O'), ('cases', 'O'), ('of', 'O'), ('hepatic', 'B-ADR'), ('failure', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction, toxic epidermal necrolysis and erythema multiforme.",Stevens-Johnson syndrome is an adverse reaction entity,"[('This', 'O'), ('includes', 'O'), ('cases', 'O'), ('of', 'O'), ('Stevens-Johnson', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('reaction', 'I-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), ('and', 'O'), ('erythema', 'B-ADR'), ('multiforme', 'I-ADR'), ('.', 'O')]"
"This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction, toxic epidermal necrolysis and erythema multiforme.",hypersensitivity reaction is an adverse reaction entity,"[('This', 'O'), ('includes', 'O'), ('cases', 'O'), ('of', 'O'), ('Stevens-Johnson', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('reaction', 'I-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), ('and', 'O'), ('erythema', 'B-ADR'), ('multiforme', 'I-ADR'), ('.', 'O')]"
"This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction, toxic epidermal necrolysis and erythema multiforme.",toxic epidermal necrolysis is an adverse reaction entity,"[('This', 'O'), ('includes', 'O'), ('cases', 'O'), ('of', 'O'), ('Stevens-Johnson', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('reaction', 'I-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), ('and', 'O'), ('erythema', 'B-ADR'), ('multiforme', 'I-ADR'), ('.', 'O')]"
"This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction, toxic epidermal necrolysis and erythema multiforme.",erythema multiforme is an adverse reaction entity,"[('This', 'O'), ('includes', 'O'), ('cases', 'O'), ('of', 'O'), ('Stevens-Johnson', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('reaction', 'I-ADR'), (',', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), ('and', 'O'), ('erythema', 'B-ADR'), ('multiforme', 'I-ADR'), ('.', 'O')]"
"The most common Grade 3 or 4 non-hematological adverse reactions (>= 5%) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.",pneumonia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('non-hematological', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('and', 'O'), ('skin', 'B-ADR'), ('infections', 'I-ADR'), ('.', 'O')]"
"The most common Grade 3 or 4 non-hematological adverse reactions (>= 5%) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.",abdominal pain is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('non-hematological', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('and', 'O'), ('skin', 'B-ADR'), ('infections', 'I-ADR'), ('.', 'O')]"
"The most common Grade 3 or 4 non-hematological adverse reactions (>= 5%) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.",atrial fibrillation is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('non-hematological', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('and', 'O'), ('skin', 'B-ADR'), ('infections', 'I-ADR'), ('.', 'O')]"
"The most common Grade 3 or 4 non-hematological adverse reactions (>= 5%) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.",diarrhea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('non-hematological', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('and', 'O'), ('skin', 'B-ADR'), ('infections', 'I-ADR'), ('.', 'O')]"
"The most common Grade 3 or 4 non-hematological adverse reactions (>= 5%) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.",fatigue is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('non-hematological', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('and', 'O'), ('skin', 'B-ADR'), ('infections', 'I-ADR'), ('.', 'O')]"
"The most common Grade 3 or 4 non-hematological adverse reactions (>= 5%) were pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.",skin infections is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('non-hematological', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('atrial', 'B-ADR'), ('fibrillation', 'I-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('and', 'O'), ('skin', 'B-ADR'), ('infections', 'I-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",thrombocytopenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",neutropenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",diarrhea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",anemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",fatigue is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",musculoskeletal pain is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",upper respiratory tract infection is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",rash is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",nausea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in Study 1 and Study 2 (>= 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, upper respiratory tract infection, rash, nausea, and pyrexia.",pyrexia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('respiratory', 'I-ADR'), ('tract', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in the WM trial (>= 20%) were neutropenia, thrombocytopenia, diarrhea, rash, nausea, muscle spasms, and fatigue.",neutropenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('the', 'O'), ('WM', 'O'), ('trial', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms', 'I-ADR'), (',', 'O'), ('and', 'O'), ('fatigue', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in the WM trial (>= 20%) were neutropenia, thrombocytopenia, diarrhea, rash, nausea, muscle spasms, and fatigue.",thrombocytopenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('the', 'O'), ('WM', 'O'), ('trial', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms', 'I-ADR'), (',', 'O'), ('and', 'O'), ('fatigue', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in the WM trial (>= 20%) were neutropenia, thrombocytopenia, diarrhea, rash, nausea, muscle spasms, and fatigue.",diarrhea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('the', 'O'), ('WM', 'O'), ('trial', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms', 'I-ADR'), (',', 'O'), ('and', 'O'), ('fatigue', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in the WM trial (>= 20%) were neutropenia, thrombocytopenia, diarrhea, rash, nausea, muscle spasms, and fatigue.",rash is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('the', 'O'), ('WM', 'O'), ('trial', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms', 'I-ADR'), (',', 'O'), ('and', 'O'), ('fatigue', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in the WM trial (>= 20%) were neutropenia, thrombocytopenia, diarrhea, rash, nausea, muscle spasms, and fatigue.",nausea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('the', 'O'), ('WM', 'O'), ('trial', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms', 'I-ADR'), (',', 'O'), ('and', 'O'), ('fatigue', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in the WM trial (>= 20%) were neutropenia, thrombocytopenia, diarrhea, rash, nausea, muscle spasms, and fatigue.",muscle spasms is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('the', 'O'), ('WM', 'O'), ('trial', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms', 'I-ADR'), (',', 'O'), ('and', 'O'), ('fatigue', 'B-ADR'), ('.', 'O')]"
"The most commonly occurring adverse reactions in the WM trial (>= 20%) were neutropenia, thrombocytopenia, diarrhea, rash, nausea, muscle spasms, and fatigue.",fatigue is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('occurring', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('the', 'O'), ('WM', 'O'), ('trial', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('thrombocytopenia', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms', 'I-ADR'), (',', 'O'), ('and', 'O'), ('fatigue', 'B-ADR'), ('.', 'O')]"
"In addition to the adverse reactions presented in Table 1, dizziness was reported in more than 1% of ULORIC-treated subjects although not at a rate more than 0.5% greater than placebo.",dizziness is an adverse reaction entity,"[('In', 'O'), ('addition', 'O'), ('to', 'O'), ('the', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('presented', 'O'), ('in', 'O'), ('Table', 'O'), ('1', 'O'), (',', 'O'), ('dizziness', 'B-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('more', 'O'), ('than', 'O'), ('1', 'O'), ('%', 'O'), ('of', 'O'), ('ULORIC-treated', 'O'), ('subjects', 'O'), ('although', 'O'), ('not', 'O'), ('at', 'O'), ('a', 'O'), ('rate', 'O'), ('more', 'O'), ('than', 'O'), ('0.5', 'O'), ('%', 'O'), ('greater', 'O'), ('than', 'O'), ('placebo', 'O'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",arthritis is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",joint stiffness is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",joint swelling is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",muscle spasms is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",muscle twitching is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",muscle tightness is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",muscle weakness is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",musculoskeletal pain is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",musculoskeletal stiffness is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"Musculoskeletal and Connective Tissue Disorders  : arthritis, joint stiffness, joint swelling, muscle spasms/twitching/tightness/weakness, musculoskeletal pain/stiffness, myalgia.",myalgia is an adverse reaction entity,"[('Musculoskeletal', 'O'), ('and', 'O'), ('Connective', 'O'), ('Tissue', 'O'), ('Disorders', 'O'), (':', 'O'), ('arthritis', 'B-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('stiffness', 'I-ADR'), (',', 'O'), ('joint', 'B-ADR'), ('swelling', 'I-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('spasms/twitching/tightness/weakness', 'I-ADR'), (',', 'O'), ('musculoskeletal', 'B-ADR'), ('pain/stiffness', 'I-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), ('.', 'O')]"
"5.3 Hepatic Effects       There have been postmarketing reports of fatal and non-fatal hepatic failure in patients taking ULORIC, although the reports contain insufficient information necessary to establish the probable cause.",fatal is an adverse reaction entity,"[('5.3', 'O'), ('Hepatic', 'O'), ('Effects', 'O'), ('There', 'O'), ('have', 'O'), ('been', 'O'), ('postmarketing', 'O'), ('reports', 'O'), ('of', 'O'), ('fatal', 'B-ADR'), ('and', 'O'), ('non-fatal', 'O'), ('hepatic', 'B-ADR'), ('failure', 'I-ADR'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('ULORIC', 'O'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('reports', 'O'), ('contain', 'O'), ('insufficient', 'O'), ('information', 'O'), ('necessary', 'O'), ('to', 'O'), ('establish', 'O'), ('the', 'O'), ('probable', 'O'), ('cause', 'O'), ('.', 'O')]"
"5.3 Hepatic Effects       There have been postmarketing reports of fatal and non-fatal hepatic failure in patients taking ULORIC, although the reports contain insufficient information necessary to establish the probable cause.",hepatic failure is an adverse reaction entity,"[('5.3', 'O'), ('Hepatic', 'O'), ('Effects', 'O'), ('There', 'O'), ('have', 'O'), ('been', 'O'), ('postmarketing', 'O'), ('reports', 'O'), ('of', 'O'), ('fatal', 'B-ADR'), ('and', 'O'), ('non-fatal', 'O'), ('hepatic', 'B-ADR'), ('failure', 'I-ADR'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('ULORIC', 'O'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('reports', 'O'), ('contain', 'O'), ('insufficient', 'O'), ('information', 'O'), ('necessary', 'O'), ('to', 'O'), ('establish', 'O'), ('the', 'O'), ('probable', 'O'), ('cause', 'O'), ('.', 'O')]"
"Most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection.",adverse reactions of the penis is an adverse reaction entity,"[('Most', 'O'), ('adverse', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('local', 'O'), ('events', 'O'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), ('and', 'O'), ('groin', 'I-ADR'), ('and', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('these', 'O'), ('events', 'O'), ('were', 'O'), ('of', 'O'), ('mild', 'O'), ('or', 'O'), ('moderate', 'O'), ('severity', 'O'), (',', 'O'), ('and', 'O'), ('most', 'O'), ('(', 'O'), ('79', 'O'), ('%', 'O'), (')', 'O'), ('resolved', 'O'), ('within', 'O'), ('14', 'O'), ('days', 'O'), ('of', 'O'), ('the', 'O'), ('injection', 'O'), ('.', 'O')]"
"Most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection.",adverse reactions of the penis is an adverse reaction entity,"[('Most', 'O'), ('adverse', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('local', 'O'), ('events', 'O'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), ('and', 'O'), ('groin', 'I-ADR'), ('and', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('these', 'O'), ('events', 'O'), ('were', 'O'), ('of', 'O'), ('mild', 'O'), ('or', 'O'), ('moderate', 'O'), ('severity', 'O'), (',', 'O'), ('and', 'O'), ('most', 'O'), ('(', 'O'), ('79', 'O'), ('%', 'O'), (')', 'O'), ('resolved', 'O'), ('within', 'O'), ('14', 'O'), ('days', 'O'), ('of', 'O'), ('the', 'O'), ('injection', 'O'), ('.', 'O')]"
"Most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection.",adverse reactions of the groin is an adverse reaction entity,"[('Most', 'O'), ('adverse', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('local', 'O'), ('events', 'O'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), ('and', 'O'), ('groin', 'I-ADR'), ('and', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('these', 'O'), ('events', 'O'), ('were', 'O'), ('of', 'O'), ('mild', 'O'), ('or', 'O'), ('moderate', 'O'), ('severity', 'O'), (',', 'O'), ('and', 'O'), ('most', 'O'), ('(', 'O'), ('79', 'O'), ('%', 'O'), (')', 'O'), ('resolved', 'O'), ('within', 'O'), ('14', 'O'), ('days', 'O'), ('of', 'O'), ('the', 'O'), ('injection', 'O'), ('.', 'O')]"
"Most adverse reactions were local events of the penis and groin and the majority of these events were of mild or moderate severity, and most (79%) resolved within 14 days of the injection.",adverse reactions of the groin is an adverse reaction entity,"[('Most', 'O'), ('adverse', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('local', 'O'), ('events', 'O'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), ('and', 'O'), ('groin', 'I-ADR'), ('and', 'O'), ('the', 'O'), ('majority', 'O'), ('of', 'O'), ('these', 'O'), ('events', 'O'), ('were', 'O'), ('of', 'O'), ('mild', 'O'), ('or', 'O'), ('moderate', 'O'), ('severity', 'O'), (',', 'O'), ('and', 'O'), ('most', 'O'), ('(', 'O'), ('79', 'O'), ('%', 'O'), (')', 'O'), ('resolved', 'O'), ('within', 'O'), ('14', 'O'), ('days', 'O'), ('of', 'O'), ('the', 'O'), ('injection', 'O'), ('.', 'O')]"
"Reports of penile ""popping"" sounds or sensations    A popping noise or popping sensation in the penis, sometimes described as ""snapping"" or ""cracking"", and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.",popping noise in the penis is an adverse reaction entity,"[('Reports', 'O'), ('of', 'O'), ('penile', 'O'), ('``', 'O'), ('popping', 'I-ADR'), (""''"", 'O'), ('sounds', 'O'), ('or', 'O'), ('sensations', 'O'), ('A', 'O'), ('popping', 'B-ADR'), ('noise', 'I-ADR'), ('or', 'O'), ('popping', 'B-ADR'), ('sensation', 'I-ADR'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('described', 'O'), ('as', 'O'), ('``', 'O'), ('snapping', 'I-ADR'), (""''"", 'O'), ('or', 'O'), ('``', 'O'), ('cracking', 'I-ADR'), (""''"", 'O'), (',', 'O'), ('and', 'O'), ('sometimes', 'O'), ('accompanied', 'O'), ('by', 'O'), ('detumescence', 'B-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), ('and/or', 'O'), ('pain', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('73/551', 'O'), ('(', 'O'), ('13.2', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('1/281', 'O'), ('(', 'O'), ('0.3', 'O'), ('%', 'O'), (')', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Reports of penile ""popping"" sounds or sensations    A popping noise or popping sensation in the penis, sometimes described as ""snapping"" or ""cracking"", and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.",popping sensation in the penis is an adverse reaction entity,"[('Reports', 'O'), ('of', 'O'), ('penile', 'O'), ('``', 'O'), ('popping', 'I-ADR'), (""''"", 'O'), ('sounds', 'O'), ('or', 'O'), ('sensations', 'O'), ('A', 'O'), ('popping', 'B-ADR'), ('noise', 'I-ADR'), ('or', 'O'), ('popping', 'B-ADR'), ('sensation', 'I-ADR'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('described', 'O'), ('as', 'O'), ('``', 'O'), ('snapping', 'I-ADR'), (""''"", 'O'), ('or', 'O'), ('``', 'O'), ('cracking', 'I-ADR'), (""''"", 'O'), (',', 'O'), ('and', 'O'), ('sometimes', 'O'), ('accompanied', 'O'), ('by', 'O'), ('detumescence', 'B-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), ('and/or', 'O'), ('pain', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('73/551', 'O'), ('(', 'O'), ('13.2', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('1/281', 'O'), ('(', 'O'), ('0.3', 'O'), ('%', 'O'), (')', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Reports of penile ""popping"" sounds or sensations    A popping noise or popping sensation in the penis, sometimes described as ""snapping"" or ""cracking"", and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.",penis snapping is an adverse reaction entity,"[('Reports', 'O'), ('of', 'O'), ('penile', 'O'), ('``', 'O'), ('popping', 'I-ADR'), (""''"", 'O'), ('sounds', 'O'), ('or', 'O'), ('sensations', 'O'), ('A', 'O'), ('popping', 'B-ADR'), ('noise', 'I-ADR'), ('or', 'O'), ('popping', 'B-ADR'), ('sensation', 'I-ADR'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('described', 'O'), ('as', 'O'), ('``', 'O'), ('snapping', 'I-ADR'), (""''"", 'O'), ('or', 'O'), ('``', 'O'), ('cracking', 'I-ADR'), (""''"", 'O'), (',', 'O'), ('and', 'O'), ('sometimes', 'O'), ('accompanied', 'O'), ('by', 'O'), ('detumescence', 'B-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), ('and/or', 'O'), ('pain', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('73/551', 'O'), ('(', 'O'), ('13.2', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('1/281', 'O'), ('(', 'O'), ('0.3', 'O'), ('%', 'O'), (')', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Reports of penile ""popping"" sounds or sensations    A popping noise or popping sensation in the penis, sometimes described as ""snapping"" or ""cracking"", and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.",penis cracking is an adverse reaction entity,"[('Reports', 'O'), ('of', 'O'), ('penile', 'O'), ('``', 'O'), ('popping', 'I-ADR'), (""''"", 'O'), ('sounds', 'O'), ('or', 'O'), ('sensations', 'O'), ('A', 'O'), ('popping', 'B-ADR'), ('noise', 'I-ADR'), ('or', 'O'), ('popping', 'B-ADR'), ('sensation', 'I-ADR'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('described', 'O'), ('as', 'O'), ('``', 'O'), ('snapping', 'I-ADR'), (""''"", 'O'), ('or', 'O'), ('``', 'O'), ('cracking', 'I-ADR'), (""''"", 'O'), (',', 'O'), ('and', 'O'), ('sometimes', 'O'), ('accompanied', 'O'), ('by', 'O'), ('detumescence', 'B-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), ('and/or', 'O'), ('pain', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('73/551', 'O'), ('(', 'O'), ('13.2', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('1/281', 'O'), ('(', 'O'), ('0.3', 'O'), ('%', 'O'), (')', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Reports of penile ""popping"" sounds or sensations    A popping noise or popping sensation in the penis, sometimes described as ""snapping"" or ""cracking"", and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.",detumescence is an adverse reaction entity,"[('Reports', 'O'), ('of', 'O'), ('penile', 'O'), ('``', 'O'), ('popping', 'I-ADR'), (""''"", 'O'), ('sounds', 'O'), ('or', 'O'), ('sensations', 'O'), ('A', 'O'), ('popping', 'B-ADR'), ('noise', 'I-ADR'), ('or', 'O'), ('popping', 'B-ADR'), ('sensation', 'I-ADR'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('described', 'O'), ('as', 'O'), ('``', 'O'), ('snapping', 'I-ADR'), (""''"", 'O'), ('or', 'O'), ('``', 'O'), ('cracking', 'I-ADR'), (""''"", 'O'), (',', 'O'), ('and', 'O'), ('sometimes', 'O'), ('accompanied', 'O'), ('by', 'O'), ('detumescence', 'B-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), ('and/or', 'O'), ('pain', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('73/551', 'O'), ('(', 'O'), ('13.2', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('1/281', 'O'), ('(', 'O'), ('0.3', 'O'), ('%', 'O'), (')', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Reports of penile ""popping"" sounds or sensations    A popping noise or popping sensation in the penis, sometimes described as ""snapping"" or ""cracking"", and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.",hematoma is an adverse reaction entity,"[('Reports', 'O'), ('of', 'O'), ('penile', 'O'), ('``', 'O'), ('popping', 'I-ADR'), (""''"", 'O'), ('sounds', 'O'), ('or', 'O'), ('sensations', 'O'), ('A', 'O'), ('popping', 'B-ADR'), ('noise', 'I-ADR'), ('or', 'O'), ('popping', 'B-ADR'), ('sensation', 'I-ADR'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('described', 'O'), ('as', 'O'), ('``', 'O'), ('snapping', 'I-ADR'), (""''"", 'O'), ('or', 'O'), ('``', 'O'), ('cracking', 'I-ADR'), (""''"", 'O'), (',', 'O'), ('and', 'O'), ('sometimes', 'O'), ('accompanied', 'O'), ('by', 'O'), ('detumescence', 'B-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), ('and/or', 'O'), ('pain', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('73/551', 'O'), ('(', 'O'), ('13.2', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('1/281', 'O'), ('(', 'O'), ('0.3', 'O'), ('%', 'O'), (')', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Reports of penile ""popping"" sounds or sensations    A popping noise or popping sensation in the penis, sometimes described as ""snapping"" or ""cracking"", and sometimes accompanied by detumescence, hematoma and/or pain, were reported in 73/551 (13.2%) XIAFLEX-treated patients and 1/281 (0.3%) placebo-treated patients.",pain is an adverse reaction entity,"[('Reports', 'O'), ('of', 'O'), ('penile', 'O'), ('``', 'O'), ('popping', 'I-ADR'), (""''"", 'O'), ('sounds', 'O'), ('or', 'O'), ('sensations', 'O'), ('A', 'O'), ('popping', 'B-ADR'), ('noise', 'I-ADR'), ('or', 'O'), ('popping', 'B-ADR'), ('sensation', 'I-ADR'), ('in', 'I-ADR'), ('the', 'I-ADR'), ('penis', 'I-ADR'), (',', 'O'), ('sometimes', 'O'), ('described', 'O'), ('as', 'O'), ('``', 'O'), ('snapping', 'I-ADR'), (""''"", 'O'), ('or', 'O'), ('``', 'O'), ('cracking', 'I-ADR'), (""''"", 'O'), (',', 'O'), ('and', 'O'), ('sometimes', 'O'), ('accompanied', 'O'), ('by', 'O'), ('detumescence', 'B-ADR'), (',', 'O'), ('hematoma', 'B-ADR'), ('and/or', 'O'), ('pain', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('73/551', 'O'), ('(', 'O'), ('13.2', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('1/281', 'O'), ('(', 'O'), ('0.3', 'O'), ('%', 'O'), (')', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
XIAFLEX was not associated with shortening of penile length in clinical trials in the treatment of Peyronie's disease.,shortening of penile length is an adverse reaction entity,"[('XIAFLEX', 'O'), ('was', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('shortening', 'B-ADR'), ('of', 'I-ADR'), ('penile', 'I-ADR'), ('length', 'I-ADR'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('Peyronie', 'O'), (""'s"", 'O'), ('disease', 'O'), ('.', 'O')]"
Injection into these structures may result in possible permanent injury such as corporal rupture (penile fracture).,permanent injury is an adverse reaction entity,"[('Injection', 'O'), ('into', 'O'), ('these', 'O'), ('structures', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('possible', 'O'), ('permanent', 'B-ADR'), ('injury', 'I-ADR'), ('such', 'O'), ('as', 'O'), ('corporal', 'B-ADR'), ('rupture', 'I-ADR'), ('(', 'O'), ('penile', 'B-ADR'), ('fracture', 'I-ADR'), (')', 'O'), ('.', 'O')]"
Injection into these structures may result in possible permanent injury such as corporal rupture (penile fracture).,corporal rupture is an adverse reaction entity,"[('Injection', 'O'), ('into', 'O'), ('these', 'O'), ('structures', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('possible', 'O'), ('permanent', 'B-ADR'), ('injury', 'I-ADR'), ('such', 'O'), ('as', 'O'), ('corporal', 'B-ADR'), ('rupture', 'I-ADR'), ('(', 'O'), ('penile', 'B-ADR'), ('fracture', 'I-ADR'), (')', 'O'), ('.', 'O')]"
Injection into these structures may result in possible permanent injury such as corporal rupture (penile fracture).,penile fracture is an adverse reaction entity,"[('Injection', 'O'), ('into', 'O'), ('these', 'O'), ('structures', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('possible', 'O'), ('permanent', 'B-ADR'), ('injury', 'I-ADR'), ('such', 'O'), ('as', 'O'), ('corporal', 'B-ADR'), ('rupture', 'I-ADR'), ('(', 'O'), ('penile', 'B-ADR'), ('fracture', 'I-ADR'), (')', 'O'), ('.', 'O')]"
5.2 Corporal Rupture (Penile Fracture) or Other Serious Injury to the Penis in the Treatment of Peyronie's Disease      Corporal rupture was reported as an adverse reaction after XIAFLEX injections in 5 of 1044 (0.5%) XIAFLEX treated patients in the controlled and uncontrolled clinical trials in Peyronie's disease.,Corporal rupture is an adverse reaction entity,"[('5.2', 'O'), ('Corporal', 'O'), ('Rupture', 'O'), ('(', 'O'), ('Penile', 'O'), ('Fracture', 'O'), (')', 'O'), ('or', 'O'), ('Other', 'O'), ('Serious', 'O'), ('Injury', 'O'), ('to', 'O'), ('the', 'O'), ('Penis', 'O'), ('in', 'O'), ('the', 'O'), ('Treatment', 'O'), ('of', 'O'), ('Peyronie', 'O'), (""'s"", 'O'), ('Disease', 'O'), ('Corporal', 'B-ADR'), ('rupture', 'I-ADR'), ('was', 'O'), ('reported', 'O'), ('as', 'O'), ('an', 'O'), ('adverse', 'O'), ('reaction', 'O'), ('after', 'O'), ('XIAFLEX', 'O'), ('injections', 'O'), ('in', 'O'), ('5', 'O'), ('of', 'O'), ('1044', 'O'), ('(', 'O'), ('0.5', 'O'), ('%', 'O'), (')', 'O'), ('XIAFLEX', 'O'), ('treated', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('controlled', 'O'), ('and', 'O'), ('uncontrolled', 'O'), ('clinical', 'O'), ('trials', 'O'), ('in', 'O'), ('Peyronie', 'O'), (""'s"", 'O'), ('disease', 'O'), ('.', 'O')]"
6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reaction in adults was diarrhea (2%).,diarrhea is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reaction', 'O'), ('in', 'O'), ('adults', 'O'), ('was', 'O'), ('diarrhea', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The most common adverse event leading to discontinuation, hypotension/orthostatic hypotension, was reported by 0.4% (8/2146) patients randomized to Edarbi 40 mg or 80 mg compared to 0% (0/801) patients randomized to placebo.",hypotension is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('event', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), (',', 'O'), ('hypotension/orthostatic', 'B-ADR'), ('hypotension', 'I-ADR'), (',', 'O'), ('was', 'O'), ('reported', 'O'), ('by', 'O'), ('0.4', 'O'), ('%', 'O'), ('(', 'O'), ('8/2146', 'O'), (')', 'O'), ('patients', 'O'), ('randomized', 'O'), ('to', 'O'), ('Edarbi', 'O'), ('40', 'O'), ('mg', 'O'), ('or', 'O'), ('80', 'O'), ('mg', 'O'), ('compared', 'O'), ('to', 'O'), ('0', 'O'), ('%', 'O'), ('(', 'O'), ('0/801', 'O'), (')', 'O'), ('patients', 'O'), ('randomized', 'O'), ('to', 'O'), ('placebo', 'O'), ('.', 'O')]"
"The most common adverse event leading to discontinuation, hypotension/orthostatic hypotension, was reported by 0.4% (8/2146) patients randomized to Edarbi 40 mg or 80 mg compared to 0% (0/801) patients randomized to placebo.",orthostatic hypotension is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('event', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), (',', 'O'), ('hypotension/orthostatic', 'B-ADR'), ('hypotension', 'I-ADR'), (',', 'O'), ('was', 'O'), ('reported', 'O'), ('by', 'O'), ('0.4', 'O'), ('%', 'O'), ('(', 'O'), ('8/2146', 'O'), (')', 'O'), ('patients', 'O'), ('randomized', 'O'), ('to', 'O'), ('Edarbi', 'O'), ('40', 'O'), ('mg', 'O'), ('or', 'O'), ('80', 'O'), ('mg', 'O'), ('compared', 'O'), ('to', 'O'), ('0', 'O'), ('%', 'O'), ('(', 'O'), ('0/801', 'O'), (')', 'O'), ('patients', 'O'), ('randomized', 'O'), ('to', 'O'), ('placebo', 'O'), ('.', 'O')]"
"(  6.1  )   *    In patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea, and headache.",nausea is an adverse reaction entity,"[('(', 'O'), ('6.1', 'O'), (')', 'O'), ('*', 'O'), ('In', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('aplastic', 'O'), ('anemia', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), (':', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"(  6.1  )   *    In patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea, and headache.",fatigue is an adverse reaction entity,"[('(', 'O'), ('6.1', 'O'), (')', 'O'), ('*', 'O'), ('In', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('aplastic', 'O'), ('anemia', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), (':', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"(  6.1  )   *    In patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea, and headache.",cough is an adverse reaction entity,"[('(', 'O'), ('6.1', 'O'), (')', 'O'), ('*', 'O'), ('In', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('aplastic', 'O'), ('anemia', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), (':', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"(  6.1  )   *    In patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea, and headache.",diarrhea is an adverse reaction entity,"[('(', 'O'), ('6.1', 'O'), (')', 'O'), ('*', 'O'), ('In', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('aplastic', 'O'), ('anemia', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), (':', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"(  6.1  )   *    In patients with severe aplastic anemia, the most common adverse reactions (greater than or equal to 20%) were: nausea, fatigue, cough, diarrhea, and headache.",headache is an adverse reaction entity,"[('(', 'O'), ('6.1', 'O'), (')', 'O'), ('*', 'O'), ('In', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('aplastic', 'O'), ('anemia', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), (':', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('fatigue', 'B-ADR'), (',', 'O'), ('cough', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"In a placebo-controlled trial of PROMACTA in patients with chronic liver diseaseand thrombocytopenia not related to ITP, six patients treated with PROMACTA and one patient in the placebo group developed portal vein thromboses  [see Warnings and Precautions (5.3)]  .",portal vein thromboses is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('placebo-controlled', 'O'), ('trial', 'O'), ('of', 'O'), ('PROMACTA', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'O'), ('liver', 'O'), ('diseaseand', 'O'), ('thrombocytopenia', 'O'), ('not', 'O'), ('related', 'O'), ('to', 'O'), ('ITP', 'O'), (',', 'O'), ('six', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('PROMACTA', 'O'), ('and', 'O'), ('one', 'O'), ('patient', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('developed', 'O'), ('portal', 'B-ADR'), ('vein', 'I-ADR'), ('thromboses', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
All of the thrombotic complications reported in the group that received PROMACTA were portal vein thrombosis (PVT).,thrombotic complications is an adverse reaction entity,"[('All', 'O'), ('of', 'O'), ('the', 'O'), ('thrombotic', 'B-ADR'), ('complications', 'I-ADR'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('that', 'O'), ('received', 'O'), ('PROMACTA', 'O'), ('were', 'O'), ('portal', 'B-ADR'), ('vein', 'I-ADR'), ('thrombosis', 'I-ADR'), ('(', 'O'), ('PVT', 'B-ADR'), (')', 'O'), ('.', 'O')]"
All of the thrombotic complications reported in the group that received PROMACTA were portal vein thrombosis (PVT).,portal vein thrombosis is an adverse reaction entity,"[('All', 'O'), ('of', 'O'), ('the', 'O'), ('thrombotic', 'B-ADR'), ('complications', 'I-ADR'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('that', 'O'), ('received', 'O'), ('PROMACTA', 'O'), ('were', 'O'), ('portal', 'B-ADR'), ('vein', 'I-ADR'), ('thrombosis', 'I-ADR'), ('(', 'O'), ('PVT', 'B-ADR'), (')', 'O'), ('.', 'O')]"
All of the thrombotic complications reported in the group that received PROMACTA were portal vein thrombosis (PVT).,PVT is an adverse reaction entity,"[('All', 'O'), ('of', 'O'), ('the', 'O'), ('thrombotic', 'B-ADR'), ('complications', 'I-ADR'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('that', 'O'), ('received', 'O'), ('PROMACTA', 'O'), ('were', 'O'), ('portal', 'B-ADR'), ('vein', 'I-ADR'), ('thrombosis', 'I-ADR'), ('(', 'O'), ('PVT', 'B-ADR'), (')', 'O'), ('.', 'O')]"
Cataracts were observed in toxicology studies of eltrombopag in rodents [see Nonclinical Toxicology (13.2)]  .,Cataracts is an adverse reaction entity,"[('Cataracts', 'B-ADR'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('toxicology', 'O'), ('studies', 'O'), ('of', 'O'), ('eltrombopag', 'O'), ('in', 'O'), ('rodents', 'O'), ('[', 'O'), ('see', 'O'), ('Nonclinical', 'O'), ('Toxicology', 'O'), ('(', 'O'), ('13.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"(  6.1  ,  6.2  ,  6.3  )     Renal angiomyolipoma with TSC: Most common adverse reaction (incidence >= 30%) is stomatitis.",stomatitis is an adverse reaction entity,"[('(', 'O'), ('6.1', 'O'), (',', 'O'), ('6.2', 'O'), (',', 'O'), ('6.3', 'O'), (')', 'O'), ('Renal', 'O'), ('angiomyolipoma', 'O'), ('with', 'O'), ('TSC', 'O'), (':', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reaction', 'O'), ('(', 'O'), ('incidence', 'O'), ('>', 'O'), ('=', 'O'), ('30', 'O'), ('%', 'O'), (')', 'O'), ('is', 'O'), ('stomatitis', 'B-ADR'), ('.', 'O')]"
"b   Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.",diarrhea is an adverse reaction entity,"[('b', 'O'), ('Includes', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('enteritis', 'B-ADR'), (',', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('colitis', 'B-ADR'), (',', 'O'), ('defecation', 'B-ADR'), ('urgency', 'I-ADR'), (',', 'O'), ('and', 'O'), ('steatorrhea', 'B-ADR'), ('.', 'O')]"
"b   Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.",enteritis is an adverse reaction entity,"[('b', 'O'), ('Includes', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('enteritis', 'B-ADR'), (',', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('colitis', 'B-ADR'), (',', 'O'), ('defecation', 'B-ADR'), ('urgency', 'I-ADR'), (',', 'O'), ('and', 'O'), ('steatorrhea', 'B-ADR'), ('.', 'O')]"
"b   Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.",enterocolitis is an adverse reaction entity,"[('b', 'O'), ('Includes', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('enteritis', 'B-ADR'), (',', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('colitis', 'B-ADR'), (',', 'O'), ('defecation', 'B-ADR'), ('urgency', 'I-ADR'), (',', 'O'), ('and', 'O'), ('steatorrhea', 'B-ADR'), ('.', 'O')]"
"b   Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.",colitis is an adverse reaction entity,"[('b', 'O'), ('Includes', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('enteritis', 'B-ADR'), (',', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('colitis', 'B-ADR'), (',', 'O'), ('defecation', 'B-ADR'), ('urgency', 'I-ADR'), (',', 'O'), ('and', 'O'), ('steatorrhea', 'B-ADR'), ('.', 'O')]"
"b   Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.",defecation urgency is an adverse reaction entity,"[('b', 'O'), ('Includes', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('enteritis', 'B-ADR'), (',', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('colitis', 'B-ADR'), (',', 'O'), ('defecation', 'B-ADR'), ('urgency', 'I-ADR'), (',', 'O'), ('and', 'O'), ('steatorrhea', 'B-ADR'), ('.', 'O')]"
"b   Includes diarrhea, enteritis, enterocolitis, colitis, defecation urgency, and steatorrhea.",steatorrhea is an adverse reaction entity,"[('b', 'O'), ('Includes', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('enteritis', 'B-ADR'), (',', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('colitis', 'B-ADR'), (',', 'O'), ('defecation', 'B-ADR'), ('urgency', 'I-ADR'), (',', 'O'), ('and', 'O'), ('steatorrhea', 'B-ADR'), ('.', 'O')]"
"Table 7: Key Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm   Grading according to CTCAE Version 3.0  a  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency.",anemia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Key', 'O'), ('Laboratory', 'O'), ('Abnormalities', 'O'), ('Reported', 'O'), ('in', 'O'), ('Patients', 'O'), ('with', 'O'), ('RCC', 'O'), ('at', 'O'), ('a', 'O'), ('Higher', 'O'), ('Rate', 'O'), ('in', 'O'), ('the', 'O'), ('AFINITOR', 'O'), ('Arm', 'O'), ('than', 'O'), ('the', 'O'), ('Placebo', 'O'), ('Arm', 'O'), ('Grading', 'O'), ('according', 'O'), ('to', 'O'), ('CTCAE', 'O'), ('Version', 'O'), ('3.0', 'O'), ('a', 'O'), ('Reflects', 'O'), ('corresponding', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('reports', 'O'), ('of', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('thrombocytopenia', 'B-ADR'), ('(', 'O'), ('collectively', 'O'), ('pancytopenia', 'B-ADR'), (')', 'O'), (',', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('lower', 'O'), ('frequency', 'O'), ('.', 'O')]"
"Table 7: Key Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm   Grading according to CTCAE Version 3.0  a  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency.",leukopenia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Key', 'O'), ('Laboratory', 'O'), ('Abnormalities', 'O'), ('Reported', 'O'), ('in', 'O'), ('Patients', 'O'), ('with', 'O'), ('RCC', 'O'), ('at', 'O'), ('a', 'O'), ('Higher', 'O'), ('Rate', 'O'), ('in', 'O'), ('the', 'O'), ('AFINITOR', 'O'), ('Arm', 'O'), ('than', 'O'), ('the', 'O'), ('Placebo', 'O'), ('Arm', 'O'), ('Grading', 'O'), ('according', 'O'), ('to', 'O'), ('CTCAE', 'O'), ('Version', 'O'), ('3.0', 'O'), ('a', 'O'), ('Reflects', 'O'), ('corresponding', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('reports', 'O'), ('of', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('thrombocytopenia', 'B-ADR'), ('(', 'O'), ('collectively', 'O'), ('pancytopenia', 'B-ADR'), (')', 'O'), (',', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('lower', 'O'), ('frequency', 'O'), ('.', 'O')]"
"Table 7: Key Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm   Grading according to CTCAE Version 3.0  a  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency.",lymphopenia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Key', 'O'), ('Laboratory', 'O'), ('Abnormalities', 'O'), ('Reported', 'O'), ('in', 'O'), ('Patients', 'O'), ('with', 'O'), ('RCC', 'O'), ('at', 'O'), ('a', 'O'), ('Higher', 'O'), ('Rate', 'O'), ('in', 'O'), ('the', 'O'), ('AFINITOR', 'O'), ('Arm', 'O'), ('than', 'O'), ('the', 'O'), ('Placebo', 'O'), ('Arm', 'O'), ('Grading', 'O'), ('according', 'O'), ('to', 'O'), ('CTCAE', 'O'), ('Version', 'O'), ('3.0', 'O'), ('a', 'O'), ('Reflects', 'O'), ('corresponding', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('reports', 'O'), ('of', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('thrombocytopenia', 'B-ADR'), ('(', 'O'), ('collectively', 'O'), ('pancytopenia', 'B-ADR'), (')', 'O'), (',', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('lower', 'O'), ('frequency', 'O'), ('.', 'O')]"
"Table 7: Key Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm   Grading according to CTCAE Version 3.0  a  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency.",neutropenia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Key', 'O'), ('Laboratory', 'O'), ('Abnormalities', 'O'), ('Reported', 'O'), ('in', 'O'), ('Patients', 'O'), ('with', 'O'), ('RCC', 'O'), ('at', 'O'), ('a', 'O'), ('Higher', 'O'), ('Rate', 'O'), ('in', 'O'), ('the', 'O'), ('AFINITOR', 'O'), ('Arm', 'O'), ('than', 'O'), ('the', 'O'), ('Placebo', 'O'), ('Arm', 'O'), ('Grading', 'O'), ('according', 'O'), ('to', 'O'), ('CTCAE', 'O'), ('Version', 'O'), ('3.0', 'O'), ('a', 'O'), ('Reflects', 'O'), ('corresponding', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('reports', 'O'), ('of', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('thrombocytopenia', 'B-ADR'), ('(', 'O'), ('collectively', 'O'), ('pancytopenia', 'B-ADR'), (')', 'O'), (',', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('lower', 'O'), ('frequency', 'O'), ('.', 'O')]"
"Table 7: Key Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm   Grading according to CTCAE Version 3.0  a  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency.",thrombocytopenia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Key', 'O'), ('Laboratory', 'O'), ('Abnormalities', 'O'), ('Reported', 'O'), ('in', 'O'), ('Patients', 'O'), ('with', 'O'), ('RCC', 'O'), ('at', 'O'), ('a', 'O'), ('Higher', 'O'), ('Rate', 'O'), ('in', 'O'), ('the', 'O'), ('AFINITOR', 'O'), ('Arm', 'O'), ('than', 'O'), ('the', 'O'), ('Placebo', 'O'), ('Arm', 'O'), ('Grading', 'O'), ('according', 'O'), ('to', 'O'), ('CTCAE', 'O'), ('Version', 'O'), ('3.0', 'O'), ('a', 'O'), ('Reflects', 'O'), ('corresponding', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('reports', 'O'), ('of', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('thrombocytopenia', 'B-ADR'), ('(', 'O'), ('collectively', 'O'), ('pancytopenia', 'B-ADR'), (')', 'O'), (',', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('lower', 'O'), ('frequency', 'O'), ('.', 'O')]"
"Table 7: Key Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm   Grading according to CTCAE Version 3.0  a  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively pancytopenia), which occurred at lower frequency.",pancytopenia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Key', 'O'), ('Laboratory', 'O'), ('Abnormalities', 'O'), ('Reported', 'O'), ('in', 'O'), ('Patients', 'O'), ('with', 'O'), ('RCC', 'O'), ('at', 'O'), ('a', 'O'), ('Higher', 'O'), ('Rate', 'O'), ('in', 'O'), ('the', 'O'), ('AFINITOR', 'O'), ('Arm', 'O'), ('than', 'O'), ('the', 'O'), ('Placebo', 'O'), ('Arm', 'O'), ('Grading', 'O'), ('according', 'O'), ('to', 'O'), ('CTCAE', 'O'), ('Version', 'O'), ('3.0', 'O'), ('a', 'O'), ('Reflects', 'O'), ('corresponding', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('reports', 'O'), ('of', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('leukopenia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('thrombocytopenia', 'B-ADR'), ('(', 'O'), ('collectively', 'O'), ('pancytopenia', 'B-ADR'), (')', 'O'), (',', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('lower', 'O'), ('frequency', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",epistaxis is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",decreased appetite is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",otitis media is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",depression is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",abnormal taste is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",increased blood luteinizing hormone levels is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",increased blood LH levels is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",increased blood follicle stimulating hormone levels is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",increased blood FSH levels is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",hypersensitivity is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",ovarian cyst is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",pneumonitis is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR -treated patients: epistaxis (9%), decreased appetite (6%), otitis media (6%), depression (5%), abnormal taste (5%), increased blood luteinizing hormone (LH) levels (4%), increased blood follicle stimulating hormone (FSH) levels (3%), hypersensitivity (3%), ovarian cyst (3%), pneumonitis (1%), and angioedema (1%).",angioedema is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR', 'O'), ('-treated', 'O'), ('patients', 'O'), (':', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('decreased', 'B-ADR'), ('appetite', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('otitis', 'B-ADR'), ('media', 'I-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('depression', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('abnormal', 'B-ADR'), ('taste', 'I-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('follicle', 'I-ADR'), ('stimulating', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('FSH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('ovarian', 'B-ADR'), ('cyst', 'I-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('angioedema', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",nausea is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",pain in extremity is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",insomnia is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",pneumonia is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",epistaxis is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",hypersensitivity is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",increased blood luteinizing hormone levels is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",increased blood LH levels is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients: nausea (8%), pain in extremity (8%), insomnia (6%), pneumonia (6%), epistaxis (5%), hypersensitivity (3%), increased blood luteinizing hormone (LH) levels (1%) and pneumonitis (1%).",pneumonitis is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('additional', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurred', 'O'), ('in', 'O'), ('less', 'O'), ('than', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('AFINITOR-treated', 'O'), ('patients', 'O'), (':', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pain', 'B-ADR'), ('in', 'I-ADR'), ('extremity', 'I-ADR'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('insomnia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('epistaxis', 'B-ADR'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('hypersensitivity', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('luteinizing', 'I-ADR'), ('hormone', 'I-ADR'), ('(', 'O'), ('LH', 'I-ADR'), (')', 'O'), ('levels', 'I-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pneumonitis', 'B-ADR'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",pneumonia is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",mycobacterial infections is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",bacterial infections is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",invasive fungal infections is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",aspergillosis is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",candidiasis is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",pneumocystis jiroveci pneumonia is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",PJP is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",viral infections is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"Localized and systemic infections, including pneumonia, mycobacterial infections, other bacterial infections, invasive fungal infections, such as aspergillosis, candidiasis, or pneumocystis jiroveci pneumonia (PJP) and viral infections including reactivation of hepatitis B virus have occurred in patients taking AFINITOR.",reactivation of hepatitis B virus is an adverse reaction entity,"[('Localized', 'O'), ('and', 'O'), ('systemic', 'O'), ('infections', 'O'), (',', 'O'), ('including', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('mycobacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('other', 'O'), ('bacterial', 'B-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('or', 'O'), ('pneumocystis', 'B-ADR'), ('jiroveci', 'I-ADR'), ('pneumonia', 'I-ADR'), ('(', 'O'), ('PJP', 'B-ADR'), (')', 'O'), ('and', 'O'), ('viral', 'B-ADR'), ('infections', 'I-ADR'), ('including', 'O'), ('reactivation', 'B-ADR'), ('of', 'I-ADR'), ('hepatitis', 'I-ADR'), ('B', 'I-ADR'), ('virus', 'I-ADR'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('AFINITOR', 'O'), ('.', 'O')]"
"For advanced HR+ BC, advanced PNET, advanced RCC, and renal angiomyolipoma with TSC patients with severe hepatic impairment (Child-Pugh class C), AFINITOR may be used at a reduced dose if the desired benefit outweighs the risk.",hepatic impairment is an adverse reaction entity,"[('For', 'O'), ('advanced', 'O'), ('HR+', 'O'), ('BC', 'O'), (',', 'O'), ('advanced', 'O'), ('PNET', 'O'), (',', 'O'), ('advanced', 'O'), ('RCC', 'O'), (',', 'O'), ('and', 'O'), ('renal', 'O'), ('angiomyolipoma', 'O'), ('with', 'O'), ('TSC', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('hepatic', 'B-ADR'), ('impairment', 'I-ADR'), ('(', 'O'), ('Child-Pugh', 'O'), ('class', 'O'), ('C', 'O'), (')', 'O'), (',', 'O'), ('AFINITOR', 'O'), ('may', 'O'), ('be', 'O'), ('used', 'O'), ('at', 'O'), ('a', 'O'), ('reduced', 'O'), ('dose', 'O'), ('if', 'O'), ('the', 'O'), ('desired', 'O'), ('benefit', 'O'), ('outweighs', 'O'), ('the', 'O'), ('risk', 'O'), ('.', 'O')]"
"5.12     Embryo-fetal Toxicity      Based on the mechanism of action, AFINITOR can cause fetal harm.",fetal harm is an adverse reaction entity,"[('5.12', 'O'), ('Embryo-fetal', 'O'), ('Toxicity', 'O'), ('Based', 'O'), ('on', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), (',', 'O'), ('AFINITOR', 'O'), ('can', 'O'), ('cause', 'O'), ('fetal', 'B-ADR'), ('harm', 'I-ADR'), ('.', 'O')]"
"EXCERPT:   Most common adverse reactions (>15%) are gastritis-like symptoms and bleeding  (6.1)           To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or        www.fda.gov/medwatch    .",gastritis is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('15', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('gastritis-like', 'B-ADR'), ('symptoms', 'O'), ('and', 'O'), ('bleeding', 'B-ADR'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), ('To', 'O'), ('report', 'O'), ('SUSPECTED', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), (',', 'O'), ('contact', 'O'), ('Boehringer', 'O'), ('Ingelheim', 'O'), ('Pharmaceuticals', 'O'), (',', 'O'), ('Inc.', 'O'), ('at', 'O'), ('(', 'O'), ('800', 'O'), (')', 'O'), ('542-6257', 'O'), ('or', 'O'), ('(', 'O'), ('800', 'O'), (')', 'O'), ('459-9906', 'O'), ('TTY', 'O'), ('or', 'O'), ('FDA', 'O'), ('at', 'O'), ('1-800-FDA-1088', 'O'), ('or', 'O'), ('www.fda.gov/medwatch', 'O'), ('.', 'O')]"
"EXCERPT:   Most common adverse reactions (>15%) are gastritis-like symptoms and bleeding  (6.1)           To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or        www.fda.gov/medwatch    .",bleeding is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('15', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('gastritis-like', 'B-ADR'), ('symptoms', 'O'), ('and', 'O'), ('bleeding', 'B-ADR'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), ('To', 'O'), ('report', 'O'), ('SUSPECTED', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), (',', 'O'), ('contact', 'O'), ('Boehringer', 'O'), ('Ingelheim', 'O'), ('Pharmaceuticals', 'O'), (',', 'O'), ('Inc.', 'O'), ('at', 'O'), ('(', 'O'), ('800', 'O'), (')', 'O'), ('542-6257', 'O'), ('or', 'O'), ('(', 'O'), ('800', 'O'), (')', 'O'), ('459-9906', 'O'), ('TTY', 'O'), ('or', 'O'), ('FDA', 'O'), ('at', 'O'), ('1-800-FDA-1088', 'O'), ('or', 'O'), ('www.fda.gov/medwatch', 'O'), ('.', 'O')]"
"The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).",bleeding is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('PRADAXA', 'O'), ('were', 'O'), ('bleeding', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('events', 'I-ADR'), ('(', 'O'), ('i.e.', 'O'), (',', 'O'), ('dyspepsia', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('abdominal', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).",gastrointestinal events is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('PRADAXA', 'O'), ('were', 'O'), ('bleeding', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('events', 'I-ADR'), ('(', 'O'), ('i.e.', 'O'), (',', 'O'), ('dyspepsia', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('abdominal', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).",dyspepsia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('PRADAXA', 'O'), ('were', 'O'), ('bleeding', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('events', 'I-ADR'), ('(', 'O'), ('i.e.', 'O'), (',', 'O'), ('dyspepsia', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('abdominal', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).",nausea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('PRADAXA', 'O'), ('were', 'O'), ('bleeding', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('events', 'I-ADR'), ('(', 'O'), ('i.e.', 'O'), (',', 'O'), ('dyspepsia', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('abdominal', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).",upper abdominal pain is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('PRADAXA', 'O'), ('were', 'O'), ('bleeding', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('events', 'I-ADR'), ('(', 'O'), ('i.e.', 'O'), (',', 'O'), ('dyspepsia', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('abdominal', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).",gastrointestinal hemorrhage is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('PRADAXA', 'O'), ('were', 'O'), ('bleeding', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('events', 'I-ADR'), ('(', 'O'), ('i.e.', 'O'), (',', 'O'), ('dyspepsia', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('abdominal', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), (')', 'O'), ('.', 'O')]"
"The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).",diarrhea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('PRADAXA', 'O'), ('were', 'O'), ('bleeding', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('events', 'I-ADR'), ('(', 'O'), ('i.e.', 'O'), (',', 'O'), ('dyspepsia', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('upper', 'B-ADR'), ('abdominal', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B-ADR'), (')', 'O'), ('.', 'O')]"
gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.,Non-intracranial bleed is an adverse reaction entity,"[('gNon-intracranial', 'O'), ('fatal', 'B-ADR'), ('bleed', 'I-ADR'), (':', 'O'), ('Adjudicated', 'O'), ('major', 'O'), ('bleed', 'B-ADR'), ('as', 'O'), ('defined', 'O'), ('above', 'O'), ('and', 'O'), ('adjudicated', 'O'), ('death', 'B-ADR'), ('with', 'O'), ('primary', 'O'), ('cause', 'O'), ('from', 'O'), ('bleeding', 'B-ADR'), ('but', 'O'), ('without', 'O'), ('symptomatic', 'B-ADR'), ('intracranial', 'I-ADR'), ('bleed', 'I-ADR'), ('based', 'O'), ('on', 'O'), ('investigator', 'O'), (""'s"", 'O'), ('clinical', 'O'), ('assessment', 'O'), ('.', 'O')]"
gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.,fatal is an adverse reaction entity,"[('gNon-intracranial', 'O'), ('fatal', 'B-ADR'), ('bleed', 'I-ADR'), (':', 'O'), ('Adjudicated', 'O'), ('major', 'O'), ('bleed', 'B-ADR'), ('as', 'O'), ('defined', 'O'), ('above', 'O'), ('and', 'O'), ('adjudicated', 'O'), ('death', 'B-ADR'), ('with', 'O'), ('primary', 'O'), ('cause', 'O'), ('from', 'O'), ('bleeding', 'B-ADR'), ('but', 'O'), ('without', 'O'), ('symptomatic', 'B-ADR'), ('intracranial', 'I-ADR'), ('bleed', 'I-ADR'), ('based', 'O'), ('on', 'O'), ('investigator', 'O'), (""'s"", 'O'), ('clinical', 'O'), ('assessment', 'O'), ('.', 'O')]"
gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.,bleed is an adverse reaction entity,"[('gNon-intracranial', 'O'), ('fatal', 'B-ADR'), ('bleed', 'I-ADR'), (':', 'O'), ('Adjudicated', 'O'), ('major', 'O'), ('bleed', 'B-ADR'), ('as', 'O'), ('defined', 'O'), ('above', 'O'), ('and', 'O'), ('adjudicated', 'O'), ('death', 'B-ADR'), ('with', 'O'), ('primary', 'O'), ('cause', 'O'), ('from', 'O'), ('bleeding', 'B-ADR'), ('but', 'O'), ('without', 'O'), ('symptomatic', 'B-ADR'), ('intracranial', 'I-ADR'), ('bleed', 'I-ADR'), ('based', 'O'), ('on', 'O'), ('investigator', 'O'), (""'s"", 'O'), ('clinical', 'O'), ('assessment', 'O'), ('.', 'O')]"
gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.,death is an adverse reaction entity,"[('gNon-intracranial', 'O'), ('fatal', 'B-ADR'), ('bleed', 'I-ADR'), (':', 'O'), ('Adjudicated', 'O'), ('major', 'O'), ('bleed', 'B-ADR'), ('as', 'O'), ('defined', 'O'), ('above', 'O'), ('and', 'O'), ('adjudicated', 'O'), ('death', 'B-ADR'), ('with', 'O'), ('primary', 'O'), ('cause', 'O'), ('from', 'O'), ('bleeding', 'B-ADR'), ('but', 'O'), ('without', 'O'), ('symptomatic', 'B-ADR'), ('intracranial', 'I-ADR'), ('bleed', 'I-ADR'), ('based', 'O'), ('on', 'O'), ('investigator', 'O'), (""'s"", 'O'), ('clinical', 'O'), ('assessment', 'O'), ('.', 'O')]"
gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.,bleeding is an adverse reaction entity,"[('gNon-intracranial', 'O'), ('fatal', 'B-ADR'), ('bleed', 'I-ADR'), (':', 'O'), ('Adjudicated', 'O'), ('major', 'O'), ('bleed', 'B-ADR'), ('as', 'O'), ('defined', 'O'), ('above', 'O'), ('and', 'O'), ('adjudicated', 'O'), ('death', 'B-ADR'), ('with', 'O'), ('primary', 'O'), ('cause', 'O'), ('from', 'O'), ('bleeding', 'B-ADR'), ('but', 'O'), ('without', 'O'), ('symptomatic', 'B-ADR'), ('intracranial', 'I-ADR'), ('bleed', 'I-ADR'), ('based', 'O'), ('on', 'O'), ('investigator', 'O'), (""'s"", 'O'), ('clinical', 'O'), ('assessment', 'O'), ('.', 'O')]"
gNon-intracranial fatal bleed: Adjudicated major bleed as defined above and adjudicated death with primary cause from bleeding but without symptomatic intracranial bleed based on investigator's clinical assessment.,symptomatic intracranial bleed is an adverse reaction entity,"[('gNon-intracranial', 'O'), ('fatal', 'B-ADR'), ('bleed', 'I-ADR'), (':', 'O'), ('Adjudicated', 'O'), ('major', 'O'), ('bleed', 'B-ADR'), ('as', 'O'), ('defined', 'O'), ('above', 'O'), ('and', 'O'), ('adjudicated', 'O'), ('death', 'B-ADR'), ('with', 'O'), ('primary', 'O'), ('cause', 'O'), ('from', 'O'), ('bleeding', 'B-ADR'), ('but', 'O'), ('without', 'O'), ('symptomatic', 'B-ADR'), ('intracranial', 'I-ADR'), ('bleed', 'I-ADR'), ('based', 'O'), ('on', 'O'), ('investigator', 'O'), (""'s"", 'O'), ('clinical', 'O'), ('assessment', 'O'), ('.', 'O')]"
Table 3 shows the number of patients experiencing bleeding events in the pooled analysis of RE-COVER and RE-COVER II studies during the full treatment including parenteral and oral only treatment periods after randomization.,bleeding is an adverse reaction entity,"[('Table', 'O'), ('3', 'O'), ('shows', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('patients', 'O'), ('experiencing', 'O'), ('bleeding', 'B-ADR'), ('events', 'O'), ('in', 'O'), ('the', 'O'), ('pooled', 'O'), ('analysis', 'O'), ('of', 'O'), ('RE-COVER', 'O'), ('and', 'O'), ('RE-COVER', 'O'), ('II', 'O'), ('studies', 'O'), ('during', 'O'), ('the', 'O'), ('full', 'O'), ('treatment', 'O'), ('including', 'O'), ('parenteral', 'O'), ('and', 'O'), ('oral', 'O'), ('only', 'O'), ('treatment', 'O'), ('periods', 'O'), ('after', 'O'), ('randomization', 'O'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",Ophthalmic Adverse Reaction is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",Hypersensitivity Reactions is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",local skin reactions is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",application site pain is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",application site pruritus is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",application site irritation is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",application site infection is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",periorbital edema is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",nasopharyngitis is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS               The following serious adverse reactions are discussed in more detail in other sections of the labeling:              *  Ophthalmic Adverse Reaction [see Warnings and Precautions (  5.1  )]    *  Hypersensitivity Reactions [see Warnings and Precautions (  5.2  )]              EXCERPT:   The most common adverse reactions (>=2 %) are local skin reactions, application site pain, application site pruritus, application site irritation, application site infection, periorbital edema, nasopharyngitis and headache.",headache is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('more', 'O'), ('detail', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Ophthalmic', 'B-ADR'), ('Adverse', 'I-ADR'), ('Reaction', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('Reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('local', 'B-ADR'), ('skin', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('pruritus', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('irritation', 'I-ADR'), (',', 'O'), ('application', 'B-ADR'), ('site', 'I-ADR'), ('infection', 'I-ADR'), (',', 'O'), ('periorbital', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('nasopharyngitis', 'B-ADR'), ('and', 'O'), ('headache', 'B-ADR'), ('.', 'O')]"
"(5.3)          5.1 Endophthalmitis and Retinal Detachments    Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments [  seeAdverse Reactions (6.1)  ].",endophthalmitis is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('5.1', 'O'), ('Endophthalmitis', 'O'), ('and', 'O'), ('Retinal', 'O'), ('Detachments', 'O'), ('Intravitreal', 'O'), ('injections', 'O'), (',', 'O'), ('including', 'O'), ('those', 'O'), ('with', 'O'), ('EYLEA', 'O'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('endophthalmitis', 'B-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('detachments', 'I-ADR'), ('[', 'O'), ('seeAdverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"(5.3)          5.1 Endophthalmitis and Retinal Detachments    Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments [  seeAdverse Reactions (6.1)  ].",retinal detachments is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('5.1', 'O'), ('Endophthalmitis', 'O'), ('and', 'O'), ('Retinal', 'O'), ('Detachments', 'O'), ('Intravitreal', 'O'), ('injections', 'O'), (',', 'O'), ('including', 'O'), ('those', 'O'), ('with', 'O'), ('EYLEA', 'O'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('endophthalmitis', 'B-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('detachments', 'I-ADR'), ('[', 'O'), ('seeAdverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"The most common adverse reactions leading to discontinuation were hot flush, abdominal pain upper, and nausea.",hot flush is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('were', 'O'), ('hot', 'B-ADR'), ('flush', 'I-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('upper', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nausea', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions leading to discontinuation were hot flush, abdominal pain upper, and nausea.",abdominal pain upper is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('were', 'O'), ('hot', 'B-ADR'), ('flush', 'I-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('upper', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nausea', 'B-ADR'), ('.', 'O')]"
"The most common adverse reactions leading to discontinuation were hot flush, abdominal pain upper, and nausea.",nausea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('leading', 'O'), ('to', 'O'), ('discontinuation', 'O'), ('were', 'O'), ('hot', 'B-ADR'), ('flush', 'I-ADR'), (',', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('upper', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nausea', 'B-ADR'), ('.', 'O')]"
"DUAVEE has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.",endometrial hyperplasia is an adverse reaction entity,"[('DUAVEE', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('reduce', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('endometrial', 'B-ADR'), ('hyperplasia', 'I-ADR'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('precursor', 'O'), ('to', 'O'), ('endometrial', 'O'), ('cancer', 'O'), ('.', 'O')]"
"Coronary Heart Disease       In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal myocardial infarction, silent myocardial infarction, or CHD death) was reported in women receiving estrogen-alone compared to placebo [see  Clinical Studies (14.5)  ]  .",coronary heart disease is an adverse reaction entity,"[('Coronary', 'O'), ('Heart', 'O'), ('Disease', 'O'), ('In', 'O'), ('the', 'O'), ('WHI', 'O'), ('estrogen-alone', 'O'), ('substudy', 'O'), (',', 'O'), ('no', 'O'), ('overall', 'O'), ('effect', 'O'), ('on', 'O'), ('coronary', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CHD', 'B-ADR'), (')', 'O'), ('events', 'O'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('nonfatal', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('silent', 'B-ADR'), ('myocardial', 'I-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('or', 'O'), ('CHD', 'B-ADR'), ('death', 'I-ADR'), (')', 'O'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('women', 'O'), ('receiving', 'O'), ('estrogen-alone', 'O'), ('compared', 'O'), ('to', 'O'), ('placebo', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Coronary Heart Disease       In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal myocardial infarction, silent myocardial infarction, or CHD death) was reported in women receiving estrogen-alone compared to placebo [see  Clinical Studies (14.5)  ]  .",CHD is an adverse reaction entity,"[('Coronary', 'O'), ('Heart', 'O'), ('Disease', 'O'), ('In', 'O'), ('the', 'O'), ('WHI', 'O'), ('estrogen-alone', 'O'), ('substudy', 'O'), (',', 'O'), ('no', 'O'), ('overall', 'O'), ('effect', 'O'), ('on', 'O'), ('coronary', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CHD', 'B-ADR'), (')', 'O'), ('events', 'O'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('nonfatal', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('silent', 'B-ADR'), ('myocardial', 'I-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('or', 'O'), ('CHD', 'B-ADR'), ('death', 'I-ADR'), (')', 'O'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('women', 'O'), ('receiving', 'O'), ('estrogen-alone', 'O'), ('compared', 'O'), ('to', 'O'), ('placebo', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Coronary Heart Disease       In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal myocardial infarction, silent myocardial infarction, or CHD death) was reported in women receiving estrogen-alone compared to placebo [see  Clinical Studies (14.5)  ]  .",myocardial infarction is an adverse reaction entity,"[('Coronary', 'O'), ('Heart', 'O'), ('Disease', 'O'), ('In', 'O'), ('the', 'O'), ('WHI', 'O'), ('estrogen-alone', 'O'), ('substudy', 'O'), (',', 'O'), ('no', 'O'), ('overall', 'O'), ('effect', 'O'), ('on', 'O'), ('coronary', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CHD', 'B-ADR'), (')', 'O'), ('events', 'O'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('nonfatal', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('silent', 'B-ADR'), ('myocardial', 'I-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('or', 'O'), ('CHD', 'B-ADR'), ('death', 'I-ADR'), (')', 'O'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('women', 'O'), ('receiving', 'O'), ('estrogen-alone', 'O'), ('compared', 'O'), ('to', 'O'), ('placebo', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Coronary Heart Disease       In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal myocardial infarction, silent myocardial infarction, or CHD death) was reported in women receiving estrogen-alone compared to placebo [see  Clinical Studies (14.5)  ]  .",silent myocardial infarction is an adverse reaction entity,"[('Coronary', 'O'), ('Heart', 'O'), ('Disease', 'O'), ('In', 'O'), ('the', 'O'), ('WHI', 'O'), ('estrogen-alone', 'O'), ('substudy', 'O'), (',', 'O'), ('no', 'O'), ('overall', 'O'), ('effect', 'O'), ('on', 'O'), ('coronary', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CHD', 'B-ADR'), (')', 'O'), ('events', 'O'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('nonfatal', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('silent', 'B-ADR'), ('myocardial', 'I-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('or', 'O'), ('CHD', 'B-ADR'), ('death', 'I-ADR'), (')', 'O'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('women', 'O'), ('receiving', 'O'), ('estrogen-alone', 'O'), ('compared', 'O'), ('to', 'O'), ('placebo', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Coronary Heart Disease       In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal myocardial infarction, silent myocardial infarction, or CHD death) was reported in women receiving estrogen-alone compared to placebo [see  Clinical Studies (14.5)  ]  .",CHD death is an adverse reaction entity,"[('Coronary', 'O'), ('Heart', 'O'), ('Disease', 'O'), ('In', 'O'), ('the', 'O'), ('WHI', 'O'), ('estrogen-alone', 'O'), ('substudy', 'O'), (',', 'O'), ('no', 'O'), ('overall', 'O'), ('effect', 'O'), ('on', 'O'), ('coronary', 'B-ADR'), ('heart', 'I-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CHD', 'B-ADR'), (')', 'O'), ('events', 'O'), ('(', 'O'), ('defined', 'O'), ('as', 'O'), ('nonfatal', 'O'), ('myocardial', 'B-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('silent', 'B-ADR'), ('myocardial', 'I-ADR'), ('infarction', 'I-ADR'), (',', 'O'), ('or', 'O'), ('CHD', 'B-ADR'), ('death', 'I-ADR'), (')', 'O'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('women', 'O'), ('receiving', 'O'), ('estrogen-alone', 'O'), ('compared', 'O'), ('to', 'O'), ('placebo', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.5', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.",elevated corticosteroid binding globulin is an adverse reaction entity,"[('Other', 'O'), ('binding', 'O'), ('proteins', 'O'), ('may', 'O'), ('be', 'O'), ('elevated', 'B-ADR'), ('in', 'O'), ('serum', 'O'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('corticosteroid', 'I-ADR'), ('binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('CBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('sex', 'I-ADR'), ('hormone-binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('SHBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('increased', 'B-ADR'), ('total', 'I-ADR'), ('circulating', 'I-ADR'), ('corticosteroids', 'I-ADR'), ('and', 'O'), ('sex', 'I-ADR'), ('steroids', 'I-ADR'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.",elevated CBG is an adverse reaction entity,"[('Other', 'O'), ('binding', 'O'), ('proteins', 'O'), ('may', 'O'), ('be', 'O'), ('elevated', 'B-ADR'), ('in', 'O'), ('serum', 'O'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('corticosteroid', 'I-ADR'), ('binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('CBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('sex', 'I-ADR'), ('hormone-binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('SHBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('increased', 'B-ADR'), ('total', 'I-ADR'), ('circulating', 'I-ADR'), ('corticosteroids', 'I-ADR'), ('and', 'O'), ('sex', 'I-ADR'), ('steroids', 'I-ADR'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.",elevated sex hormone-binding globulin is an adverse reaction entity,"[('Other', 'O'), ('binding', 'O'), ('proteins', 'O'), ('may', 'O'), ('be', 'O'), ('elevated', 'B-ADR'), ('in', 'O'), ('serum', 'O'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('corticosteroid', 'I-ADR'), ('binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('CBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('sex', 'I-ADR'), ('hormone-binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('SHBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('increased', 'B-ADR'), ('total', 'I-ADR'), ('circulating', 'I-ADR'), ('corticosteroids', 'I-ADR'), ('and', 'O'), ('sex', 'I-ADR'), ('steroids', 'I-ADR'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.",elevated SHBG is an adverse reaction entity,"[('Other', 'O'), ('binding', 'O'), ('proteins', 'O'), ('may', 'O'), ('be', 'O'), ('elevated', 'B-ADR'), ('in', 'O'), ('serum', 'O'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('corticosteroid', 'I-ADR'), ('binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('CBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('sex', 'I-ADR'), ('hormone-binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('SHBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('increased', 'B-ADR'), ('total', 'I-ADR'), ('circulating', 'I-ADR'), ('corticosteroids', 'I-ADR'), ('and', 'O'), ('sex', 'I-ADR'), ('steroids', 'I-ADR'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.",increased total circulating corticosteroids is an adverse reaction entity,"[('Other', 'O'), ('binding', 'O'), ('proteins', 'O'), ('may', 'O'), ('be', 'O'), ('elevated', 'B-ADR'), ('in', 'O'), ('serum', 'O'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('corticosteroid', 'I-ADR'), ('binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('CBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('sex', 'I-ADR'), ('hormone-binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('SHBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('increased', 'B-ADR'), ('total', 'I-ADR'), ('circulating', 'I-ADR'), ('corticosteroids', 'I-ADR'), ('and', 'O'), ('sex', 'I-ADR'), ('steroids', 'I-ADR'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.",increased total circulating sex steroids is an adverse reaction entity,"[('Other', 'O'), ('binding', 'O'), ('proteins', 'O'), ('may', 'O'), ('be', 'O'), ('elevated', 'B-ADR'), ('in', 'O'), ('serum', 'O'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('corticosteroid', 'I-ADR'), ('binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('CBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('sex', 'I-ADR'), ('hormone-binding', 'I-ADR'), ('globulin', 'I-ADR'), ('(', 'O'), ('SHBG', 'I-ADR'), (')', 'O'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('increased', 'B-ADR'), ('total', 'I-ADR'), ('circulating', 'I-ADR'), ('corticosteroids', 'I-ADR'), ('and', 'O'), ('sex', 'I-ADR'), ('steroids', 'I-ADR'), (',', 'O'), ('respectively', 'O'), ('.', 'O')]"
"EXCERPT:    *  The most common adverse reactions occurring in >=3% of KALBITOR-treated patients and greater than placebo are headache, nausea, diarrhea, pyrexia, injection site reactions, and nasopharyngitis.",headache is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('>', 'O'), ('=3', 'O'), ('%', 'O'), ('of', 'O'), ('KALBITOR-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('greater', 'O'), ('than', 'O'), ('placebo', 'O'), ('are', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nasopharyngitis', 'B-ADR'), ('.', 'O')]"
"EXCERPT:    *  The most common adverse reactions occurring in >=3% of KALBITOR-treated patients and greater than placebo are headache, nausea, diarrhea, pyrexia, injection site reactions, and nasopharyngitis.",nausea is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('>', 'O'), ('=3', 'O'), ('%', 'O'), ('of', 'O'), ('KALBITOR-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('greater', 'O'), ('than', 'O'), ('placebo', 'O'), ('are', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nasopharyngitis', 'B-ADR'), ('.', 'O')]"
"EXCERPT:    *  The most common adverse reactions occurring in >=3% of KALBITOR-treated patients and greater than placebo are headache, nausea, diarrhea, pyrexia, injection site reactions, and nasopharyngitis.",diarrhea is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('>', 'O'), ('=3', 'O'), ('%', 'O'), ('of', 'O'), ('KALBITOR-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('greater', 'O'), ('than', 'O'), ('placebo', 'O'), ('are', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nasopharyngitis', 'B-ADR'), ('.', 'O')]"
"EXCERPT:    *  The most common adverse reactions occurring in >=3% of KALBITOR-treated patients and greater than placebo are headache, nausea, diarrhea, pyrexia, injection site reactions, and nasopharyngitis.",pyrexia is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('>', 'O'), ('=3', 'O'), ('%', 'O'), ('of', 'O'), ('KALBITOR-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('greater', 'O'), ('than', 'O'), ('placebo', 'O'), ('are', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nasopharyngitis', 'B-ADR'), ('.', 'O')]"
"EXCERPT:    *  The most common adverse reactions occurring in >=3% of KALBITOR-treated patients and greater than placebo are headache, nausea, diarrhea, pyrexia, injection site reactions, and nasopharyngitis.",injection site reactions is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('>', 'O'), ('=3', 'O'), ('%', 'O'), ('of', 'O'), ('KALBITOR-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('greater', 'O'), ('than', 'O'), ('placebo', 'O'), ('are', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nasopharyngitis', 'B-ADR'), ('.', 'O')]"
"EXCERPT:    *  The most common adverse reactions occurring in >=3% of KALBITOR-treated patients and greater than placebo are headache, nausea, diarrhea, pyrexia, injection site reactions, and nasopharyngitis.",nasopharyngitis is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('occurring', 'O'), ('in', 'O'), ('>', 'O'), ('=3', 'O'), ('%', 'O'), ('of', 'O'), ('KALBITOR-treated', 'O'), ('patients', 'O'), ('and', 'O'), ('greater', 'O'), ('than', 'O'), ('placebo', 'O'), ('are', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('pyrexia', 'B-ADR'), (',', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('and', 'O'), ('nasopharyngitis', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS    The following serious reactions are described in greater detail in the Warnings and Precautions section:     *  Hypersensitivity reactions [see  Warnings and Precautions (5.2)  ]    *   Clostridium difficile -associated diarrhea [see  Warnings and Precautions (5.3)  ]         EXCERPT:   The most common adverse reactions (>=5% in either indication) are nausea, diarrhea, headache and pyrexia.",Hypersensitivity reactions is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('reactions', 'O'), ('are', 'O'), ('described', 'O'), ('in', 'O'), ('greater', 'O'), ('detail', 'O'), ('in', 'O'), ('the', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('section', 'O'), (':', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Clostridium', 'B-ADR'), ('difficile', 'I-ADR'), ('-associated', 'I-ADR'), ('diarrhea', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=5', 'O'), ('%', 'O'), ('in', 'O'), ('either', 'O'), ('indication', 'O'), (')', 'O'), ('are', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS    The following serious reactions are described in greater detail in the Warnings and Precautions section:     *  Hypersensitivity reactions [see  Warnings and Precautions (5.2)  ]    *   Clostridium difficile -associated diarrhea [see  Warnings and Precautions (5.3)  ]         EXCERPT:   The most common adverse reactions (>=5% in either indication) are nausea, diarrhea, headache and pyrexia.",Clostridium difficile -associated diarrhea is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('reactions', 'O'), ('are', 'O'), ('described', 'O'), ('in', 'O'), ('greater', 'O'), ('detail', 'O'), ('in', 'O'), ('the', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('section', 'O'), (':', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Clostridium', 'B-ADR'), ('difficile', 'I-ADR'), ('-associated', 'I-ADR'), ('diarrhea', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=5', 'O'), ('%', 'O'), ('in', 'O'), ('either', 'O'), ('indication', 'O'), (')', 'O'), ('are', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS    The following serious reactions are described in greater detail in the Warnings and Precautions section:     *  Hypersensitivity reactions [see  Warnings and Precautions (5.2)  ]    *   Clostridium difficile -associated diarrhea [see  Warnings and Precautions (5.3)  ]         EXCERPT:   The most common adverse reactions (>=5% in either indication) are nausea, diarrhea, headache and pyrexia.",nausea is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('reactions', 'O'), ('are', 'O'), ('described', 'O'), ('in', 'O'), ('greater', 'O'), ('detail', 'O'), ('in', 'O'), ('the', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('section', 'O'), (':', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Clostridium', 'B-ADR'), ('difficile', 'I-ADR'), ('-associated', 'I-ADR'), ('diarrhea', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=5', 'O'), ('%', 'O'), ('in', 'O'), ('either', 'O'), ('indication', 'O'), (')', 'O'), ('are', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS    The following serious reactions are described in greater detail in the Warnings and Precautions section:     *  Hypersensitivity reactions [see  Warnings and Precautions (5.2)  ]    *   Clostridium difficile -associated diarrhea [see  Warnings and Precautions (5.3)  ]         EXCERPT:   The most common adverse reactions (>=5% in either indication) are nausea, diarrhea, headache and pyrexia.",diarrhea is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('reactions', 'O'), ('are', 'O'), ('described', 'O'), ('in', 'O'), ('greater', 'O'), ('detail', 'O'), ('in', 'O'), ('the', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('section', 'O'), (':', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Clostridium', 'B-ADR'), ('difficile', 'I-ADR'), ('-associated', 'I-ADR'), ('diarrhea', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=5', 'O'), ('%', 'O'), ('in', 'O'), ('either', 'O'), ('indication', 'O'), (')', 'O'), ('are', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS    The following serious reactions are described in greater detail in the Warnings and Precautions section:     *  Hypersensitivity reactions [see  Warnings and Precautions (5.2)  ]    *   Clostridium difficile -associated diarrhea [see  Warnings and Precautions (5.3)  ]         EXCERPT:   The most common adverse reactions (>=5% in either indication) are nausea, diarrhea, headache and pyrexia.",headache is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('reactions', 'O'), ('are', 'O'), ('described', 'O'), ('in', 'O'), ('greater', 'O'), ('detail', 'O'), ('in', 'O'), ('the', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('section', 'O'), (':', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Clostridium', 'B-ADR'), ('difficile', 'I-ADR'), ('-associated', 'I-ADR'), ('diarrhea', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=5', 'O'), ('%', 'O'), ('in', 'O'), ('either', 'O'), ('indication', 'O'), (')', 'O'), ('are', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"6 ADVERSE REACTIONS    The following serious reactions are described in greater detail in the Warnings and Precautions section:     *  Hypersensitivity reactions [see  Warnings and Precautions (5.2)  ]    *   Clostridium difficile -associated diarrhea [see  Warnings and Precautions (5.3)  ]         EXCERPT:   The most common adverse reactions (>=5% in either indication) are nausea, diarrhea, headache and pyrexia.",pyrexia is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('serious', 'O'), ('reactions', 'O'), ('are', 'O'), ('described', 'O'), ('in', 'O'), ('greater', 'O'), ('detail', 'O'), ('in', 'O'), ('the', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('section', 'O'), (':', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('*', 'O'), ('Clostridium', 'B-ADR'), ('difficile', 'I-ADR'), ('-associated', 'I-ADR'), ('diarrhea', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=5', 'O'), ('%', 'O'), ('in', 'O'), ('either', 'O'), ('indication', 'O'), (')', 'O'), ('are', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), ('and', 'O'), ('pyrexia', 'B-ADR'), ('.', 'O')]"
"EXCERPT:    *    Most common adverse reaction to GRANIX is bone pain (  6  )      To report SUSPECTED ADVERSE REACTIONS, contact TEVA at 1-866-832-8537 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",bone pain is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reaction', 'O'), ('to', 'O'), ('GRANIX', 'O'), ('is', 'O'), ('bone', 'B-ADR'), ('pain', 'I-ADR'), ('(', 'O'), ('6', 'O'), (')', 'O'), ('To', 'O'), ('report', 'O'), ('SUSPECTED', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), (',', 'O'), ('contact', 'O'), ('TEVA', 'O'), ('at', 'O'), ('1-866-832-8537', 'O'), ('or', 'O'), ('FDA', 'O'), ('at', 'O'), ('1-800-FDA-1088', 'O'), ('or', 'O'), ('www.fda.gov/medwatch', 'O'), ('.', 'O')]"
"Serious adverse reactions, whether considered drug-related or not by the investigators, that occurred more frequently in KALYDECO-treated patients included abdominal pain, increased hepatic enzymes, and hypoglycemia.",abdominal pain is an adverse reaction entity,"[('Serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), (',', 'O'), ('whether', 'O'), ('considered', 'O'), ('drug-related', 'O'), ('or', 'O'), ('not', 'O'), ('by', 'O'), ('the', 'O'), ('investigators', 'O'), (',', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('in', 'O'), ('KALYDECO-treated', 'O'), ('patients', 'O'), ('included', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('hepatic', 'I-ADR'), ('enzymes', 'I-ADR'), (',', 'O'), ('and', 'O'), ('hypoglycemia', 'B-ADR'), ('.', 'O')]"
"Serious adverse reactions, whether considered drug-related or not by the investigators, that occurred more frequently in KALYDECO-treated patients included abdominal pain, increased hepatic enzymes, and hypoglycemia.",increased hepatic enzymes is an adverse reaction entity,"[('Serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), (',', 'O'), ('whether', 'O'), ('considered', 'O'), ('drug-related', 'O'), ('or', 'O'), ('not', 'O'), ('by', 'O'), ('the', 'O'), ('investigators', 'O'), (',', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('in', 'O'), ('KALYDECO-treated', 'O'), ('patients', 'O'), ('included', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('hepatic', 'I-ADR'), ('enzymes', 'I-ADR'), (',', 'O'), ('and', 'O'), ('hypoglycemia', 'B-ADR'), ('.', 'O')]"
"Serious adverse reactions, whether considered drug-related or not by the investigators, that occurred more frequently in KALYDECO-treated patients included abdominal pain, increased hepatic enzymes, and hypoglycemia.",hypoglycemia is an adverse reaction entity,"[('Serious', 'O'), ('adverse', 'O'), ('reactions', 'O'), (',', 'O'), ('whether', 'O'), ('considered', 'O'), ('drug-related', 'O'), ('or', 'O'), ('not', 'O'), ('by', 'O'), ('the', 'O'), ('investigators', 'O'), (',', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('in', 'O'), ('KALYDECO-treated', 'O'), ('patients', 'O'), ('included', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), (',', 'O'), ('increased', 'B-ADR'), ('hepatic', 'I-ADR'), ('enzymes', 'I-ADR'), (',', 'O'), ('and', 'O'), ('hypoglycemia', 'B-ADR'), ('.', 'O')]"
(  5.2  )             5.1 Nephrogenic Systemic Fibrosis      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,nephrogenic systemic fibrosis is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('5.1', 'O'), ('Nephrogenic', 'O'), ('Systemic', 'O'), ('Fibrosis', 'O'), ('Gadolinium-based', 'O'), ('contrast', 'O'), ('agents', 'O'), ('(', 'O'), ('GBCAs', 'O'), (')', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('nephrogenic', 'B-ADR'), ('systemic', 'I-ADR'), ('fibrosis', 'I-ADR'), ('(', 'O'), ('NSF', 'B-ADR'), (')', 'O'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), ('impaired', 'O'), ('elimination', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('.', 'O')]"
(  5.2  )             5.1 Nephrogenic Systemic Fibrosis      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('5.1', 'O'), ('Nephrogenic', 'O'), ('Systemic', 'O'), ('Fibrosis', 'O'), ('Gadolinium-based', 'O'), ('contrast', 'O'), ('agents', 'O'), ('(', 'O'), ('GBCAs', 'O'), (')', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('nephrogenic', 'B-ADR'), ('systemic', 'I-ADR'), ('fibrosis', 'I-ADR'), ('(', 'O'), ('NSF', 'B-ADR'), (')', 'O'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), ('impaired', 'O'), ('elimination', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('.', 'O')]"
"The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m  2  ) as well as patients with acute kidney injury.",NSF is an adverse reaction entity,"[('The', 'O'), ('GBCA-associated', 'O'), ('NSF', 'B-ADR'), ('risk', 'O'), ('appears', 'O'), ('highest', 'O'), ('for', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'O'), (',', 'O'), ('severe', 'O'), ('kidney', 'O'), ('disease', 'O'), ('(', 'O'), ('GFR', 'O'), ('<', 'O'), ('30', 'O'), ('mL/min/1.73m', 'O'), ('2', 'O'), (')', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('patients', 'O'), ('with', 'O'), ('acute', 'O'), ('kidney', 'O'), ('injury', 'O'), ('.', 'O')]"
"Other Malignancies    Malignancies, excluding non-melanoma skin cancer and PTLD, were reported in Study 1 and Study 2 in 3.5% (14/401) of patients treated with the recommended NULOJIX regimen and 3.7% (15/405) of patients treated with the cyclosporine control regimen.",Malignancies is an adverse reaction entity,"[('Other', 'O'), ('Malignancies', 'O'), ('Malignancies', 'B-ADR'), (',', 'O'), ('excluding', 'O'), ('non-melanoma', 'B-ADR'), ('skin', 'I-ADR'), ('cancer', 'I-ADR'), ('and', 'O'), ('PTLD', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('in', 'O'), ('3.5', 'O'), ('%', 'O'), ('(', 'O'), ('14/401', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('recommended', 'O'), ('NULOJIX', 'O'), ('regimen', 'O'), ('and', 'O'), ('3.7', 'O'), ('%', 'O'), ('(', 'O'), ('15/405', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('cyclosporine', 'O'), ('control', 'O'), ('regimen', 'O'), ('.', 'O')]"
"Other Malignancies    Malignancies, excluding non-melanoma skin cancer and PTLD, were reported in Study 1 and Study 2 in 3.5% (14/401) of patients treated with the recommended NULOJIX regimen and 3.7% (15/405) of patients treated with the cyclosporine control regimen.",non-melanoma skin cancer is an adverse reaction entity,"[('Other', 'O'), ('Malignancies', 'O'), ('Malignancies', 'B-ADR'), (',', 'O'), ('excluding', 'O'), ('non-melanoma', 'B-ADR'), ('skin', 'I-ADR'), ('cancer', 'I-ADR'), ('and', 'O'), ('PTLD', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('in', 'O'), ('3.5', 'O'), ('%', 'O'), ('(', 'O'), ('14/401', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('recommended', 'O'), ('NULOJIX', 'O'), ('regimen', 'O'), ('and', 'O'), ('3.7', 'O'), ('%', 'O'), ('(', 'O'), ('15/405', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('cyclosporine', 'O'), ('control', 'O'), ('regimen', 'O'), ('.', 'O')]"
"Other Malignancies    Malignancies, excluding non-melanoma skin cancer and PTLD, were reported in Study 1 and Study 2 in 3.5% (14/401) of patients treated with the recommended NULOJIX regimen and 3.7% (15/405) of patients treated with the cyclosporine control regimen.",PTLD is an adverse reaction entity,"[('Other', 'O'), ('Malignancies', 'O'), ('Malignancies', 'B-ADR'), (',', 'O'), ('excluding', 'O'), ('non-melanoma', 'B-ADR'), ('skin', 'I-ADR'), ('cancer', 'I-ADR'), ('and', 'O'), ('PTLD', 'B-ADR'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('and', 'O'), ('Study', 'O'), ('2', 'O'), ('in', 'O'), ('3.5', 'O'), ('%', 'O'), ('(', 'O'), ('14/401', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('recommended', 'O'), ('NULOJIX', 'O'), ('regimen', 'O'), ('and', 'O'), ('3.7', 'O'), ('%', 'O'), ('(', 'O'), ('15/405', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('cyclosporine', 'O'), ('control', 'O'), ('regimen', 'O'), ('.', 'O')]"
"Bacterial, Mycobacterial, Viral, and Fungal Infections    Adverse reactions of infectious etiology were reported based on clinical assessment by physicians.",infectious etiology is an adverse reaction entity,"[('Bacterial', 'O'), (',', 'O'), ('Mycobacterial', 'O'), (',', 'O'), ('Viral', 'O'), (',', 'O'), ('and', 'O'), ('Fungal', 'O'), ('Infections', 'O'), ('Adverse', 'O'), ('reactions', 'O'), ('of', 'O'), ('infectious', 'B-ADR'), ('etiology', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('based', 'O'), ('on', 'O'), ('clinical', 'O'), ('assessment', 'O'), ('by', 'O'), ('physicians', 'O'), ('.', 'O')]"
Tuberculosis and herpes infections were reported more frequently in patients receiving NULOJIX than cyclosporine.,Tuberculosis is an adverse reaction entity,"[('Tuberculosis', 'B-ADR'), ('and', 'O'), ('herpes', 'B-ADR'), ('infections', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('more', 'O'), ('frequently', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('NULOJIX', 'O'), ('than', 'O'), ('cyclosporine', 'O'), ('.', 'O')]"
Tuberculosis and herpes infections were reported more frequently in patients receiving NULOJIX than cyclosporine.,herpes infections is an adverse reaction entity,"[('Tuberculosis', 'B-ADR'), ('and', 'O'), ('herpes', 'B-ADR'), ('infections', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('more', 'O'), ('frequently', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('NULOJIX', 'O'), ('than', 'O'), ('cyclosporine', 'O'), ('.', 'O')]"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Post-Transplant Lymphoproliferative Disorder (PTLD) : increased risk, predominantly involving the CNS; monitor for new or worsening neurological, cognitive, or behavioral signs and symptoms.",Post-Transplant Lymphoproliferative Disorder is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Post-Transplant', 'B-ADR'), ('Lymphoproliferative', 'I-ADR'), ('Disorder', 'I-ADR'), ('(', 'O'), ('PTLD', 'B-ADR'), (')', 'O'), (':', 'O'), ('increased', 'O'), ('risk', 'O'), (',', 'O'), ('predominantly', 'O'), ('involving', 'O'), ('the', 'O'), ('CNS', 'O'), (';', 'O'), ('monitor', 'O'), ('for', 'O'), ('new', 'O'), ('or', 'O'), ('worsening', 'O'), ('neurological', 'O'), (',', 'O'), ('cognitive', 'O'), (',', 'O'), ('or', 'O'), ('behavioral', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('.', 'O')]"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Post-Transplant Lymphoproliferative Disorder (PTLD) : increased risk, predominantly involving the CNS; monitor for new or worsening neurological, cognitive, or behavioral signs and symptoms.",PTLD is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Post-Transplant', 'B-ADR'), ('Lymphoproliferative', 'I-ADR'), ('Disorder', 'I-ADR'), ('(', 'O'), ('PTLD', 'B-ADR'), (')', 'O'), (':', 'O'), ('increased', 'O'), ('risk', 'O'), (',', 'O'), ('predominantly', 'O'), ('involving', 'O'), ('the', 'O'), ('CNS', 'O'), (';', 'O'), ('monitor', 'O'), ('for', 'O'), ('new', 'O'), ('or', 'O'), ('worsening', 'O'), ('neurological', 'O'), (',', 'O'), ('cognitive', 'O'), (',', 'O'), ('or', 'O'), ('behavioral', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('.', 'O')]"
"In clinical trials with NULOJIX, two cases of PML were reported in patients receiving NULOJIX at higher cumulative doses and more frequently than the recommended regimen, along with mycophenolate mofetil (MMF) and corticosteroids; one case occurred in a kidney transplant recipient and the second case occurred in a liver transplant recipient [see   Warnings and Precautions (5.6)    ].",PML is an adverse reaction entity,"[('In', 'O'), ('clinical', 'O'), ('trials', 'O'), ('with', 'O'), ('NULOJIX', 'O'), (',', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('PML', 'B-ADR'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('NULOJIX', 'O'), ('at', 'O'), ('higher', 'O'), ('cumulative', 'O'), ('doses', 'O'), ('and', 'O'), ('more', 'O'), ('frequently', 'O'), ('than', 'O'), ('the', 'O'), ('recommended', 'O'), ('regimen', 'O'), (',', 'O'), ('along', 'O'), ('with', 'O'), ('mycophenolate', 'O'), ('mofetil', 'O'), ('(', 'O'), ('MMF', 'O'), (')', 'O'), ('and', 'O'), ('corticosteroids', 'O'), (';', 'O'), ('one', 'O'), ('case', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('kidney', 'O'), ('transplant', 'O'), ('recipient', 'O'), ('and', 'O'), ('the', 'O'), ('second', 'O'), ('case', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('liver', 'O'), ('transplant', 'O'), ('recipient', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.6', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
The fatal case of PML was reported in a patient receiving higher than recommended doses of NULOJIX and MMF [see   Warnings and Precautions (5.4)    ].,fatal is an adverse reaction entity,"[('The', 'O'), ('fatal', 'B-ADR'), ('case', 'O'), ('of', 'O'), ('PML', 'B-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('receiving', 'O'), ('higher', 'O'), ('than', 'O'), ('recommended', 'O'), ('doses', 'O'), ('of', 'O'), ('NULOJIX', 'O'), ('and', 'O'), ('MMF', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
The fatal case of PML was reported in a patient receiving higher than recommended doses of NULOJIX and MMF [see   Warnings and Precautions (5.4)    ].,PML is an adverse reaction entity,"[('The', 'O'), ('fatal', 'B-ADR'), ('case', 'O'), ('of', 'O'), ('PML', 'B-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('receiving', 'O'), ('higher', 'O'), ('than', 'O'), ('recommended', 'O'), ('doses', 'O'), ('of', 'O'), ('NULOJIX', 'O'), ('and', 'O'), ('MMF', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"5.6 Suicidal Behavior and Ideation        Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",suicidal thoughts is an adverse reaction entity,"[('5.6', 'O'), ('Suicidal', 'O'), ('Behavior', 'O'), ('and', 'O'), ('Ideation', 'O'), ('Antiepileptic', 'O'), ('drugs', 'O'), ('(', 'O'), ('AEDs', 'O'), (')', 'O'), (',', 'O'), ('including', 'O'), ('ONFI', 'O'), (',', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thoughts', 'I-ADR'), ('or', 'O'), ('behavior', 'I-ADR'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('these', 'O'), ('drugs', 'O'), ('for', 'O'), ('any', 'O'), ('indication', 'O'), ('.', 'O')]"
"5.6 Suicidal Behavior and Ideation        Antiepileptic drugs (AEDs), including ONFI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",suicidal behavior is an adverse reaction entity,"[('5.6', 'O'), ('Suicidal', 'O'), ('Behavior', 'O'), ('and', 'O'), ('Ideation', 'O'), ('Antiepileptic', 'O'), ('drugs', 'O'), ('(', 'O'), ('AEDs', 'O'), (')', 'O'), (',', 'O'), ('including', 'O'), ('ONFI', 'O'), (',', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thoughts', 'I-ADR'), ('or', 'O'), ('behavior', 'I-ADR'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('these', 'O'), ('drugs', 'O'), ('for', 'O'), ('any', 'O'), ('indication', 'O'), ('.', 'O')]"
"5.3     Neuroleptic Malignant Syndrome (NMS)      A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including FANAPT.",Neuroleptic Malignant Syndrome is an adverse reaction entity,"[('5.3', 'O'), ('Neuroleptic', 'O'), ('Malignant', 'O'), ('Syndrome', 'O'), ('(', 'O'), ('NMS', 'O'), (')', 'O'), ('A', 'O'), ('potentially', 'O'), ('fatal', 'O'), ('symptom', 'O'), ('complex', 'O'), ('sometimes', 'O'), ('referred', 'O'), ('to', 'O'), ('as', 'O'), ('Neuroleptic', 'B-ADR'), ('Malignant', 'I-ADR'), ('Syndrome', 'I-ADR'), ('(', 'O'), ('NMS', 'B-ADR'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('administration', 'O'), ('of', 'O'), ('antipsychotic', 'O'), ('drugs', 'O'), (',', 'O'), ('including', 'O'), ('FANAPT', 'O'), ('.', 'O')]"
"5.3     Neuroleptic Malignant Syndrome (NMS)      A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including FANAPT.",NMS is an adverse reaction entity,"[('5.3', 'O'), ('Neuroleptic', 'O'), ('Malignant', 'O'), ('Syndrome', 'O'), ('(', 'O'), ('NMS', 'O'), (')', 'O'), ('A', 'O'), ('potentially', 'O'), ('fatal', 'O'), ('symptom', 'O'), ('complex', 'O'), ('sometimes', 'O'), ('referred', 'O'), ('to', 'O'), ('as', 'O'), ('Neuroleptic', 'B-ADR'), ('Malignant', 'I-ADR'), ('Syndrome', 'I-ADR'), ('(', 'O'), ('NMS', 'B-ADR'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('administration', 'O'), ('of', 'O'), ('antipsychotic', 'O'), ('drugs', 'O'), (',', 'O'), ('including', 'O'), ('FANAPT', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",hyperpyrexia is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",muscle rigidity is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",altered mental status is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",catatonic signs is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",autonomic instability is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",irregular pulse is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",irregular blood pressure is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",tachycardia is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",diaphoresis is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",cardiac dysrhythmia is an adverse reaction entity,"[('Clinical', 'O'), ('manifestations', 'O'), ('include', 'O'), ('hyperpyrexia', 'B-ADR'), (',', 'O'), ('muscle', 'B-ADR'), ('rigidity', 'I-ADR'), (',', 'O'), ('altered', 'B-ADR'), ('mental', 'I-ADR'), ('status', 'I-ADR'), ('(', 'O'), ('including', 'O'), ('catatonic', 'B-ADR'), ('signs', 'I-ADR'), (')', 'O'), ('and', 'O'), ('evidence', 'O'), ('of', 'O'), ('autonomic', 'B-ADR'), ('instability', 'I-ADR'), ('(', 'O'), ('irregular', 'B-ADR'), ('pulse', 'I-ADR'), ('or', 'O'), ('blood', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('tachycardia', 'B-ADR'), (',', 'O'), ('diaphoresis', 'B-ADR'), (',', 'O'), ('and', 'O'), ('cardiac', 'B-ADR'), ('dysrhythmia', 'I-ADR'), (')', 'O'), ('.', 'O')]"
"5.4     Tardive Dyskinesia      Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, which may develop in patients treated with antipsychotic drugs.",Tardive dyskinesia is an adverse reaction entity,"[('5.4', 'O'), ('Tardive', 'O'), ('Dyskinesia', 'O'), ('Tardive', 'B-ADR'), ('dyskinesia', 'I-ADR'), ('is', 'O'), ('a', 'O'), ('syndrome', 'O'), ('consisting', 'O'), ('of', 'O'), ('potentially', 'O'), ('irreversible', 'O'), (',', 'O'), ('involuntary', 'B-ADR'), (',', 'I-ADR'), ('dyskinetic', 'I-ADR'), ('movements', 'I-ADR'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('develop', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('antipsychotic', 'O'), ('drugs', 'O'), ('.', 'O')]"
"5.4     Tardive Dyskinesia      Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, which may develop in patients treated with antipsychotic drugs.","involuntary, dyskinetic movements is an adverse reaction entity","[('5.4', 'O'), ('Tardive', 'O'), ('Dyskinesia', 'O'), ('Tardive', 'B-ADR'), ('dyskinesia', 'I-ADR'), ('is', 'O'), ('a', 'O'), ('syndrome', 'O'), ('consisting', 'O'), ('of', 'O'), ('potentially', 'O'), ('irreversible', 'O'), (',', 'O'), ('involuntary', 'B-ADR'), (',', 'I-ADR'), ('dyskinetic', 'I-ADR'), ('movements', 'I-ADR'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('develop', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('antipsychotic', 'O'), ('drugs', 'O'), ('.', 'O')]"
Table 2: Change in Glucose    Mean Change from Baseline (mg/dL)                         3-6 months       6-12 months      >12 months         FANAPT 10-16 mg/day  1.8 (N=773)      5.4 (N=723)      5.4 (N=425)         FANAPT 20-24 mg/day  -3.6 (N=34)      -9.0 (N=31)      -18.0 (N=20)                  Dyslipidemia       Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.,Undesirable alterations in lipids is an adverse reaction entity,"[('Table', 'O'), ('2', 'O'), (':', 'O'), ('Change', 'O'), ('in', 'O'), ('Glucose', 'O'), ('Mean', 'O'), ('Change', 'O'), ('from', 'O'), ('Baseline', 'O'), ('(', 'O'), ('mg/dL', 'O'), (')', 'O'), ('3-6', 'O'), ('months', 'O'), ('6-12', 'O'), ('months', 'O'), ('>', 'O'), ('12', 'O'), ('months', 'O'), ('FANAPT', 'O'), ('10-16', 'O'), ('mg/day', 'O'), ('1.8', 'O'), ('(', 'O'), ('N=773', 'O'), (')', 'O'), ('5.4', 'O'), ('(', 'O'), ('N=723', 'O'), (')', 'O'), ('5.4', 'O'), ('(', 'O'), ('N=425', 'O'), (')', 'O'), ('FANAPT', 'O'), ('20-24', 'O'), ('mg/day', 'O'), ('-3.6', 'O'), ('(', 'O'), ('N=34', 'O'), (')', 'O'), ('-9.0', 'O'), ('(', 'O'), ('N=31', 'O'), (')', 'O'), ('-18.0', 'O'), ('(', 'O'), ('N=20', 'O'), (')', 'O'), ('Dyslipidemia', 'O'), ('Undesirable', 'B-ADR'), ('alterations', 'I-ADR'), ('in', 'I-ADR'), ('lipids', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('atypical', 'O'), ('antipsychotics', 'O'), ('.', 'O')]"
Table 4: Change in Cholesterol    Mean Change from Baseline (mg/dL)                         3-6 months       6-12 months      >12 months         FANAPT 10-16 mg/day  -3.9 (N=783)     -3.9 (N=726)     -7.7 (N=428)        FANAPT 20-24 mg/day  -19.4 (N=34)     -23.2 (N=31)     -19.4 (N=20)                Table 5: Change in Triglycerides    Mean Change from Baseline (mg/dL)                         3-6 months       6-12 months      >12 months         FANAPT 10-16 mg/day  -8.9 (N=783)     -8.9 (N=726)     -17.7 (N=428)       FANAPT 20-24 mg/day  -26.6 (N=34)     -35.4 (N=31)     -17.7 (N=20)                  Weight Gain       Weight gain has been observed with atypical antipsychotic use.,Weight gain is an adverse reaction entity,"[('Table', 'O'), ('4', 'O'), (':', 'O'), ('Change', 'O'), ('in', 'O'), ('Cholesterol', 'O'), ('Mean', 'O'), ('Change', 'O'), ('from', 'O'), ('Baseline', 'O'), ('(', 'O'), ('mg/dL', 'O'), (')', 'O'), ('3-6', 'O'), ('months', 'O'), ('6-12', 'O'), ('months', 'O'), ('>', 'O'), ('12', 'O'), ('months', 'O'), ('FANAPT', 'O'), ('10-16', 'O'), ('mg/day', 'O'), ('-3.9', 'O'), ('(', 'O'), ('N=783', 'O'), (')', 'O'), ('-3.9', 'O'), ('(', 'O'), ('N=726', 'O'), (')', 'O'), ('-7.7', 'O'), ('(', 'O'), ('N=428', 'O'), (')', 'O'), ('FANAPT', 'O'), ('20-24', 'O'), ('mg/day', 'O'), ('-19.4', 'O'), ('(', 'O'), ('N=34', 'O'), (')', 'O'), ('-23.2', 'O'), ('(', 'O'), ('N=31', 'O'), (')', 'O'), ('-19.4', 'O'), ('(', 'O'), ('N=20', 'O'), (')', 'O'), ('Table', 'O'), ('5', 'O'), (':', 'O'), ('Change', 'O'), ('in', 'O'), ('Triglycerides', 'O'), ('Mean', 'O'), ('Change', 'O'), ('from', 'O'), ('Baseline', 'O'), ('(', 'O'), ('mg/dL', 'O'), (')', 'O'), ('3-6', 'O'), ('months', 'O'), ('6-12', 'O'), ('months', 'O'), ('>', 'O'), ('12', 'O'), ('months', 'O'), ('FANAPT', 'O'), ('10-16', 'O'), ('mg/day', 'O'), ('-8.9', 'O'), ('(', 'O'), ('N=783', 'O'), (')', 'O'), ('-8.9', 'O'), ('(', 'O'), ('N=726', 'O'), (')', 'O'), ('-17.7', 'O'), ('(', 'O'), ('N=428', 'O'), (')', 'O'), ('FANAPT', 'O'), ('20-24', 'O'), ('mg/day', 'O'), ('-26.6', 'O'), ('(', 'O'), ('N=34', 'O'), (')', 'O'), ('-35.4', 'O'), ('(', 'O'), ('N=31', 'O'), (')', 'O'), ('-17.7', 'O'), ('(', 'O'), ('N=20', 'O'), (')', 'O'), ('Weight', 'O'), ('Gain', 'O'), ('Weight', 'B-ADR'), ('gain', 'I-ADR'), ('has', 'O'), ('been', 'O'), ('observed', 'O'), ('with', 'O'), ('atypical', 'O'), ('antipsychotic', 'O'), ('use', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds.",Galactorrhea is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds.",amenorrhea is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds.",gynecomastia is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds.",impotence is an adverse reaction entity,"[('Galactorrhea', 'B-ADR'), (',', 'O'), ('amenorrhea', 'B-ADR'), (',', 'O'), ('gynecomastia', 'B-ADR'), (',', 'O'), ('and', 'O'), ('impotence', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('prolactin-elevating', 'O'), ('compounds', 'O'), ('.', 'O')]"
"Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",Hemorrhage is an adverse reaction entity,"[('Hemorrhage', 'B-ADR'), (':', 'O'), ('Severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('including', 'O'), ('hemoptysis', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('3', 'O'), ('%', 'O'), ('of', 'O'), ('COMETRIQ-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",fatal is an adverse reaction entity,"[('Hemorrhage', 'B-ADR'), (':', 'O'), ('Severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('including', 'O'), ('hemoptysis', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('3', 'O'), ('%', 'O'), ('of', 'O'), ('COMETRIQ-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",hemorrhage is an adverse reaction entity,"[('Hemorrhage', 'B-ADR'), (':', 'O'), ('Severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('including', 'O'), ('hemoptysis', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('3', 'O'), ('%', 'O'), ('of', 'O'), ('COMETRIQ-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",hemorrhage is an adverse reaction entity,"[('Hemorrhage', 'B-ADR'), (':', 'O'), ('Severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('including', 'O'), ('hemoptysis', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('3', 'O'), ('%', 'O'), ('of', 'O'), ('COMETRIQ-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",hemoptysis is an adverse reaction entity,"[('Hemorrhage', 'B-ADR'), (':', 'O'), ('Severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('including', 'O'), ('hemoptysis', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('3', 'O'), ('%', 'O'), ('of', 'O'), ('COMETRIQ-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
"Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",gastrointestinal hemorrhage is an adverse reaction entity,"[('Hemorrhage', 'B-ADR'), (':', 'O'), ('Severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('including', 'O'), ('hemoptysis', 'B-ADR'), ('and', 'O'), ('gastrointestinal', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('3', 'O'), ('%', 'O'), ('of', 'O'), ('COMETRIQ-treated', 'O'), ('patients', 'O'), ('.', 'O')]"
5.4 Wound Complications      Wound complications have been reported with COMETRIQ.,Wound complications is an adverse reaction entity,"[('5.4', 'O'), ('Wound', 'O'), ('Complications', 'O'), ('Wound', 'B-ADR'), ('complications', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('COMETRIQ', 'O'), ('.', 'O')]"
"5.8 Proteinuria      Proteinuria was observed in 4 (2%) of patients receiving COMETRIQ, including one with nephrotic syndrome, as compared to none of the patients receiving placebo.",Proteinuria is an adverse reaction entity,"[('5.8', 'O'), ('Proteinuria', 'O'), ('Proteinuria', 'B-ADR'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('4', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('COMETRIQ', 'O'), (',', 'O'), ('including', 'O'), ('one', 'O'), ('with', 'O'), ('nephrotic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('none', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('.', 'O')]"
"5.8 Proteinuria      Proteinuria was observed in 4 (2%) of patients receiving COMETRIQ, including one with nephrotic syndrome, as compared to none of the patients receiving placebo.",nephrotic syndrome is an adverse reaction entity,"[('5.8', 'O'), ('Proteinuria', 'O'), ('Proteinuria', 'B-ADR'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('4', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('COMETRIQ', 'O'), (',', 'O'), ('including', 'O'), ('one', 'O'), ('with', 'O'), ('nephrotic', 'B-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('none', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('.', 'O')]"
"Skin and subcutaneous tissue disorders  -  Rash, alopecia, photosensitivity reaction, angioedema.",Rash is an adverse reaction entity,"[('Skin', 'O'), ('and', 'O'), ('subcutaneous', 'O'), ('tissue', 'O'), ('disorders', 'O'), ('-', 'O'), ('Rash', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('photosensitivity', 'B-ADR'), ('reaction', 'O'), (',', 'O'), ('angioedema', 'B-ADR'), ('.', 'O')]"
"Skin and subcutaneous tissue disorders  -  Rash, alopecia, photosensitivity reaction, angioedema.",alopecia is an adverse reaction entity,"[('Skin', 'O'), ('and', 'O'), ('subcutaneous', 'O'), ('tissue', 'O'), ('disorders', 'O'), ('-', 'O'), ('Rash', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('photosensitivity', 'B-ADR'), ('reaction', 'O'), (',', 'O'), ('angioedema', 'B-ADR'), ('.', 'O')]"
"Skin and subcutaneous tissue disorders  -  Rash, alopecia, photosensitivity reaction, angioedema.",photosensitivity is an adverse reaction entity,"[('Skin', 'O'), ('and', 'O'), ('subcutaneous', 'O'), ('tissue', 'O'), ('disorders', 'O'), ('-', 'O'), ('Rash', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('photosensitivity', 'B-ADR'), ('reaction', 'O'), (',', 'O'), ('angioedema', 'B-ADR'), ('.', 'O')]"
"Skin and subcutaneous tissue disorders  -  Rash, alopecia, photosensitivity reaction, angioedema.",angioedema is an adverse reaction entity,"[('Skin', 'O'), ('and', 'O'), ('subcutaneous', 'O'), ('tissue', 'O'), ('disorders', 'O'), ('-', 'O'), ('Rash', 'B-ADR'), (',', 'O'), ('alopecia', 'B-ADR'), (',', 'O'), ('photosensitivity', 'B-ADR'), ('reaction', 'O'), (',', 'O'), ('angioedema', 'B-ADR'), ('.', 'O')]"
"Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders.",suicidal thinking is an adverse reaction entity,"[('Pooled', 'O'), ('analyses', 'O'), ('of', 'O'), ('short-term', 'O'), ('placebo-controlled', 'O'), ('studies', 'O'), ('of', 'O'), ('antidepressant', 'O'), ('drugs', 'O'), ('(', 'O'), ('SSRIs', 'O'), ('and', 'O'), ('others', 'O'), (')', 'O'), ('showed', 'O'), ('that', 'O'), ('these', 'O'), ('drugs', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thinking', 'I-ADR'), ('and', 'O'), ('behavior', 'I-ADR'), ('(', 'O'), ('suicidality', 'B-ADR'), (')', 'O'), ('in', 'O'), ('children', 'O'), (',', 'O'), ('adolescents', 'O'), (',', 'O'), ('and', 'O'), ('young', 'O'), ('adults', 'O'), ('(', 'O'), ('ages', 'O'), ('18', 'O'), ('to', 'O'), ('24', 'O'), (')', 'O'), ('with', 'O'), ('major', 'O'), ('depressive', 'O'), ('disorder', 'O'), ('(', 'O'), ('MDD', 'O'), (')', 'O'), ('and', 'O'), ('other', 'O'), ('psychiatric', 'O'), ('disorders', 'O'), ('.', 'O')]"
"Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders.",suicidal behavior is an adverse reaction entity,"[('Pooled', 'O'), ('analyses', 'O'), ('of', 'O'), ('short-term', 'O'), ('placebo-controlled', 'O'), ('studies', 'O'), ('of', 'O'), ('antidepressant', 'O'), ('drugs', 'O'), ('(', 'O'), ('SSRIs', 'O'), ('and', 'O'), ('others', 'O'), (')', 'O'), ('showed', 'O'), ('that', 'O'), ('these', 'O'), ('drugs', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thinking', 'I-ADR'), ('and', 'O'), ('behavior', 'I-ADR'), ('(', 'O'), ('suicidality', 'B-ADR'), (')', 'O'), ('in', 'O'), ('children', 'O'), (',', 'O'), ('adolescents', 'O'), (',', 'O'), ('and', 'O'), ('young', 'O'), ('adults', 'O'), ('(', 'O'), ('ages', 'O'), ('18', 'O'), ('to', 'O'), ('24', 'O'), (')', 'O'), ('with', 'O'), ('major', 'O'), ('depressive', 'O'), ('disorder', 'O'), ('(', 'O'), ('MDD', 'O'), (')', 'O'), ('and', 'O'), ('other', 'O'), ('psychiatric', 'O'), ('disorders', 'O'), ('.', 'O')]"
"Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders.",suicidality is an adverse reaction entity,"[('Pooled', 'O'), ('analyses', 'O'), ('of', 'O'), ('short-term', 'O'), ('placebo-controlled', 'O'), ('studies', 'O'), ('of', 'O'), ('antidepressant', 'O'), ('drugs', 'O'), ('(', 'O'), ('SSRIs', 'O'), ('and', 'O'), ('others', 'O'), (')', 'O'), ('showed', 'O'), ('that', 'O'), ('these', 'O'), ('drugs', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('thinking', 'I-ADR'), ('and', 'O'), ('behavior', 'I-ADR'), ('(', 'O'), ('suicidality', 'B-ADR'), (')', 'O'), ('in', 'O'), ('children', 'O'), (',', 'O'), ('adolescents', 'O'), (',', 'O'), ('and', 'O'), ('young', 'O'), ('adults', 'O'), ('(', 'O'), ('ages', 'O'), ('18', 'O'), ('to', 'O'), ('24', 'O'), (')', 'O'), ('with', 'O'), ('major', 'O'), ('depressive', 'O'), ('disorder', 'O'), ('(', 'O'), ('MDD', 'O'), (')', 'O'), ('and', 'O'), ('other', 'O'), ('psychiatric', 'O'), ('disorders', 'O'), ('.', 'O')]"
"It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months.",suicidality is an adverse reaction entity,"[('It', 'O'), ('is', 'O'), ('unknown', 'O'), ('whether', 'O'), ('the', 'O'), ('suicidality', 'B-ADR'), ('risk', 'O'), ('extends', 'O'), ('to', 'O'), ('longer-term', 'O'), ('use', 'O'), (',', 'O'), ('i.e.', 'O'), (',', 'O'), ('beyond', 'O'), ('several', 'O'), ('months', 'O'), ('.', 'O')]"
"Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.",worsening of depression is an adverse reaction entity,"[('Although', 'O'), ('a', 'O'), ('causal', 'O'), ('link', 'O'), ('between', 'O'), ('the', 'O'), ('emergence', 'O'), ('of', 'O'), ('such', 'O'), ('symptoms', 'O'), ('and', 'O'), ('either', 'O'), ('the', 'O'), ('worsening', 'B-ADR'), ('of', 'I-ADR'), ('depression', 'I-ADR'), ('and/or', 'O'), ('the', 'O'), ('emergence', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('impulses', 'I-ADR'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('established', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('concern', 'O'), ('that', 'O'), ('such', 'O'), ('symptoms', 'O'), ('may', 'O'), ('represent', 'O'), ('precursors', 'O'), ('to', 'O'), ('emerging', 'O'), ('suicidality', 'B-ADR'), ('.', 'O')]"
"Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.",suicidal impulses is an adverse reaction entity,"[('Although', 'O'), ('a', 'O'), ('causal', 'O'), ('link', 'O'), ('between', 'O'), ('the', 'O'), ('emergence', 'O'), ('of', 'O'), ('such', 'O'), ('symptoms', 'O'), ('and', 'O'), ('either', 'O'), ('the', 'O'), ('worsening', 'B-ADR'), ('of', 'I-ADR'), ('depression', 'I-ADR'), ('and/or', 'O'), ('the', 'O'), ('emergence', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('impulses', 'I-ADR'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('established', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('concern', 'O'), ('that', 'O'), ('such', 'O'), ('symptoms', 'O'), ('may', 'O'), ('represent', 'O'), ('precursors', 'O'), ('to', 'O'), ('emerging', 'O'), ('suicidality', 'B-ADR'), ('.', 'O')]"
"Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.",suicidality is an adverse reaction entity,"[('Although', 'O'), ('a', 'O'), ('causal', 'O'), ('link', 'O'), ('between', 'O'), ('the', 'O'), ('emergence', 'O'), ('of', 'O'), ('such', 'O'), ('symptoms', 'O'), ('and', 'O'), ('either', 'O'), ('the', 'O'), ('worsening', 'B-ADR'), ('of', 'I-ADR'), ('depression', 'I-ADR'), ('and/or', 'O'), ('the', 'O'), ('emergence', 'O'), ('of', 'O'), ('suicidal', 'B-ADR'), ('impulses', 'I-ADR'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('established', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('concern', 'O'), ('that', 'O'), ('such', 'O'), ('symptoms', 'O'), ('may', 'O'), ('represent', 'O'), ('precursors', 'O'), ('to', 'O'), ('emerging', 'O'), ('suicidality', 'B-ADR'), ('.', 'O')]"
5.5 Angle Closure Glaucoma       Angle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including Pristiq may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.,Angle-Closure Glaucoma is an adverse reaction entity,"[('5.5', 'O'), ('Angle', 'O'), ('Closure', 'O'), ('Glaucoma', 'O'), ('Angle-Closure', 'B-ADR'), ('Glaucoma', 'I-ADR'), (':', 'O'), ('The', 'O'), ('pupillary', 'O'), ('dilation', 'O'), ('that', 'O'), ('occurs', 'O'), ('following', 'O'), ('use', 'O'), ('of', 'O'), ('many', 'O'), ('antidepressant', 'O'), ('drugs', 'O'), ('including', 'O'), ('Pristiq', 'O'), ('may', 'O'), ('trigger', 'O'), ('an', 'O'), ('angle', 'B-ADR'), ('closure', 'I-ADR'), ('attack', 'I-ADR'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('anatomically', 'O'), ('narrow', 'O'), ('angles', 'O'), ('who', 'O'), ('does', 'O'), ('not', 'O'), ('have', 'O'), ('a', 'O'), ('patent', 'O'), ('iridectomy', 'O'), ('.', 'O')]"
5.5 Angle Closure Glaucoma       Angle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including Pristiq may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.,angle closure attack is an adverse reaction entity,"[('5.5', 'O'), ('Angle', 'O'), ('Closure', 'O'), ('Glaucoma', 'O'), ('Angle-Closure', 'B-ADR'), ('Glaucoma', 'I-ADR'), (':', 'O'), ('The', 'O'), ('pupillary', 'O'), ('dilation', 'O'), ('that', 'O'), ('occurs', 'O'), ('following', 'O'), ('use', 'O'), ('of', 'O'), ('many', 'O'), ('antidepressant', 'O'), ('drugs', 'O'), ('including', 'O'), ('Pristiq', 'O'), ('may', 'O'), ('trigger', 'O'), ('an', 'O'), ('angle', 'B-ADR'), ('closure', 'I-ADR'), ('attack', 'I-ADR'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('anatomically', 'O'), ('narrow', 'O'), ('angles', 'O'), ('who', 'O'), ('does', 'O'), ('not', 'O'), ('have', 'O'), ('a', 'O'), ('patent', 'O'), ('iridectomy', 'O'), ('.', 'O')]"
(  5.2  )   *  Neutropenia - The addition of VICTRELIS to peginterferon alfa and ribavirin may result in worsening of neutropenia associated with peginterferon alfa and ribavirin therapy alone.,Neutropenia is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Neutropenia', 'B-ADR'), ('-', 'O'), ('The', 'O'), ('addition', 'O'), ('of', 'O'), ('VICTRELIS', 'O'), ('to', 'O'), ('peginterferon', 'O'), ('alfa', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('worsening', 'B-ADR'), ('of', 'I-ADR'), ('neutropenia', 'I-ADR'), ('associated', 'O'), ('with', 'O'), ('peginterferon', 'O'), ('alfa', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('therapy', 'O'), ('alone', 'O'), ('.', 'O')]"
(  5.2  )   *  Neutropenia - The addition of VICTRELIS to peginterferon alfa and ribavirin may result in worsening of neutropenia associated with peginterferon alfa and ribavirin therapy alone.,worsening of neutropenia is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Neutropenia', 'B-ADR'), ('-', 'O'), ('The', 'O'), ('addition', 'O'), ('of', 'O'), ('VICTRELIS', 'O'), ('to', 'O'), ('peginterferon', 'O'), ('alfa', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('worsening', 'B-ADR'), ('of', 'I-ADR'), ('neutropenia', 'I-ADR'), ('associated', 'O'), ('with', 'O'), ('peginterferon', 'O'), ('alfa', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('therapy', 'O'), ('alone', 'O'), ('.', 'O')]"
"Thromboembolic events were reported in clinical trials with VICTRELIS among subjects receiving the combination of VICTRELIS with PegIntron/REBETOL, and among those receiving PegIntron/REBETOL alone, regardless of ESA use.",Thromboembolic events is an adverse reaction entity,"[('Thromboembolic', 'B-ADR'), ('events', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('clinical', 'O'), ('trials', 'O'), ('with', 'O'), ('VICTRELIS', 'O'), ('among', 'O'), ('subjects', 'O'), ('receiving', 'O'), ('the', 'O'), ('combination', 'O'), ('of', 'O'), ('VICTRELIS', 'O'), ('with', 'O'), ('PegIntron/REBETOL', 'O'), (',', 'O'), ('and', 'O'), ('among', 'O'), ('those', 'O'), ('receiving', 'O'), ('PegIntron/REBETOL', 'O'), ('alone', 'O'), (',', 'O'), ('regardless', 'O'), ('of', 'O'), ('ESA', 'O'), ('use', 'O'), ('.', 'O')]"
"5.3 Neutropenia (Use with Ribavirin and Peginterferon Alfa)      In Phase 2 and 3 clinical trials, seven percent of subjects receiving the combination of VICTRELIS with PegIntron/REBETOL had neutrophil counts of less than 0.5 * 10  9  per L compared to 4% of subjects receiving PegIntron/REBETOL alone (see  Table 4  ).",neutrophil counts of less than 0.5 * 10 9 per L is an adverse reaction entity,"[('5.3', 'O'), ('Neutropenia', 'O'), ('(', 'O'), ('Use', 'O'), ('with', 'O'), ('Ribavirin', 'O'), ('and', 'O'), ('Peginterferon', 'O'), ('Alfa', 'O'), (')', 'O'), ('In', 'O'), ('Phase', 'O'), ('2', 'O'), ('and', 'O'), ('3', 'O'), ('clinical', 'O'), ('trials', 'O'), (',', 'O'), ('seven', 'O'), ('percent', 'O'), ('of', 'O'), ('subjects', 'O'), ('receiving', 'O'), ('the', 'O'), ('combination', 'O'), ('of', 'O'), ('VICTRELIS', 'O'), ('with', 'O'), ('PegIntron/REBETOL', 'O'), ('had', 'O'), ('neutrophil', 'B-ADR'), ('counts', 'I-ADR'), ('of', 'I-ADR'), ('less', 'I-ADR'), ('than', 'I-ADR'), ('0.5', 'I-ADR'), ('*', 'I-ADR'), ('10', 'I-ADR'), ('9', 'I-ADR'), ('per', 'I-ADR'), ('L', 'I-ADR'), ('compared', 'O'), ('to', 'O'), ('4', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('receiving', 'O'), ('PegIntron/REBETOL', 'O'), ('alone', 'O'), ('(', 'O'), ('see', 'O'), ('Table', 'O'), ('4', 'O'), (')', 'O'), ('.', 'O')]"
In vitro  studies with human platelets indicate that STENDRA potentiates the anti-aggregatory effect of sodium nitroprusside (a nitric oxide [NO] donor).,potentiates the anti-aggregatory effect of sodium nitroprusside is an adverse reaction entity,"[('In', 'O'), ('vitro', 'O'), ('studies', 'O'), ('with', 'O'), ('human', 'O'), ('platelets', 'O'), ('indicate', 'O'), ('that', 'O'), ('STENDRA', 'O'), ('potentiates', 'B-ADR'), ('the', 'I-ADR'), ('anti-aggregatory', 'I-ADR'), ('effect', 'I-ADR'), ('of', 'I-ADR'), ('sodium', 'I-ADR'), ('nitroprusside', 'I-ADR'), ('(', 'O'), ('a', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('[', 'O'), ('NO', 'O'), (']', 'O'), ('donor', 'O'), (')', 'O'), ('.', 'O')]"
"Fatal adverse reactions in GILOTRIF-treated patients in Study 1 included pulmonary toxicity/ILD-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%).",Fatal is an adverse reaction entity,"[('Fatal', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('GILOTRIF-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('included', 'O'), ('pulmonary', 'B-ADR'), ('toxicity/ILD-like', 'I-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('1.3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('sepsis', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Fatal adverse reactions in GILOTRIF-treated patients in Study 1 included pulmonary toxicity/ILD-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%).",pulmonary toxicity is an adverse reaction entity,"[('Fatal', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('GILOTRIF-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('included', 'O'), ('pulmonary', 'B-ADR'), ('toxicity/ILD-like', 'I-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('1.3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('sepsis', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Fatal adverse reactions in GILOTRIF-treated patients in Study 1 included pulmonary toxicity/ILD-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%).",ILD-like adverse reactions is an adverse reaction entity,"[('Fatal', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('GILOTRIF-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('included', 'O'), ('pulmonary', 'B-ADR'), ('toxicity/ILD-like', 'I-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('1.3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('sepsis', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Fatal adverse reactions in GILOTRIF-treated patients in Study 1 included pulmonary toxicity/ILD-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%).",sepsis is an adverse reaction entity,"[('Fatal', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('GILOTRIF-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('included', 'O'), ('pulmonary', 'B-ADR'), ('toxicity/ILD-like', 'I-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('1.3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('sepsis', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"Fatal adverse reactions in GILOTRIF-treated patients in Study 1 included pulmonary toxicity/ILD-like adverse reactions (1.3%), sepsis (0.43%), and pneumonia (0.43%).",pneumonia is an adverse reaction entity,"[('Fatal', 'B-ADR'), ('adverse', 'O'), ('reactions', 'O'), ('in', 'O'), ('GILOTRIF-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('included', 'O'), ('pulmonary', 'B-ADR'), ('toxicity/ILD-like', 'I-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('1.3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('sepsis', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('pneumonia', 'B-ADR'), ('(', 'O'), ('0.43', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"5.6 Embryofetal Toxicity    Based on its mechanism of action, GILOTRIF can cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity,"[('5.6', 'O'), ('Embryofetal', 'O'), ('Toxicity', 'O'), ('Based', 'O'), ('on', 'O'), ('its', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), (',', 'O'), ('GILOTRIF', 'O'), ('can', 'O'), ('cause', 'O'), ('fetal', 'B-ADR'), ('harm', 'I-ADR'), ('when', 'O'), ('administered', 'O'), ('to', 'O'), ('a', 'O'), ('pregnant', 'O'), ('woman', 'O'), ('.', 'O')]"
The most commonly reported adverse event in patients treated with Toviaz was dry mouth.,dry mouth is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('commonly', 'O'), ('reported', 'O'), ('adverse', 'O'), ('event', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('Toviaz', 'O'), ('was', 'O'), ('dry', 'B-ADR'), ('mouth', 'I-ADR'), ('.', 'O')]"
"(  5.3  )   *    Toviaz should be used with caution in patients being treated for narrow-angle glaucoma, and only where the potential benefits outweigh the risks (  5.4  )   *    Central Nervous System Effects: Somnolence has been reported with Toviaz.",Central Nervous System Effects is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Toviaz', 'O'), ('should', 'O'), ('be', 'O'), ('used', 'O'), ('with', 'O'), ('caution', 'O'), ('in', 'O'), ('patients', 'O'), ('being', 'O'), ('treated', 'O'), ('for', 'O'), ('narrow-angle', 'O'), ('glaucoma', 'O'), (',', 'O'), ('and', 'O'), ('only', 'O'), ('where', 'O'), ('the', 'O'), ('potential', 'O'), ('benefits', 'O'), ('outweigh', 'O'), ('the', 'O'), ('risks', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Central', 'B-ADR'), ('Nervous', 'I-ADR'), ('System', 'I-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Somnolence', 'B-ADR'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('Toviaz', 'O'), ('.', 'O')]"
"(  5.3  )   *    Toviaz should be used with caution in patients being treated for narrow-angle glaucoma, and only where the potential benefits outweigh the risks (  5.4  )   *    Central Nervous System Effects: Somnolence has been reported with Toviaz.",Somnolence is an adverse reaction entity,"[('(', 'O'), ('5.3', 'O'), (')', 'O'), ('*', 'O'), ('Toviaz', 'O'), ('should', 'O'), ('be', 'O'), ('used', 'O'), ('with', 'O'), ('caution', 'O'), ('in', 'O'), ('patients', 'O'), ('being', 'O'), ('treated', 'O'), ('for', 'O'), ('narrow-angle', 'O'), ('glaucoma', 'O'), (',', 'O'), ('and', 'O'), ('only', 'O'), ('where', 'O'), ('the', 'O'), ('potential', 'O'), ('benefits', 'O'), ('outweigh', 'O'), ('the', 'O'), ('risks', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), ('*', 'O'), ('Central', 'B-ADR'), ('Nervous', 'I-ADR'), ('System', 'I-ADR'), ('Effects', 'I-ADR'), (':', 'O'), ('Somnolence', 'B-ADR'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('Toviaz', 'O'), ('.', 'O')]"
(  5.2  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions have been reported following DaTscan administration [ see  Adverse Reactions (6.2)    ].,Hypersensitivity reactions is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('5.1', 'O'), ('Hypersensitivity', 'O'), ('Reactions', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('following', 'O'), ('DaTscan', 'O'), ('administration', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",anemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",elevated alkaline phosphatase is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypertriglyceridemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",lymphopenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypercholesterolemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hyperglycemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",elevated AST is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypophosphatemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",elevated ALT is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypokalemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",anemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",elevated alkaline phosphatase is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypertriglyceridemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",lymphopenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypercholesterolemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hyperglycemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",elevated AST is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypophosphatemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",elevated ALT is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"The most common laboratory abnormalities (>20%) reported in the two randomized clinical trials that occurred more commonly (>=2%) in the abiraterone acetate arm were anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, elevated AST, hypophosphatemia, elevated ALT and hypokalemia.",hypokalemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('>', 'O'), ('20', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('that', 'O'), ('occurred', 'O'), ('more', 'O'), ('commonly', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('abiraterone', 'O'), ('acetate', 'O'), ('arm', 'O'), ('were', 'O'), ('anemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('alkaline', 'I-ADR'), ('phosphatase', 'I-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('lymphopenia', 'B-ADR'), (',', 'O'), ('hypercholesterolemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('AST', 'I-ADR'), (',', 'O'), ('hypophosphatemia', 'B-ADR'), (',', 'O'), ('elevated', 'B-ADR'), ('ALT', 'I-ADR'), ('and', 'O'), ('hypokalemia', 'B-ADR'), ('.', 'O')]"
"(5.5)   *  Gastrointestinal perforation and fistula, including death, have occurred.",Gastrointestinal perforation is an adverse reaction entity,"[('(', 'O'), ('5.5', 'O'), (')', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('perforation', 'I-ADR'), ('and', 'O'), ('fistula', 'I-ADR'), (',', 'O'), ('including', 'O'), ('death', 'B-ADR'), (',', 'O'), ('have', 'O'), ('occurred', 'O'), ('.', 'O')]"
"(5.5)   *  Gastrointestinal perforation and fistula, including death, have occurred.",Gastrointestinal fistula is an adverse reaction entity,"[('(', 'O'), ('5.5', 'O'), (')', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('perforation', 'I-ADR'), ('and', 'O'), ('fistula', 'I-ADR'), (',', 'O'), ('including', 'O'), ('death', 'B-ADR'), (',', 'O'), ('have', 'O'), ('occurred', 'O'), ('.', 'O')]"
"(5.5)   *  Gastrointestinal perforation and fistula, including death, have occurred.",death is an adverse reaction entity,"[('(', 'O'), ('5.5', 'O'), (')', 'O'), ('*', 'O'), ('Gastrointestinal', 'B-ADR'), ('perforation', 'I-ADR'), ('and', 'O'), ('fistula', 'I-ADR'), (',', 'O'), ('including', 'O'), ('death', 'B-ADR'), (',', 'O'), ('have', 'O'), ('occurred', 'O'), ('.', 'O')]"
"(2.2,5.12)   *  INLYTA can cause fetal harm when administered to a pregnant woman based on its mechanism of action.",fetal harm is an adverse reaction entity,"[('(', 'O'), ('2.2,5.12', 'O'), (')', 'O'), ('*', 'O'), ('INLYTA', 'O'), ('can', 'O'), ('cause', 'O'), ('fetal', 'B-ADR'), ('harm', 'I-ADR'), ('when', 'O'), ('administered', 'O'), ('to', 'O'), ('a', 'O'), ('pregnant', 'O'), ('woman', 'O'), ('based', 'O'), ('on', 'O'), ('its', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('.', 'O')]"
Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)]  .,Fatal is an adverse reaction entity,"[('Fatal', 'B-ADR'), ('cerebrovascular', 'B-ADR'), ('accident', 'I-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('1/359', 'O'), ('patients', 'O'), ('(', 'O'), ('<', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('receiving', 'O'), ('INLYTA', 'O'), ('and', 'O'), ('none', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('receiving', 'O'), ('sorafenib', 'O'), ('[', 'O'), ('seeAdverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)]  .,cerebrovascular accident is an adverse reaction entity,"[('Fatal', 'B-ADR'), ('cerebrovascular', 'B-ADR'), ('accident', 'I-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('1/359', 'O'), ('patients', 'O'), ('(', 'O'), ('<', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('receiving', 'O'), ('INLYTA', 'O'), ('and', 'O'), ('none', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('receiving', 'O'), ('sorafenib', 'O'), ('[', 'O'), ('seeAdverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"5.5 Cardiac Failure      In a controlled clinical study with INLYTA for the treatment of patients with RCC, cardiac failure was reported in 6/359 patients (2%) receiving INLYTA and 3/355 patients (1%) receiving sorafenib.",cardiac failure is an adverse reaction entity,"[('5.5', 'O'), ('Cardiac', 'O'), ('Failure', 'O'), ('In', 'O'), ('a', 'O'), ('controlled', 'O'), ('clinical', 'O'), ('study', 'O'), ('with', 'O'), ('INLYTA', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('RCC', 'O'), (',', 'O'), ('cardiac', 'B-ADR'), ('failure', 'I-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('6/359', 'O'), ('patients', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('receiving', 'O'), ('INLYTA', 'O'), ('and', 'O'), ('3/355', 'O'), ('patients', 'O'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('receiving', 'O'), ('sorafenib', 'O'), ('.', 'O')]"
Hypoglycemia was more frequent when FARXIGA was added to sulfonylurea or insulin  [see  Warnings and Precautions (5.3)  ]  .,Hypoglycemia is an adverse reaction entity,"[('Hypoglycemia', 'B-ADR'), ('was', 'O'), ('more', 'O'), ('frequent', 'O'), ('when', 'O'), ('FARXIGA', 'O'), ('was', 'O'), ('added', 'O'), ('to', 'O'), ('sulfonylurea', 'O'), ('or', 'O'), ('insulin', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.3', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"and MinorMinor episodes of hypoglycemia were defined as either a symptomatic episode with a capillary or plasma glucose measurement <63 mg/dL regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement <63 mg/dL that does not qualify as a major episode.",hypoglycemia is an adverse reaction entity,"[('and', 'O'), ('MinorMinor', 'O'), ('episodes', 'O'), ('of', 'O'), ('hypoglycemia', 'B-ADR'), ('were', 'O'), ('defined', 'O'), ('as', 'O'), ('either', 'O'), ('a', 'O'), ('symptomatic', 'O'), ('episode', 'O'), ('with', 'O'), ('a', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('regardless', 'O'), ('of', 'O'), ('need', 'O'), ('for', 'O'), ('external', 'O'), ('assistance', 'O'), (',', 'O'), ('or', 'O'), ('an', 'O'), ('asymptomatic', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('that', 'O'), ('does', 'O'), ('not', 'O'), ('qualify', 'O'), ('as', 'O'), ('a', 'O'), ('major', 'O'), ('episode', 'O'), ('.', 'O')]"
"and MinorMinor episodes of hypoglycemia were defined as either a symptomatic episode with a capillary or plasma glucose measurement <63 mg/dL regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement <63 mg/dL that does not qualify as a major episode.",capillary glucose measurement <63 mg/dL is an adverse reaction entity,"[('and', 'O'), ('MinorMinor', 'O'), ('episodes', 'O'), ('of', 'O'), ('hypoglycemia', 'B-ADR'), ('were', 'O'), ('defined', 'O'), ('as', 'O'), ('either', 'O'), ('a', 'O'), ('symptomatic', 'O'), ('episode', 'O'), ('with', 'O'), ('a', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('regardless', 'O'), ('of', 'O'), ('need', 'O'), ('for', 'O'), ('external', 'O'), ('assistance', 'O'), (',', 'O'), ('or', 'O'), ('an', 'O'), ('asymptomatic', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('that', 'O'), ('does', 'O'), ('not', 'O'), ('qualify', 'O'), ('as', 'O'), ('a', 'O'), ('major', 'O'), ('episode', 'O'), ('.', 'O')]"
"and MinorMinor episodes of hypoglycemia were defined as either a symptomatic episode with a capillary or plasma glucose measurement <63 mg/dL regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement <63 mg/dL that does not qualify as a major episode.",plasma glucose measurement <63 mg/dL is an adverse reaction entity,"[('and', 'O'), ('MinorMinor', 'O'), ('episodes', 'O'), ('of', 'O'), ('hypoglycemia', 'B-ADR'), ('were', 'O'), ('defined', 'O'), ('as', 'O'), ('either', 'O'), ('a', 'O'), ('symptomatic', 'O'), ('episode', 'O'), ('with', 'O'), ('a', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('regardless', 'O'), ('of', 'O'), ('need', 'O'), ('for', 'O'), ('external', 'O'), ('assistance', 'O'), (',', 'O'), ('or', 'O'), ('an', 'O'), ('asymptomatic', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('that', 'O'), ('does', 'O'), ('not', 'O'), ('qualify', 'O'), ('as', 'O'), ('a', 'O'), ('major', 'O'), ('episode', 'O'), ('.', 'O')]"
"and MinorMinor episodes of hypoglycemia were defined as either a symptomatic episode with a capillary or plasma glucose measurement <63 mg/dL regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement <63 mg/dL that does not qualify as a major episode.",capillary glucose measurement <63 mg/dL is an adverse reaction entity,"[('and', 'O'), ('MinorMinor', 'O'), ('episodes', 'O'), ('of', 'O'), ('hypoglycemia', 'B-ADR'), ('were', 'O'), ('defined', 'O'), ('as', 'O'), ('either', 'O'), ('a', 'O'), ('symptomatic', 'O'), ('episode', 'O'), ('with', 'O'), ('a', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('regardless', 'O'), ('of', 'O'), ('need', 'O'), ('for', 'O'), ('external', 'O'), ('assistance', 'O'), (',', 'O'), ('or', 'O'), ('an', 'O'), ('asymptomatic', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('that', 'O'), ('does', 'O'), ('not', 'O'), ('qualify', 'O'), ('as', 'O'), ('a', 'O'), ('major', 'O'), ('episode', 'O'), ('.', 'O')]"
"and MinorMinor episodes of hypoglycemia were defined as either a symptomatic episode with a capillary or plasma glucose measurement <63 mg/dL regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement <63 mg/dL that does not qualify as a major episode.",plasma glucose measurement <63 mg/dL is an adverse reaction entity,"[('and', 'O'), ('MinorMinor', 'O'), ('episodes', 'O'), ('of', 'O'), ('hypoglycemia', 'B-ADR'), ('were', 'O'), ('defined', 'O'), ('as', 'O'), ('either', 'O'), ('a', 'O'), ('symptomatic', 'O'), ('episode', 'O'), ('with', 'O'), ('a', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('regardless', 'O'), ('of', 'O'), ('need', 'O'), ('for', 'O'), ('external', 'O'), ('assistance', 'O'), (',', 'O'), ('or', 'O'), ('an', 'O'), ('asymptomatic', 'O'), ('capillary', 'B-ADR'), ('or', 'O'), ('plasma', 'B-ADR'), ('glucose', 'I-ADR'), ('measurement', 'I-ADR'), ('<', 'I-ADR'), ('63', 'I-ADR'), ('mg/dL', 'I-ADR'), ('that', 'O'), ('does', 'O'), ('not', 'O'), ('qualify', 'O'), ('as', 'O'), ('a', 'O'), ('major', 'O'), ('episode', 'O'), ('.', 'O')]"
"Patients with a history of genital mycotic infections were more likely to have a genital mycotic infection during the study than those with no prior history (10.0%, 23.1%, and 25.0% versus 0.8%, 5.9%, and 5.0% on placebo, FARXIGA 5 mg, and FARXIGA 10 mg, respectively).",genital mycotic infection is an adverse reaction entity,"[('Patients', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('genital', 'O'), ('mycotic', 'O'), ('infections', 'O'), ('were', 'O'), ('more', 'O'), ('likely', 'O'), ('to', 'O'), ('have', 'O'), ('a', 'O'), ('genital', 'B-ADR'), ('mycotic', 'I-ADR'), ('infection', 'I-ADR'), ('during', 'O'), ('the', 'O'), ('study', 'O'), ('than', 'O'), ('those', 'O'), ('with', 'O'), ('no', 'O'), ('prior', 'O'), ('history', 'O'), ('(', 'O'), ('10.0', 'O'), ('%', 'O'), (',', 'O'), ('23.1', 'O'), ('%', 'O'), (',', 'O'), ('and', 'O'), ('25.0', 'O'), ('%', 'O'), ('versus', 'O'), ('0.8', 'O'), ('%', 'O'), (',', 'O'), ('5.9', 'O'), ('%', 'O'), (',', 'O'), ('and', 'O'), ('5.0', 'O'), ('%', 'O'), ('on', 'O'), ('placebo', 'O'), (',', 'O'), ('FARXIGA', 'O'), ('5', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('FARXIGA', 'O'), ('10', 'O'), ('mg', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O')]"
"Increase in Serum Inorganic Phosphorus      In the pool of 13 placebo-controlled studies, increases from baseline in mean serum phosphorus levels were reported at Week 24 in FARXIGA-treated patients compared with placebo-treated patients (mean increase of 0.13 versus -0.04 mg/dL, respectively).",increases in mean serum phosphorus levels is an adverse reaction entity,"[('Increase', 'O'), ('in', 'O'), ('Serum', 'O'), ('Inorganic', 'O'), ('Phosphorus', 'O'), ('In', 'O'), ('the', 'O'), ('pool', 'O'), ('of', 'O'), ('13', 'O'), ('placebo-controlled', 'O'), ('studies', 'O'), (',', 'O'), ('increases', 'B-ADR'), ('from', 'O'), ('baseline', 'O'), ('in', 'I-ADR'), ('mean', 'I-ADR'), ('serum', 'I-ADR'), ('phosphorus', 'I-ADR'), ('levels', 'I-ADR'), ('were', 'O'), ('reported', 'O'), ('at', 'O'), ('Week', 'O'), ('24', 'O'), ('in', 'O'), ('FARXIGA-treated', 'O'), ('patients', 'O'), ('compared', 'O'), ('with', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), ('(', 'O'), ('mean', 'O'), ('increase', 'O'), ('of', 'O'), ('0.13', 'O'), ('versus', 'O'), ('-0.04', 'O'), ('mg/dL', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O')]"
6 ADVERSE REACTIONS    The following adverse drug reactions (adverse events assessed as causally related by the investigator or ADRs) are discussed in other sections of the labeling:     *    Hypersensitivity reactions [see Warnings and Precautions (5.1)] .,Hypersensitivity is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reactions', 'O'), ('(', 'O'), ('adverse', 'O'), ('events', 'O'), ('assessed', 'O'), ('as', 'O'), ('causally', 'O'), ('related', 'O'), ('by', 'O'), ('the', 'O'), ('investigator', 'O'), ('or', 'O'), ('ADRs', 'O'), (')', 'O'), ('are', 'O'), ('discussed', 'O'), ('in', 'O'), ('other', 'O'), ('sections', 'O'), ('of', 'O'), ('the', 'O'), ('labeling', 'O'), (':', 'O'), ('*', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
In some cases the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn.,elevations in transaminases is an adverse reaction entity,"[('In', 'O'), ('some', 'O'), ('cases', 'O'), ('the', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('transaminases', 'I-ADR'), ('were', 'O'), ('consistent', 'O'), ('with', 'O'), ('immune', 'B-ADR'), ('reconstitution', 'I-ADR'), ('syndrome', 'I-ADR'), ('or', 'O'), ('hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('reactivation', 'I-ADR'), ('particularly', 'O'), ('in', 'O'), ('the', 'O'), ('setting', 'O'), ('where', 'O'), ('anti-hepatitis', 'O'), ('therapy', 'O'), ('was', 'O'), ('withdrawn', 'O'), ('.', 'O')]"
In some cases the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn.,immune reconstitution syndrome is an adverse reaction entity,"[('In', 'O'), ('some', 'O'), ('cases', 'O'), ('the', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('transaminases', 'I-ADR'), ('were', 'O'), ('consistent', 'O'), ('with', 'O'), ('immune', 'B-ADR'), ('reconstitution', 'I-ADR'), ('syndrome', 'I-ADR'), ('or', 'O'), ('hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('reactivation', 'I-ADR'), ('particularly', 'O'), ('in', 'O'), ('the', 'O'), ('setting', 'O'), ('where', 'O'), ('anti-hepatitis', 'O'), ('therapy', 'O'), ('was', 'O'), ('withdrawn', 'O'), ('.', 'O')]"
In some cases the elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn.,hepatitis B reactivation is an adverse reaction entity,"[('In', 'O'), ('some', 'O'), ('cases', 'O'), ('the', 'O'), ('elevations', 'B-ADR'), ('in', 'I-ADR'), ('transaminases', 'I-ADR'), ('were', 'O'), ('consistent', 'O'), ('with', 'O'), ('immune', 'B-ADR'), ('reconstitution', 'I-ADR'), ('syndrome', 'I-ADR'), ('or', 'O'), ('hepatitis', 'B-ADR'), ('B', 'I-ADR'), ('reactivation', 'I-ADR'), ('particularly', 'O'), ('in', 'O'), ('the', 'O'), ('setting', 'O'), ('where', 'O'), ('anti-hepatitis', 'O'), ('therapy', 'O'), ('was', 'O'), ('withdrawn', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",Redistribution of body fat is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",accumulation of body fat is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",body fat peripheral wasting is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",central obesity is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",dorsocervical fat enlargement is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",buffalo hump is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",facial wasting is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",breast enlargement is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended in patients with underlying hepatic disease such as hepatitis B or C.        5.3 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",cushingoid appearance is an adverse reaction entity,"[('Appropriate', 'O'), ('laboratory', 'O'), ('testing', 'O'), ('prior', 'O'), ('to', 'O'), ('initiating', 'O'), ('therapy', 'O'), ('and', 'O'), ('monitoring', 'O'), ('for', 'O'), ('hepatotoxicity', 'O'), ('during', 'O'), ('therapy', 'O'), ('with', 'O'), ('TIVICAY', 'O'), ('are', 'O'), ('recommended', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('underlying', 'O'), ('hepatic', 'O'), ('disease', 'O'), ('such', 'O'), ('as', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('or', 'O'), ('C.', 'O'), ('5.3', 'O'), ('Fat', 'O'), ('Redistribution', 'O'), ('Redistribution/accumulation', 'B-ADR'), ('of', 'I-ADR'), ('body', 'I-ADR'), ('fat', 'I-ADR'), (',', 'O'), ('including', 'O'), ('central', 'B-ADR'), ('obesity', 'I-ADR'), (',', 'O'), ('dorsocervical', 'B-ADR'), ('fat', 'I-ADR'), ('enlargement', 'I-ADR'), ('(', 'O'), ('buffalo', 'B-ADR'), ('hump', 'I-ADR'), (')', 'O'), (',', 'O'), ('peripheral', 'I-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('wasting', 'I-ADR'), (',', 'O'), ('breast', 'B-ADR'), ('enlargement', 'I-ADR'), (',', 'O'), ('and', 'O'), ('``', 'O'), ('cushingoid', 'B-ADR'), ('appearance', 'I-ADR'), (""''"", 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('.', 'O')]"
"These adverse events were related to cardiac disorders in 10 (2%) patients, infections in 8 (1%) patients, renal disorders in 4 (< 1%) patients, and other adverse events in 8 (1%) patients.",cardiac disorders is an adverse reaction entity,"[('These', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('related', 'O'), ('to', 'O'), ('cardiac', 'B-ADR'), ('disorders', 'I-ADR'), ('in', 'O'), ('10', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('infections', 'B-ADR'), ('in', 'O'), ('8', 'O'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('renal', 'B-ADR'), ('disorders', 'I-ADR'), ('in', 'O'), ('4', 'O'), ('(', 'O'), ('<', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('adverse', 'O'), ('events', 'O'), ('in', 'O'), ('8', 'O'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('.', 'O')]"
"These adverse events were related to cardiac disorders in 10 (2%) patients, infections in 8 (1%) patients, renal disorders in 4 (< 1%) patients, and other adverse events in 8 (1%) patients.",infections is an adverse reaction entity,"[('These', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('related', 'O'), ('to', 'O'), ('cardiac', 'B-ADR'), ('disorders', 'I-ADR'), ('in', 'O'), ('10', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('infections', 'B-ADR'), ('in', 'O'), ('8', 'O'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('renal', 'B-ADR'), ('disorders', 'I-ADR'), ('in', 'O'), ('4', 'O'), ('(', 'O'), ('<', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('adverse', 'O'), ('events', 'O'), ('in', 'O'), ('8', 'O'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('.', 'O')]"
"These adverse events were related to cardiac disorders in 10 (2%) patients, infections in 8 (1%) patients, renal disorders in 4 (< 1%) patients, and other adverse events in 8 (1%) patients.",renal disorders is an adverse reaction entity,"[('These', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('related', 'O'), ('to', 'O'), ('cardiac', 'B-ADR'), ('disorders', 'I-ADR'), ('in', 'O'), ('10', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('infections', 'B-ADR'), ('in', 'O'), ('8', 'O'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('renal', 'B-ADR'), ('disorders', 'I-ADR'), ('in', 'O'), ('4', 'O'), ('(', 'O'), ('<', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('adverse', 'O'), ('events', 'O'), ('in', 'O'), ('8', 'O'), ('(', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('.', 'O')]"
"Table 7: Most Commonly Reported Adverse Events (>= 10%) with Kyprolis Monotherapy     a    Pneumonia includes the preferred terms of pneumonia, bronchopneumonia.",Pneumonia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Most', 'O'), ('Commonly', 'O'), ('Reported', 'O'), ('Adverse', 'O'), ('Events', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('with', 'O'), ('Kyprolis', 'O'), ('Monotherapy', 'O'), ('a', 'O'), ('Pneumonia', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('preferred', 'O'), ('terms', 'O'), ('of', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('bronchopneumonia', 'B-ADR'), ('.', 'O')]"
"Table 7: Most Commonly Reported Adverse Events (>= 10%) with Kyprolis Monotherapy     a    Pneumonia includes the preferred terms of pneumonia, bronchopneumonia.",pneumonia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Most', 'O'), ('Commonly', 'O'), ('Reported', 'O'), ('Adverse', 'O'), ('Events', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('with', 'O'), ('Kyprolis', 'O'), ('Monotherapy', 'O'), ('a', 'O'), ('Pneumonia', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('preferred', 'O'), ('terms', 'O'), ('of', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('bronchopneumonia', 'B-ADR'), ('.', 'O')]"
"Table 7: Most Commonly Reported Adverse Events (>= 10%) with Kyprolis Monotherapy     a    Pneumonia includes the preferred terms of pneumonia, bronchopneumonia.",bronchopneumonia is an adverse reaction entity,"[('Table', 'O'), ('7', 'O'), (':', 'O'), ('Most', 'O'), ('Commonly', 'O'), ('Reported', 'O'), ('Adverse', 'O'), ('Events', 'O'), ('(', 'O'), ('>', 'O'), ('=', 'O'), ('10', 'O'), ('%', 'O'), (')', 'O'), ('with', 'O'), ('Kyprolis', 'O'), ('Monotherapy', 'O'), ('a', 'O'), ('Pneumonia', 'B-ADR'), ('includes', 'O'), ('the', 'O'), ('preferred', 'O'), ('terms', 'O'), ('of', 'O'), ('pneumonia', 'B-ADR'), (',', 'O'), ('bronchopneumonia', 'B-ADR'), ('.', 'O')]"
b    Peripheral neuropathies NEC includes the preferred terms under HLT peripheral neuropathies NEC.,Peripheral neuropathies NEC is an adverse reaction entity,"[('b', 'O'), ('Peripheral', 'B-ADR'), ('neuropathies', 'I-ADR'), ('NEC', 'I-ADR'), ('includes', 'O'), ('the', 'O'), ('preferred', 'O'), ('terms', 'O'), ('under', 'O'), ('HLT', 'O'), ('peripheral', 'B-ADR'), ('neuropathies', 'I-ADR'), ('NEC', 'I-ADR'), ('.', 'O')]"
b    Peripheral neuropathies NEC includes the preferred terms under HLT peripheral neuropathies NEC.,peripheral neuropathies NEC is an adverse reaction entity,"[('b', 'O'), ('Peripheral', 'B-ADR'), ('neuropathies', 'I-ADR'), ('NEC', 'I-ADR'), ('includes', 'O'), ('the', 'O'), ('preferred', 'O'), ('terms', 'O'), ('under', 'O'), ('HLT', 'O'), ('peripheral', 'B-ADR'), ('neuropathies', 'I-ADR'), ('NEC', 'I-ADR'), ('.', 'O')]"
(  5.6  )   *    Hypertension including hypertensive crisis: Monitor blood pressure regularly.,Hypertension is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Hypertension', 'B-ADR'), ('including', 'O'), ('hypertensive', 'B-ADR'), ('crisis', 'I-ADR'), (':', 'O'), ('Monitor', 'O'), ('blood', 'O'), ('pressure', 'O'), ('regularly', 'O'), ('.', 'O')]"
(  5.6  )   *    Hypertension including hypertensive crisis: Monitor blood pressure regularly.,hypertensive crisis is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('*', 'O'), ('Hypertension', 'B-ADR'), ('including', 'O'), ('hypertensive', 'B-ADR'), ('crisis', 'I-ADR'), (':', 'O'), ('Monitor', 'O'), ('blood', 'O'), ('pressure', 'O'), ('regularly', 'O'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",fever is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",chills is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",arthralgia is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",myalgia is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",facial flushing is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",facial edema is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",vomiting is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",weakness is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",shortness of breath is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",hypotension is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",syncope is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",chest tightness is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"Symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina.",angina is an adverse reaction entity,"[('Symptoms', 'O'), ('include', 'O'), ('fever', 'B-ADR'), (',', 'O'), ('chills', 'B-ADR'), (',', 'O'), ('arthralgia', 'B-ADR'), (',', 'O'), ('myalgia', 'B-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('flushing', 'I-ADR'), (',', 'O'), ('facial', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('weakness', 'B-ADR'), (',', 'O'), ('shortness', 'B-ADR'), ('of', 'I-ADR'), ('breath', 'I-ADR'), (',', 'O'), ('hypotension', 'B-ADR'), (',', 'O'), ('syncope', 'B-ADR'), (',', 'O'), ('chest', 'B-ADR'), ('tightness', 'I-ADR'), (',', 'O'), ('or', 'O'), ('angina', 'B-ADR'), ('.', 'O')]"
"*  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member (5.2).",Lymphoma is an adverse reaction entity,"[('*', 'O'), ('Lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), (',', 'O'), ('some', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescent', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('of', 'O'), ('which', 'O'), ('SIMPONI', 'O'), ('ARIA', 'O'), ('is', 'O'), ('a', 'O'), ('member', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('.', 'O')]"
"*  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member (5.2).",malignancies is an adverse reaction entity,"[('*', 'O'), ('Lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), (',', 'O'), ('some', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescent', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('of', 'O'), ('which', 'O'), ('SIMPONI', 'O'), ('ARIA', 'O'), ('is', 'O'), ('a', 'O'), ('member', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('.', 'O')]"
"*  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member (5.2).",fatal is an adverse reaction entity,"[('*', 'O'), ('Lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), (',', 'O'), ('some', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescent', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('of', 'O'), ('which', 'O'), ('SIMPONI', 'O'), ('ARIA', 'O'), ('is', 'O'), ('a', 'O'), ('member', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), ('.', 'O')]"
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.",Invasive fungal infections is an adverse reaction entity,"[('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('including', 'O'), ('histoplasmosis', 'B-ADR'), (',', 'O'), ('coccidioidomycosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('blastomycosis', 'B-ADR'), ('and', 'O'), ('pneumocystosis', 'B-ADR'), ('.', 'O')]"
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.",histoplasmosis is an adverse reaction entity,"[('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('including', 'O'), ('histoplasmosis', 'B-ADR'), (',', 'O'), ('coccidioidomycosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('blastomycosis', 'B-ADR'), ('and', 'O'), ('pneumocystosis', 'B-ADR'), ('.', 'O')]"
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.",coccidioidomycosis is an adverse reaction entity,"[('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('including', 'O'), ('histoplasmosis', 'B-ADR'), (',', 'O'), ('coccidioidomycosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('blastomycosis', 'B-ADR'), ('and', 'O'), ('pneumocystosis', 'B-ADR'), ('.', 'O')]"
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.",candidiasis is an adverse reaction entity,"[('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('including', 'O'), ('histoplasmosis', 'B-ADR'), (',', 'O'), ('coccidioidomycosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('blastomycosis', 'B-ADR'), ('and', 'O'), ('pneumocystosis', 'B-ADR'), ('.', 'O')]"
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.",aspergillosis is an adverse reaction entity,"[('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('including', 'O'), ('histoplasmosis', 'B-ADR'), (',', 'O'), ('coccidioidomycosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('blastomycosis', 'B-ADR'), ('and', 'O'), ('pneumocystosis', 'B-ADR'), ('.', 'O')]"
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.",blastomycosis is an adverse reaction entity,"[('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('including', 'O'), ('histoplasmosis', 'B-ADR'), (',', 'O'), ('coccidioidomycosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('blastomycosis', 'B-ADR'), ('and', 'O'), ('pneumocystosis', 'B-ADR'), ('.', 'O')]"
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis and pneumocystosis.",pneumocystosis is an adverse reaction entity,"[('*', 'O'), ('Invasive', 'B-ADR'), ('fungal', 'I-ADR'), ('infections', 'I-ADR'), (',', 'O'), ('including', 'O'), ('histoplasmosis', 'B-ADR'), (',', 'O'), ('coccidioidomycosis', 'B-ADR'), (',', 'O'), ('candidiasis', 'B-ADR'), (',', 'O'), ('aspergillosis', 'B-ADR'), (',', 'O'), ('blastomycosis', 'B-ADR'), ('and', 'O'), ('pneumocystosis', 'B-ADR'), ('.', 'O')]"
"*  Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.",Bacterial infections is an adverse reaction entity,"[('*', 'O'), ('Bacterial', 'B-ADR'), (',', 'O'), ('viral', 'B-ADR'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('infections', 'I-ADR'), ('due', 'I-ADR'), ('to', 'I-ADR'), ('opportunistic', 'I-ADR'), ('pathogens', 'I-ADR'), (',', 'O'), ('including', 'O'), ('Legionella', 'I-ADR'), ('and', 'O'), ('Listeria', 'I-ADR'), ('.', 'O')]"
"*  Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.",viral infections is an adverse reaction entity,"[('*', 'O'), ('Bacterial', 'B-ADR'), (',', 'O'), ('viral', 'B-ADR'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('infections', 'I-ADR'), ('due', 'I-ADR'), ('to', 'I-ADR'), ('opportunistic', 'I-ADR'), ('pathogens', 'I-ADR'), (',', 'O'), ('including', 'O'), ('Legionella', 'I-ADR'), ('and', 'O'), ('Listeria', 'I-ADR'), ('.', 'O')]"
"*  Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.",infections due to opportunistic pathogens is an adverse reaction entity,"[('*', 'O'), ('Bacterial', 'B-ADR'), (',', 'O'), ('viral', 'B-ADR'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('infections', 'I-ADR'), ('due', 'I-ADR'), ('to', 'I-ADR'), ('opportunistic', 'I-ADR'), ('pathogens', 'I-ADR'), (',', 'O'), ('including', 'O'), ('Legionella', 'I-ADR'), ('and', 'O'), ('Listeria', 'I-ADR'), ('.', 'O')]"
"*  Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.",infections Legionella is an adverse reaction entity,"[('*', 'O'), ('Bacterial', 'B-ADR'), (',', 'O'), ('viral', 'B-ADR'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('infections', 'I-ADR'), ('due', 'I-ADR'), ('to', 'I-ADR'), ('opportunistic', 'I-ADR'), ('pathogens', 'I-ADR'), (',', 'O'), ('including', 'O'), ('Legionella', 'I-ADR'), ('and', 'O'), ('Listeria', 'I-ADR'), ('.', 'O')]"
"*  Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.",infections Listeria is an adverse reaction entity,"[('*', 'O'), ('Bacterial', 'B-ADR'), (',', 'O'), ('viral', 'B-ADR'), (',', 'O'), ('and', 'O'), ('other', 'O'), ('infections', 'I-ADR'), ('due', 'I-ADR'), ('to', 'I-ADR'), ('opportunistic', 'I-ADR'), ('pathogens', 'I-ADR'), (',', 'O'), ('including', 'O'), ('Legionella', 'I-ADR'), ('and', 'O'), ('Listeria', 'I-ADR'), ('.', 'O')]"
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member   [see   Warnings and Precautions (5.2)  ]  .",Lymphoma is an adverse reaction entity,"[('MALIGNANCY', 'O'), ('Lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), (',', 'O'), ('some', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescent', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('of', 'O'), ('which', 'O'), ('SIMPONI', 'O'), ('ARIA', 'O'), ('is', 'O'), ('a', 'O'), ('member', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member   [see   Warnings and Precautions (5.2)  ]  .",malignancies is an adverse reaction entity,"[('MALIGNANCY', 'O'), ('Lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), (',', 'O'), ('some', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescent', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('of', 'O'), ('which', 'O'), ('SIMPONI', 'O'), ('ARIA', 'O'), ('is', 'O'), ('a', 'O'), ('member', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member   [see   Warnings and Precautions (5.2)  ]  .",fatal is an adverse reaction entity,"[('MALIGNANCY', 'O'), ('Lymphoma', 'B-ADR'), ('and', 'O'), ('other', 'O'), ('malignancies', 'B-ADR'), (',', 'O'), ('some', 'O'), ('fatal', 'B-ADR'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescent', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TNF', 'O'), ('blockers', 'O'), (',', 'O'), ('of', 'O'), ('which', 'O'), ('SIMPONI', 'O'), ('ARIA', 'O'), ('is', 'O'), ('a', 'O'), ('member', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.2', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"In an exploratory clinical trial evaluating the use of the subcutaneous formulation of golimumab in patients with severe persistent asthma, more patients treated with golimumab reported malignancies compared with control patients.",malignancies is an adverse reaction entity,"[('In', 'O'), ('an', 'O'), ('exploratory', 'O'), ('clinical', 'O'), ('trial', 'O'), ('evaluating', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('the', 'O'), ('subcutaneous', 'O'), ('formulation', 'O'), ('of', 'O'), ('golimumab', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('persistent', 'O'), ('asthma', 'O'), (',', 'O'), ('more', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('golimumab', 'O'), ('reported', 'O'), ('malignancies', 'B-ADR'), ('compared', 'O'), ('with', 'O'), ('control', 'O'), ('patients', 'O'), ('.', 'O')]"
"Cases of central demyelination, MS, optic neuritis, and peripheral demyelinating polyneuropathy have rarely been reported in patients treated with the subcutaneous formulation of golimumab.",central demyelination is an adverse reaction entity,"[('Cases', 'O'), ('of', 'O'), ('central', 'B-ADR'), ('demyelination', 'I-ADR'), (',', 'O'), ('MS', 'B-ADR'), (',', 'O'), ('optic', 'B-ADR'), ('neuritis', 'I-ADR'), (',', 'O'), ('and', 'O'), ('peripheral', 'B-ADR'), ('demyelinating', 'I-ADR'), ('polyneuropathy', 'I-ADR'), ('have', 'O'), ('rarely', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('subcutaneous', 'O'), ('formulation', 'O'), ('of', 'O'), ('golimumab', 'O'), ('.', 'O')]"
"Cases of central demyelination, MS, optic neuritis, and peripheral demyelinating polyneuropathy have rarely been reported in patients treated with the subcutaneous formulation of golimumab.",MS is an adverse reaction entity,"[('Cases', 'O'), ('of', 'O'), ('central', 'B-ADR'), ('demyelination', 'I-ADR'), (',', 'O'), ('MS', 'B-ADR'), (',', 'O'), ('optic', 'B-ADR'), ('neuritis', 'I-ADR'), (',', 'O'), ('and', 'O'), ('peripheral', 'B-ADR'), ('demyelinating', 'I-ADR'), ('polyneuropathy', 'I-ADR'), ('have', 'O'), ('rarely', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('subcutaneous', 'O'), ('formulation', 'O'), ('of', 'O'), ('golimumab', 'O'), ('.', 'O')]"
"Cases of central demyelination, MS, optic neuritis, and peripheral demyelinating polyneuropathy have rarely been reported in patients treated with the subcutaneous formulation of golimumab.",optic neuritis is an adverse reaction entity,"[('Cases', 'O'), ('of', 'O'), ('central', 'B-ADR'), ('demyelination', 'I-ADR'), (',', 'O'), ('MS', 'B-ADR'), (',', 'O'), ('optic', 'B-ADR'), ('neuritis', 'I-ADR'), (',', 'O'), ('and', 'O'), ('peripheral', 'B-ADR'), ('demyelinating', 'I-ADR'), ('polyneuropathy', 'I-ADR'), ('have', 'O'), ('rarely', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('subcutaneous', 'O'), ('formulation', 'O'), ('of', 'O'), ('golimumab', 'O'), ('.', 'O')]"
"Cases of central demyelination, MS, optic neuritis, and peripheral demyelinating polyneuropathy have rarely been reported in patients treated with the subcutaneous formulation of golimumab.",peripheral demyelinating polyneuropathy is an adverse reaction entity,"[('Cases', 'O'), ('of', 'O'), ('central', 'B-ADR'), ('demyelination', 'I-ADR'), (',', 'O'), ('MS', 'B-ADR'), (',', 'O'), ('optic', 'B-ADR'), ('neuritis', 'I-ADR'), (',', 'O'), ('and', 'O'), ('peripheral', 'B-ADR'), ('demyelinating', 'I-ADR'), ('polyneuropathy', 'I-ADR'), ('have', 'O'), ('rarely', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('subcutaneous', 'O'), ('formulation', 'O'), ('of', 'O'), ('golimumab', 'O'), ('.', 'O')]"
Studies have shown an increased risk of developing hepatocellular carcinoma in long-term (> 8 years) COC users.,hepatocellular carcinoma is an adverse reaction entity,"[('Studies', 'O'), ('have', 'O'), ('shown', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('developing', 'O'), ('hepatocellular', 'B-ADR'), ('carcinoma', 'I-ADR'), ('in', 'O'), ('long-term', 'O'), ('(', 'O'), ('>', 'O'), ('8', 'O'), ('years', 'O'), (')', 'O'), ('COC', 'O'), ('users', 'O'), ('.', 'O')]"
"However, the attributable risk of liver cancers in COC users is less than one case per million users.",liver cancers is an adverse reaction entity,"[('However', 'O'), (',', 'O'), ('the', 'O'), ('attributable', 'O'), ('risk', 'O'), ('of', 'O'), ('liver', 'B-ADR'), ('cancers', 'I-ADR'), ('in', 'O'), ('COC', 'O'), ('users', 'O'), ('is', 'O'), ('less', 'O'), ('than', 'O'), ('one', 'O'), ('case', 'O'), ('per', 'O'), ('million', 'O'), ('users', 'O'), ('.', 'O')]"
Women with a history of COC-related cholestasis may have the condition recur with subsequent COC use.,cholestasis is an adverse reaction entity,"[('Women', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('COC-related', 'O'), ('cholestasis', 'B-ADR'), ('may', 'O'), ('have', 'O'), ('the', 'O'), ('condition', 'O'), ('recur', 'O'), ('with', 'O'), ('subsequent', 'O'), ('COC', 'O'), ('use', 'O'), ('.', 'O')]"
"5.7 Headache      If a woman taking Natazia develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Natazia if indicated.",headaches recurrent is an adverse reaction entity,"[('5.7', 'O'), ('Headache', 'O'), ('If', 'O'), ('a', 'O'), ('woman', 'O'), ('taking', 'O'), ('Natazia', 'O'), ('develops', 'O'), ('new', 'O'), ('headaches', 'B-ADR'), ('that', 'O'), ('are', 'O'), ('recurrent', 'I-ADR'), (',', 'O'), ('persistent', 'I-ADR'), (',', 'O'), ('or', 'O'), ('severe', 'O'), (',', 'O'), ('evaluate', 'O'), ('the', 'O'), ('cause', 'O'), ('and', 'O'), ('discontinue', 'O'), ('Natazia', 'O'), ('if', 'O'), ('indicated', 'O'), ('.', 'O')]"
"5.7 Headache      If a woman taking Natazia develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Natazia if indicated.",headaches recurrent is an adverse reaction entity,"[('5.7', 'O'), ('Headache', 'O'), ('If', 'O'), ('a', 'O'), ('woman', 'O'), ('taking', 'O'), ('Natazia', 'O'), ('develops', 'O'), ('new', 'O'), ('headaches', 'B-ADR'), ('that', 'O'), ('are', 'O'), ('recurrent', 'I-ADR'), (',', 'O'), ('persistent', 'I-ADR'), (',', 'O'), ('or', 'O'), ('severe', 'O'), (',', 'O'), ('evaluate', 'O'), ('the', 'O'), ('cause', 'O'), ('and', 'O'), ('discontinue', 'O'), ('Natazia', 'O'), ('if', 'O'), ('indicated', 'O'), ('.', 'O')]"
"5.7 Headache      If a woman taking Natazia develops new headaches that are recurrent, persistent, or severe, evaluate the cause and discontinue Natazia if indicated.",headaches persistent is an adverse reaction entity,"[('5.7', 'O'), ('Headache', 'O'), ('If', 'O'), ('a', 'O'), ('woman', 'O'), ('taking', 'O'), ('Natazia', 'O'), ('develops', 'O'), ('new', 'O'), ('headaches', 'B-ADR'), ('that', 'O'), ('are', 'O'), ('recurrent', 'I-ADR'), (',', 'O'), ('persistent', 'I-ADR'), (',', 'O'), ('or', 'O'), ('severe', 'O'), (',', 'O'), ('evaluate', 'O'), ('the', 'O'), ('cause', 'O'), ('and', 'O'), ('discontinue', 'O'), ('Natazia', 'O'), ('if', 'O'), ('indicated', 'O'), ('.', 'O')]"
BOXED WARNING: WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS    WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS      YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,IMMUNE-MEDIATED ADVERSE REACTIONS is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('YERVOY', 'O'), ('can', 'O'), ('result', 'O'), ('in', 'O'), ('severe', 'O'), ('and', 'O'), ('fatal', 'B-ADR'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('T-cell', 'O'), ('activation', 'O'), ('and', 'O'), ('proliferation', 'O'), ('.', 'O')]"
BOXED WARNING: WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS    WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS      YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,IMMUNE-MEDIATED ADVERSE REACTIONS is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('YERVOY', 'O'), ('can', 'O'), ('result', 'O'), ('in', 'O'), ('severe', 'O'), ('and', 'O'), ('fatal', 'B-ADR'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('T-cell', 'O'), ('activation', 'O'), ('and', 'O'), ('proliferation', 'O'), ('.', 'O')]"
BOXED WARNING: WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS    WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS      YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,fatal is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('YERVOY', 'O'), ('can', 'O'), ('result', 'O'), ('in', 'O'), ('severe', 'O'), ('and', 'O'), ('fatal', 'B-ADR'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('T-cell', 'O'), ('activation', 'O'), ('and', 'O'), ('proliferation', 'O'), ('.', 'O')]"
BOXED WARNING: WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS    WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS      YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,immune-mediated adverse reactions is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('IMMUNE-MEDIATED', 'B-ADR'), ('ADVERSE', 'I-ADR'), ('REACTIONS', 'I-ADR'), ('YERVOY', 'O'), ('can', 'O'), ('result', 'O'), ('in', 'O'), ('severe', 'O'), ('and', 'O'), ('fatal', 'B-ADR'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('due', 'O'), ('to', 'O'), ('T-cell', 'O'), ('activation', 'O'), ('and', 'O'), ('proliferation', 'O'), ('.', 'O')]"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",immune-mediated adverse reactions is an adverse reaction entity,"[('These', 'O'), ('immune-mediated', 'O'), ('reactions', 'O'), ('may', 'O'), ('involve', 'O'), ('any', 'O'), ('organ', 'O'), ('system', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('severe', 'O'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('are', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('dermatitis', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), (')', 'O'), (',', 'O'), ('neuropathy', 'B-ADR'), (',', 'O'), ('and', 'O'), ('endocrinopathy', 'B-ADR'), ('.', 'O')]"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",enterocolitis is an adverse reaction entity,"[('These', 'O'), ('immune-mediated', 'O'), ('reactions', 'O'), ('may', 'O'), ('involve', 'O'), ('any', 'O'), ('organ', 'O'), ('system', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('severe', 'O'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('are', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('dermatitis', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), (')', 'O'), (',', 'O'), ('neuropathy', 'B-ADR'), (',', 'O'), ('and', 'O'), ('endocrinopathy', 'B-ADR'), ('.', 'O')]"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",hepatitis is an adverse reaction entity,"[('These', 'O'), ('immune-mediated', 'O'), ('reactions', 'O'), ('may', 'O'), ('involve', 'O'), ('any', 'O'), ('organ', 'O'), ('system', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('severe', 'O'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('are', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('dermatitis', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), (')', 'O'), (',', 'O'), ('neuropathy', 'B-ADR'), (',', 'O'), ('and', 'O'), ('endocrinopathy', 'B-ADR'), ('.', 'O')]"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",dermatitis is an adverse reaction entity,"[('These', 'O'), ('immune-mediated', 'O'), ('reactions', 'O'), ('may', 'O'), ('involve', 'O'), ('any', 'O'), ('organ', 'O'), ('system', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('severe', 'O'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('are', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('dermatitis', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), (')', 'O'), (',', 'O'), ('neuropathy', 'B-ADR'), (',', 'O'), ('and', 'O'), ('endocrinopathy', 'B-ADR'), ('.', 'O')]"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",toxic epidermal necrolysis is an adverse reaction entity,"[('These', 'O'), ('immune-mediated', 'O'), ('reactions', 'O'), ('may', 'O'), ('involve', 'O'), ('any', 'O'), ('organ', 'O'), ('system', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('severe', 'O'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('are', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('dermatitis', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), (')', 'O'), (',', 'O'), ('neuropathy', 'B-ADR'), (',', 'O'), ('and', 'O'), ('endocrinopathy', 'B-ADR'), ('.', 'O')]"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",neuropathy is an adverse reaction entity,"[('These', 'O'), ('immune-mediated', 'O'), ('reactions', 'O'), ('may', 'O'), ('involve', 'O'), ('any', 'O'), ('organ', 'O'), ('system', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('severe', 'O'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('are', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('dermatitis', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), (')', 'O'), (',', 'O'), ('neuropathy', 'B-ADR'), (',', 'O'), ('and', 'O'), ('endocrinopathy', 'B-ADR'), ('.', 'O')]"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",endocrinopathy is an adverse reaction entity,"[('These', 'O'), ('immune-mediated', 'O'), ('reactions', 'O'), ('may', 'O'), ('involve', 'O'), ('any', 'O'), ('organ', 'O'), ('system', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('severe', 'O'), ('immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('are', 'O'), ('enterocolitis', 'B-ADR'), (',', 'O'), ('hepatitis', 'B-ADR'), (',', 'O'), ('dermatitis', 'B-ADR'), ('(', 'O'), ('including', 'O'), ('toxic', 'B-ADR'), ('epidermal', 'I-ADR'), ('necrolysis', 'I-ADR'), (')', 'O'), (',', 'O'), ('neuropathy', 'B-ADR'), (',', 'O'), ('and', 'O'), ('endocrinopathy', 'B-ADR'), ('.', 'O')]"
EXCERPT:   Immune-mediated adverse reactions: Permanently discontinue for severe reactions.,Immune-mediated adverse reactions is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('Immune-mediated', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), (':', 'O'), ('Permanently', 'O'), ('discontinue', 'O'), ('for', 'O'), ('severe', 'O'), ('reactions', 'O'), ('.', 'O')]"
Seven (54%) YERVOY-treated patients with severe dermatitis received high-dose corticosteroids (median dose 60 mg prednisone/day or equivalent) for up to 14.9 weeks followed by corticosteroid taper.,dermatitis is an adverse reaction entity,"[('Seven', 'O'), ('(', 'O'), ('54', 'O'), ('%', 'O'), (')', 'O'), ('YERVOY-treated', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('dermatitis', 'B-ADR'), ('received', 'O'), ('high-dose', 'O'), ('corticosteroids', 'O'), ('(', 'O'), ('median', 'O'), ('dose', 'O'), ('60', 'O'), ('mg', 'O'), ('prednisone/day', 'O'), ('or', 'O'), ('equivalent', 'O'), (')', 'O'), ('for', 'O'), ('up', 'O'), ('to', 'O'), ('14.9', 'O'), ('weeks', 'O'), ('followed', 'O'), ('by', 'O'), ('corticosteroid', 'O'), ('taper', 'O'), ('.', 'O')]"
"In a limited number of patients, hypophysitis was diagnosed by imaging studies through enlargement of the pituitary gland.",hypophysitis is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('limited', 'O'), ('number', 'O'), ('of', 'O'), ('patients', 'O'), (',', 'O'), ('hypophysitis', 'B-ADR'), ('was', 'O'), ('diagnosed', 'O'), ('by', 'O'), ('imaging', 'O'), ('studies', 'O'), ('through', 'O'), ('enlargement', 'O'), ('of', 'O'), ('the', 'O'), ('pituitary', 'O'), ('gland', 'O'), ('.', 'O')]"
EXCERPT:   WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS       See full prescribing information for complete boxed warning.,RETINAL ABNORMALITIES is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('RETINAL', 'B-ADR'), ('ABNORMALITIES', 'I-ADR'), ('AND', 'O'), ('POTENTIAL', 'O'), ('VISION', 'B-ADR'), ('LOSS', 'I-ADR'), ('See', 'O'), ('full', 'O'), ('prescribing', 'O'), ('information', 'O'), ('for', 'O'), ('complete', 'O'), ('boxed', 'O'), ('warning', 'O'), ('.', 'O')]"
EXCERPT:   WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS       See full prescribing information for complete boxed warning.,VISION LOSS is an adverse reaction entity,"[('EXCERPT', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('RETINAL', 'B-ADR'), ('ABNORMALITIES', 'I-ADR'), ('AND', 'O'), ('POTENTIAL', 'O'), ('VISION', 'B-ADR'), ('LOSS', 'I-ADR'), ('See', 'O'), ('full', 'O'), ('prescribing', 'O'), ('information', 'O'), ('for', 'O'), ('complete', 'O'), ('boxed', 'O'), ('warning', 'O'), ('.', 'O')]"
"*  POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",retinal abnormalities is an adverse reaction entity,"[('*', 'O'), ('POTIGA', 'O'), ('can', 'O'), ('cause', 'O'), ('retinal', 'B-ADR'), ('abnormalities', 'I-ADR'), ('with', 'O'), ('funduscopic', 'O'), ('features', 'O'), ('similar', 'I-ADR'), ('to', 'I-ADR'), ('those', 'O'), ('seen', 'O'), ('in', 'O'), ('retinal', 'O'), ('pigment', 'I-ADR'), ('dystrophies', 'I-ADR'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('known', 'O'), ('to', 'O'), ('result', 'O'), ('in', 'O'), ('damage', 'B-ADR'), ('to', 'I-ADR'), ('the', 'I-ADR'), ('photoreceptors', 'I-ADR'), ('and', 'O'), ('vision', 'B-ADR'), ('loss', 'I-ADR'), ('.', 'O')]"
"*  POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",retinal abnormalities similar to pigment dystrophies is an adverse reaction entity,"[('*', 'O'), ('POTIGA', 'O'), ('can', 'O'), ('cause', 'O'), ('retinal', 'B-ADR'), ('abnormalities', 'I-ADR'), ('with', 'O'), ('funduscopic', 'O'), ('features', 'O'), ('similar', 'I-ADR'), ('to', 'I-ADR'), ('those', 'O'), ('seen', 'O'), ('in', 'O'), ('retinal', 'O'), ('pigment', 'I-ADR'), ('dystrophies', 'I-ADR'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('known', 'O'), ('to', 'O'), ('result', 'O'), ('in', 'O'), ('damage', 'B-ADR'), ('to', 'I-ADR'), ('the', 'I-ADR'), ('photoreceptors', 'I-ADR'), ('and', 'O'), ('vision', 'B-ADR'), ('loss', 'I-ADR'), ('.', 'O')]"
"*  POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",damage to the photoreceptors is an adverse reaction entity,"[('*', 'O'), ('POTIGA', 'O'), ('can', 'O'), ('cause', 'O'), ('retinal', 'B-ADR'), ('abnormalities', 'I-ADR'), ('with', 'O'), ('funduscopic', 'O'), ('features', 'O'), ('similar', 'I-ADR'), ('to', 'I-ADR'), ('those', 'O'), ('seen', 'O'), ('in', 'O'), ('retinal', 'O'), ('pigment', 'I-ADR'), ('dystrophies', 'I-ADR'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('known', 'O'), ('to', 'O'), ('result', 'O'), ('in', 'O'), ('damage', 'B-ADR'), ('to', 'I-ADR'), ('the', 'I-ADR'), ('photoreceptors', 'I-ADR'), ('and', 'O'), ('vision', 'B-ADR'), ('loss', 'I-ADR'), ('.', 'O')]"
"*  POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",vision loss is an adverse reaction entity,"[('*', 'O'), ('POTIGA', 'O'), ('can', 'O'), ('cause', 'O'), ('retinal', 'B-ADR'), ('abnormalities', 'I-ADR'), ('with', 'O'), ('funduscopic', 'O'), ('features', 'O'), ('similar', 'I-ADR'), ('to', 'I-ADR'), ('those', 'O'), ('seen', 'O'), ('in', 'O'), ('retinal', 'O'), ('pigment', 'I-ADR'), ('dystrophies', 'I-ADR'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('known', 'O'), ('to', 'O'), ('result', 'O'), ('in', 'O'), ('damage', 'B-ADR'), ('to', 'I-ADR'), ('the', 'I-ADR'), ('photoreceptors', 'I-ADR'), ('and', 'O'), ('vision', 'B-ADR'), ('loss', 'I-ADR'), ('.', 'O')]"
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Urinary retention: Patients should be carefully monitored for urologic symptoms.,Urinary retention is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Urinary', 'B-ADR'), ('retention', 'I-ADR'), (':', 'O'), ('Patients', 'O'), ('should', 'O'), ('be', 'O'), ('carefully', 'O'), ('monitored', 'O'), ('for', 'O'), ('urologic', 'O'), ('symptoms', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",skin discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",nail discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",lip discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",mucous membrane discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",retinal pigmentary abnormalities is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",skin discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",nail discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",lip discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",mucous membrane discoloration is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Among patients in whom the status of both skin, nail, lip, or mucous membrane discoloration and retinal pigmentary abnormalities are reported, approximately a quarter of those with skin, nail, lip, or mucous membrane discoloration had concurrent retinal pigmentary abnormalities [see Warnings and Precautions (5.1)]  .",retinal pigmentary abnormalities is an adverse reaction entity,"[('Among', 'O'), ('patients', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('status', 'O'), ('of', 'O'), ('both', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('and', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('are', 'O'), ('reported', 'O'), (',', 'O'), ('approximately', 'O'), ('a', 'O'), ('quarter', 'O'), ('of', 'O'), ('those', 'O'), ('with', 'O'), ('skin', 'B-ADR'), (',', 'O'), ('nail', 'B-ADR'), (',', 'O'), ('lip', 'B-ADR'), (',', 'O'), ('or', 'O'), ('mucous', 'B-ADR'), ('membrane', 'I-ADR'), ('discoloration', 'I-ADR'), ('had', 'O'), ('concurrent', 'O'), ('retinal', 'B-ADR'), ('pigmentary', 'I-ADR'), ('abnormalities', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",suicides is an adverse reaction entity,"[('There', 'O'), ('were', 'O'), ('4', 'O'), ('suicides', 'B-ADR'), ('in', 'O'), ('drug-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('trials', 'O'), ('and', 'O'), ('none', 'O'), ('in', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('number', 'O'), ('is', 'O'), ('too', 'O'), ('small', 'O'), ('to', 'O'), ('allow', 'O'), ('any', 'O'), ('conclusion', 'O'), ('about', 'O'), ('drug', 'O'), ('effect', 'O'), ('on', 'O'), ('suicide', 'B-ADR'), ('.', 'O')]"
"There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",suicide is an adverse reaction entity,"[('There', 'O'), ('were', 'O'), ('4', 'O'), ('suicides', 'B-ADR'), ('in', 'O'), ('drug-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('trials', 'O'), ('and', 'O'), ('none', 'O'), ('in', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('number', 'O'), ('is', 'O'), ('too', 'O'), ('small', 'O'), ('to', 'O'), ('allow', 'O'), ('any', 'O'), ('conclusion', 'O'), ('about', 'O'), ('drug', 'O'), ('effect', 'O'), ('on', 'O'), ('suicide', 'B-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",brain stem hemorrhage is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",cerebral hemorrhage is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",gastric hemorrhage is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",epistaxis is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",gingival hemorrhage is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",hematuria is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",vaginal hemorrhage is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",hemorrhage intracranial is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",eye hemorrhage is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"e  Includes the following terms: brain stem hemorrhage, cerebral hemorrhage, gastric hemorrhage, epistaxis, gingival hemorrhage, hematuria, vaginal hemorrhage, hemorrhage intracranial, eye hemorrhage, and vitreous hemorrhage.",vitreous hemorrhage is an adverse reaction entity,"[('e', 'O'), ('Includes', 'O'), ('the', 'O'), ('following', 'O'), ('terms', 'O'), (':', 'O'), ('brain', 'B-ADR'), ('stem', 'I-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('cerebral', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('gastric', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('gingival', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hematuria', 'B-ADR'), (',', 'O'), ('vaginal', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('hemorrhage', 'B-ADR'), ('intracranial', 'I-ADR'), (',', 'O'), ('eye', 'B-ADR'), ('hemorrhage', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vitreous', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
The QTcF was increased more than 60 msec from baseline in 13% (7/55) of patients treated with TAFINLAR in combination with trametinib and 2% (1/53) of patients treated with TAFINLAR as a single agent.,QTcF was increased is an adverse reaction entity,"[('The', 'O'), ('QTcF', 'B-ADR'), ('was', 'I-ADR'), ('increased', 'I-ADR'), ('more', 'O'), ('than', 'O'), ('60', 'O'), ('msec', 'O'), ('from', 'O'), ('baseline', 'O'), ('in', 'O'), ('13', 'O'), ('%', 'O'), ('(', 'O'), ('7/55', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('and', 'O'), ('2', 'O'), ('%', 'O'), ('(', 'O'), ('1/53', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TAFINLAR', 'O'), ('as', 'O'), ('a', 'O'), ('single', 'O'), ('agent', 'O'), ('.', 'O')]"
(  5.2  )   *    Hemorrhage: Major hemorrhagic events can occur in patients receiving TAFINLAR in combination with trametinib.,Hemorrhage is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Hemorrhage', 'B-ADR'), (':', 'O'), ('Major', 'O'), ('hemorrhagic', 'B-ADR'), ('events', 'I-ADR'), ('can', 'O'), ('occur', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('.', 'O')]"
(  5.2  )   *    Hemorrhage: Major hemorrhagic events can occur in patients receiving TAFINLAR in combination with trametinib.,hemorrhagic events is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('*', 'O'), ('Hemorrhage', 'B-ADR'), (':', 'O'), ('Major', 'O'), ('hemorrhagic', 'B-ADR'), ('events', 'I-ADR'), ('can', 'O'), ('occur', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('.', 'O')]"
"(  5.8  ,  2.3  )   *    Hyperglycemia: Monitor serum glucose levels in patients with pre-existing diabetes or hyperglycemia.",Hyperglycemia is an adverse reaction entity,"[('(', 'O'), ('5.8', 'O'), (',', 'O'), ('2.3', 'O'), (')', 'O'), ('*', 'O'), ('Hyperglycemia', 'B-ADR'), (':', 'O'), ('Monitor', 'O'), ('serum', 'O'), ('glucose', 'O'), ('levels', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('pre-existing', 'O'), ('diabetes', 'O'), ('or', 'O'), ('hyperglycemia', 'O'), ('.', 'O')]"
The range of time to diagnosis of basal cell carcinoma was 28 to 249 days in patients receiving TAFINLAR in combination with trametinib and was 197 days for the patient receiving TAFINLAR as a single agent.,basal cell carcinoma is an adverse reaction entity,"[('The', 'O'), ('range', 'O'), ('of', 'O'), ('time', 'O'), ('to', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('basal', 'B-ADR'), ('cell', 'I-ADR'), ('carcinoma', 'I-ADR'), ('was', 'O'), ('28', 'O'), ('to', 'O'), ('249', 'O'), ('days', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('and', 'O'), ('was', 'O'), ('197', 'O'), ('days', 'O'), ('for', 'O'), ('the', 'O'), ('patient', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('as', 'O'), ('a', 'O'), ('single', 'O'), ('agent', 'O'), ('.', 'O')]"
5.2 Tumor Promotion in BRAF Wild-Type Melanoma      In vitro experiments have demonstrated paradoxical activation of MAP-kinase signaling and increased cell proliferation in BRAF wild-type cells which are exposed to BRAF inhibitors.,increased cell proliferation is an adverse reaction entity,"[('5.2', 'O'), ('Tumor', 'O'), ('Promotion', 'O'), ('in', 'O'), ('BRAF', 'O'), ('Wild-Type', 'O'), ('Melanoma', 'O'), ('In', 'O'), ('vitro', 'O'), ('experiments', 'O'), ('have', 'O'), ('demonstrated', 'O'), ('paradoxical', 'O'), ('activation', 'O'), ('of', 'O'), ('MAP-kinase', 'O'), ('signaling', 'O'), ('and', 'O'), ('increased', 'B-ADR'), ('cell', 'I-ADR'), ('proliferation', 'I-ADR'), ('in', 'O'), ('BRAF', 'O'), ('wild-type', 'O'), ('cells', 'O'), ('which', 'O'), ('are', 'O'), ('exposed', 'O'), ('to', 'O'), ('BRAF', 'O'), ('inhibitors', 'O'), ('.', 'O')]"
Intracranial hemorrhage was fatal in 4% (2/55) of patients receiving TAFINLAR in combination with trametinib.,Intracranial hemorrhage is an adverse reaction entity,"[('Intracranial', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('was', 'O'), ('fatal', 'B-ADR'), ('in', 'O'), ('4', 'O'), ('%', 'O'), ('(', 'O'), ('2/55', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('.', 'O')]"
Intracranial hemorrhage was fatal in 4% (2/55) of patients receiving TAFINLAR in combination with trametinib.,fatal is an adverse reaction entity,"[('Intracranial', 'B-ADR'), ('hemorrhage', 'I-ADR'), ('was', 'O'), ('fatal', 'B-ADR'), ('in', 'O'), ('4', 'O'), ('%', 'O'), ('(', 'O'), ('2/55', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('.', 'O')]"
Pulmonary embolism was fatal in 2% (1/55) of patients receiving TAFINLAR in combination with trametinib.,Pulmonary embolism is an adverse reaction entity,"[('Pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('was', 'O'), ('fatal', 'B-ADR'), ('in', 'O'), ('2', 'O'), ('%', 'O'), ('(', 'O'), ('1/55', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('.', 'O')]"
Pulmonary embolism was fatal in 2% (1/55) of patients receiving TAFINLAR in combination with trametinib.,fatal is an adverse reaction entity,"[('Pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('was', 'O'), ('fatal', 'B-ADR'), ('in', 'O'), ('2', 'O'), ('%', 'O'), ('(', 'O'), ('1/55', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('TAFINLAR', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('trametinib', 'O'), ('.', 'O')]"
Transient increases in pain were commonly observed on the day of treatment in patients treated with Qutenza.,increases in pain is an adverse reaction entity,"[('Transient', 'O'), ('increases', 'B-ADR'), ('in', 'I-ADR'), ('pain', 'I-ADR'), ('were', 'O'), ('commonly', 'O'), ('observed', 'O'), ('on', 'O'), ('the', 'O'), ('day', 'O'), ('of', 'O'), ('treatment', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('Qutenza', 'O'), ('.', 'O')]"
"5     WARNINGS AND PRECAUTIONS       EXCERPT:    *   Severe or Persistent Gastrointestinal Toxicity : Dose modification due to diarrhea, nausea, vomiting or abdominal pain occurred in 38% of patients.",diarrhea is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Severe', 'O'), ('or', 'O'), ('Persistent', 'O'), ('Gastrointestinal', 'O'), ('Toxicity', 'O'), (':', 'O'), ('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
"5     WARNINGS AND PRECAUTIONS       EXCERPT:    *   Severe or Persistent Gastrointestinal Toxicity : Dose modification due to diarrhea, nausea, vomiting or abdominal pain occurred in 38% of patients.",nausea is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Severe', 'O'), ('or', 'O'), ('Persistent', 'O'), ('Gastrointestinal', 'O'), ('Toxicity', 'O'), (':', 'O'), ('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
"5     WARNINGS AND PRECAUTIONS       EXCERPT:    *   Severe or Persistent Gastrointestinal Toxicity : Dose modification due to diarrhea, nausea, vomiting or abdominal pain occurred in 38% of patients.",vomiting is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Severe', 'O'), ('or', 'O'), ('Persistent', 'O'), ('Gastrointestinal', 'O'), ('Toxicity', 'O'), (':', 'O'), ('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
"5     WARNINGS AND PRECAUTIONS       EXCERPT:    *   Severe or Persistent Gastrointestinal Toxicity : Dose modification due to diarrhea, nausea, vomiting or abdominal pain occurred in 38% of patients.",abdominal pain is an adverse reaction entity,"[('5', 'O'), ('WARNINGS', 'O'), ('AND', 'O'), ('PRECAUTIONS', 'O'), ('EXCERPT', 'O'), (':', 'O'), ('*', 'O'), ('Severe', 'O'), ('or', 'O'), ('Persistent', 'O'), ('Gastrointestinal', 'O'), ('Toxicity', 'O'), (':', 'O'), ('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
"Dose modification due to diarrhea, nausea, vomiting, or abdominal pain occurred in 38% of patients.",diarrhea is an adverse reaction entity,"[('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
"Dose modification due to diarrhea, nausea, vomiting, or abdominal pain occurred in 38% of patients.",nausea is an adverse reaction entity,"[('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
"Dose modification due to diarrhea, nausea, vomiting, or abdominal pain occurred in 38% of patients.",vomiting is an adverse reaction entity,"[('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
"Dose modification due to diarrhea, nausea, vomiting, or abdominal pain occurred in 38% of patients.",abdominal pain is an adverse reaction entity,"[('Dose', 'O'), ('modification', 'O'), ('due', 'O'), ('to', 'O'), ('diarrhea', 'B-ADR'), (',', 'O'), ('nausea', 'B-ADR'), (',', 'O'), ('vomiting', 'B-ADR'), (',', 'O'), ('or', 'O'), ('abdominal', 'B-ADR'), ('pain', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O')]"
CTCAE Grade 3-4 elevations of lipase and/or amylase occurred in 15% of patients receiving ZYKADIA in Study 1.,elevations of lipase is an adverse reaction entity,"[('CTCAE', 'O'), ('Grade', 'O'), ('3-4', 'O'), ('elevations', 'B-ADR'), ('of', 'I-ADR'), ('lipase', 'I-ADR'), ('and/or', 'O'), ('amylase', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('15', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('ZYKADIA', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('.', 'O')]"
CTCAE Grade 3-4 elevations of lipase and/or amylase occurred in 15% of patients receiving ZYKADIA in Study 1.,elevations of amylase is an adverse reaction entity,"[('CTCAE', 'O'), ('Grade', 'O'), ('3-4', 'O'), ('elevations', 'B-ADR'), ('of', 'I-ADR'), ('lipase', 'I-ADR'), ('and/or', 'O'), ('amylase', 'I-ADR'), ('occurred', 'O'), ('in', 'O'), ('15', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('ZYKADIA', 'O'), ('in', 'O'), ('Study', 'O'), ('1', 'O'), ('.', 'O')]"
The most frequent serious adverse events reported in patients treated with XALKORI were dyspnea (4.1%) and pulmonary embolism (2.9%).,dyspnea is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('serious', 'O'), ('adverse', 'O'), ('events', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('XALKORI', 'O'), ('were', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('4.1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('(', 'O'), ('2.9', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
The most frequent serious adverse events reported in patients treated with XALKORI were dyspnea (4.1%) and pulmonary embolism (2.9%).,pulmonary embolism is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('serious', 'O'), ('adverse', 'O'), ('events', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('XALKORI', 'O'), ('were', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('4.1', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('(', 'O'), ('2.9', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"The majority of patients on the XALKORI arms in Studies 1 and 2 (>50%) reported visual disturbances which occurred at a frequency of 4-7 days each week, lasted up to 1 minute, and had mild or no impact (scores 0 to 3 out of a maximum score of 10) on daily activities as captured in the VSAQ-ALK questionnaire.",visual disturbances is an adverse reaction entity,"[('The', 'O'), ('majority', 'O'), ('of', 'O'), ('patients', 'O'), ('on', 'O'), ('the', 'O'), ('XALKORI', 'O'), ('arms', 'O'), ('in', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), ('(', 'O'), ('>', 'O'), ('50', 'O'), ('%', 'O'), (')', 'O'), ('reported', 'O'), ('visual', 'B-ADR'), ('disturbances', 'I-ADR'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('a', 'O'), ('frequency', 'O'), ('of', 'O'), ('4-7', 'O'), ('days', 'O'), ('each', 'O'), ('week', 'O'), (',', 'O'), ('lasted', 'O'), ('up', 'O'), ('to', 'O'), ('1', 'O'), ('minute', 'O'), (',', 'O'), ('and', 'O'), ('had', 'O'), ('mild', 'O'), ('or', 'O'), ('no', 'O'), ('impact', 'O'), ('(', 'O'), ('scores', 'O'), ('0', 'O'), ('to', 'O'), ('3', 'O'), ('out', 'O'), ('of', 'O'), ('a', 'O'), ('maximum', 'O'), ('score', 'O'), ('of', 'O'), ('10', 'O'), (')', 'O'), ('on', 'O'), ('daily', 'O'), ('activities', 'O'), ('as', 'O'), ('captured', 'O'), ('in', 'O'), ('the', 'O'), ('VSAQ-ALK', 'O'), ('questionnaire', 'O'), ('.', 'O')]"
"Local cystic invasion beyond the kidney occurred, in some cases with imaging characteristics suggestive of abscess formation.",Local cystic invasion beyond the kidney is an adverse reaction entity,"[('Local', 'B-ADR'), ('cystic', 'I-ADR'), ('invasion', 'I-ADR'), ('beyond', 'I-ADR'), ('the', 'I-ADR'), ('kidney', 'I-ADR'), ('occurred', 'O'), (',', 'O'), ('in', 'O'), ('some', 'O'), ('cases', 'O'), ('with', 'O'), ('imaging', 'O'), ('characteristics', 'O'), ('suggestive', 'O'), ('of', 'O'), ('abscess', 'B-ADR'), ('formation', 'O'), ('.', 'O')]"
"Local cystic invasion beyond the kidney occurred, in some cases with imaging characteristics suggestive of abscess formation.",abscess is an adverse reaction entity,"[('Local', 'B-ADR'), ('cystic', 'I-ADR'), ('invasion', 'I-ADR'), ('beyond', 'I-ADR'), ('the', 'I-ADR'), ('kidney', 'I-ADR'), ('occurred', 'O'), (',', 'O'), ('in', 'O'), ('some', 'O'), ('cases', 'O'), ('with', 'O'), ('imaging', 'O'), ('characteristics', 'O'), ('suggestive', 'O'), ('of', 'O'), ('abscess', 'B-ADR'), ('formation', 'O'), ('.', 'O')]"
"Across clinical trials (n=1669), 49 XALKORI-treated patients (2.9%) had ILD of any grade, 18 patients (1.1%) had Grade 3 or 4 ILD, and 8 patients (0.5%) had fatal ILD.",ILD is an adverse reaction entity,"[('Across', 'O'), ('clinical', 'O'), ('trials', 'O'), ('(', 'O'), ('n=1669', 'O'), (')', 'O'), (',', 'O'), ('49', 'O'), ('XALKORI-treated', 'O'), ('patients', 'O'), ('(', 'O'), ('2.9', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('ILD', 'B-ADR'), ('of', 'O'), ('any', 'O'), ('grade', 'O'), (',', 'O'), ('18', 'O'), ('patients', 'O'), ('(', 'O'), ('1.1', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('ILD', 'B-ADR'), (',', 'O'), ('and', 'O'), ('8', 'O'), ('patients', 'O'), ('(', 'O'), ('0.5', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('fatal', 'B-ADR'), ('ILD', 'B-ADR'), ('.', 'O')]"
"Across clinical trials (n=1669), 49 XALKORI-treated patients (2.9%) had ILD of any grade, 18 patients (1.1%) had Grade 3 or 4 ILD, and 8 patients (0.5%) had fatal ILD.",ILD is an adverse reaction entity,"[('Across', 'O'), ('clinical', 'O'), ('trials', 'O'), ('(', 'O'), ('n=1669', 'O'), (')', 'O'), (',', 'O'), ('49', 'O'), ('XALKORI-treated', 'O'), ('patients', 'O'), ('(', 'O'), ('2.9', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('ILD', 'B-ADR'), ('of', 'O'), ('any', 'O'), ('grade', 'O'), (',', 'O'), ('18', 'O'), ('patients', 'O'), ('(', 'O'), ('1.1', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('ILD', 'B-ADR'), (',', 'O'), ('and', 'O'), ('8', 'O'), ('patients', 'O'), ('(', 'O'), ('0.5', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('fatal', 'B-ADR'), ('ILD', 'B-ADR'), ('.', 'O')]"
"Across clinical trials (n=1669), 49 XALKORI-treated patients (2.9%) had ILD of any grade, 18 patients (1.1%) had Grade 3 or 4 ILD, and 8 patients (0.5%) had fatal ILD.",fatal is an adverse reaction entity,"[('Across', 'O'), ('clinical', 'O'), ('trials', 'O'), ('(', 'O'), ('n=1669', 'O'), (')', 'O'), (',', 'O'), ('49', 'O'), ('XALKORI-treated', 'O'), ('patients', 'O'), ('(', 'O'), ('2.9', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('ILD', 'B-ADR'), ('of', 'O'), ('any', 'O'), ('grade', 'O'), (',', 'O'), ('18', 'O'), ('patients', 'O'), ('(', 'O'), ('1.1', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('ILD', 'B-ADR'), (',', 'O'), ('and', 'O'), ('8', 'O'), ('patients', 'O'), ('(', 'O'), ('0.5', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('fatal', 'B-ADR'), ('ILD', 'B-ADR'), ('.', 'O')]"
"Across clinical trials (n=1669), 49 XALKORI-treated patients (2.9%) had ILD of any grade, 18 patients (1.1%) had Grade 3 or 4 ILD, and 8 patients (0.5%) had fatal ILD.",ILD is an adverse reaction entity,"[('Across', 'O'), ('clinical', 'O'), ('trials', 'O'), ('(', 'O'), ('n=1669', 'O'), (')', 'O'), (',', 'O'), ('49', 'O'), ('XALKORI-treated', 'O'), ('patients', 'O'), ('(', 'O'), ('2.9', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('ILD', 'B-ADR'), ('of', 'O'), ('any', 'O'), ('grade', 'O'), (',', 'O'), ('18', 'O'), ('patients', 'O'), ('(', 'O'), ('1.1', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('ILD', 'B-ADR'), (',', 'O'), ('and', 'O'), ('8', 'O'), ('patients', 'O'), ('(', 'O'), ('0.5', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('fatal', 'B-ADR'), ('ILD', 'B-ADR'), ('.', 'O')]"
"This study showed a statistically significant reduction in heart rate compared to baseline, averaging about three beats per minute, observed thirty minutes after injection.",reduction in heart rate is an adverse reaction entity,"[('This', 'O'), ('study', 'O'), ('showed', 'O'), ('a', 'O'), ('statistically', 'O'), ('significant', 'O'), ('reduction', 'B-ADR'), ('in', 'I-ADR'), ('heart', 'I-ADR'), ('rate', 'I-ADR'), ('compared', 'O'), ('to', 'O'), ('baseline', 'O'), (',', 'O'), ('averaging', 'O'), ('about', 'O'), ('three', 'O'), ('beats', 'O'), ('per', 'O'), ('minute', 'O'), (',', 'O'), ('observed', 'O'), ('thirty', 'O'), ('minutes', 'O'), ('after', 'O'), ('injection', 'O'), ('.', 'O')]"
"There is a risk for transmission of Creutzfeldt-Jakob disease (CJD) however, no cases of transmission of viral diseases or CJD have ever been identified for albumin (5.6)          5.1 Lack of Interchangeability between Botulinum Toxin Products    The potency Units of DYSPORT  (r)  are specific to the preparation and assay method utilized.",Creutzfeldt-Jakob disease is an adverse reaction entity,"[('There', 'O'), ('is', 'O'), ('a', 'O'), ('risk', 'O'), ('for', 'O'), ('transmission', 'O'), ('of', 'O'), ('Creutzfeldt-Jakob', 'B-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CJD', 'B-ADR'), (')', 'O'), ('however', 'O'), (',', 'O'), ('no', 'O'), ('cases', 'O'), ('of', 'O'), ('transmission', 'O'), ('of', 'O'), ('viral', 'B-ADR'), ('diseases', 'I-ADR'), ('or', 'O'), ('CJD', 'B-ADR'), ('have', 'O'), ('ever', 'O'), ('been', 'O'), ('identified', 'O'), ('for', 'O'), ('albumin', 'O'), ('(', 'O'), ('5.6', 'O'), (')', 'O'), ('5.1', 'O'), ('Lack', 'O'), ('of', 'O'), ('Interchangeability', 'O'), ('between', 'O'), ('Botulinum', 'O'), ('Toxin', 'O'), ('Products', 'O'), ('The', 'O'), ('potency', 'O'), ('Units', 'O'), ('of', 'O'), ('DYSPORT', 'O'), ('(', 'O'), ('r', 'O'), (')', 'O'), ('are', 'O'), ('specific', 'O'), ('to', 'O'), ('the', 'O'), ('preparation', 'O'), ('and', 'O'), ('assay', 'O'), ('method', 'O'), ('utilized', 'O'), ('.', 'O')]"
"There is a risk for transmission of Creutzfeldt-Jakob disease (CJD) however, no cases of transmission of viral diseases or CJD have ever been identified for albumin (5.6)          5.1 Lack of Interchangeability between Botulinum Toxin Products    The potency Units of DYSPORT  (r)  are specific to the preparation and assay method utilized.",CJD is an adverse reaction entity,"[('There', 'O'), ('is', 'O'), ('a', 'O'), ('risk', 'O'), ('for', 'O'), ('transmission', 'O'), ('of', 'O'), ('Creutzfeldt-Jakob', 'B-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CJD', 'B-ADR'), (')', 'O'), ('however', 'O'), (',', 'O'), ('no', 'O'), ('cases', 'O'), ('of', 'O'), ('transmission', 'O'), ('of', 'O'), ('viral', 'B-ADR'), ('diseases', 'I-ADR'), ('or', 'O'), ('CJD', 'B-ADR'), ('have', 'O'), ('ever', 'O'), ('been', 'O'), ('identified', 'O'), ('for', 'O'), ('albumin', 'O'), ('(', 'O'), ('5.6', 'O'), (')', 'O'), ('5.1', 'O'), ('Lack', 'O'), ('of', 'O'), ('Interchangeability', 'O'), ('between', 'O'), ('Botulinum', 'O'), ('Toxin', 'O'), ('Products', 'O'), ('The', 'O'), ('potency', 'O'), ('Units', 'O'), ('of', 'O'), ('DYSPORT', 'O'), ('(', 'O'), ('r', 'O'), (')', 'O'), ('are', 'O'), ('specific', 'O'), ('to', 'O'), ('the', 'O'), ('preparation', 'O'), ('and', 'O'), ('assay', 'O'), ('method', 'O'), ('utilized', 'O'), ('.', 'O')]"
"There is a risk for transmission of Creutzfeldt-Jakob disease (CJD) however, no cases of transmission of viral diseases or CJD have ever been identified for albumin (5.6)          5.1 Lack of Interchangeability between Botulinum Toxin Products    The potency Units of DYSPORT  (r)  are specific to the preparation and assay method utilized.",viral diseases is an adverse reaction entity,"[('There', 'O'), ('is', 'O'), ('a', 'O'), ('risk', 'O'), ('for', 'O'), ('transmission', 'O'), ('of', 'O'), ('Creutzfeldt-Jakob', 'B-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CJD', 'B-ADR'), (')', 'O'), ('however', 'O'), (',', 'O'), ('no', 'O'), ('cases', 'O'), ('of', 'O'), ('transmission', 'O'), ('of', 'O'), ('viral', 'B-ADR'), ('diseases', 'I-ADR'), ('or', 'O'), ('CJD', 'B-ADR'), ('have', 'O'), ('ever', 'O'), ('been', 'O'), ('identified', 'O'), ('for', 'O'), ('albumin', 'O'), ('(', 'O'), ('5.6', 'O'), (')', 'O'), ('5.1', 'O'), ('Lack', 'O'), ('of', 'O'), ('Interchangeability', 'O'), ('between', 'O'), ('Botulinum', 'O'), ('Toxin', 'O'), ('Products', 'O'), ('The', 'O'), ('potency', 'O'), ('Units', 'O'), ('of', 'O'), ('DYSPORT', 'O'), ('(', 'O'), ('r', 'O'), (')', 'O'), ('are', 'O'), ('specific', 'O'), ('to', 'O'), ('the', 'O'), ('preparation', 'O'), ('and', 'O'), ('assay', 'O'), ('method', 'O'), ('utilized', 'O'), ('.', 'O')]"
"There is a risk for transmission of Creutzfeldt-Jakob disease (CJD) however, no cases of transmission of viral diseases or CJD have ever been identified for albumin (5.6)          5.1 Lack of Interchangeability between Botulinum Toxin Products    The potency Units of DYSPORT  (r)  are specific to the preparation and assay method utilized.",CJD is an adverse reaction entity,"[('There', 'O'), ('is', 'O'), ('a', 'O'), ('risk', 'O'), ('for', 'O'), ('transmission', 'O'), ('of', 'O'), ('Creutzfeldt-Jakob', 'B-ADR'), ('disease', 'I-ADR'), ('(', 'O'), ('CJD', 'B-ADR'), (')', 'O'), ('however', 'O'), (',', 'O'), ('no', 'O'), ('cases', 'O'), ('of', 'O'), ('transmission', 'O'), ('of', 'O'), ('viral', 'B-ADR'), ('diseases', 'I-ADR'), ('or', 'O'), ('CJD', 'B-ADR'), ('have', 'O'), ('ever', 'O'), ('been', 'O'), ('identified', 'O'), ('for', 'O'), ('albumin', 'O'), ('(', 'O'), ('5.6', 'O'), (')', 'O'), ('5.1', 'O'), ('Lack', 'O'), ('of', 'O'), ('Interchangeability', 'O'), ('between', 'O'), ('Botulinum', 'O'), ('Toxin', 'O'), ('Products', 'O'), ('The', 'O'), ('potency', 'O'), ('Units', 'O'), ('of', 'O'), ('DYSPORT', 'O'), ('(', 'O'), ('r', 'O'), (')', 'O'), ('are', 'O'), ('specific', 'O'), ('to', 'O'), ('the', 'O'), ('preparation', 'O'), ('and', 'O'), ('assay', 'O'), ('method', 'O'), ('utilized', 'O'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",asthenia is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",generalized muscle weakness is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",diplopia is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",blurred vision is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",ptosis is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysphagia is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysphonia is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysarthria is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",urinary incontinence is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",breathing difficulties is an adverse reaction entity,"[('The', 'O'), ('symptoms', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('of', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('and', 'O'), ('may', 'O'), ('include', 'O'), ('asthenia', 'B-ADR'), (',', 'O'), ('generalized', 'B-ADR'), ('muscle', 'I-ADR'), ('weakness', 'I-ADR'), (',', 'O'), ('diplopia', 'B-ADR'), (',', 'O'), ('blurred', 'B-ADR'), ('vision', 'I-ADR'), (',', 'O'), ('ptosis', 'B-ADR'), (',', 'O'), ('dysphagia', 'B-ADR'), (',', 'O'), ('dysphonia', 'B-ADR'), (',', 'O'), ('dysarthria', 'B-ADR'), (',', 'O'), ('urinary', 'B-ADR'), ('incontinence', 'I-ADR'), ('and', 'O'), ('breathing', 'B-ADR'), ('difficulties', 'I-ADR'), ('.', 'O')]"
Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin.,Deaths is an adverse reaction entity,"[('Deaths', 'B-ADR'), ('as', 'O'), ('a', 'O'), ('complication', 'O'), ('of', 'O'), ('severe', 'O'), ('dysphagia', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('.', 'O')]"
Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin.,dysphagia is an adverse reaction entity,"[('Deaths', 'B-ADR'), ('as', 'O'), ('a', 'O'), ('complication', 'O'), ('of', 'O'), ('severe', 'O'), ('dysphagia', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.",acute respiratory distress syndrome is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('distress', 'I-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('hemoptysis', 'B-ADR'), (',', 'O'), ('pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.",epistaxis is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('distress', 'I-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('hemoptysis', 'B-ADR'), (',', 'O'), ('pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.",hemoptysis is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('distress', 'I-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('hemoptysis', 'B-ADR'), (',', 'O'), ('pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.",pulmonary embolism is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('acute', 'B-ADR'), ('respiratory', 'I-ADR'), ('distress', 'I-ADR'), ('syndrome', 'I-ADR'), (',', 'O'), ('epistaxis', 'B-ADR'), (',', 'O'), ('hemoptysis', 'B-ADR'), (',', 'O'), ('pulmonary', 'B-ADR'), ('embolism', 'I-ADR'), ('.', 'O')]"
Plasma Zinc Concentration          Decreased plasma zinc concentrations have been observed on Ferriprox therapy.,Decreased plasma zinc concentrations is an adverse reaction entity,"[('Plasma', 'O'), ('Zinc', 'O'), ('Concentration', 'O'), ('Decreased', 'B-ADR'), ('plasma', 'I-ADR'), ('zinc', 'I-ADR'), ('concentrations', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('on', 'O'), ('Ferriprox', 'O'), ('therapy', 'O'), ('.', 'O')]"
The incidence of GI events was higher early in the course of treatment (primarily in month 1) and usually decreased over time in patients treated with TECFIDERA compared with placebo.,GI events is an adverse reaction entity,"[('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('GI', 'B-ADR'), ('events', 'I-ADR'), ('was', 'O'), ('higher', 'O'), ('early', 'O'), ('in', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), ('(', 'O'), ('primarily', 'O'), ('in', 'O'), ('month', 'O'), ('1', 'O'), (')', 'O'), ('and', 'O'), ('usually', 'O'), ('decreased', 'O'), ('over', 'O'), ('time', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('TECFIDERA', 'O'), ('compared', 'O'), ('with', 'O'), ('placebo', 'O'), ('.', 'O')]"
(  5.1  )   *  Progressive multifocal leukoencephalopathy (PML): Withhold TECFIDERA at the first sign or symptom suggestive of PML.,Progressive multifocal leukoencephalopathy is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Progressive', 'B-ADR'), ('multifocal', 'I-ADR'), ('leukoencephalopathy', 'I-ADR'), ('(', 'O'), ('PML', 'B-ADR'), (')', 'O'), (':', 'O'), ('Withhold', 'O'), ('TECFIDERA', 'O'), ('at', 'O'), ('the', 'O'), ('first', 'O'), ('sign', 'O'), ('or', 'O'), ('symptom', 'O'), ('suggestive', 'O'), ('of', 'O'), ('PML', 'O'), ('.', 'O')]"
(  5.1  )   *  Progressive multifocal leukoencephalopathy (PML): Withhold TECFIDERA at the first sign or symptom suggestive of PML.,PML is an adverse reaction entity,"[('(', 'O'), ('5.1', 'O'), (')', 'O'), ('*', 'O'), ('Progressive', 'B-ADR'), ('multifocal', 'I-ADR'), ('leukoencephalopathy', 'I-ADR'), ('(', 'O'), ('PML', 'B-ADR'), (')', 'O'), (':', 'O'), ('Withhold', 'O'), ('TECFIDERA', 'O'), ('at', 'O'), ('the', 'O'), ('first', 'O'), ('sign', 'O'), ('or', 'O'), ('symptom', 'O'), ('suggestive', 'O'), ('of', 'O'), ('PML', 'O'), ('.', 'O')]"
Three percent (3%) of patients discontinued TECFIDERA for flushing and <1% had serious flushing symptoms that were not life-threatening but led to hospitalization.,flushing is an adverse reaction entity,"[('Three', 'O'), ('percent', 'O'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('discontinued', 'O'), ('TECFIDERA', 'O'), ('for', 'O'), ('flushing', 'B-ADR'), ('and', 'O'), ('<', 'O'), ('1', 'O'), ('%', 'O'), ('had', 'O'), ('serious', 'O'), ('flushing', 'B-ADR'), ('symptoms', 'O'), ('that', 'O'), ('were', 'O'), ('not', 'O'), ('life-threatening', 'O'), ('but', 'O'), ('led', 'O'), ('to', 'O'), ('hospitalization', 'O'), ('.', 'O')]"
Three percent (3%) of patients discontinued TECFIDERA for flushing and <1% had serious flushing symptoms that were not life-threatening but led to hospitalization.,flushing is an adverse reaction entity,"[('Three', 'O'), ('percent', 'O'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('discontinued', 'O'), ('TECFIDERA', 'O'), ('for', 'O'), ('flushing', 'B-ADR'), ('and', 'O'), ('<', 'O'), ('1', 'O'), ('%', 'O'), ('had', 'O'), ('serious', 'O'), ('flushing', 'B-ADR'), ('symptoms', 'O'), ('that', 'O'), ('were', 'O'), ('not', 'O'), ('life-threatening', 'O'), ('but', 'O'), ('led', 'O'), ('to', 'O'), ('hospitalization', 'O'), ('.', 'O')]"
"In Study 3, 22/230 (9.6%) patients had alanine aminotransferase or aspartate aminotransferase greater than or equal to 3 times the upper limit of normal during the overall treatment period.",alanine aminotransferase 3 times the upper limit of normal is an adverse reaction entity,"[('In', 'O'), ('Study', 'O'), ('3', 'O'), (',', 'O'), ('22/230', 'O'), ('(', 'O'), ('9.6', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('had', 'O'), ('alanine', 'B-ADR'), ('aminotransferase', 'I-ADR'), ('or', 'O'), ('aspartate', 'B-ADR'), ('aminotransferase', 'I-ADR'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('3', 'I-ADR'), ('times', 'I-ADR'), ('the', 'I-ADR'), ('upper', 'I-ADR'), ('limit', 'I-ADR'), ('of', 'I-ADR'), ('normal', 'I-ADR'), ('during', 'O'), ('the', 'O'), ('overall', 'O'), ('treatment', 'O'), ('period', 'O'), ('.', 'O')]"
"In Study 3, 22/230 (9.6%) patients had alanine aminotransferase or aspartate aminotransferase greater than or equal to 3 times the upper limit of normal during the overall treatment period.",aspartate aminotransferase 3 times the upper limit of normal is an adverse reaction entity,"[('In', 'O'), ('Study', 'O'), ('3', 'O'), (',', 'O'), ('22/230', 'O'), ('(', 'O'), ('9.6', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('had', 'O'), ('alanine', 'B-ADR'), ('aminotransferase', 'I-ADR'), ('or', 'O'), ('aspartate', 'B-ADR'), ('aminotransferase', 'I-ADR'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('3', 'I-ADR'), ('times', 'I-ADR'), ('the', 'I-ADR'), ('upper', 'I-ADR'), ('limit', 'I-ADR'), ('of', 'I-ADR'), ('normal', 'I-ADR'), ('during', 'O'), ('the', 'O'), ('overall', 'O'), ('treatment', 'O'), ('period', 'O'), ('.', 'O')]"
"(5.2)              Increased Mortality       *  An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial.",death is an adverse reaction entity,"[('(', 'O'), ('5.2', 'O'), (')', 'O'), ('Increased', 'O'), ('Mortality', 'O'), ('*', 'O'), ('An', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('death', 'B-ADR'), ('was', 'O'), ('seen', 'O'), ('in', 'O'), ('the', 'O'), ('SIRTURO', 'O'), ('treatment', 'O'), ('group', 'O'), ('(', 'O'), ('9/79', 'O'), (',', 'O'), ('11.4', 'O'), ('%', 'O'), (')', 'O'), ('compared', 'O'), ('to', 'O'), ('the', 'O'), ('placebo', 'O'), ('treatment', 'O'), ('group', 'O'), ('(', 'O'), ('2/81', 'O'), (',', 'O'), ('2.5', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('one', 'O'), ('placebo-controlled', 'O'), ('trial', 'O'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",somnolence is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",sedation is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",dizziness is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",feeling drunk is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",libido decreased is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",depression is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",headache is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",peripheral edema is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"The following adverse reactions were dose-related: somnolence/sedation, dizziness, feeling drunk, libido decreased, depression, headache, peripheral edema, and vertigo.",vertigo is an adverse reaction entity,"[('The', 'O'), ('following', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('dose-related', 'O'), (':', 'O'), ('somnolence/sedation', 'B-ADR'), (',', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('feeling', 'B-ADR'), ('drunk', 'I-ADR'), (',', 'O'), ('libido', 'B-ADR'), ('decreased', 'I-ADR'), (',', 'O'), ('depression', 'B-ADR'), (',', 'O'), ('headache', 'B-ADR'), (',', 'O'), ('peripheral', 'B-ADR'), ('edema', 'I-ADR'), (',', 'O'), ('and', 'O'), ('vertigo', 'B-ADR'), ('.', 'O')]"
"During the controlled trials in patients with RLS, somnolence/sedation was reported in 20% of patients treated with 600 mg of HORIZANT per day compared with 6% of patients receiving placebo.",somnolence is an adverse reaction entity,"[('During', 'O'), ('the', 'O'), ('controlled', 'O'), ('trials', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('RLS', 'O'), (',', 'O'), ('somnolence/sedation', 'B-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('20', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('600', 'O'), ('mg', 'O'), ('of', 'O'), ('HORIZANT', 'O'), ('per', 'O'), ('day', 'O'), ('compared', 'O'), ('with', 'O'), ('6', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('.', 'O')]"
"During the controlled trials in patients with RLS, somnolence/sedation was reported in 20% of patients treated with 600 mg of HORIZANT per day compared with 6% of patients receiving placebo.",sedation is an adverse reaction entity,"[('During', 'O'), ('the', 'O'), ('controlled', 'O'), ('trials', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('RLS', 'O'), (',', 'O'), ('somnolence/sedation', 'B-ADR'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('20', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('600', 'O'), ('mg', 'O'), ('of', 'O'), ('HORIZANT', 'O'), ('per', 'O'), ('day', 'O'), ('compared', 'O'), ('with', 'O'), ('6', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('receiving', 'O'), ('placebo', 'O'), ('.', 'O')]"
"In those patients treated with 1,200 mg of HORIZANT per day who reported dizziness, symptoms persisted during treatment in about 6%.",dizziness is an adverse reaction entity,"[('In', 'O'), ('those', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('1,200', 'O'), ('mg', 'O'), ('of', 'O'), ('HORIZANT', 'O'), ('per', 'O'), ('day', 'O'), ('who', 'O'), ('reported', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('symptoms', 'O'), ('persisted', 'O'), ('during', 'O'), ('treatment', 'O'), ('in', 'O'), ('about', 'O'), ('6', 'O'), ('%', 'O'), ('.', 'O')]"
"There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",suicides is an adverse reaction entity,"[('There', 'O'), ('were', 'O'), ('4', 'O'), ('suicides', 'B-ADR'), ('in', 'O'), ('drug-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('trials', 'O'), ('and', 'O'), ('none', 'O'), ('in', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('number', 'O'), ('is', 'O'), ('too', 'O'), ('small', 'O'), ('to', 'O'), ('allow', 'O'), ('any', 'O'), ('conclusion', 'O'), ('about', 'O'), ('drug', 'O'), ('effect', 'O'), ('on', 'O'), ('suicide', 'B-ADR'), ('.', 'O')]"
"There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",suicide is an adverse reaction entity,"[('There', 'O'), ('were', 'O'), ('4', 'O'), ('suicides', 'B-ADR'), ('in', 'O'), ('drug-treated', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('trials', 'O'), ('and', 'O'), ('none', 'O'), ('in', 'O'), ('placebo-treated', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('number', 'O'), ('is', 'O'), ('too', 'O'), ('small', 'O'), ('to', 'O'), ('allow', 'O'), ('any', 'O'), ('conclusion', 'O'), ('about', 'O'), ('drug', 'O'), ('effect', 'O'), ('on', 'O'), ('suicide', 'B-ADR'), ('.', 'O')]"
"Adverse reactions were all mild to moderate in severity and were predominantly isolated occurrences (<= 2 patients) of one of the following reactions: dizziness, rash, pruritus, flushing or injection site hemorrhage.",dizziness is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('all', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('in', 'O'), ('severity', 'O'), ('and', 'O'), ('were', 'O'), ('predominantly', 'O'), ('isolated', 'O'), ('occurrences', 'O'), ('(', 'O'), ('<', 'O'), ('=', 'O'), ('2', 'O'), ('patients', 'O'), (')', 'O'), ('of', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('following', 'O'), ('reactions', 'O'), (':', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('pruritus', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), ('or', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"Adverse reactions were all mild to moderate in severity and were predominantly isolated occurrences (<= 2 patients) of one of the following reactions: dizziness, rash, pruritus, flushing or injection site hemorrhage.",rash is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('all', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('in', 'O'), ('severity', 'O'), ('and', 'O'), ('were', 'O'), ('predominantly', 'O'), ('isolated', 'O'), ('occurrences', 'O'), ('(', 'O'), ('<', 'O'), ('=', 'O'), ('2', 'O'), ('patients', 'O'), (')', 'O'), ('of', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('following', 'O'), ('reactions', 'O'), (':', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('pruritus', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), ('or', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"Adverse reactions were all mild to moderate in severity and were predominantly isolated occurrences (<= 2 patients) of one of the following reactions: dizziness, rash, pruritus, flushing or injection site hemorrhage.",pruritus is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('all', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('in', 'O'), ('severity', 'O'), ('and', 'O'), ('were', 'O'), ('predominantly', 'O'), ('isolated', 'O'), ('occurrences', 'O'), ('(', 'O'), ('<', 'O'), ('=', 'O'), ('2', 'O'), ('patients', 'O'), (')', 'O'), ('of', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('following', 'O'), ('reactions', 'O'), (':', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('pruritus', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), ('or', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"Adverse reactions were all mild to moderate in severity and were predominantly isolated occurrences (<= 2 patients) of one of the following reactions: dizziness, rash, pruritus, flushing or injection site hemorrhage.",flushing is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('all', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('in', 'O'), ('severity', 'O'), ('and', 'O'), ('were', 'O'), ('predominantly', 'O'), ('isolated', 'O'), ('occurrences', 'O'), ('(', 'O'), ('<', 'O'), ('=', 'O'), ('2', 'O'), ('patients', 'O'), (')', 'O'), ('of', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('following', 'O'), ('reactions', 'O'), (':', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('pruritus', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), ('or', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"Adverse reactions were all mild to moderate in severity and were predominantly isolated occurrences (<= 2 patients) of one of the following reactions: dizziness, rash, pruritus, flushing or injection site hemorrhage.",injection site hemorrhage is an adverse reaction entity,"[('Adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('all', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('in', 'O'), ('severity', 'O'), ('and', 'O'), ('were', 'O'), ('predominantly', 'O'), ('isolated', 'O'), ('occurrences', 'O'), ('(', 'O'), ('<', 'O'), ('=', 'O'), ('2', 'O'), ('patients', 'O'), (')', 'O'), ('of', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('following', 'O'), ('reactions', 'O'), (':', 'O'), ('dizziness', 'B-ADR'), (',', 'O'), ('rash', 'B-ADR'), (',', 'O'), ('pruritus', 'B-ADR'), (',', 'O'), ('flushing', 'B-ADR'), ('or', 'O'), ('injection', 'B-ADR'), ('site', 'I-ADR'), ('hemorrhage', 'I-ADR'), ('.', 'O')]"
"In a trial carried out in patients with moderate renal impairment with a baseline eGFR of 30 to less than 50 mL/min/1.73 m  2  (mean baseline eGFR 39 mL/min/1.73 m  2  )  [see  Clinical Studies (14.3)  ]  , the proportion of patients who experienced at least one event of significant renal function decline, defined as an eGFR 30% lower than baseline, was 6.9% with placebo, 18% with INVOKANA 100 mg, and 22.5% with INVOKANA 300 mg. At the end of treatment, 4.6% with placebo, 3.4% with INVOKANA 100 mg, and 2.2% with INVOKANA 300 mg had a significant renal function decline.",renal function decline is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('trial', 'O'), ('carried', 'O'), ('out', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('with', 'O'), ('a', 'O'), ('baseline', 'O'), ('eGFR', 'O'), ('of', 'O'), ('30', 'O'), ('to', 'O'), ('less', 'O'), ('than', 'O'), ('50', 'O'), ('mL/min/1.73', 'O'), ('m', 'O'), ('2', 'O'), ('(', 'O'), ('mean', 'O'), ('baseline', 'O'), ('eGFR', 'O'), ('39', 'O'), ('mL/min/1.73', 'O'), ('m', 'O'), ('2', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.3', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('the', 'O'), ('proportion', 'O'), ('of', 'O'), ('patients', 'O'), ('who', 'O'), ('experienced', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('event', 'O'), ('of', 'O'), ('significant', 'O'), ('renal', 'B-ADR'), ('function', 'I-ADR'), ('decline', 'I-ADR'), (',', 'O'), ('defined', 'O'), ('as', 'O'), ('an', 'O'), ('eGFR', 'B-ADR'), ('30', 'I-ADR'), ('%', 'I-ADR'), ('lower', 'I-ADR'), ('than', 'I-ADR'), ('baseline', 'I-ADR'), (',', 'O'), ('was', 'O'), ('6.9', 'O'), ('%', 'O'), ('with', 'O'), ('placebo', 'O'), (',', 'O'), ('18', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('22.5', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('300', 'O'), ('mg.', 'O'), ('At', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('treatment', 'O'), (',', 'O'), ('4.6', 'O'), ('%', 'O'), ('with', 'O'), ('placebo', 'O'), (',', 'O'), ('3.4', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('2.2', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('300', 'O'), ('mg', 'O'), ('had', 'O'), ('a', 'O'), ('significant', 'O'), ('renal', 'B-ADR'), ('function', 'I-ADR'), ('decline', 'I-ADR'), ('.', 'O')]"
"In a trial carried out in patients with moderate renal impairment with a baseline eGFR of 30 to less than 50 mL/min/1.73 m  2  (mean baseline eGFR 39 mL/min/1.73 m  2  )  [see  Clinical Studies (14.3)  ]  , the proportion of patients who experienced at least one event of significant renal function decline, defined as an eGFR 30% lower than baseline, was 6.9% with placebo, 18% with INVOKANA 100 mg, and 22.5% with INVOKANA 300 mg. At the end of treatment, 4.6% with placebo, 3.4% with INVOKANA 100 mg, and 2.2% with INVOKANA 300 mg had a significant renal function decline.",eGFR 30% lower than baseline is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('trial', 'O'), ('carried', 'O'), ('out', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('with', 'O'), ('a', 'O'), ('baseline', 'O'), ('eGFR', 'O'), ('of', 'O'), ('30', 'O'), ('to', 'O'), ('less', 'O'), ('than', 'O'), ('50', 'O'), ('mL/min/1.73', 'O'), ('m', 'O'), ('2', 'O'), ('(', 'O'), ('mean', 'O'), ('baseline', 'O'), ('eGFR', 'O'), ('39', 'O'), ('mL/min/1.73', 'O'), ('m', 'O'), ('2', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.3', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('the', 'O'), ('proportion', 'O'), ('of', 'O'), ('patients', 'O'), ('who', 'O'), ('experienced', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('event', 'O'), ('of', 'O'), ('significant', 'O'), ('renal', 'B-ADR'), ('function', 'I-ADR'), ('decline', 'I-ADR'), (',', 'O'), ('defined', 'O'), ('as', 'O'), ('an', 'O'), ('eGFR', 'B-ADR'), ('30', 'I-ADR'), ('%', 'I-ADR'), ('lower', 'I-ADR'), ('than', 'I-ADR'), ('baseline', 'I-ADR'), (',', 'O'), ('was', 'O'), ('6.9', 'O'), ('%', 'O'), ('with', 'O'), ('placebo', 'O'), (',', 'O'), ('18', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('22.5', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('300', 'O'), ('mg.', 'O'), ('At', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('treatment', 'O'), (',', 'O'), ('4.6', 'O'), ('%', 'O'), ('with', 'O'), ('placebo', 'O'), (',', 'O'), ('3.4', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('2.2', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('300', 'O'), ('mg', 'O'), ('had', 'O'), ('a', 'O'), ('significant', 'O'), ('renal', 'B-ADR'), ('function', 'I-ADR'), ('decline', 'I-ADR'), ('.', 'O')]"
"In a trial carried out in patients with moderate renal impairment with a baseline eGFR of 30 to less than 50 mL/min/1.73 m  2  (mean baseline eGFR 39 mL/min/1.73 m  2  )  [see  Clinical Studies (14.3)  ]  , the proportion of patients who experienced at least one event of significant renal function decline, defined as an eGFR 30% lower than baseline, was 6.9% with placebo, 18% with INVOKANA 100 mg, and 22.5% with INVOKANA 300 mg. At the end of treatment, 4.6% with placebo, 3.4% with INVOKANA 100 mg, and 2.2% with INVOKANA 300 mg had a significant renal function decline.",renal function decline is an adverse reaction entity,"[('In', 'O'), ('a', 'O'), ('trial', 'O'), ('carried', 'O'), ('out', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('with', 'O'), ('a', 'O'), ('baseline', 'O'), ('eGFR', 'O'), ('of', 'O'), ('30', 'O'), ('to', 'O'), ('less', 'O'), ('than', 'O'), ('50', 'O'), ('mL/min/1.73', 'O'), ('m', 'O'), ('2', 'O'), ('(', 'O'), ('mean', 'O'), ('baseline', 'O'), ('eGFR', 'O'), ('39', 'O'), ('mL/min/1.73', 'O'), ('m', 'O'), ('2', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Clinical', 'O'), ('Studies', 'O'), ('(', 'O'), ('14.3', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('the', 'O'), ('proportion', 'O'), ('of', 'O'), ('patients', 'O'), ('who', 'O'), ('experienced', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('event', 'O'), ('of', 'O'), ('significant', 'O'), ('renal', 'B-ADR'), ('function', 'I-ADR'), ('decline', 'I-ADR'), (',', 'O'), ('defined', 'O'), ('as', 'O'), ('an', 'O'), ('eGFR', 'B-ADR'), ('30', 'I-ADR'), ('%', 'I-ADR'), ('lower', 'I-ADR'), ('than', 'I-ADR'), ('baseline', 'I-ADR'), (',', 'O'), ('was', 'O'), ('6.9', 'O'), ('%', 'O'), ('with', 'O'), ('placebo', 'O'), (',', 'O'), ('18', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('22.5', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('300', 'O'), ('mg.', 'O'), ('At', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('treatment', 'O'), (',', 'O'), ('4.6', 'O'), ('%', 'O'), ('with', 'O'), ('placebo', 'O'), (',', 'O'), ('3.4', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('and', 'O'), ('2.2', 'O'), ('%', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('300', 'O'), ('mg', 'O'), ('had', 'O'), ('a', 'O'), ('significant', 'O'), ('renal', 'B-ADR'), ('function', 'I-ADR'), ('decline', 'I-ADR'), ('.', 'O')]"
"Use of INVOKANA has been associated with an increased incidence of renal-related adverse reactions (e.g., increased blood creatinine, decreased glomerular filtration rate, renal impairment, and acute renal failure), particularly in patients with moderate renal impairment.",renal-related adverse reactions is an adverse reaction entity,"[('Use', 'O'), ('of', 'O'), ('INVOKANA', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('renal-related', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('decreased', 'B-ADR'), ('glomerular', 'I-ADR'), ('filtration', 'I-ADR'), ('rate', 'I-ADR'), (',', 'O'), ('renal', 'B-ADR'), ('impairment', 'I-ADR'), (',', 'O'), ('and', 'O'), ('acute', 'B-ADR'), ('renal', 'I-ADR'), ('failure', 'I-ADR'), (')', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('.', 'O')]"
"Use of INVOKANA has been associated with an increased incidence of renal-related adverse reactions (e.g., increased blood creatinine, decreased glomerular filtration rate, renal impairment, and acute renal failure), particularly in patients with moderate renal impairment.",increased blood creatinine is an adverse reaction entity,"[('Use', 'O'), ('of', 'O'), ('INVOKANA', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('renal-related', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('decreased', 'B-ADR'), ('glomerular', 'I-ADR'), ('filtration', 'I-ADR'), ('rate', 'I-ADR'), (',', 'O'), ('renal', 'B-ADR'), ('impairment', 'I-ADR'), (',', 'O'), ('and', 'O'), ('acute', 'B-ADR'), ('renal', 'I-ADR'), ('failure', 'I-ADR'), (')', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('.', 'O')]"
"Use of INVOKANA has been associated with an increased incidence of renal-related adverse reactions (e.g., increased blood creatinine, decreased glomerular filtration rate, renal impairment, and acute renal failure), particularly in patients with moderate renal impairment.",decreased glomerular filtration rate is an adverse reaction entity,"[('Use', 'O'), ('of', 'O'), ('INVOKANA', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('renal-related', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('decreased', 'B-ADR'), ('glomerular', 'I-ADR'), ('filtration', 'I-ADR'), ('rate', 'I-ADR'), (',', 'O'), ('renal', 'B-ADR'), ('impairment', 'I-ADR'), (',', 'O'), ('and', 'O'), ('acute', 'B-ADR'), ('renal', 'I-ADR'), ('failure', 'I-ADR'), (')', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('.', 'O')]"
"Use of INVOKANA has been associated with an increased incidence of renal-related adverse reactions (e.g., increased blood creatinine, decreased glomerular filtration rate, renal impairment, and acute renal failure), particularly in patients with moderate renal impairment.",renal impairment is an adverse reaction entity,"[('Use', 'O'), ('of', 'O'), ('INVOKANA', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('renal-related', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('decreased', 'B-ADR'), ('glomerular', 'I-ADR'), ('filtration', 'I-ADR'), ('rate', 'I-ADR'), (',', 'O'), ('renal', 'B-ADR'), ('impairment', 'I-ADR'), (',', 'O'), ('and', 'O'), ('acute', 'B-ADR'), ('renal', 'I-ADR'), ('failure', 'I-ADR'), (')', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('.', 'O')]"
"Use of INVOKANA has been associated with an increased incidence of renal-related adverse reactions (e.g., increased blood creatinine, decreased glomerular filtration rate, renal impairment, and acute renal failure), particularly in patients with moderate renal impairment.",acute renal failure is an adverse reaction entity,"[('Use', 'O'), ('of', 'O'), ('INVOKANA', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('renal-related', 'B-ADR'), ('adverse', 'I-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('increased', 'B-ADR'), ('blood', 'I-ADR'), ('creatinine', 'I-ADR'), (',', 'O'), ('decreased', 'B-ADR'), ('glomerular', 'I-ADR'), ('filtration', 'I-ADR'), ('rate', 'I-ADR'), (',', 'O'), ('renal', 'B-ADR'), ('impairment', 'I-ADR'), (',', 'O'), ('and', 'O'), ('acute', 'B-ADR'), ('renal', 'I-ADR'), ('failure', 'I-ADR'), (')', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('.', 'O')]"
"Male patients who developed genital mycotic infections on INVOKANA were more likely to experience recurrent infections (22% on INVOKANA versus none on placebo), and require treatment with oral or topical antifungal agents and anti-microbial agents than patients on comparators.",Male genital mycotic infections is an adverse reaction entity,"[('Male', 'B-ADR'), ('patients', 'O'), ('who', 'O'), ('developed', 'O'), ('genital', 'I-ADR'), ('mycotic', 'I-ADR'), ('infections', 'I-ADR'), ('on', 'O'), ('INVOKANA', 'O'), ('were', 'O'), ('more', 'O'), ('likely', 'O'), ('to', 'O'), ('experience', 'O'), ('recurrent', 'O'), ('infections', 'O'), ('(', 'O'), ('22', 'O'), ('%', 'O'), ('on', 'O'), ('INVOKANA', 'O'), ('versus', 'O'), ('none', 'O'), ('on', 'O'), ('placebo', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('require', 'O'), ('treatment', 'O'), ('with', 'O'), ('oral', 'O'), ('or', 'O'), ('topical', 'O'), ('antifungal', 'O'), ('agents', 'O'), ('and', 'O'), ('anti-microbial', 'O'), ('agents', 'O'), ('than', 'O'), ('patients', 'O'), ('on', 'O'), ('comparators', 'O'), ('.', 'O')]"
"Patients with moderate renal impairment who are taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, or medications that interfere with the renin-angiotensin-aldosterone system are at an increased risk of developing hyperkalemia [see  Dosage and Administration (2.2)  and  Adverse Reactions (6.1)  ]  .",hyperkalemia is an adverse reaction entity,"[('Patients', 'O'), ('with', 'O'), ('moderate', 'O'), ('renal', 'O'), ('impairment', 'O'), ('who', 'O'), ('are', 'O'), ('taking', 'O'), ('medications', 'O'), ('that', 'O'), ('interfere', 'O'), ('with', 'O'), ('potassium', 'O'), ('excretion', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('potassium-sparing', 'O'), ('diuretics', 'O'), (',', 'O'), ('or', 'O'), ('medications', 'O'), ('that', 'O'), ('interfere', 'O'), ('with', 'O'), ('the', 'O'), ('renin-angiotensin-aldosterone', 'O'), ('system', 'O'), ('are', 'O'), ('at', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('developing', 'O'), ('hyperkalemia', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Dosage', 'O'), ('and', 'O'), ('Administration', 'O'), ('(', 'O'), ('2.2', 'O'), (')', 'O'), ('and', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"5.6 Hypersensitivity Reactions      Hypersensitivity reactions (e.g., generalized urticaria), some serious, were reported with INVOKANA treatment; these reactions generally occurred within hours to days after initiating INVOKANA.",Hypersensitivity reactions is an adverse reaction entity,"[('5.6', 'O'), ('Hypersensitivity', 'O'), ('Reactions', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('generalized', 'B-ADR'), ('urticaria', 'I-ADR'), (')', 'O'), (',', 'O'), ('some', 'O'), ('serious', 'O'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('treatment', 'O'), (';', 'O'), ('these', 'O'), ('reactions', 'O'), ('generally', 'O'), ('occurred', 'O'), ('within', 'O'), ('hours', 'O'), ('to', 'O'), ('days', 'O'), ('after', 'O'), ('initiating', 'O'), ('INVOKANA', 'O'), ('.', 'O')]"
"5.6 Hypersensitivity Reactions      Hypersensitivity reactions (e.g., generalized urticaria), some serious, were reported with INVOKANA treatment; these reactions generally occurred within hours to days after initiating INVOKANA.",Hypersensitivity reactions is an adverse reaction entity,"[('5.6', 'O'), ('Hypersensitivity', 'O'), ('Reactions', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('generalized', 'B-ADR'), ('urticaria', 'I-ADR'), (')', 'O'), (',', 'O'), ('some', 'O'), ('serious', 'O'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('treatment', 'O'), (';', 'O'), ('these', 'O'), ('reactions', 'O'), ('generally', 'O'), ('occurred', 'O'), ('within', 'O'), ('hours', 'O'), ('to', 'O'), ('days', 'O'), ('after', 'O'), ('initiating', 'O'), ('INVOKANA', 'O'), ('.', 'O')]"
"5.6 Hypersensitivity Reactions      Hypersensitivity reactions (e.g., generalized urticaria), some serious, were reported with INVOKANA treatment; these reactions generally occurred within hours to days after initiating INVOKANA.",generalized urticaria is an adverse reaction entity,"[('5.6', 'O'), ('Hypersensitivity', 'O'), ('Reactions', 'O'), ('Hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('generalized', 'B-ADR'), ('urticaria', 'I-ADR'), (')', 'O'), (',', 'O'), ('some', 'O'), ('serious', 'O'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('with', 'O'), ('INVOKANA', 'O'), ('treatment', 'O'), (';', 'O'), ('these', 'O'), ('reactions', 'O'), ('generally', 'O'), ('occurred', 'O'), ('within', 'O'), ('hours', 'O'), ('to', 'O'), ('days', 'O'), ('after', 'O'), ('initiating', 'O'), ('INVOKANA', 'O'), ('.', 'O')]"
"*  Radiation risk: Amyvid, similar to all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.",Radiation risk is an adverse reaction entity,"[('*', 'O'), ('Radiation', 'B-ADR'), ('risk', 'I-ADR'), (':', 'O'), ('Amyvid', 'O'), (',', 'O'), ('similar', 'O'), ('to', 'O'), ('all', 'O'), ('radiopharmaceuticals', 'O'), (',', 'O'), ('contributes', 'O'), ('to', 'O'), ('a', 'O'), ('patient', 'O'), (""'s"", 'O'), ('long-term', 'B-ADR'), ('cumulative', 'I-ADR'), ('radiation', 'I-ADR'), ('exposure', 'I-ADR'), ('.', 'O')]"
"*  Radiation risk: Amyvid, similar to all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.",long-term cumulative radiation exposure is an adverse reaction entity,"[('*', 'O'), ('Radiation', 'B-ADR'), ('risk', 'I-ADR'), (':', 'O'), ('Amyvid', 'O'), (',', 'O'), ('similar', 'O'), ('to', 'O'), ('all', 'O'), ('radiopharmaceuticals', 'O'), (',', 'O'), ('contributes', 'O'), ('to', 'O'), ('a', 'O'), ('patient', 'O'), (""'s"", 'O'), ('long-term', 'B-ADR'), ('cumulative', 'I-ADR'), ('radiation', 'I-ADR'), ('exposure', 'I-ADR'), ('.', 'O')]"
Two patients receiving alglucosidase alfa discontinued the trial due to anaphylactic reactions.,anaphylactic reactions is an adverse reaction entity,"[('Two', 'O'), ('patients', 'O'), ('receiving', 'O'), ('alglucosidase', 'O'), ('alfa', 'O'), ('discontinued', 'O'), ('the', 'O'), ('trial', 'O'), ('due', 'O'), ('to', 'O'), ('anaphylactic', 'B-ADR'), ('reactions', 'I-ADR'), ('.', 'O')]"
5.1 Anaphylaxis and Hypersensitivity Reactions      Anaphylaxis and hypersensitivity reactions have been observed in patients during and up to 3 hours after alglucosidase alfa infusion.,Anaphylaxis is an adverse reaction entity,"[('5.1', 'O'), ('Anaphylaxis', 'O'), ('and', 'O'), ('Hypersensitivity', 'O'), ('Reactions', 'O'), ('Anaphylaxis', 'B-ADR'), ('and', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('during', 'O'), ('and', 'O'), ('up', 'O'), ('to', 'O'), ('3', 'O'), ('hours', 'O'), ('after', 'O'), ('alglucosidase', 'O'), ('alfa', 'O'), ('infusion', 'O'), ('.', 'O')]"
5.1 Anaphylaxis and Hypersensitivity Reactions      Anaphylaxis and hypersensitivity reactions have been observed in patients during and up to 3 hours after alglucosidase alfa infusion.,hypersensitivity reactions is an adverse reaction entity,"[('5.1', 'O'), ('Anaphylaxis', 'O'), ('and', 'O'), ('Hypersensitivity', 'O'), ('Reactions', 'O'), ('Anaphylaxis', 'B-ADR'), ('and', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('during', 'O'), ('and', 'O'), ('up', 'O'), ('to', 'O'), ('3', 'O'), ('hours', 'O'), ('after', 'O'), ('alglucosidase', 'O'), ('alfa', 'O'), ('infusion', 'O'), ('.', 'O')]"
5.2 Immune-Mediated Reactions    Immune-mediated cutaneous reactions have been reported with alglucosidase alfa including necrotizing skin lesions  [seeAdverse Reactions (6.3)]  .,Immune-mediated cutaneous reactions is an adverse reaction entity,"[('5.2', 'O'), ('Immune-Mediated', 'O'), ('Reactions', 'O'), ('Immune-mediated', 'B-ADR'), ('cutaneous', 'I-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('alglucosidase', 'O'), ('alfa', 'O'), ('including', 'O'), ('necrotizing', 'B-ADR'), ('skin', 'I-ADR'), ('lesions', 'I-ADR'), ('[', 'O'), ('seeAdverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.3', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
5.2 Immune-Mediated Reactions    Immune-mediated cutaneous reactions have been reported with alglucosidase alfa including necrotizing skin lesions  [seeAdverse Reactions (6.3)]  .,necrotizing skin lesions is an adverse reaction entity,"[('5.2', 'O'), ('Immune-Mediated', 'O'), ('Reactions', 'O'), ('Immune-mediated', 'B-ADR'), ('cutaneous', 'I-ADR'), ('reactions', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('alglucosidase', 'O'), ('alfa', 'O'), ('including', 'O'), ('necrotizing', 'B-ADR'), ('skin', 'I-ADR'), ('lesions', 'I-ADR'), ('[', 'O'), ('seeAdverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.3', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Ventricular arrhythmias and bradycardia, resulting in cardiac arrest or death, or requiring cardiac resuscitation or defibrillation have been observed in infantile-onset Pompe disease patients with cardiac hypertrophy during general anesthesia for central venous catheter placement.",Ventricular arrhythmias is an adverse reaction entity,"[('Ventricular', 'B-ADR'), ('arrhythmias', 'I-ADR'), ('and', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('cardiac', 'B-ADR'), ('arrest', 'I-ADR'), ('or', 'O'), ('death', 'B-ADR'), (',', 'O'), ('or', 'O'), ('requiring', 'O'), ('cardiac', 'O'), ('resuscitation', 'O'), ('or', 'O'), ('defibrillation', 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('infantile-onset', 'O'), ('Pompe', 'O'), ('disease', 'O'), ('patients', 'O'), ('with', 'O'), ('cardiac', 'O'), ('hypertrophy', 'O'), ('during', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('central', 'O'), ('venous', 'O'), ('catheter', 'O'), ('placement', 'O'), ('.', 'O')]"
"Ventricular arrhythmias and bradycardia, resulting in cardiac arrest or death, or requiring cardiac resuscitation or defibrillation have been observed in infantile-onset Pompe disease patients with cardiac hypertrophy during general anesthesia for central venous catheter placement.",bradycardia is an adverse reaction entity,"[('Ventricular', 'B-ADR'), ('arrhythmias', 'I-ADR'), ('and', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('cardiac', 'B-ADR'), ('arrest', 'I-ADR'), ('or', 'O'), ('death', 'B-ADR'), (',', 'O'), ('or', 'O'), ('requiring', 'O'), ('cardiac', 'O'), ('resuscitation', 'O'), ('or', 'O'), ('defibrillation', 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('infantile-onset', 'O'), ('Pompe', 'O'), ('disease', 'O'), ('patients', 'O'), ('with', 'O'), ('cardiac', 'O'), ('hypertrophy', 'O'), ('during', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('central', 'O'), ('venous', 'O'), ('catheter', 'O'), ('placement', 'O'), ('.', 'O')]"
"Ventricular arrhythmias and bradycardia, resulting in cardiac arrest or death, or requiring cardiac resuscitation or defibrillation have been observed in infantile-onset Pompe disease patients with cardiac hypertrophy during general anesthesia for central venous catheter placement.",cardiac arrest is an adverse reaction entity,"[('Ventricular', 'B-ADR'), ('arrhythmias', 'I-ADR'), ('and', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('cardiac', 'B-ADR'), ('arrest', 'I-ADR'), ('or', 'O'), ('death', 'B-ADR'), (',', 'O'), ('or', 'O'), ('requiring', 'O'), ('cardiac', 'O'), ('resuscitation', 'O'), ('or', 'O'), ('defibrillation', 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('infantile-onset', 'O'), ('Pompe', 'O'), ('disease', 'O'), ('patients', 'O'), ('with', 'O'), ('cardiac', 'O'), ('hypertrophy', 'O'), ('during', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('central', 'O'), ('venous', 'O'), ('catheter', 'O'), ('placement', 'O'), ('.', 'O')]"
"Ventricular arrhythmias and bradycardia, resulting in cardiac arrest or death, or requiring cardiac resuscitation or defibrillation have been observed in infantile-onset Pompe disease patients with cardiac hypertrophy during general anesthesia for central venous catheter placement.",death is an adverse reaction entity,"[('Ventricular', 'B-ADR'), ('arrhythmias', 'I-ADR'), ('and', 'O'), ('bradycardia', 'B-ADR'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('cardiac', 'B-ADR'), ('arrest', 'I-ADR'), ('or', 'O'), ('death', 'B-ADR'), (',', 'O'), ('or', 'O'), ('requiring', 'O'), ('cardiac', 'O'), ('resuscitation', 'O'), ('or', 'O'), ('defibrillation', 'O'), ('have', 'O'), ('been', 'O'), ('observed', 'O'), ('in', 'O'), ('infantile-onset', 'O'), ('Pompe', 'O'), ('disease', 'O'), ('patients', 'O'), ('with', 'O'), ('cardiac', 'O'), ('hypertrophy', 'O'), ('during', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('central', 'O'), ('venous', 'O'), ('catheter', 'O'), ('placement', 'O'), ('.', 'O')]"
"6       ADVERSE REACTIONS    Serious allergic reactions, including anaphylactic reactions, may occur.",allergic reactions is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('Serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('including', 'O'), ('anaphylactic', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
"6       ADVERSE REACTIONS    Serious allergic reactions, including anaphylactic reactions, may occur.",anaphylactic reactions is an adverse reaction entity,"[('6', 'O'), ('ADVERSE', 'O'), ('REACTIONS', 'O'), ('Serious', 'O'), ('allergic', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('including', 'O'), ('anaphylactic', 'B-ADR'), ('reactions', 'I-ADR'), (',', 'O'), ('may', 'O'), ('occur', 'O'), ('.', 'O')]"
Laboratory Tests    Increase in Low-Density Lipoprotein Cholesterol (LDL-C)  Dose-related increases in low-density lipoprotein cholesterol (LDL-C) were observed in patients treated with JARDIANCE.,Increase in Low-Density Lipoprotein Cholesterol is an adverse reaction entity,"[('Laboratory', 'O'), ('Tests', 'O'), ('Increase', 'B-ADR'), ('in', 'I-ADR'), ('Low-Density', 'I-ADR'), ('Lipoprotein', 'I-ADR'), ('Cholesterol', 'I-ADR'), ('(', 'O'), ('LDL-C', 'O'), (')', 'O'), ('Dose-related', 'O'), ('increases', 'B-ADR'), ('in', 'I-ADR'), ('low-density', 'I-ADR'), ('lipoprotein', 'I-ADR'), ('cholesterol', 'I-ADR'), ('(', 'O'), ('LDL-C', 'O'), (')', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('JARDIANCE', 'O'), ('.', 'O')]"
Laboratory Tests    Increase in Low-Density Lipoprotein Cholesterol (LDL-C)  Dose-related increases in low-density lipoprotein cholesterol (LDL-C) were observed in patients treated with JARDIANCE.,increases in low-density lipoprotein cholesterol is an adverse reaction entity,"[('Laboratory', 'O'), ('Tests', 'O'), ('Increase', 'B-ADR'), ('in', 'I-ADR'), ('Low-Density', 'I-ADR'), ('Lipoprotein', 'I-ADR'), ('Cholesterol', 'I-ADR'), ('(', 'O'), ('LDL-C', 'O'), (')', 'O'), ('Dose-related', 'O'), ('increases', 'B-ADR'), ('in', 'I-ADR'), ('low-density', 'I-ADR'), ('lipoprotein', 'I-ADR'), ('cholesterol', 'I-ADR'), ('(', 'O'), ('LDL-C', 'O'), (')', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('JARDIANCE', 'O'), ('.', 'O')]"
"The risk of hypoglycemia is increased when JARDIANCE is used in combination with insulin secretagogues (e.g., sulfonylurea) or insulin [see Adverse Reactions (  6.1  )]  .",hypoglycemia is an adverse reaction entity,"[('The', 'O'), ('risk', 'O'), ('of', 'O'), ('hypoglycemia', 'B-ADR'), ('is', 'O'), ('increased', 'O'), ('when', 'O'), ('JARDIANCE', 'O'), ('is', 'O'), ('used', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('insulin', 'O'), ('secretagogues', 'O'), ('(', 'O'), ('e.g.', 'O'), (',', 'O'), ('sulfonylurea', 'O'), (')', 'O'), ('or', 'O'), ('insulin', 'O'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
5.4 Genital Mycotic Infections      JARDIANCE increases the risk for genital mycotic infections [see Adverse Reactions (  6.1  )]  .,genital mycotic infections is an adverse reaction entity,"[('5.4', 'O'), ('Genital', 'O'), ('Mycotic', 'O'), ('Infections', 'O'), ('JARDIANCE', 'O'), ('increases', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('genital', 'B-ADR'), ('mycotic', 'I-ADR'), ('infections', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
(5.6)          5.1 Pancreatitis    There have been postmarketing reports of acute pancreatitis in patients taking NESINA.,acute pancreatitis is an adverse reaction entity,"[('(', 'O'), ('5.6', 'O'), (')', 'O'), ('5.1', 'O'), ('Pancreatitis', 'O'), ('There', 'O'), ('have', 'O'), ('been', 'O'), ('postmarketing', 'O'), ('reports', 'O'), ('of', 'O'), ('acute', 'B-ADR'), ('pancreatitis', 'I-ADR'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('NESINA', 'O'), ('.', 'O')]"
5.2 Hypersensitivity Reactions    There have been postmarketing reports of serious hypersensitivity reactions in patients treated with NESINA.,hypersensitivity reactions is an adverse reaction entity,"[('5.2', 'O'), ('Hypersensitivity', 'O'), ('Reactions', 'O'), ('There', 'O'), ('have', 'O'), ('been', 'O'), ('postmarketing', 'O'), ('reports', 'O'), ('of', 'O'), ('serious', 'O'), ('hypersensitivity', 'B-ADR'), ('reactions', 'I-ADR'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('NESINA', 'O'), ('.', 'O')]"
"The most common laboratory abnormalities (incidence >=30%) are neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations (  6.1  ).",neutropenia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('incidence', 'O'), ('>', 'O'), ('=30', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('ALT', 'B-ADR'), ('elevations', 'I-ADR'), (',', 'O'), ('and', 'O'), ('AST', 'B-ADR'), ('elevations', 'I-ADR'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), ('.', 'O')]"
"The most common laboratory abnormalities (incidence >=30%) are neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations (  6.1  ).",hypertriglyceridemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('incidence', 'O'), ('>', 'O'), ('=30', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('ALT', 'B-ADR'), ('elevations', 'I-ADR'), (',', 'O'), ('and', 'O'), ('AST', 'B-ADR'), ('elevations', 'I-ADR'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), ('.', 'O')]"
"The most common laboratory abnormalities (incidence >=30%) are neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations (  6.1  ).",hyperglycemia is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('incidence', 'O'), ('>', 'O'), ('=30', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('ALT', 'B-ADR'), ('elevations', 'I-ADR'), (',', 'O'), ('and', 'O'), ('AST', 'B-ADR'), ('elevations', 'I-ADR'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), ('.', 'O')]"
"The most common laboratory abnormalities (incidence >=30%) are neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations (  6.1  ).",ALT elevations is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('incidence', 'O'), ('>', 'O'), ('=30', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('ALT', 'B-ADR'), ('elevations', 'I-ADR'), (',', 'O'), ('and', 'O'), ('AST', 'B-ADR'), ('elevations', 'I-ADR'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), ('.', 'O')]"
"The most common laboratory abnormalities (incidence >=30%) are neutropenia, hypertriglyceridemia, hyperglycemia, ALT elevations, and AST elevations (  6.1  ).",AST elevations is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('laboratory', 'O'), ('abnormalities', 'O'), ('(', 'O'), ('incidence', 'O'), ('>', 'O'), ('=30', 'O'), ('%', 'O'), (')', 'O'), ('are', 'O'), ('neutropenia', 'B-ADR'), (',', 'O'), ('hypertriglyceridemia', 'B-ADR'), (',', 'O'), ('hyperglycemia', 'B-ADR'), (',', 'O'), ('ALT', 'B-ADR'), ('elevations', 'I-ADR'), (',', 'O'), ('and', 'O'), ('AST', 'B-ADR'), ('elevations', 'I-ADR'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), ('.', 'O')]"
(  5.8  )             5.1 Hepatotoxicity      Fatal and/or serious hepatotoxicity occurred in 14% of patients treated with Zydelig.,Fatal is an adverse reaction entity,"[('(', 'O'), ('5.8', 'O'), (')', 'O'), ('5.1', 'O'), ('Hepatotoxicity', 'O'), ('Fatal', 'B-ADR'), ('and/or', 'O'), ('serious', 'O'), ('hepatotoxicity', 'B-ADR'), ('occurred', 'O'), ('in', 'O'), ('14', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('Zydelig', 'O'), ('.', 'O')]"
(  5.8  )             5.1 Hepatotoxicity      Fatal and/or serious hepatotoxicity occurred in 14% of patients treated with Zydelig.,hepatotoxicity is an adverse reaction entity,"[('(', 'O'), ('5.8', 'O'), (')', 'O'), ('5.1', 'O'), ('Hepatotoxicity', 'O'), ('Fatal', 'B-ADR'), ('and/or', 'O'), ('serious', 'O'), ('hepatotoxicity', 'B-ADR'), ('occurred', 'O'), ('in', 'O'), ('14', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('Zydelig', 'O'), ('.', 'O')]"
"Idelalisib is teratogenic in rats, at systemic exposures 12 times those reported in patients at the recommended dose of 150 mg twice daily.",teratogenic is an adverse reaction entity,"[('Idelalisib', 'O'), ('is', 'O'), ('teratogenic', 'B-ADR'), ('in', 'O'), ('rats', 'O'), (',', 'O'), ('at', 'O'), ('systemic', 'O'), ('exposures', 'O'), ('12', 'O'), ('times', 'O'), ('those', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('at', 'O'), ('the', 'O'), ('recommended', 'O'), ('dose', 'O'), ('of', 'O'), ('150', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), ('.', 'O')]"
"In Studies 1 and 2, the most common adverse reactions (>=2%) associated with infusion-related reactions were chills (4%), nausea (3%), dyspnea (3%), pruritus (3%), pyrexia (2%), and cough (2%).",infusion-related reactions is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('chills', 'B-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pruritus', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"In Studies 1 and 2, the most common adverse reactions (>=2%) associated with infusion-related reactions were chills (4%), nausea (3%), dyspnea (3%), pruritus (3%), pyrexia (2%), and cough (2%).",chills is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('chills', 'B-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pruritus', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"In Studies 1 and 2, the most common adverse reactions (>=2%) associated with infusion-related reactions were chills (4%), nausea (3%), dyspnea (3%), pruritus (3%), pyrexia (2%), and cough (2%).",nausea is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('chills', 'B-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pruritus', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"In Studies 1 and 2, the most common adverse reactions (>=2%) associated with infusion-related reactions were chills (4%), nausea (3%), dyspnea (3%), pruritus (3%), pyrexia (2%), and cough (2%).",dyspnea is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('chills', 'B-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pruritus', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"In Studies 1 and 2, the most common adverse reactions (>=2%) associated with infusion-related reactions were chills (4%), nausea (3%), dyspnea (3%), pruritus (3%), pyrexia (2%), and cough (2%).",pruritus is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('chills', 'B-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pruritus', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"In Studies 1 and 2, the most common adverse reactions (>=2%) associated with infusion-related reactions were chills (4%), nausea (3%), dyspnea (3%), pruritus (3%), pyrexia (2%), and cough (2%).",pyrexia is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('chills', 'B-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pruritus', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
"In Studies 1 and 2, the most common adverse reactions (>=2%) associated with infusion-related reactions were chills (4%), nausea (3%), dyspnea (3%), pruritus (3%), pyrexia (2%), and cough (2%).",cough is an adverse reaction entity,"[('In', 'O'), ('Studies', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('(', 'O'), ('>', 'O'), ('=2', 'O'), ('%', 'O'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('were', 'O'), ('chills', 'B-ADR'), ('(', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('dyspnea', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pruritus', 'B-ADR'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('pyrexia', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B-ADR'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O')]"
Grade 3 events were reported in 3 of the 25 patients treated with ADCETRIS who experienced infusion-related reactions.,infusion-related reactions is an adverse reaction entity,"[('Grade', 'O'), ('3', 'O'), ('events', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('3', 'O'), ('of', 'O'), ('the', 'O'), ('25', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('ADCETRIS', 'O'), ('who', 'O'), ('experienced', 'O'), ('infusion-related', 'B-ADR'), ('reactions', 'I-ADR'), ('.', 'O')]"
"Infections  : PML  [see  Boxed Warning,     Warnings and Precautions (5.9)  ]  , serious infections and opportunistic infections  [see  Warnings and Precautions (        5.4        )  ]  .",PML is an adverse reaction entity,"[('Infections', 'O'), (':', 'O'), ('PML', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Boxed', 'O'), ('Warning', 'O'), (',', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.9', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('serious', 'O'), ('infections', 'B-ADR'), ('and', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Infections  : PML  [see  Boxed Warning,     Warnings and Precautions (5.9)  ]  , serious infections and opportunistic infections  [see  Warnings and Precautions (        5.4        )  ]  .",infections is an adverse reaction entity,"[('Infections', 'O'), (':', 'O'), ('PML', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Boxed', 'O'), ('Warning', 'O'), (',', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.9', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('serious', 'O'), ('infections', 'B-ADR'), ('and', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Infections  : PML  [see  Boxed Warning,     Warnings and Precautions (5.9)  ]  , serious infections and opportunistic infections  [see  Warnings and Precautions (        5.4        )  ]  .",opportunistic infections is an adverse reaction entity,"[('Infections', 'O'), (':', 'O'), ('PML', 'B-ADR'), ('[', 'O'), ('see', 'O'), ('Boxed', 'O'), ('Warning', 'O'), (',', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.9', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('serious', 'O'), ('infections', 'B-ADR'), ('and', 'O'), ('opportunistic', 'B-ADR'), ('infections', 'I-ADR'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.4', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and ARDS (some with fatal outcomes)  [see  Warnings and Precautions (5.10)  and  Adverse Reactions (        6.1        )  ]  .",noninfectious pulmonary toxicity is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('noninfectious', 'B-ADR'), ('pulmonary', 'I-ADR'), ('toxicity', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), (',', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ARDS', 'B-ADR'), ('(', 'O'), ('some', 'O'), ('with', 'O'), ('fatal', 'B-ADR'), ('outcomes', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.10', 'O'), (')', 'O'), ('and', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and ARDS (some with fatal outcomes)  [see  Warnings and Precautions (5.10)  and  Adverse Reactions (        6.1        )  ]  .",pneumonitis is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('noninfectious', 'B-ADR'), ('pulmonary', 'I-ADR'), ('toxicity', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), (',', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ARDS', 'B-ADR'), ('(', 'O'), ('some', 'O'), ('with', 'O'), ('fatal', 'B-ADR'), ('outcomes', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.10', 'O'), (')', 'O'), ('and', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and ARDS (some with fatal outcomes)  [see  Warnings and Precautions (5.10)  and  Adverse Reactions (        6.1        )  ]  .",interstitial lung disease is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('noninfectious', 'B-ADR'), ('pulmonary', 'I-ADR'), ('toxicity', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), (',', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ARDS', 'B-ADR'), ('(', 'O'), ('some', 'O'), ('with', 'O'), ('fatal', 'B-ADR'), ('outcomes', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.10', 'O'), (')', 'O'), ('and', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and ARDS (some with fatal outcomes)  [see  Warnings and Precautions (5.10)  and  Adverse Reactions (        6.1        )  ]  .",ARDS is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('noninfectious', 'B-ADR'), ('pulmonary', 'I-ADR'), ('toxicity', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), (',', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ARDS', 'B-ADR'), ('(', 'O'), ('some', 'O'), ('with', 'O'), ('fatal', 'B-ADR'), ('outcomes', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.10', 'O'), (')', 'O'), ('and', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Respiratory, thoracic and mediastinal disorders  : noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and ARDS (some with fatal outcomes)  [see  Warnings and Precautions (5.10)  and  Adverse Reactions (        6.1        )  ]  .",fatal is an adverse reaction entity,"[('Respiratory', 'O'), (',', 'O'), ('thoracic', 'O'), ('and', 'O'), ('mediastinal', 'O'), ('disorders', 'O'), (':', 'O'), ('noninfectious', 'B-ADR'), ('pulmonary', 'I-ADR'), ('toxicity', 'I-ADR'), ('including', 'O'), ('pneumonitis', 'B-ADR'), (',', 'O'), ('interstitial', 'B-ADR'), ('lung', 'I-ADR'), ('disease', 'I-ADR'), (',', 'O'), ('and', 'O'), ('ARDS', 'B-ADR'), ('(', 'O'), ('some', 'O'), ('with', 'O'), ('fatal', 'B-ADR'), ('outcomes', 'O'), (')', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.10', 'O'), (')', 'O'), ('and', 'O'), ('Adverse', 'O'), ('Reactions', 'O'), ('(', 'O'), ('6.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
"Overall, a higher incidence of infusion related reactions was observed in patients who developed persistently positive antibodies.",infusion related reactions is an adverse reaction entity,"[('Overall', 'O'), (',', 'O'), ('a', 'O'), ('higher', 'O'), ('incidence', 'O'), ('of', 'O'), ('infusion', 'B-ADR'), ('related', 'I-ADR'), ('reactions', 'I-ADR'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('developed', 'O'), ('persistently', 'O'), ('positive', 'O'), ('antibodies', 'O'), ('.', 'O')]"
5.3 Hematologic Toxicities      Prolonged (>=1 week) severe neutropenia and Grade 3 or Grade 4 thrombocytopenia or anemia can occur with ADCETRIS.,neutropenia is an adverse reaction entity,"[('5.3', 'O'), ('Hematologic', 'O'), ('Toxicities', 'O'), ('Prolonged', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('week', 'O'), (')', 'O'), ('severe', 'O'), ('neutropenia', 'B-ADR'), ('and', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('Grade', 'O'), ('4', 'O'), ('thrombocytopenia', 'B-ADR'), ('or', 'O'), ('anemia', 'B-ADR'), ('can', 'O'), ('occur', 'O'), ('with', 'O'), ('ADCETRIS', 'O'), ('.', 'O')]"
5.3 Hematologic Toxicities      Prolonged (>=1 week) severe neutropenia and Grade 3 or Grade 4 thrombocytopenia or anemia can occur with ADCETRIS.,thrombocytopenia is an adverse reaction entity,"[('5.3', 'O'), ('Hematologic', 'O'), ('Toxicities', 'O'), ('Prolonged', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('week', 'O'), (')', 'O'), ('severe', 'O'), ('neutropenia', 'B-ADR'), ('and', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('Grade', 'O'), ('4', 'O'), ('thrombocytopenia', 'B-ADR'), ('or', 'O'), ('anemia', 'B-ADR'), ('can', 'O'), ('occur', 'O'), ('with', 'O'), ('ADCETRIS', 'O'), ('.', 'O')]"
5.3 Hematologic Toxicities      Prolonged (>=1 week) severe neutropenia and Grade 3 or Grade 4 thrombocytopenia or anemia can occur with ADCETRIS.,anemia is an adverse reaction entity,"[('5.3', 'O'), ('Hematologic', 'O'), ('Toxicities', 'O'), ('Prolonged', 'O'), ('(', 'O'), ('>', 'O'), ('=1', 'O'), ('week', 'O'), (')', 'O'), ('severe', 'O'), ('neutropenia', 'B-ADR'), ('and', 'O'), ('Grade', 'O'), ('3', 'O'), ('or', 'O'), ('Grade', 'O'), ('4', 'O'), ('thrombocytopenia', 'B-ADR'), ('or', 'O'), ('anemia', 'B-ADR'), ('can', 'O'), ('occur', 'O'), ('with', 'O'), ('ADCETRIS', 'O'), ('.', 'O')]"
"Because of physiological diurnal variation, there is a second period of heart rate decrease within 24 hours after the first dose.",heart rate decrease is an adverse reaction entity,"[('Because', 'O'), ('of', 'O'), ('physiological', 'O'), ('diurnal', 'O'), ('variation', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('second', 'O'), ('period', 'O'), ('of', 'O'), ('heart', 'B-ADR'), ('rate', 'I-ADR'), ('decrease', 'I-ADR'), ('within', 'O'), ('24', 'O'), ('hours', 'O'), ('after', 'O'), ('the', 'O'), ('first', 'O'), ('dose', 'O'), ('.', 'O')]"
"The conduction abnormalities were usually transient and asymptomatic, and resolved within the first 24 hours on treatment, but they occasionally required treatment with atropine or isoproterenol.",conduction abnormalities is an adverse reaction entity,"[('The', 'O'), ('conduction', 'B-ADR'), ('abnormalities', 'I-ADR'), ('were', 'O'), ('usually', 'O'), ('transient', 'O'), ('and', 'O'), ('asymptomatic', 'O'), (',', 'O'), ('and', 'O'), ('resolved', 'O'), ('within', 'O'), ('the', 'O'), ('first', 'O'), ('24', 'O'), ('hours', 'O'), ('on', 'O'), ('treatment', 'O'), (',', 'O'), ('but', 'O'), ('they', 'O'), ('occasionally', 'O'), ('required', 'O'), ('treatment', 'O'), ('with', 'O'), ('atropine', 'O'), ('or', 'O'), ('isoproterenol', 'O'), ('.', 'O')]"
Serious infections occurred at a rate of 2.3% in the GILENYA group versus 1.6% in the placebo group.,infections is an adverse reaction entity,"[('Serious', 'O'), ('infections', 'B-ADR'), ('occurred', 'O'), ('at', 'O'), ('a', 'O'), ('rate', 'O'), ('of', 'O'), ('2.3', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('GILENYA', 'O'), ('group', 'O'), ('versus', 'O'), ('1.6', 'O'), ('%', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O')]"
One death was due to disseminated primary herpes zoster and the other to herpes simplex encephalitis.,death is an adverse reaction entity,"[('One', 'O'), ('death', 'B-ADR'), ('was', 'O'), ('due', 'O'), ('to', 'O'), ('disseminated', 'B-ADR'), ('primary', 'I-ADR'), ('herpes', 'I-ADR'), ('zoster', 'I-ADR'), ('and', 'O'), ('the', 'O'), ('other', 'O'), ('to', 'O'), ('herpes', 'B-ADR'), ('simplex', 'I-ADR'), ('encephalitis', 'I-ADR'), ('.', 'O')]"
One death was due to disseminated primary herpes zoster and the other to herpes simplex encephalitis.,disseminated primary herpes zoster is an adverse reaction entity,"[('One', 'O'), ('death', 'B-ADR'), ('was', 'O'), ('due', 'O'), ('to', 'O'), ('disseminated', 'B-ADR'), ('primary', 'I-ADR'), ('herpes', 'I-ADR'), ('zoster', 'I-ADR'), ('and', 'O'), ('the', 'O'), ('other', 'O'), ('to', 'O'), ('herpes', 'B-ADR'), ('simplex', 'I-ADR'), ('encephalitis', 'I-ADR'), ('.', 'O')]"
One death was due to disseminated primary herpes zoster and the other to herpes simplex encephalitis.,herpes simplex encephalitis is an adverse reaction entity,"[('One', 'O'), ('death', 'B-ADR'), ('was', 'O'), ('due', 'O'), ('to', 'O'), ('disseminated', 'B-ADR'), ('primary', 'I-ADR'), ('herpes', 'I-ADR'), ('zoster', 'I-ADR'), ('and', 'O'), ('the', 'O'), ('other', 'O'), ('to', 'O'), ('herpes', 'B-ADR'), ('simplex', 'I-ADR'), ('encephalitis', 'I-ADR'), ('.', 'O')]"
"PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.",PML is an adverse reaction entity,"[('PML', 'B-ADR'), ('is', 'O'), ('an', 'O'), ('opportunistic', 'B-ADR'), ('viral', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('brain', 'I-ADR'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('JC', 'B-ADR'), ('virus', 'I-ADR'), ('(', 'O'), ('JCV', 'B-ADR'), (')', 'O'), ('that', 'O'), ('typically', 'O'), ('only', 'O'), ('occurs', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('immunocompromised', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('usually', 'O'), ('leads', 'O'), ('to', 'O'), ('death', 'B-ADR'), ('or', 'O'), ('severe', 'O'), ('disability', 'B-ADR'), ('.', 'O')]"
"PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.",opportunistic viral infection of the brain is an adverse reaction entity,"[('PML', 'B-ADR'), ('is', 'O'), ('an', 'O'), ('opportunistic', 'B-ADR'), ('viral', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('brain', 'I-ADR'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('JC', 'B-ADR'), ('virus', 'I-ADR'), ('(', 'O'), ('JCV', 'B-ADR'), (')', 'O'), ('that', 'O'), ('typically', 'O'), ('only', 'O'), ('occurs', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('immunocompromised', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('usually', 'O'), ('leads', 'O'), ('to', 'O'), ('death', 'B-ADR'), ('or', 'O'), ('severe', 'O'), ('disability', 'B-ADR'), ('.', 'O')]"
"PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.",JC virus is an adverse reaction entity,"[('PML', 'B-ADR'), ('is', 'O'), ('an', 'O'), ('opportunistic', 'B-ADR'), ('viral', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('brain', 'I-ADR'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('JC', 'B-ADR'), ('virus', 'I-ADR'), ('(', 'O'), ('JCV', 'B-ADR'), (')', 'O'), ('that', 'O'), ('typically', 'O'), ('only', 'O'), ('occurs', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('immunocompromised', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('usually', 'O'), ('leads', 'O'), ('to', 'O'), ('death', 'B-ADR'), ('or', 'O'), ('severe', 'O'), ('disability', 'B-ADR'), ('.', 'O')]"
"PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.",JCV is an adverse reaction entity,"[('PML', 'B-ADR'), ('is', 'O'), ('an', 'O'), ('opportunistic', 'B-ADR'), ('viral', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('brain', 'I-ADR'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('JC', 'B-ADR'), ('virus', 'I-ADR'), ('(', 'O'), ('JCV', 'B-ADR'), (')', 'O'), ('that', 'O'), ('typically', 'O'), ('only', 'O'), ('occurs', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('immunocompromised', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('usually', 'O'), ('leads', 'O'), ('to', 'O'), ('death', 'B-ADR'), ('or', 'O'), ('severe', 'O'), ('disability', 'B-ADR'), ('.', 'O')]"
"PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.",death is an adverse reaction entity,"[('PML', 'B-ADR'), ('is', 'O'), ('an', 'O'), ('opportunistic', 'B-ADR'), ('viral', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('brain', 'I-ADR'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('JC', 'B-ADR'), ('virus', 'I-ADR'), ('(', 'O'), ('JCV', 'B-ADR'), (')', 'O'), ('that', 'O'), ('typically', 'O'), ('only', 'O'), ('occurs', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('immunocompromised', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('usually', 'O'), ('leads', 'O'), ('to', 'O'), ('death', 'B-ADR'), ('or', 'O'), ('severe', 'O'), ('disability', 'B-ADR'), ('.', 'O')]"
"PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability.",disability is an adverse reaction entity,"[('PML', 'B-ADR'), ('is', 'O'), ('an', 'O'), ('opportunistic', 'B-ADR'), ('viral', 'I-ADR'), ('infection', 'I-ADR'), ('of', 'I-ADR'), ('the', 'I-ADR'), ('brain', 'I-ADR'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('JC', 'B-ADR'), ('virus', 'I-ADR'), ('(', 'O'), ('JCV', 'B-ADR'), (')', 'O'), ('that', 'O'), ('typically', 'O'), ('only', 'O'), ('occurs', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('immunocompromised', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('usually', 'O'), ('leads', 'O'), ('to', 'O'), ('death', 'B-ADR'), ('or', 'O'), ('severe', 'O'), ('disability', 'B-ADR'), ('.', 'O')]"
Some patients had residual visual acuity loss even after resolution of macular edema.,visual acuity loss is an adverse reaction entity,"[('Some', 'O'), ('patients', 'O'), ('had', 'O'), ('residual', 'O'), ('visual', 'B-ADR'), ('acuity', 'I-ADR'), ('loss', 'I-ADR'), ('even', 'O'), ('after', 'O'), ('resolution', 'O'), ('of', 'O'), ('macular', 'B-ADR'), ('edema', 'I-ADR'), ('.', 'O')]"
Some patients had residual visual acuity loss even after resolution of macular edema.,macular edema is an adverse reaction entity,"[('Some', 'O'), ('patients', 'O'), ('had', 'O'), ('residual', 'O'), ('visual', 'B-ADR'), ('acuity', 'I-ADR'), ('loss', 'I-ADR'), ('even', 'O'), ('after', 'O'), ('resolution', 'O'), ('of', 'O'), ('macular', 'B-ADR'), ('edema', 'I-ADR'), ('.', 'O')]"
"5.9     Blood Pressure Effects      In MS controlled clinical trials, patients treated with GILENYA 0.5 mg had an average increase over placebo of approximately 3 mmHg in systolic pressure, and approximately 2 mmHg in diastolic pressure, first detected after approximately 1 month of treatment initiation, and persisting with continued treatment.",increase systolic pressure is an adverse reaction entity,"[('5.9', 'O'), ('Blood', 'O'), ('Pressure', 'O'), ('Effects', 'O'), ('In', 'O'), ('MS', 'O'), ('controlled', 'O'), ('clinical', 'O'), ('trials', 'O'), (',', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('GILENYA', 'O'), ('0.5', 'O'), ('mg', 'O'), ('had', 'O'), ('an', 'O'), ('average', 'O'), ('increase', 'B-ADR'), ('over', 'O'), ('placebo', 'O'), ('of', 'O'), ('approximately', 'O'), ('3', 'O'), ('mmHg', 'O'), ('in', 'O'), ('systolic', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('approximately', 'O'), ('2', 'O'), ('mmHg', 'O'), ('in', 'O'), ('diastolic', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('first', 'O'), ('detected', 'O'), ('after', 'O'), ('approximately', 'O'), ('1', 'O'), ('month', 'O'), ('of', 'O'), ('treatment', 'O'), ('initiation', 'O'), (',', 'O'), ('and', 'O'), ('persisting', 'O'), ('with', 'O'), ('continued', 'O'), ('treatment', 'O'), ('.', 'O')]"
"5.9     Blood Pressure Effects      In MS controlled clinical trials, patients treated with GILENYA 0.5 mg had an average increase over placebo of approximately 3 mmHg in systolic pressure, and approximately 2 mmHg in diastolic pressure, first detected after approximately 1 month of treatment initiation, and persisting with continued treatment.",increase diastolic pressure is an adverse reaction entity,"[('5.9', 'O'), ('Blood', 'O'), ('Pressure', 'O'), ('Effects', 'O'), ('In', 'O'), ('MS', 'O'), ('controlled', 'O'), ('clinical', 'O'), ('trials', 'O'), (',', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('GILENYA', 'O'), ('0.5', 'O'), ('mg', 'O'), ('had', 'O'), ('an', 'O'), ('average', 'O'), ('increase', 'B-ADR'), ('over', 'O'), ('placebo', 'O'), ('of', 'O'), ('approximately', 'O'), ('3', 'O'), ('mmHg', 'O'), ('in', 'O'), ('systolic', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('and', 'O'), ('approximately', 'O'), ('2', 'O'), ('mmHg', 'O'), ('in', 'O'), ('diastolic', 'I-ADR'), ('pressure', 'I-ADR'), (',', 'O'), ('first', 'O'), ('detected', 'O'), ('after', 'O'), ('approximately', 'O'), ('1', 'O'), ('month', 'O'), ('of', 'O'), ('treatment', 'O'), ('initiation', 'O'), (',', 'O'), ('and', 'O'), ('persisting', 'O'), ('with', 'O'), ('continued', 'O'), ('treatment', 'O'), ('.', 'O')]"
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS    Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('NEPHROGENIC', 'B-ADR'), ('SYSTEMIC', 'I-ADR'), ('FIBROSIS', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('NEPHROGENIC', 'B-ADR'), ('SYSTEMIC', 'I-ADR'), ('FIBROSIS', 'I-ADR'), ('Gadolinium-based', 'O'), ('contrast', 'O'), ('agents', 'O'), ('(', 'O'), ('GBCAs', 'O'), (')', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('NSF', 'B-ADR'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), ('impaired', 'O'), ('elimination', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('.', 'O')]"
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS    Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('NEPHROGENIC', 'B-ADR'), ('SYSTEMIC', 'I-ADR'), ('FIBROSIS', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('NEPHROGENIC', 'B-ADR'), ('SYSTEMIC', 'I-ADR'), ('FIBROSIS', 'I-ADR'), ('Gadolinium-based', 'O'), ('contrast', 'O'), ('agents', 'O'), ('(', 'O'), ('GBCAs', 'O'), (')', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('NSF', 'B-ADR'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), ('impaired', 'O'), ('elimination', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('.', 'O')]"
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS    Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('NEPHROGENIC', 'B-ADR'), ('SYSTEMIC', 'I-ADR'), ('FIBROSIS', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('NEPHROGENIC', 'B-ADR'), ('SYSTEMIC', 'I-ADR'), ('FIBROSIS', 'I-ADR'), ('Gadolinium-based', 'O'), ('contrast', 'O'), ('agents', 'O'), ('(', 'O'), ('GBCAs', 'O'), (')', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('NSF', 'B-ADR'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), ('impaired', 'O'), ('elimination', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('.', 'O')]"
"*  The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), orAcute kidney injury.",NSF is an adverse reaction entity,"[('*', 'O'), ('The', 'O'), ('risk', 'O'), ('for', 'O'), ('NSF', 'B-ADR'), ('appears', 'O'), ('highest', 'O'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), (':', 'O'), ('Chronic', 'O'), (',', 'O'), ('severe', 'O'), ('kidney', 'O'), ('disease', 'O'), ('(', 'O'), ('GFR', 'O'), ('<', 'O'), ('30', 'O'), ('mL/min/1.73m2', 'O'), (')', 'O'), (',', 'O'), ('orAcute', 'O'), ('kidney', 'O'), ('injury', 'O'), ('.', 'O')]"
The most common reported adverse reaction occurring in approximately 25% of subjects was a mild taste following instillation.,taste following instillation is an adverse reaction entity,"[('The', 'O'), ('most', 'O'), ('common', 'O'), ('reported', 'O'), ('adverse', 'O'), ('reaction', 'O'), ('occurring', 'O'), ('in', 'O'), ('approximately', 'O'), ('25', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('was', 'O'), ('a', 'O'), ('mild', 'O'), ('taste', 'B-ADR'), ('following', 'I-ADR'), ('instillation', 'I-ADR'), ('.', 'O')]"
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT      WARNING: DISTANT SPREAD OF TOXIN EFFECT        Postmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,DISTANT SPREAD OF TOXIN EFFECT is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('Postmarketing', 'O'), ('reports', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('XEOMIN', 'O'), ('and', 'O'), ('all', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('products', 'O'), ('may', 'O'), ('spread', 'B-ADR'), ('from', 'I-ADR'), ('the', 'I-ADR'), ('area', 'I-ADR'), ('of', 'I-ADR'), ('injection', 'I-ADR'), ('to', 'O'), ('produce', 'O'), ('symptoms', 'O'), ('consistent', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'B-ADR'), ('effects', 'I-ADR'), ('.', 'O')]"
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT      WARNING: DISTANT SPREAD OF TOXIN EFFECT        Postmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,DISTANT SPREAD OF TOXIN EFFECT is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('Postmarketing', 'O'), ('reports', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('XEOMIN', 'O'), ('and', 'O'), ('all', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('products', 'O'), ('may', 'O'), ('spread', 'B-ADR'), ('from', 'I-ADR'), ('the', 'I-ADR'), ('area', 'I-ADR'), ('of', 'I-ADR'), ('injection', 'I-ADR'), ('to', 'O'), ('produce', 'O'), ('symptoms', 'O'), ('consistent', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'B-ADR'), ('effects', 'I-ADR'), ('.', 'O')]"
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT      WARNING: DISTANT SPREAD OF TOXIN EFFECT        Postmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,spread from the area of injection is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('Postmarketing', 'O'), ('reports', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('XEOMIN', 'O'), ('and', 'O'), ('all', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('products', 'O'), ('may', 'O'), ('spread', 'B-ADR'), ('from', 'I-ADR'), ('the', 'I-ADR'), ('area', 'I-ADR'), ('of', 'I-ADR'), ('injection', 'I-ADR'), ('to', 'O'), ('produce', 'O'), ('symptoms', 'O'), ('consistent', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'B-ADR'), ('effects', 'I-ADR'), ('.', 'O')]"
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT      WARNING: DISTANT SPREAD OF TOXIN EFFECT        Postmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,toxin effects is an adverse reaction entity,"[('BOXED', 'O'), ('WARNING', 'O'), (':', 'O'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('WARNING', 'O'), (':', 'O'), ('DISTANT', 'B-ADR'), ('SPREAD', 'I-ADR'), ('OF', 'I-ADR'), ('TOXIN', 'I-ADR'), ('EFFECT', 'I-ADR'), ('Postmarketing', 'O'), ('reports', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('XEOMIN', 'O'), ('and', 'O'), ('all', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('products', 'O'), ('may', 'O'), ('spread', 'B-ADR'), ('from', 'I-ADR'), ('the', 'I-ADR'), ('area', 'I-ADR'), ('of', 'I-ADR'), ('injection', 'I-ADR'), ('to', 'O'), ('produce', 'O'), ('symptoms', 'O'), ('consistent', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'B-ADR'), ('effects', 'I-ADR'), ('.', 'O')]"
"In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses     [see   Warnings and Precautions (5.1)  ]    .",spread of effect is an adverse reaction entity,"[('In', 'O'), ('unapproved', 'O'), ('uses', 'O'), (',', 'O'), ('including', 'O'), ('spasticity', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adults', 'O'), (',', 'O'), ('and', 'O'), ('in', 'O'), ('approved', 'O'), ('indications', 'O'), (',', 'O'), ('cases', 'O'), ('of', 'O'), ('spread', 'B-ADR'), ('of', 'I-ADR'), ('effect', 'I-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('at', 'O'), ('doses', 'O'), ('comparable', 'O'), ('to', 'O'), ('those', 'O'), ('used', 'O'), ('to', 'O'), ('treat', 'O'), ('cervical', 'O'), ('dystonia', 'O'), ('and', 'O'), ('at', 'O'), ('lower', 'O'), ('doses', 'O'), ('[', 'O'), ('see', 'O'), ('Warnings', 'O'), ('and', 'O'), ('Precautions', 'O'), ('(', 'O'), ('5.1', 'O'), (')', 'O'), (']', 'O'), ('.', 'O')]"
The effects of   XEOMIN   and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,spread from the area of injection is an adverse reaction entity,"[('The', 'O'), ('effects', 'O'), ('of', 'O'), ('XEOMIN', 'O'), ('and', 'O'), ('all', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('products', 'O'), ('may', 'O'), ('spread', 'B-ADR'), ('from', 'I-ADR'), ('the', 'I-ADR'), ('area', 'I-ADR'), ('of', 'I-ADR'), ('injection', 'I-ADR'), ('to', 'O'), ('produce', 'O'), ('symptoms', 'O'), ('consistent', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'B-ADR'), ('effects', 'I-ADR'), ('.', 'O')]"
The effects of   XEOMIN   and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,toxin effects is an adverse reaction entity,"[('The', 'O'), ('effects', 'O'), ('of', 'O'), ('XEOMIN', 'O'), ('and', 'O'), ('all', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('products', 'O'), ('may', 'O'), ('spread', 'B-ADR'), ('from', 'I-ADR'), ('the', 'I-ADR'), ('area', 'I-ADR'), ('of', 'I-ADR'), ('injection', 'I-ADR'), ('to', 'O'), ('produce', 'O'), ('symptoms', 'O'), ('consistent', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'B-ADR'), ('effects', 'I-ADR'), ('.', 'O')]"
Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin.,Deaths is an adverse reaction entity,"[('Deaths', 'B-ADR'), ('as', 'O'), ('a', 'O'), ('complication', 'O'), ('of', 'O'), ('severe', 'O'), ('dysphagia', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('.', 'O')]"
Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin.,dysphagia is an adverse reaction entity,"[('Deaths', 'B-ADR'), ('as', 'O'), ('a', 'O'), ('complication', 'O'), ('of', 'O'), ('severe', 'O'), ('dysphagia', 'B-ADR'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('botulinum', 'O'), ('toxin', 'O'), ('.', 'O')]"
